final programme

Transcription

final programme

FINAL
PROGRAMME
Congress Organizers
The 81st EAS Congress
1-3, rue du Chantepoulet; P.O. Box 1726
CH-1211 Geneva 1, Switzerland
Tel: +41 22 908 0488; Fax: +41 22 906 9140
E-Mail: [email protected]
Website: www.kenes.com/eas
CONTENTS
Welcoming Words III
Committees IV
Faculty List V
EAS Society VI
Acknowledgements VII
About LyonX
Anitschkow Prize in Atherosclerosis Research XI
Young Investigator Awards XII
General Information XIII
Mandatory Conflict of Interest Disclosure
XV
Instructions for Presenters XVI
Overview of Moderated Poster Sessions XVII
Poster OverviewXVIII
Company Sponsored Educational Symposia XX
Opening Ceremony XXIII
Social Events XXIV
Hall Name Eulogy of Distinguished Scientists XXV
Venue Floor Plans XXIX
Exhibition Floor Plan and Exhibitors List
XXX
Sponsor and Exhibitor Profiles
XXXI
Scientific Programme
Sunday, June 2, 2013 1
Monday, June 3, 2013 5
Tuesday, June 4, 2013 15
Wednesday, June 5, 2013 25
Poster Presentations 29
Index 129
II
WELCOMING WORDS
Dear Colleagues,
It is our pleasure to welcome you to the 81st EAS Congress in Lyon, France, from 2 to 5 June 2013. The
Congress is hosted by the New French Society for Atherosclerosis. The local Organizing Committee and the
EAS Scientific Programme Committee have worked together to prepare a programme that will include the
latest developments in the field of atherosclerosis, together with timely reviews presented by outstanding
plenary speakers.
The EAS meeting remains a unique opportunity to bring together the various actors in the field of
atherosclerosis. The EAS 2013 programme is of interest to both junior and established basic scientists, as well
as clinical researchers and practitioners.
The meeting promotes interactions between these different groups, and provides cutting-edge basic research
translatable into disease prevention and treatment. More than 800 posters are on display and organized into
interesting and interactive poster sessions.
The Congress takes place in the Lyon Convention Center, designed by Renzo Piano, and located downtown on
the banks of the Rhone River.
Lyon, named a UNESCO Humanities World Heritage Site, is famous not only for world-class landmarks and
thousands of years of history but also for its gorgeous food. Ranked among the top European cities for quality
of life, Lyon in June provides an excellent opportunity to discover the charm of this unique location.
On behalf of the Organizing Committee, we welcome you to Lyon. We are delighted that you joined us for the
81st EAS Congress in 2013 - a stimulating meeting offering enjoyable and rewarding interactions between
basic and clinical researchers in the field of atherosclerosis.
Philippe Moulin
Congress Chair EAS 2013
Petri Kovanen
Chairman of the Scientific
Programme Committee
Alberico L. Catapano
EAS President
III
COMMITTEES
CONGRESS CHAIRPERSON
Philippe Moulin, France
EAS EXECUTIVE COMMITTEE
LOCAL ORGANIZING COMMITTEE
Alberico L. Catapano, President
Olov Wiklund, Vice President
M. John Chapman, Past President
Petri Kovanen, Secretary & Award Committee Chair
Jan Borén, Treasurer
Geesje Dallinga-Thie
Børge Nordestgaard
Arnold von Eckardstein
Michal Vrablík
Jacques Bonnet, Bordeaux
Eric Bruckert, Paris
M. John Chapman, Paris
Geneviève Derumeaux, Lyon
Alain Gadeaux, Bordeaux
Michel Krempf, Nantes
Michel Lagarde, Lyon
Pierre Morange, Marseille
Agnes Sassolas, Lyon
Bart Staels, Lille
SCIENTIFIC PROGRAMME COMMITTEE
Petri Kovanen, Finland, Chair
Alberico Catapano, Italy
Matti Jauhiainen, Finland
Jan Kuivenhoven, Holland
Jesús Millán Núñez-Cortés, Spain
Børge Nordestgaard, Denmark
Marju Orho-Melander, Sweden
Gabriele Riccardi, Italy
Wolfgang Schneider, Austria
Bart Staels, France
Lale Tokgozoglu, Turkey
IV
CONGRESS COMMITTEE
Marja-Riitta Taskinen, Finland, Chair
Jan Borén, Sweden
Alberico L. Catapano, Italy
Olov Wiklund, Sweden
FACULTY LIST
Marcello Arca, Italy
Jean-Francois Arnal, France
Maurizio Averna, Italy
Christie Ballantyne, USA
Philip Barter, Australia
Christoph Binder, Austria
Dirk Blom, South Africa
Jacques Bonnet, France
Jan Borén, Sweden
Adrian J.B. Brady, UK
Eric Bruckert, France
Sebastiano Calandra, Italy
Giuseppina Caligiuri, France
François Cambien, France
M. John Chapman, France
Yiannis Chatzizisis, Greece
Xavier Collet, France
Claudio Cortese, France
Jean-Claude Coubard, Canada
Filippo Crea, Italy
Marina Cuchel, USA
Geesje Dallinga-Thie, The Netherlands
George Davey-Smith, UK
Menno De Winther, The Netherlands
John Deanfield, UK
Vincent Durlach, France
Michel Farnier, France
Steven Feinstein, USA
Edward Fisher, USA
Robert Gerszten, USA
François N. Gilly, France
Henry Ginsberg, USA
Andreas Habenicht, Germany
Marten Hofker, The Netherlands
G. Kees Hovingh, The Netherlands
Frank Hu, USA
Patricia Iozzo, Italy
Dimitris Kardassis, Greece
Sander Kersten, The Netherlands
George D. Kitas, UK
Wolfgang Koenig, Germany
Petri Kovanen, Finland
Michel Krempf, France
Jan Kuivenhoven, The Netherlands
Muriel Laffargue, France
Laurent Lagrost, France
Gilles Lambert, France
Eicke Latz, Germany
Gary Lewis, Canada
Peter Libby, USA
Jean-Baptiste Michel, France
John Millar, USA
Gilles Montalescot, France
Kathryn Moore, USA
Pierre Morange, France
Jan Nilsson, Sweden
Steven Nissen, USA
Danilo Norata, Italy
Vesa M. Olkkonen, Finland
Anders G. Olsson, Sweden
Marju Orho-Melander, Sweden
Chris Packard, UK
Klaus Parhofer, Germany
Terje Pedersen, Norway
Jogchum Plat, The Netherlands
Frederick Raal, South Africa
Željko Reiner, Croatia
Gabriele Riccardi, Italy
Angela Rivellese, Italy
Robert Ross, Canada
Yasushi Saito, Japan
Raul D. Santos, Brazil
Agnes Sassolas, France
Naveed Sattar, UK
Wolfgang Schneider, Austria
Catherine Shanahan, UK
Henrik Sillesen, USA
Bart Staels, France
Anton Stalenhoef, The Netherlands
Evan Stein, USA
Erik Stroes, The Netherlands
Marja-Riitta Taskinen, Finland
Maciej Tomaszewski, UK
Anne Tybjaerg-Hansen, Denmark
Luc Van Gaal, Belgium
Arie van Tol, The Netherlands
Arnold von Eckardstein, Switzerland
Michal Vrablík, Czech Republic
Qingbo Xu, UK
Laurent Yvan-Charvet, France
Rudolf Zechner, Austria
Andreas M. Zeiher, Germany
APPRECIATION AND THANKS
We would like to thank the reviewers of the submitted abstracts and the Young Investigator Award Jury for their valuable help and
assistance.
V
THE
EUROPEAN
ATHEROSCLEROSIS
SOCIETY
Advancing and exchanging knowledge of the causes, natural history, treatments and prevenƟon
of atheroscleroƟc disease.
EAS AcƟviƟes
EAS organizes educaƟonal acƟviƟes, including Advanced Courses and an annual Congress. Online educaƟonal
content will be available from the Society's E-learning resource, EAS Academy, starƟng summer 2013.
The Society is also acƟve in the development and publicaƟon of Guidelines and Consensus PosiƟon Papers on
atherosclerosis-related topics.
The Society’s journal, Atherosclerosis, brings together from diverse sources papers concerned with research
and invesƟgaƟon on atherosclerosis.
EAS also supports researchers and clinicians in the eld of atherosclerosis with various grants and awards.
EAS Members
•
•
•
•
•
•
•
have access to online educaƟonal material via the Society's E-learning plaƞorm, EAS Academy
receive complimentary online access to the EAS Journal Atherosclerosis
benet from reduced registraƟon fee at EAS Congress*, Workshops and Symposia
are eligible to apply for EAS Grants and Awards
are eligible to apply to aƩend EAS educaƟonal acƟviƟes, including Advanced Courses
receive 15% reducƟon on Elsevier books purchased via the EAS Website
receive regular scienƟc commentaries and newsleƩers with informaƟon on the Society’s acƟviƟes
* Payment of EAS annual membership subscripƟon means you are eligible for member-rate congress registraƟon fee for the
following year (i.e. members who have paid membership subscripƟon during 2013 are eligible for member-rate registraƟon
fee at EAS 2014 Madrid)
For futher details about the ac�vi�es of the Society, or to become a member, visit the EAS
website www.eas-society.org or contact us using email address offi[email protected]
VI
ACKNOWLEDGEMENTS
CORPORATE PARTNERS
The EAS Executive Committee would like to express its sincere appreciation to the following Corporate Partners for their continued
support of the goals and activities of the European Atherosclerosis Society
VII
ACKNOWLEDGEMENTS
The Organising Committee and the EAS Executive Committee would like to express their sincere appreciation to the following
organisations for their support in the 81st EAS Annual Congress.
PLATINUM SPONSORS
GOLD SPONSOR
SILVER SPONSOR
VIII
SPONSORS
Exhibitors
institutional support
IX
About Lyon
Lyon is France’s second-largest city and capital of the Rhône-Alpes region. Combining an exceptional historical heritage with a natural
liking for good food, Lyon is an ideal city for discovering all the charm of the French way of life.
A stage for more than 2000 years of history, the city has a remarkable architectural heritage. Expanding towards the east throughout
the centuries, while preserving the existing areas, 500 hectares of its city centre became a UNESCO World Heritage Site in 1998.
Wandering around Lyon is like embarking on a fascinating journey through time. In each district Lyon displays an astonishing variety
of architecture, from the roman theatres and the medieval district, via the elegant peninsula situated between the Rhône and the
Saône, to the contemporary and original creations by Renzo Piano, Jean Nouvel and Santiago Calatrava.
The city also has a strong academic profile with 120 000 students (12 500 from outside France) in 3 universities, and - with a rich
medical history from Rabelais, to Claude Bernard, Alexis Carrel, Marcel and Charles Merieux - was a cradle of pharmaceutical industry.
All year round at nightfall the city is lit up thanks to its “Lighting Plan” that shows off some 325 monuments. For night owls, the city
is teeming with festive, friendly places, with trendy bars from the Old Lyon to barge-restaurants moored on the banks of the Rhône,
not forgetting the wine bars on the peninsula.
Lyon has several famous museums, such as the Lumière Institute, on the invention of cinematography, and the Fabric Museum,
which traces two thousand years of the history of textile and silk weaving. Located in a wonderful Renaissance building, the Lyon
History Museum and the Puppets of the World Museum have formed the Gadagne Museums in Old Lyon since 2009. The Fine Arts
Museum is one of the largest museums in France - its collections, spread out over 70 rooms, giving visitors an exceptional journey
from Antiquity to Modern Art.
Lyon has been the ultimate gastronomic city for centuries, reputed around the world thanks to Chef Paul Bocuse. It now boasts more
than 2 000 restaurants, including the famous bouchons (typical local eateries) as well as Michelin star-awarded establishments. From
traditional Mères Lyonnaises (19th century cooks for the bourgeoisie) to inspired and innovative young chefs, Lyon is a place for
culinary experimentation with new tastes and concepts to be savoured.
The city was the first to establish a public bicycle-rental system, and has more than 350 stations with 2500 bicycles available, offering
visitors the opportunity to explore by bike the parks beside the river banks and to visit new districts such as the confluences.
The EAS Congress venue is situated downtown, within walking distance from several congress hotels and 10-20 minutes from others by
public transportation system. Easy to get to, and easy to get about, its various resources and charms at the cross-road of influences from
south and north of Europe makes Lyon an ideal venue for the EAS. Your visit to EAS2013 will be both an exciting scientific experience
and a memorable taste of French culture.
X
THE ANITSCHKOW PRIZE
THE ANITSCHKOW PRIZE IN ATHEROSCLEROSIS RESEARCH, 2013
Professor Peter Libby
Mallinckrodt Professor of Medicine at Harvard Medical
School and Chief of the Cardiovascular Division at Brigham
and Women’s Hospital, Boston, Massachusetts, USA
The EAS is delighted to announce that the recipient of the Society’s prestigious Anitschkow Prize
2013 is Professor Peter Libby, Mallinckrodt Professor of Medicine at Harvard Medical School and
Chief of the Cardiovascular Division at Brigham and Women’s Hospital, Boston, Massachusetts.
Professor Libby will give the Anitschkow Lecture as part of the Congress Opening Ceremony
Sunday June 02, 2013, 18:00.
Over the past three decades Prof. Libby has made numerous major discoveries that have changed
the way we think about the etiology and potential management of atherosclerotic cardiovascular
disease. Prof. Libby’s seminal experimental and translational observations on the pathophysiological
pathways leading to plaque formation and destabilization have affected our current knowledge
of atherosclerosis with far reaching clinical implications. His work will pave the way for new
strategies designed to prevent the onset and progression of atherosclerosis in those who do not
yet have manifest cardiovascular disease.
Prof. Libby has been a role model, gifted teacher and mentor for a generation of emerging
clinical and basic cardiovascular researchers who have been inspired by his ability to translate
basic research into clinical setting. This attribute has greatly magnified his contribution to the
understanding of atherosclerosis.
XI
YOUNG INVESTIGATOR AWARDS
These annual awards are presented by the EAS for outstanding publications by young scientists
in the field of atherosclerosis.
Department of Cardiovascular Sciences, University of Leicester,
Clinical Sciences Wing, Glenfield General Hospital, Leicester, UK.
For his publication Inheritance of coronary artery disease in men: an analysis of the role of the
Y chromosome, the LANCET, 2012; 379: 915–22. Fadi J Charchar, Lisa D S Bloomer, Timothy
A Barnes, Mark J Cowley, Christopher P Nelson, Yanzhong Wang, Matthew Denniff, Radoslaw
Debiec, Paraskevi Christofi dou, Scott Nankervis, Anna F Dominiczak, Ahmed Bani-Mustafa,
Anthony J Balmforth, Alistair S Hall, Jeanette Erdmann, Francois Cambien, Panos Deloukas,
Christian Hengstenberg, Chris Packard, Heribert Schunkert, Willem H Ouwehand, Ian Ford, Alison
H Goodall, Mark A Jobling, Nilesh J Samani, Maciej Tomaszewski.
Dr Tomaszewski is a specialist in internal medicine. He holds a senior clinical lectureship in cardiovascular medicine in the Department
of Clinical Sciences, University of Leicester. He is also a consultant physician in University Hospitals of Leicester NHS Trust. He chairs
New Investigators Committee of the International Society of Hypertension. His main research interests focus on genomics and
genetics of cardiovascular disease with a particular emphasis on the role of sex chromosomes.
Department of Molecular Medicine, Research Center C3M, UMR
INSERM U1065/UNS, Nice, France.
For his publication Cholesterol efflux and atheroprotection: advancing the concept of reverse
cholesterol transport, Cell Stem Cell 2012; Vol 11, Nr.2, p. 195-206. Marit Westerterp, Samuel
Gourion-Arsiquaud, Andrew J Murphy, Alan Shih, Serge Cremers, Ross L Levine, Alan R Tall and
Laurent Yvan-Charvet.
Dr. Laurent Yvan-Charvet obtained his Ph.D. in Endocrinology in 2005 from the University of
Paris XI, France. His research work at Columbia University has been mainly focused on how regulation of inflammation and stem
cell biology by cholesterol efflux pathways affect cardiovascular diseases. He was the recipient of the Roger Davis Award in 2010
and finalist of the I.H. Page Young Investigator Award in 2011. After a contribution to the development of new therapeutics for
cardiovascular diseases at Pfizer, his current research interest as a group leader lies in hematopoietic cell metabolism – a new area of
research for cardiovascular diseases.
XII
GENERAL INFORMATION
Venue
Cyber Center
LYON Congress centre
50 Quai Charles de Gaulle 69463 Lyon cedex 06
Tel. no. 33(0) 4 72 82 26 26
Website: www.ccc-lyon.com
A Cyber Centre will be available for participants’ use in the
exhibition area during exhibition hours.
Dialing Codes & Important Telephone
Numbers
The International dialing code for France is +33
The Lyon area code is +04
Emergency numbers are as follows:
Police - 17; Fire brigade - 18; Medical emergency – 15 or CCC
security 04 72 82 27 67 (direct access for medical assistance)
Registration / Information /
Secretariat Desk
The Registration Desk will be situated at the Congress Centre
for the duration of the congress and will be open as follows:
Opening Hours
Sunday, June 2, 11:00 – 20:30
Monday, June 3, 7:30 – 18:30
Tuesday, June 4, 7:30 – 19:00
Wednesday, June 5, 7:30 – 13:00
Badges
On registering you will receive your name badge. You are kindly
requested to wear your badge during all congress sessions and
events.
Exhibition Hours
Sunday, June 2, 17:30 – End of Welcome Reception
Monday, June 3, 10:00 – 17:00
Tuesday, June 4, 10:00 – 17:00
Food & Beverage
Abstract Book
The congress abstracts will be published in an online Abstract
Book available on the website. If you would like to print any of
the abstracts while at the congress, please look for the printing
stations in the exhibition area.
Certificate of Attendance
The Certificate of Attendance may be printed from one of the
automatic registration areas from Tuesday, June 4, 2013.
EBAC CME Accreditation
The 81st EAS Congress is accredited by the European Board
for Accreditation in Cardiology (EBAC) for18 hours of External
CME credits - Up to 3 hours per half-day and up to 6 hours per
full day.
Each participant should claim only those hours of
credit that have actually been spent in the educational
activity. EBAC works according to the quality standards of the
European Accreditation Council for Continuing Medical Education
(EACCME), which is an institution of the European Union of
Medical Specialists (UEMS).
Participants are kindly requested to scan their badges when they
enter and leave the congress area.
Banking & Exchange
The official currency is the Euro. Foreign currency may be
changed at banks during normal banking hours, at hotels, at
airports and in exchange offices. All major credit cards are
acceptable in most hotels, restaurants and shops.
Mail, Messages, Medical Assistance,
Lost & Found
Please approach the Registration Desk.
We wish to thank
for providing their products during
the Tuesday, June 4 morning coffee break.
XIII
Language
Press Room hours
English is the official language of the Congress. All presentations
will be made in English.
Sunday, June 2, 11:00 – 20:30
Monday, June 3, 7:30 – 18:30
Tuesday, June 4, 7:30 – 19:00
Clothing
Clothing is informal for all occasions.
Mobile Phones
Please note that mobile phones must be switched off during all
sessions.
Sessions
Please make sure to be in session halls on time as all sessions
will begin as per schedule.
Smoking Policy
Smoking is prohibited at all times in the meeting halls, exhibit
halls and restrooms.
Your compliance is appreciated.
Liability and Insurance
The Congress Secretariat and Organisers cannot accept liability
for personal accidents or loss of or damage to private property
of participants and accompanying persons. Participants are
advised to take out their own personal travel and health
insurance for their trip.
A selection of sessions will be webcast and will be available on
the Society website after the congress.
Paperless Scientific Programme on
smartphones and Tablets
The paperless application is designed for cross platform
access via laptop and mobile devices such as Smartphone,
iPad, Android etc. This innovative and intuitive app gives the
participant the power to choose and plan and, therefore,
maximize his or her time at the congress. Access to the
application is via http://eas.ekonnect.co
Participants will have full access to the scientific programme
and the abstracts. The application has smart search possibilities
within the scientific programme by session type and faculty.
TRANSPORTATION
The public transportation pass, available at the congress center,
gives access to any subway, tram, cable car and bus line for the
4 Congress days, Sunday to Wednesday.
Safety and Security
Congress Organisers
Please do not leave bags or suitcases unattended at any time,
whether inside or outside session halls.
Hotels strongly recommend that you use their safety deposit
boxes for your valuables.
The 81st EAS Congress
Press Room
A press lounge with internet access including Wi-Fi is freely
available to registered journalists. Journalists must register at
the Registration Desk. Upon registration the journalists will
receive a press kit including the detailed press briefing schedule.
Press releases will be available to the journalists in association
to the press briefings in the Press Briefing Room.
XIV
Webcast
1-3, rue du Chantepoulet; P.O. Box 1726
CH-1211 Geneva 1, Switzerland
Tel: +41 22 908 0488
Fax: +41 22 906 9140
E-Mail: [email protected]
Mandatory Conflict of Interest Disclosure
EAS wishes to promote independence, objectivity, scientific rigor and a fair balance of representation, and has adopted a Conflict of
Interest (COI) Disclosure Policy for this purpose.
Persons taking part in the Society’s Congress are therefore expected to disclose their financial or in-kind relationships both with
health industry that develop, manufacture, distribute or sell health care materials or services, or other organizations that could
represent a potential COI. Such relationships exclude personal or family medical care. Full disclosure is expected even when it is not
clear whether a relationship or affiliation constitutes a conflicting interest.
EAS recognizes that these relationships do not necessarily imply bias or decrease the value of participation.
Please note that it is mandatory for all Congress participants to include in their presentation a statement either to disclose any
potential or direct conflict of interest, or, alternatively, to state that they have no conflict of interest.
» For oral presentations: your conflict of interest disclosure statement should be at the beginning of your presentation (i.e., first
or second slide to be the disclosure statement slide)
» For poster presentations: your conflict of interest disclosure statement should be included at the bottom of your poster
Even if you have no conflict of interest to declare, your presentation must include the statement
“I have no potential conflicts of interest to report”
Please note that this policy will be strictly enforced – presentation at EAS 2013 Lyon will only be permitted if
your slides or poster contain a Conflict of Interest disclosure statement.
XV
INSTRUCTIONS FOR PRESENTERS
Speakers’ Ready Room
A Speakers’ Ready Room will be available every day throughout the Congress for speakers.
If using a PowerPoint (or any other computer) presentation, please note you need to bring it on a CD, a DVD or on a “disk on key”
memory stick (using the USB port in the computer) and load it on one of the congress’ computers in the Speakers’ Ready Room, at
least 1 hour before the start of the session. You may supply your own laptop computer as a back-up.
If combining video films with PowerPoint, please make sure to check it in the session hall where your lecture is taking place during a
coffee or lunch break prior to your session, at least 30 minutes before the start of the session - even after checking it in the Speakers’
Ready Room.
Please note that the Congress’ computers in the session halls are being supplied with Windows and Office 2007.
Important note For Macintosh users
In order to use MAC presentations on a PC compatible computer please note that you need to prepare it according to the instructions
below, before bringing it to the Speakers’ Ready Room.
» Use a common font, such as Arial, Times New Roman, Verdana, etc. (special fonts might be changed to a default font on a
PowerPoint based PC).
» Insert pictures as JPG files (and not TIF, PNG or PICT - these images will not be visible on a PowerPoint based PC).
» Use a common movie format, such as AVI, MPG and WMV (MOV files from QuickTime will not be visible on a PowerPoint based PC).
You may use your own Macintosh laptop computer as a back-up. In such a case, please confirm that it has a VGA socket for external
signal and come to check it first in the Speakers’ Ready Room as soon as you arrive and later on in the session hall where your lecture is
taking place during the coffee or lunch break prior to your session, at least 30 minutes before the start of the session. Please note that
VHS Video projection, 35 mm’ slide projection and Overhead projection (projection of transparencies) will not be available.
INSTRUCTIONS FOR POSTER PRESENTERS
Posters will be on display for the entire congress. Please check the Scientific Programme to see the exact poster board number, date,
and time of the poster discussion groups. Posters may be mounted from Sunday, June 2 from 15:30.
Presenters are requested to stand next to their posters during the lunchtimes on
» Monday June 3 from 12:40 - 14:45 and
» Tuesday, June 4 from 12:40 - 14:45.
The organisers are not responsible for any posters that have not been removed by the end of sessions on Wednesday, June 5.
MODERATED POSTER PRESENTATIONS
EAS is proud to have moderated poster sessions that will be located in the Exhibition area, providing the unique opportunity for
convivial scientific discussions and exchange. For further details please refer to the Overview of Moderated Poster Sessions on the
following page.
XVI
OVERVIEW OF MODERATED POSTER SESSIONS
Session
Topic
Moderator
Poster Number
Moderated Session A: Monday, June 3, 13:40 – 14:40
1
Endothelium and atherothrombosis
T1: M1-M8
2
Regulation of cellular lipid metabolism in atherogenesis
Bart Staels, France
T2: M59-M66
3
Role of lipases in lipid and lipoprotein metabolism
Geesje Dallinga-Thie,
Netherlands
T2: M67-M74
4
Evaluation and treatment of cardiovascular risk factors in the young and the
elderly
T3: M117-M125
5
Inflammation and HDL
T2: M75-M81
6
Thrombosis and hemostasis: relation to atherothrombosis and lipoproteins
Pierre Morange, France
T1: M9-M14
7
Fatty acids influence atherosclerosis and its risk factors: the double bonds decide
Michel Lagarde, France
T3: M126-M130
8
Insulin-resistant states: modulators of lipid metabolism and cardiovascular disease
T3: M131-M139
Moderated Session B: Tuesday, June 4, 12:40 – 13:40
9
Cell dysfunctions in atherogenesis
Catherine Shanahan, UK
T1: M15-M22
10
Angiogenesis
Jan Nilsson, Sweden
T1: M23-M30
11
Lifestyle
T3: M140-M148
12
CV risk factors 1
Jacques Bonnet, France
T3: M149-M157
13
Atherosclerosis-regulating factors in mouse and man 2
T1: M31-M38
14
Multiple roles of HDL and its transporters in atherosclerosis and related diseases
Arie van Tol, Netherlands
T2: M82-M89
15
Novel insights into the role of micronutrients in cardiovascular risk and disease
T3: M158-M164
16
Treatment of dyslipidemia: from guidelines to goals and mechanisms
Anders G. Olsson, Sweden
T2: M90-M99
17
Imaging of the arterial wall as a diagnostic and prognostic indicator of
atherosclerotic disease
T3: M165-M171
Moderated Session C: Tuesday, June 4, 13:40 – 14:40
18
Immunity and atherosclerosis
Menno De Winther,
Netherlands
T1: M39-M44
19
Metabolic regulation of apoliprotein A-I-containing lipoproteins
T2: M100-M106
20
Cardiovascular disease and its prevention in patients with chronic inflammatory
and chronic renal disease
Naveed Sattar, UK
T3: M172-M181
21
Primary dyslipidemia
T2: M107-M116
22
Inflammation and infection in experimental and clinical atherosclerosis
Giuseppina Caligiuri, Italy
T1: M45-M53
23
Regulation of ischemia reperfusion injury
Jean-Francois Arnal, France
T1: M54-M58
24
Exercise and cardiovascular health: both quantity and quality count
T3: M182-M187
CV risk fators 2
Anne Tybjaerg-Hansen,
Denmark
T3: M188-M195
25
ACKNOWLEDGEMENT OF POSTER MODERATORS
EAS is indebted to the distinguished scientists and clinicians who have kindly accepted the role of moderator during the Moderated
Poster Sessions at the Congress.
XVII
POSTER OVERVIEW
Posters will be on display from Monday June 3 – Wednesday June 5.
Poster presenters are requested to stand by their posters during lunch breaks
Track 1:
VASCULAR BIOLOGY OF THE
ARTERIAL WALL
Topic
Track 2:
LIPID AND LIPOPROTEIN METABOLISM:
FROM ALTERATIONS TO TREATMENTS
Poster Board
Numbers
1-134
Endothelial cells and function
1-20
Endothelial dysfunction clinical assessment
21-29
Smooth muscle cells
30-44
Extracellular matrix and calcification
45-67
Gene expression
68-74
Infection and atherosclerosis
75-82
Inflammation
83-103
Innate immunity
104-120
Adaptive immunity
121-128
Hormones and atherosclerosis
129-134
Topic
Sub-topic
apoB-Containing
lipoproteins
Modified lipoproteins
135-137
apoB-Containing
lipoproteins
Lp(a)
138-140
HDL
CETP
141-145
HDL
Cholesterol efflux
146-152
HDL
Function and metabolism
153-164
HDL
apoA1 functions
165-168
Intracellular metabolism
169-177
Lipases and lipoprotein
metabolism
178-183
Lp-PLA2
184-195
Biomarkers
Lipid metabolism
196-199
Dyslipidaemia:
epidemiology,
biomarkers
HDL
200-205
Dyslipidaemia:
epidemiology,
biomarkers
206-227
Familial
hypercholesterolaemia
229-246
Primary dyslipidaemia
247-255
Secondary dyslipidaemia
XVIII
Poster Board
Numbers
135-330
256-262
Genetics
HDL metabolism
263-266
Genetics
Lipid metabolism
267-282
Lipid-lowering therapy
Ezetimibe
283-290
Miscellaneous
291-296
Nicotinic acid
297-299
PCSK9
300-304
Statins
305-330
Track 3:
RISK FACTORS, EPIDEMIOLOGY, PREVENTION, AND TREATMENT OF
CARDIOVASCULAR DISEASES
Topic
Sub-topic
Poster Board
Numbers
331-684
Topic
Sub-topic
Poster Board
Numbers
331-684
Lifestyle and CV risk
Miscellaneous
578-580
Tobacco
581-584
Therapeutic
education
585-588
Cardiovascular epidemiology
331-351
Woman and cardiovascular
risk
352-356
Biomarkers
357-370
Functional assessment of
arterial wall
371-383
Psychosocial
factors
589-591
Nutrition and CV risk
Alcohol
592-593
Antioxidants
594-597
Carbohydrates/
fibres
598-600
Imaging
IMTc
384-387
Imaging
Calcifications
assessment
388-396
Imaging
Miscellaneous
397-402
Imaging
Vulnerability
403-408
Fatty acids
601-605
Genetics
409-426
Miscellaneous
606-619
Obesity and fat distribution
427-445
Omega-3 fatty acids
Metabolic syndrome
446-467
Phytosterols
NASH and related disorders
468-480
Treatment
Miscellaneous
635-647
Treatment
Blood pressure
treatment
648-653
Sub inflammatory states
481-494
620-631
632-634
Diabetes macroangiopathy
Dyslipidaemia
495-499
Treatment
500-507
Intravascular procedures
654-660
508-523
Miscellaneous
665-700
Nephropathy
524-536
Phytosterols
634-636
Thrombosis
537-551
Aneurysms
Miscellaneous
Arteriopathy
Exercise
Treatment
Miscellaneous
637-649
552-554
Treatment
Blood pressure
treatment
650-655
555-561
656-622
562-577
Miscellaneous
633-684
Please note that posters of Abstract Presenters that were not registered to the Congress by the deadline, were not allocated poster
boards. Such Abstract Presenters are requested to approach the Poster Helpdesk to receive an available poster board onsite.
XIX
EDUCATIONAL SYMPOSIA AND SPECIAL SESSIONS
SUNDAY, JUNE 2, 2013
13:30-15:00 - EBAC ACCREDITED EDUCATIONAL PROGRAMME - Claude Bernard Hall
Supported by an unrestricted educational grant from AstraZeneca
ADVANCES IN THE UNDERSTANDING OF CARDIOVASCULAR DISEASE AND DYSLIPIDAEMIA IN DIABETES
Programme created in collaboration with Sahlgrenska Academy, University of Gothenburg
See page 1 of the Scientific Programme
14:15-15:00 - Special Lecture - Marcel Mérieux Hall
HYPERCHOLESTEROLEMIA – WHAT CAN WE DO FOR HIGH-RISK PATIENTS?
Sponsored by Amgen
15:15-16:00 - Special Lecture - Michel Macheboeuf Hall
CETP INHIBITION: WHAT’S NEW?
Sponsored by Merck
16:20-17:50 - Educational Symposium - Michel Macheboeuf Hall
NEW STRATEGIES FOR THE MANAGEMENT OF PATIENTS WITH HoFH
Sponsored by Aegerion
XX
MONDAY, JUNE 3, 2013
13.00–14.30 - Educational Programme - Claude Bernard Hall
CLINICAL ADVANCES IN DIFFICULT-TO-TREAT PATIENTS WITH HYPERCHOLESTEROLEMIA
Sponsored by Sanofi/Regeneron & Genzyme
17.00–18.30 - Educational Symposium – Anitschkow Hall
ON THE FOREFRONT OF CHOLESTEROL MANAGEMENT: CLINICAL CONSIDERATIONS AND PRACTICAL
APPROACHES BEYOND STATINS
Sponsored by MSD
17.00–17.45 - KOWA Special Lecture - Claude Bernard Hall
NORMALISING DYSLIPIDEMIA AND REVERSING ATHEROSCLEROSIS IN CARDIO-METABOLIC DISEASE
Sponsored by KOWA
17.00–17.45 - Special Lecture - Michel Macheboeuf Hall
THE ROLE OF PLANT STANOLS/STEROLS IN THE MANAGEMENT OF DYSLIPIDAEMIAS
Sponsored by BASF, Danone, Raisio, Unilever
XXI
TUESDAY, JUNE 4, 2013
13:00–14:30 - Educational Symposium – Anitschkow Hall
CONTEXT AND FUTURE CHALLENGES IN THE EFFECTIVE MANAGEMENT OF DYSLIPIDAEMIA
Sponsored by Roche
15:40–16:40 - Meet the Expert - Michel Macheboeuf Hall
CLINICAL EXPERIENCE OF LOMITAPIDE THERAPY IN PATIENTS WITH HoFH DURING CLINICAL TRIALS
Sponsored by Aegerion
17:00–19:00 - Reviewer & Author Workshop - Meeting room “Rene Leriche”
Sponsored by Elsevier
XXII
Opening Ceremony
SUNDAY
JUNE 2, 2013, 18:00
N.N. Anitschkow Hall
WELCOME FROM THE EAS PRESIDENT
WELCOME FROM THE PRESIDENT OF THE CLAUDE BERNARD LYON UNIVERSITY
François Noel Gilly, France
WELCOME FROM THE NFSA PRESIDENT
IAS AND EAS WORKING TOGETHER
Philip Barter, IAS President, Australia
WELCOME FROM THE CONGRESS CHAIRPERSON
Choir Resonance IUFM de Lyon, Conductor: Jean Duvillard
Magnificat (John Rutter)
INTRODUCTION OF THE ANITSCHKOW PRIZE WINNER
THE ANITSCHKOW LECTURE
Peter Libby, USA
Choir Resonance IUFM de Lyon, Conductor: Jean Duvillard
Les Djinns (Victor Hugo – Gabriel Fauré)
Followed by a Wine and Cheese Welcome Reception
Choir Resonance IUFM de Lyon, Conductor: Dany Landry
Carmina Burana (Carl Orff)
XXIII
SOCIAL EVENTS PROGRAMME
SUNDAY, JUNE 2 2013
OPENING CEREMONY FOLLOWED BY A WINE AND CHEESE WELCOME RECEPTION
Guests will enjoy glorious choir music in the opening ceremony followed by a Wine and Cheese Welcome Reception in the exhibition
area at the congress centre.
For non-registered participants €15
MONDAY, JUNE 3 2013
FACULTY DINNER (for invitees only)
This event is exclusive to Invited Speakers
Time: 20:00
Pick-up from Hilton Hotel: 19:30
TUESDAY, JUNE 4 2013
EAS INTERNATIONAL EVENING (ticket required)
A ‘not to be missed’ networking evening will be held in at Lyon’s imposing City Hall.
This magnificent building, with its tall clock tower and blue-domed pavilions, is an excellent example of the French tradition of
dignified government buildings.
The event is catered by JP Pignol who was named “meilleur ouvrier de France” (MOF Best Chef of France in 1979)
Tickets can be purchased at the Registration Desk (Limited Availability)
Time: 20:00
Ticket Price: €35 and €25 for students.
XXIV
HALL NAME EULOGY OF DISTINGUISHED SCIENTISTS
Nikolai N. Anitschkow (1885-1964)
Professor of the Department of Pathological Physiology of the Military Medical Academy
St. Petersburg, Russia
In 1913, experimental pathologist Dr. Nikolai N. Anitschkow showed that simply feeding to rabbits purified cholesterol dissolved in
sunflower oil induced vascular lesions closely resembling those of human atherosclerosis, both grossly and microscopically. Controls
fed with only the sunflower oil showed no lesions. It is fair to say that this paper marked the beginning of the modern era of atherosclerosis research. Dr. Anitschkow was not only a keen-eyed structural pathologist and a careful experimentalist; he thought in terms
of function and time-related pathogenesis.
However, the landmark studies by Dr. Anitschkow were largely rejected at the time. An important reason for this was that the
findings were inconsistent with the prevailing view of atherosclerosis. It was generally accepted to be an inevitable accompaniment
of aging (the “senescence hypothesis”). If the full significance of his findings had been appreciated at the time, we might have saved
more than 30 years in the long struggle to settle the cholesterol controversy.
In honor of Dr. Nikolai N. Anitschkow, the “Anitschkow Prize in Atherosclerosis Research” awarded annually by the EAS recognizes
outstanding research in the field of atherosclerosis and linked metabolic disturbances.
XXV
Claude Bernard (1813-1878)
Physiologist. Born: 1813, Saint-Julien near Lyon. Died: 1878, Paris
By the age of 21, Bernard had already written several plays and set off to Paris, France, to show them around. He entered the
Faculty of Medicine, obtaining a medical degree in 1843. He became an assistant to François Magendie, one of France’s most
prominent--and controversial--physiologists.
In 1855, when Magendie died, Bernard took his place as Professor of Experimental Medicine at the College de France. Bernard, who
tended to be more disciplined and organized than Magendie had been, began attracting more and more scientific attention to the
comparatively new discipline.
Bernard found that the stomach was not the sole digestive organ: while the stomach began the digestive process, much more digestion took place throughout the small intestine. He also demonstrated the importance of the pancreas, whose secretions were clearly
necessary to break down fat molecules, and later went on to identify the various nerves that control gastric secretion. In 1857,
Bernard isolated glycogen in the liver of animals and evidenced that it served as the body’s reserve supply of carbohydrates.
In 1851, he discovered that certain specific nerves governed the dilation and constriction of blood vessels. He theorized that, by doing
so, the body was better able to control its distribution of heat. While studying the vasomotor system, Bernard also discovered that
the blood’s red corpuscles carry oxygen from the lungs to body tissues. He therefore concluded that the body must be under the
control of one strong and central regulating force. Bernard’s theory, although widely accepted today, appeared quite radical in his
own time, when most scientists believed that the body’s various organs acted quite independently of each other.
In 1865, Bernard published the highly influential textbook, An Introduction to the Study of Experimental Medicine, which won him
election to the prestigious French Academy in 1869. He even served in the French senate under Napoleon III (1808-1873) and, when
he died in 1878, Bernard became the first scientist to be given a national funeral.
XXVI
Marcel Mérieux (1870-1937)
Biochemist. Born: 1870 Terrenoire near Lyon. Died: 1937.
In 1894 Marcel Mérieux became the personal assistant of Émile Roux at the Pasteur Institute of Paris. As a student of Louis Pasteur
he worked on the bacillus Yersinia pestis and on asepsis. He founded a private laboratory in order to produce an anti-streptococcic
serum used against puerperal fever in Lyon. This laboratory would become Institut Mérieux, today part of Sanofi Pasteur. He set up a
private research lab.
In 1937, his son, Dr. Charles Mérieux, took up the reins of his father’s laboratory. In the 1940’s, Charles Mérieux introduced a
technique developed by the Dutch Professor Frenkel - in vitro culture – which revolutionized the manufacture of vaccines and led to
the production of reagents for in vitro diagnostic testing. In 1963, his grandson Alain Mérieux, established the diagnostics company,
bioMérieux. Today it is part of the Institut Mérieux, whose companies work in the area of diagnostics, immunotherapy, food safety
and nutrition.
Michel Macheboeuf (1900-1953)
Head of laboratory at Pasteur Institute, Paris (1929). Professor of Biochemistry at Lille
University, then Bordeaux University (1936-1942). Head of department of biochemistry at
Pasteur Institute, Paris (1942-1954).
Born: 1900, Châtel-Guyon (Puy-de-Dome). Died: 1953, Paris.
In 1929, Michel Macheboeuf, working at the Pasteur Institute in Paris, reported the isolation from horse serum of a stable, watersoluble lipoprotein that could be precipitated from a neutral 50% saturated ammonium sulfate extract of serum by lowering the pH
to 3.8. This lipoprotein contained 59% protein and 41% lipid, which consisted of 18% cholesterol and 23% phospholipid and could
be redissolved in water to form a clear solution. Later on it was shown that this lipoprotein was an α-globulin and had the same
composition as the α-lipoprotein that we now recognize as HDL.
Adapted from: Olsson R, J. Nutr. February 1, 1998 vol. 128 no. 2 439S-443S
Macheboeuf M., Recherches sur les phosphoaminolipides et les steroids du serum et du plasma sanguins. II Etude physiochimique de
la fraction proteidique la plus riche en phospholipids et in sterides. Bull. Soc. Chim. Biol.,1929; 11:485–503
XXVII
René Leriche (1879-1955)
Surgeon. Born: 1879, Roanne, Loire. Died: 1955, Cassis, near Marseille.
Leriche began his career in Lyon. In 1924 he was appointed Professor of Surgery at the University of Strasbourg. In 1927 he was
made an honorary Fellow of the Royal College of Surgeons of England. He was the first surgeon to be made Professeur au Collège de
France.
Leriche was a technically gifted surgeon and had flair for teaching. He emphasized the importance of regarding the patient as a whole
- the holistic approach. He was a flamboyant character who enjoyed French cuisine and fine wine. He had a fine collection of art - one
of his patients was Matisse. He was also an excellent public speaker who never needed notes.
Leriche gave his name to two syndromes:
Leriche’s syndrome - Impotence and buttock claudication and absent pulses in the groin and legs due to saddle embolus or
atherosclerosis at the aortic bifurcation.
Sudek-Leriche syndrome - Aseptic necrosis of bone following injury (also known as Sudek atrophy)
He devised a surgical procedure, the sympathectomy, to increase blood flow within arteries.
Leriche was awarded the Lister Medal in 1939 for his contributions to surgical science.
Adapted from: Wikipedia
XXVIII
VENUE FLOOR PLANS
XXIX
EXHIBITION FLOOR PLAN
@
16
17
06
14 05
12 13 07
09 08
11
10
TO POSTER
AREA
04
02A
03
01
ENTRANCE
ENTRANCE
EXHIBITION LIST
Company
Aegerion
XXX
Booth #
5
Amgen
14
B. Braun Avitum AG
2A
Denka Seiken
8
DIADEXUS Inc
12
European Atherosclerosis Society
7
Fresenius Medical Care
9
Itamar Medical Ltd
17
Merck
3
Mercodia
16
NSFA
11
Randox Cardiology
1
Sanofi/Regeneron/Genzyme
4
Synageva Biopharma
10
Wisepress Medical Bookshop
6
SPONSOR AND EXHIBITOR PROFILES
Aegerion Pharmaceuticals, Inc.
101 Main Street - Suite 1850
Cambridge, MA 02142
USA
www.aegerion.com
Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of novel life-altering
therapies for patients with debilitating, often fatal, rare diseases. Founded in 2005, our emerging global organization is based in
Cambridge, Massachusetts with an established presence in Europe, and is growing internationally. In 2013, we successfully launched
in the US our first product, Juxtapid™ (lomitapide) as an adjunct to a low fat diet and other lipid lowering treatments, including
apheresis, for patients with homozygous familial hypercholesterolemia (HoFH). Lomitapide is currently in review by the European
Medicines Agency (EMA).
The company’s mission statement is:
To develop therapeutic compounds on behalf of people with serious diseases using the highest ethical standards with demonstrated
patient benefits.
Aegerion is motivated by its commitment to patients first. We are also attentive to our core values of integrity, innovation, responsibility to healthcare providers, development of employees and always – scientific excellence.
Amgen (Europe) GmbH
Dammstrasse 23
6301 Zug
Switzerland
www.amgen.com
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen
was one of the first companies to realise the new science’s promise by bringing safe, effective medicines from lab to manufacturing
plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight
against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of
potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives. To learn more about
our pioneering science and vital medicines, visit www.amgen.com. Follow us on twitter at www.twitter.com/amgen.
AstraZeneca
SE-431 83 Mölndal
Sweden
www.astrazeneca.com
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune,
oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by
millions of patients worldwide.
XXXI
BASF
BASF’s Nutrition & Health division develops, produces and markets a comprehensive range of products and services for the human
and animal nutrition, pharmaceutical as well as flavor and fragrance industries. The division strives to contribute to a better life
through improving the nutrition, health and wellbeing of people across the world. Important human nutrition products are vitamins
and carotenoids, plant sterols, emulsifiers and omega-3 fatty acids. Its feed additives such as vitamins, carotenoids, enzymes and
organic acids make Nutrition & Health a worldwide leader for the animal nutrition market. The division provides the pharmaceutical
industry with active ingredients such as caffeine and ibuprofen, as well as excipients and custom synthesis services. Furthermore, it
produces aroma ingredients such as citral, geraniol and L-menthol for the flavor and fragrance industry.
B. Braun Avitum AG
Schwarzenberger Weg 73-79
34212 Melsungen
Germany
www.bbraun.com
B. Braun is one of the world´s leading healthcare suppliers. Our four divisions orient their products and services toward different
medical fields: hospital, surgery, private practice (medical care and doctors´ offices) and extracorporeal blood treatment. The B.
Braun Avitum Division concentrates on therapy systems for hemodialysis, acute dialysis and apheresis and is one of the largest
systems providers in the field of extracorporeal blood treatment worldwide. The competency held herein extends from high-grade
equipment and disposables to an international network of dialysis centers. As a full-range systems provider B. Braun Avitum works as
an interface, linking theory to practice.
DANONE
17 Boulevard Haussmann
75009 Paris cedex
France
www.danone.com
DANONE is one of the largest healthy food companies worldwide with 4 expertise areas in dairy products, bottled waters, baby and
medical nutrition. Its mission is to bring health through food to as many people as possible at all the ages of the life, in more than
120 countries.
DANONE and its 100,000 employees are entirely focused on this mission and R&D budget is dedicated to projects associated with
nutrition and health.
Its major research centres, Palaiseau (France) and Wageningen (Netherlands) have established more than 200 external scientific
partnerships, to develop products with relevant, scientifically proven health benefits.
XXXII
DENKA SEIKEN CO.,LTD.
Nihonbashi Mitsui Tower
2-1-1, Nihonbashi-Muromachi
Chuo-ku, Tokyo 103-8338
Japan
www.denka-seiken.co.jp
Denka Seiken manufactures clinical chemistry and latex-enhanced serum protein reagents for automated chemistry analyzers such as
CRP, Lp(a), Myoglobin, HDL-C, LDL-C, etc. Denka Seiken currently features a reagent that can quantitatively determines small, dense
low-density lipoproteins (small, dense LDL). The s LDL-EX “SEIKEN” is a homogeneous assay consisting of two ready-to-use liquid
reagents to be used on automated chemistry analyzers. The test is fully automated and has within-run precisions of 1 – 2 %. Test
result is available in 10 minutes. The assay methodology correlates well with the traditional ultracentrifugation method.
diaDexus, Inc.
349 Oyster Point Blvd
South San Francisco, CA 94080
USA
www.diadexus.com
diaDexus, Inc., is a biotechnology company focused on the development and commercialization of novel in vitro diagnostic tests
for cardiovascular disease. The PLAC Test for Lp-PLA2 (lipoprotein-associated phospholipase A2) is a blood test that measures the
enzyme activity of Lp-PLA2. Lp-PLA2 is a vascular-specific inflammatory enzyme implicated in the formation of rupture-prone plaque.
Plaque rupture and thrombosis cause the majority of cardiac events. The PLAC Test helps to identify the patients with hidden CVD
risk independent from traditional risk factors. Visit www.plactest.com for more information.
European Atherosclerosis Society
Kronhusgatan 11
Gothenburg 411 05
Sweden
www.eas-society.org
The Society’s goal is to provide a framework for concerted scientific and clinical discussion of new developments in basic research,
diagnosis and therapy of atherosclerosis.
EAS is active in the publication of Guidelines and Consensus Position Papers, and its official Journal is Atherosclerosis. The Society
organizes an annual Congress for approximately 2000 delegates, and runs a programme of Advanced Courses for both basic scientists
and clinicians.
Our website, www.eas-society.org, contains information on activities involving the Society and its members, and online educational
material, including webcasts recorded both at Congress and Advanced Courses, Featured Commentaries, and a newsfeed direct from
theheart.org.
XXXIII
Fresenius Medical Care Deutschland GmbH
Else-Kröner-Str. 1
Bad Homburg v.d.H., 61352
Germany
www.fmc-ag.com
Fresenius Medical Care is the world’s largest integrated provider of products and services for individuals undergoing dialysis because
of chronic kidney failure, a condition that affects more than 2 million individuals worldwide.
In patients suffering from severe liver failure (like acute or “acute-on-chronic”), elimination of toxins by dialysis is not enough
because here albumin-bound toxins have to be removed too. With Prometheus®, Fresenius Medical Care offers a therapy system
that combines a procedure where a fraction of plasma is separated from blood to remove albumin bound toxins by adsorption with
hemodialysis to clear the blood from water soluble substances.
Itamar Medical Ltd
9 Halamish St.
PO Box 3579
Caesarea 38900
Israel
www.itamar-medical.com
Itamar Medical a publicly-traded medical technology company developing state-of-the-art biomedical products based on a proprietary
signal for noninvasive, early detection of heart disease & obstructive sleep apnea.
Technology & Product:
The patented Peripheral Arterial Tone (PAT®) signal -- the noninvasive “window” to both the cardiovascular and autonomic nervous
systems.
EndoPAT™: The only noninvasive, FDA-cleared device diagnosing endothelial dysfunction – the early indicator of arterial health. This
15-minute, office-based diagnostic is used by Mayo Clinic, Framingham Heart Study & others.
WatchPAT™: Convenient, portable sleep apnea testing device installed by the patient in their own home.
Genzyme, a Sanofi Company
Genzyme Corporate Offices
500 Kendall Street
Cambridge, MA 02142
USA
www.genzyme.com Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating
diseases for over 30 years.
With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and
families we serve.
Genzyme’s portfolio of transformative therapies, which are marketed in countries around the world, represent groundbreaking and
life-saving advances in medicine.
In partnership with Isis Pharmaceuticals, we are committed to the development of potential innovative treatments for severe Familial
Hypercholesterolemia (severe FH).
XXXIV
Kowa
105 Wharfedale Road
Winnersh Triangle
Wokingham, RG41 5RB
UK
www.kowa.co.jp/eng
Kowa Company, Ltd. (KCL) is a privately held multinational company headquartered in Nagoya, Japan. Established in 1894, KCL is
actively engaged in manufacturing activities in the fields of pharmaceutical, life science, information technology, textiles, machinery
and various consumer products. KCL’s pharmaceutical division is focused on cardiovascular therapeutics, with sales of the company’s
flagship product, LIVALO (pitavastatin) making sales of 51 billion JPY during 2012 in Japan.
KCL has research and commercial affiliates in the US (Kowa Research Institute and Kowa Pharmaceuticals America) and Europe
(Kowa Research Europe and Kowa Pharmaceutical Europe).
Mercodia AB
Street: Sylveniusgatan 8A
Uppsala 754 50
Sweden
www.mercodia.com
Mercodia AB is a Swedish biotech company focusing on the development of immunoassays for research within the field of metabolic
disorders. Our assays are applicable to both animal and human models and are used for research ranging from basic scientific studies
to large pre-clinical and clinical phase trials.
The company was founded in 1991 and is today a world-leading supplier of products to all major international markets. More than
ninety percent of our production is exported from our facilities in Uppsala to approximately 100 different countries around the world.
MSD
One Merck Drive
Whitehouse Station, NJ 08889
USA
www.merck.com
Today’s Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States
and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we
work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our
commitment to increasing access to healthcare through far-reaching policies, programs and partnerships that donate and deliver our
products to the people who need them. For more information, visit www.merck.com
Raisio Group
Raisio Group is an international expert in plant-based nutrition with strong international and local food brands. Benecol® is the expert
brand in cholesterol reduction and a pioneer in the cholesterol lowering functional food category.
Raisio Group produces the unique cholesterol-lowering ingredient, Plant stanol ester, and licenses the Benecol brand worldwide.
Benecol products are manufactured and sold by local food companies in 30 countries on five continents.
Over 70 clinical studies support the use of Benecol as an effective, easy and safe dietary tool to lower LDL-cholesterol. The
cholesterol-lowering effect of Benecol is additive to those of a healthy diet and statin medication.
XXXV
NSFA
13 Avenue des Arts
94100 Saint maur
France
http://www.nsfa.asso.fr
French Atherosclerosis Society (NSFA) is composed of more than 200 members and is involved in the promotion of fundamental
and clinical researches in the domain of atherosclerosis and thromboembolic complications. NSFA supports institutional research
laboratories by allocating PHD grants.
NSFA supports different national and international actions or educational programs for prevention of atherosclerosis. The society
is also involved in the diffusion of information, research programs and clinician education by organizing seminars, conferences and
workshops. The next annual meeting of the society will be held in Biarritz, June 19-21, 2014
Randox Cardiology
55 Diamond Road, Crumlin, Co. Antrim
BT29 4QY
Northern Ireland, UK
www.randox.com
Randox are an international clinical diagnostics company based in Northern Ireland, with a presence in over 150 countries worldwide.
Cardiovascular disease is a key area of focus for Randox and we offer a huge range of relevant products, both for clinical research
and clinical practice. Such products include automated clinical chemistry assays for Lp(a), sdLDL, Heart-type Fatty Acid Binding
Protein (H-FABP), aspirin resistance, lipids and anti-oxidants. In addition to these is Randox’s pioneering multiplexing platforms, utilising the revolutionary Biochip Array Technology. Arrays available include cytokines, adhesion molecules, cardiac, cerebral & metabolic
biomarkers.
Regeneron
777 Old Saw Mill River Road Tarrytown
NY 10591
USA
www.regeneron.com
Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes
medicines for the treatment of serious medical conditions. Regeneron markets two products, ARCALYST® (rilonacept) Injection For
Subcutaneous Use and EYLEA™ (aflibercept) Injection. Regeneron also has completed several Phase 3 studies and is conducting an
additional Phase 3 clinical trial for the product candidate ZALTRAP® (aflibercept) Concentrate for Intravenous Infusion. Additional
therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in
development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune
conditions, and cancer
XXXVI
Roche
Grenzacherstrasse 124
4070
Switzerland
www.roche.com
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals
and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in
diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible
improvements in the health, quality of life and survival of patients. For more information: www.roche.com
Sanofi
174 avenue de France 75635
Paris Cedex 13
France
www.sanofi.com
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs.
Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative
drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in
New York (NYSE: SNY).
Unilever
www.unilever.com
Make sustainable living commonplace
Unilever’s purpose is to make sustainable living commonplace. We help people feel good, look good
and get more out of life with brands and services that are good for them and good for others. 160
million times a day, in 190 countries, people use our home, personal care and foods products at key
moments of their day. We produce world-leading brands including Lipton, Knorr, Hellmann’s,
Becel/Flora, Ben & Jerry’s, Dove, Axe, and Omo.
Wisepress Medical Bookshop
25 High Path, Merton Abbey
London, SW19 2JL
UK
www.wisepress.com
Wisepress.com, Europe’s leading conference bookseller, has a complete range of books and journals relevant to the themes of
the meeting. Books can be purchased at the stand or, if you would rather not carry them, posted to you – Wisepress will deliver
worldwide. In addition to attending 200 conferences per year, Wisepress has a comprehensive medical and scientific bookshop online
with great offers.
XXXVII
81 st Congress of the European Atherosclerosis Society • 2 – 5 June 2013 • Lyon, France
Satellite Symposium Sponsored by MSD
CETP Inhibition: What’s New?
Sunday, 2 June 2013
15:15 – 16:00
MODERATOR:
Lyon Convention Center
Hall D
Lyon, France
M. John Chapman
Director Emeritus , INSERM
Past- President, EAS
Research Professor
Pitie-Salpetriere University Hospital
Paris, France
Moderator: John Chapman (France)
FACULTY:
Henry Ginsberg
Irving Professor of Medicine
Columbia University College of
Physicians and Surgeons
Director, Irving Institute for Clinical
and Translational Research
Columbia University Medical Center
New York, New York, USA
John Millar
Director
Metabolic Tracer Resource
Institute for Diabetes,
Obesity and Metabolism
University of Pennsylvania
Philadelphia, Pennsylvania, USA
AGENDA
Sunday, 2 June 2013
15:15 – 15:20
Introduction
15:20 – 15:35
HDL and CETP Metabolism
Henry Ginsberg
15:35 – 15:50
Apo B and PCSK9 Kinetics
John Millar
15:50 – 16:00
Q&A/Conclusion
John Chapman
John Chapman
Copyright © 2013 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA. All rights reserved.
CVT-177134-AB
SCIENTIFIC PROGRAMME
SUNDAY, JUNE 2, 2013
Clinical advances
in difficult-to-treat patients
with hypercholesterolemia
13:00–14:30, Monday, 3 June 2013
81st European Atherosclerosis Society Congress
Claude Bernard Hall
Lyon Congress Centre, Lyon, France
Agenda
13:00
Introduction and welcome
Michel Farnier and Christie M. Ballantyne (Co-Chairs)
13:05
The spectrum of difficult-to-treat
hypercholesterolemic patients
Christie M. Ballantyne
13:30
New and emerging LDL-C lowering therapies –
Targeting production
Erik S. G. Stroes
13:55
Emerging LDL-C lowering therapies –
Targeting clearance
Michel Farnier
14:20
Panel discussion
M. John Chapman (Moderator) and all faculty
14:30
© 2013, Sanofi and Regeneron Pharmaceuticals, Inc.
5/2013 PCS-0184
GLB.ALI.13.05.01
Close of symposium
Sunday, June 2, 2013
11:00-20:30
Registration Area
REGISTRATION DESK OPEN
13:30-15:00
Forum 1: Claude Bernard
EBAC ACCREDITED EDUCATIONAL PROGRAMME
ADVANCES IN THE UNDERSTANDING OF CARDIOVASCULAR DISEASE AND
DYSLIPIDAEMIA IN DIABETES
Supported by an Unrestricted Educational Grant from AstraZeneca
Programme created in collaboration with Sahlgrenska Academy, University of Gothenburg
Chairperson: Olov Wiklund
Time
13:30
INTRODUCTION
13:35
CHARACTERISTICS OF THE VASCULAR LESION IN DIABETES
Peter Libby, USA
14:00
LIPID METABOLISM AND CARDIOVASCULAR DISEASE IN DIABETES
14:20
RISK OF DIABETES DEVELOPMENT DURING STATIN TREATMENT
Naveed Sattar, UK
14:40
CURRENT TREATMENT OF DYSLIPIDAEMIA IN PATIENTS WITH THE
METABOLIC SYNDROME AND DIABETES
14:55
DISCUSSION
1
14:15-15:00
Forum 2: Marcel Mérieux
HYPERCHOLESTEROLEMIA – WHAT CAN WE DO FOR HIGH-RISK PATIENTS?
SPONSORED BY AMGEN
Chairperson: Alberico L. Catapano
Time
14:15
INTRODUCTION
14:20
HYPERCHOLESTEROLEMIA - WHAT CAN WE DO FOR HIGH-RISK
PATIENTS?
G. Kees Hovingh, The Netherlands
14:50
Q&A AND CLOSE
15:15-16:00
Forum 3: Michel Macheboeuf
CETP INHIBITION: WHAT'S NEW?
SPONSORED BY MSD
Chairperson: M. John Chapman
Time
15:15
INTRODUCTION
15:20
HDL AND CETP METABOLISM
Henry Ginsberg, USA
15:35
APO B AND PCSK9 KINETICS
John Millar, USA
15:50
Q&A/CONCLUSION
2
16:20-17:50
NEW STRATEGIES FOR THE MANAGEMENT OF PATIENTS WITH HoFH
SPONSORED BY AEGERION
Chairpersons:
Børge Nordestgaard
Time
16:20
WELCOME
Børge Nordestgaard; A.L. Catapano, Denmark, Italy
16:25
WHAT ARE WE ABLE TO ACHIEVE FOR OUR PATIENTS TODAY?
Raul D. Santos, Brazil
16:50
EAS/ESC RECOMMENDATIONS FOR THE MANAGEMENT OF
PATIENTS WITH HoFH
17:15
LOMITAPIDE IN THE MANAGEMENT OF HoFH - CLINICAL EXPERIENCE
Marina Cuchel, USA
3
18:00-19:30
Auditorium Anitschkow
OPENING CEREMONY, INCLUDING THE ANITSCHKOW LECTURE
Chairpersons:
Philippe Moulin
Time
18:00
WELCOME FROM THE EAS PRESIDENT
18:10
WELCOME FROM THE PRESIDENT OF THE CLAUDE BERNARD
LYON1 UNIVERSITY
François N. Gilly, France
18:13
WELCOME FROM THE NFSA PRESIDENT
18:16
IAS AND EAS WORKING TOGETHER
18:19
WELCOME FROM THE CONGRESS CHAIRPERSON
18:22
Choir
18:30
INTRODUCTION OF THE ANITSCHKOW PRIZE WINNER
18:35
THE ANITSCHKOW LECTURE
Peter Libby, USA
19:25
Choir
19:30-20:30
Exhibition Area
WINE AND CHEESE WELCOME RECEPTION
4
MONDAY, JUNE 3, 2013
81st Congress of the European Atherosclerosis Society
2 – 5 June 2013 • Lyon, France
Satellite Symposium Sponsored by MSD
On The Forefront of CHOLESTEROL MANAGEMENT:
Clinical Considerations and Practical Approaches Beyond Statins
Monday, 3 June 2013
CHAIRMAN:
17:00 – 18:30
Lyon Convention Center
Hall A
Lyon, France
President EAS
Professor of Pharmacology
Director, SISA Center for the Study
of Atherosclerosis
Director, Center of Epidemiology and
Preventive Pharmacology
Director, Laboratory of Lipoproteins
and Atherosclerosis
Department of Pharmacological and
Biomolecular Sciences
University of Milan
Milan, Italy
FACULTY:
Philip Barter
President, International
Atherosclerosis Society
Conjoint Professor
The University of New South Wales
Sydney, Australia
John E. Deanfield
BHF Vandervell Chair of Congenital
Heart Disease
Director, Centre for Cardiovascular
Prevention & Outcomes
Deputy Cardiovascular Program
Director, UCL Partners
London, United Kingdom
Chairman: Alberico Catapano (Italy)
AGENDA Monday, 3 June 2013
17:00 – 17:05
Chair Welcome and Opening Remarks
Alberico Catapano
17:05 – 17:25
Unmet Medical Needs in Dyslipidemia
Philip Barter
17:25 – 17:45
Achieving Superior Efficacy by intensive LDL-C lowering;
Arguments for the use of a cholesterol absorption inhibitor
Michel Farnier
17:45 – 18:05
Improving Clinical Outcomes in Statin Treated Patients
John Deanfield
18:05 – 18:25
Panel Discussion
Alberico Catapano
Philip Barter
Michel Farnier
18:25 – 18:30
Closing Remarks
Alberico Catapano
Michel Farnier
Department of Endocrinology and
Lipidology
Point Medical Clinic
Dijon, France
Copyright © 2013 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.,
Whitehouse Station, NJ, USA. All rights reserved.
CVT-176000-AB
Monday, June 3, 2013
08:30-10:30
PLENARY SESSION: PLAQUE INSTABILITY AND ATHEROTHROMBOSIS
Chairpersons:
Lale Tokgozoglu
Time
08:30
BIOMARKERS OF PLAQUE OF INSTABILITY
Jean-Baptiste Michel, France
09:00
NEW INSIGHTS INTO THE ROLE OF HEMODYNAMICS IN PLAQUE
INSTABILITY
09:30
ADVANCES IN VISUALIZING THE UNSTABLE PLAQUE
Filippo Crea, Italy
10:00
PREVENTION AND TREATMENT OF PLAQUE THROMBOGENICITY
Gilles Montalescot, France
10:30-10:50
Exhibition Area
COFFEE BREAK, POSTER VIEWING AND EXHIBITION
10:50-12:40
ADVANCED CLINICAL SEMINAR EVALUATION AND MANAGEMENT OF LOW HDL: WHY
AND HOW?
Chairpersons:
Anne Tybjaerg-Hansen
Sebastiano Calandra
Time
10:50
GENETIC AND NON-GENETIC FACTORS AFFECTING HDL LEVELS
AND FUNCTIONS
11:20
WHAT IS THE MESSAGE FROM INTERVENTION STUDIES?
11:50
HDL AND REVERSE CHOLESTEROL TRANSPORT: HOW TO
PROCEED?
5
10:50-12:40
REGULATION OF CELLULAR LIPID METABOLISM IN ATHEROGENESIS
Chairpersons:
Vesa M Olkkonen
Marcello Arca
Time
10:50
OXYSTEROL-BINDING PROTEINS: EMERGING FUNCTIONS IN CELL
REGULATION AND ATHEROGENESIS
Vesa M. Olkkonen, Finland
11:15
PPARS, NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND
ATHEROSCLEROSIS
Bart Staels, France
Abstract No
11:40
TRANS INTESTINAL CHOLESTEROL EXCRETION IS AN ACTIVE
METABOLIC PROCESS MODULATED BY PCSK9 AND STATIN,
INVOLVING ABCB1
Jean Mathieu Berger, C. Le May, B. Pillot, J. Magré, X. Prieur, E.
Letessier, B. Cariou1,2, P. Costet1,2, France
1037
11:55
IDENTIFICATION OF AN ENDOGENOUS PROTEIN WHICH BLOCKS
THE INTERACTION BETWEEN OXLDL AND ITS RECEPTORS
Akemi Kakino, Y. Fujita, T. Sawamura, Japan
1471
12:10
MYELOID CELL-SPECIFIC SERINE PALMITOYLTRANSFERASE
SUBUNIT 2 HAPLOINSUFFICIENCY REDUCES ATHEROSCLEROSIS IN
MICE
M. Chakraborty, C. Lou, M.-S. Kuo, G. Cao, Xian-Cheng Jiang, USA
185
12:25
AGGREGATED LDL INDUCES LRP1 PROTEIN STABILIZATION
THROUGH E3 UBIQUITIN-LIGASE CHFR DOWNREGULATION IN
HUMAN VSMC
R. Cal, M. Garcia-Arguinzonis, E. Revuelta-Lopez, J. Castellano, T.
Padro, L. Badimon, Vicenta Llorente-Cortes, Spain
6
473
10:50-12:40
EVALUATION AND TREATMENT OF CARDIOVASCULAR RISK FACTORS IN THE YOUNG
AND THE ELDERLY
Chairpersons:
George Davey-Smith
Michel Krempf
Time
10:50
IS THERE AN UPPER AGE LIMIT FOR LIPID LOWERING IN
CARDIOVASCULAR PREVENTION?
11:15
EPIDEMIOLOGICAL METHODS TO IDENTIFY STRENGTH OF CAUSAL
ASSOCIATIONS BETWEEN RISK FACTORS AND CARDIOVASCULAR
OUTCOMES
Abstract No.
11:40
ELEVATED REMNANT CHOLESTEROL CAUSES LOW-GRADE
INFLAMMATION AND ISCHEMIC HEART DISEASE
Anette Varbo, M. Benn, A. Tybjærg-Hansen, B.G. Nordestgaard, Denmark 985
11:55
COMBINED EFFECTS OF CHILD AND ADULT ELEVATED BLOOD
PRESSURE ON SUBCLINICAL ATHEROSCLEROSIS. THE
INTERNATIONAL CHILDHOOD CARDIOVASCULAR COHORT
CONSORTIUM
Markus Juonala, J. Juhola, C.G. Magnussen, M.A. Sabin, T. Dwyer, A.
Venn, T.L. Burns, G.S. Berenson, M. Kähönen, J.S. Viikari, S.R. Daniels,
O.T. Raitakari, Finland, Australia, USA
12:10
12:25
SOCIOECONOMIC POSITION AND TRUNCAL FAT INFLUENCE
CAROTID INTIMA-MEDIA THICKNESS IN ADOLESCENTS: THE
HELENA STUDY
Christophe Lamotte, C. Iliescu, L. Beghin, J. Salleron, S. De Henauw,
L.A. Moreno, C. Libersa, F. Gottrand, France, Belgium, Spain
336
1480
SERUM LEVELS OF DEHYDROEPIANDROSTERONE (DHEA) AND ITS
SULFATE (DHEA-S) PREDICT THE FIVE YEAR RISK OF
CARDIOVASCULAR EVENTS IN ELDERLY MEN
Åsa Tivesten, M. Nilsson, D. Carlzon, L. Vandenput, M.K. Karlsson, Ö.
Ljunggren, E. Barrett-Connor, D. Mellström, C. Ohlsson, Sweden, USA
875
7
10:50-12:40
ENDOTHELIAL DYSFUNCTION IN ATHEROTHROMBOSIS
Chairpersons:
Qingbo Xu
Erik Stroes
Time
10:50
ENDOTHELIAL REPAIR BY STEM CELLS
Qingbo Xu, UK
11:15
ROLE OF ENDOTHELIAL MICRORNAS IN VASCULAR DISEASE
Andreas M. Zeiher, Germany
11:40
ADRENOMEDULLIN IS ASSOCIATED TO ARTERIAL STIFFNESS: AN
INTEGRATIVE APPROACH COMBINING MONOCYTE ADM
EXPRESSION, PLASMA MR-PROADM AND GENOME-WIDE
ASSOCIATION STUDY
Farzin Beygui1,2, P.S. Wild, T. Zeller, M. Germain, R. Castagné, T. Münzel,
G. Montalescot2,5, D.-A. Trégouët, F. Cambien, S. Blankenberg, L. Tiret,
France, Germany
553
11:55
HEDGEHOG PATHWAY AGONISM AMELIORATES DYSFUNCTION OF
VASCULAR ENDOTHELIUM IN OBESITY: ROLE OF
PHOSPHATIDYLINOSITOL-3-KINASE AND ENDOTHELIUM NITRIC
OXIDE SYNTHATASE
Saurabh Sharma, P.L. Sharma, India
365
12:10
THE RNA-BINDING PROTEIN QUAKING MAINTAINS ENDOTHELIAL
BARRIER FUNCTION THROUGH TARGETING VE-CADHERIN MRNA
Janine M. van Gils, R.G. de Bruin, I. Schmidt, E.P. van der Veer, M.K.
Roeten, T.J. Rabelink, A.J. van Zonneveld, The Netherlands
Abstract No.
12:25
1035
PLASMA ASYMMETRIC DIMETHYLARGININE, ENDOTHELIUMDEPENDENT NITRIC OXIDE-MEDIATED RELAXATION AND VASCULAR
REMODELING OF UTERINE SMALL ARTERIES IN PREGNANT WOMEN
Malene Rohr Andersen, U. Simonsen, S. Stender, M. Hedegaard, C.
Aalkjær, Denmark
1518
12:40-14:45
Exhibition Area
LUNCH BREAK, EXHIBITION AND POSTER PRESENTATIONS
13:40 – 14:40 MODERATED POSTER SESSION A (See page 29)
8
12:50-13:40
EAS GENERAL ASSEMBLY
13:00-14:30
CLINICAL ADVANCES IN DIFFICULT-TO-TREAT PATIENTS WITH
HYPERCHOLESTEROLEMIA
SPONSORED BY SANOFI / REGENERON / GENZYME
Chairpersons:
Michel Farnier
Christie Ballantyne
Time
13:00
INTRODUCTION AND WELCOME
C. Ballantyne; M. Farnier, USA, France
13:05
THE SPECTRUM OF DIFFICULT-TO-TREAT HYPERCHOLESTEROLEMIC
PATIENTS
C. Ballantyne, USA
13:30
NEW AND EMERGING LDL-C-LOWERING THERAPIES - TARGETING
PRODUCTION
13:55
EMERGING LDL-C-LOWERING THERAPIES - TARGETING CLEARANCE
14:50-16:40
JOINT ICCR/EAS SYMPOSIUM: LIFESTYLE FACTORS AND CARDIOVASCULAR
DISEASES
Chairpersons:
Marja-Riitta Taskinen
Frank Hu
Time
14:50
OPENING REMARKS
15:00
TARGETING HEALTHY DRINKING FOR CVD RISK REDUCTION
Frank Hu, USA
15:25
PHYSICAL ACTIVITY AND CVD RISK MANAGEMENT
Robert Ross, Canada
15:50
ECTOPIC FAT AS A NEW TARGET FOR CVD RISK MANAGEMENT
16:15
EVOLVING MOSAIC OF MODIFIABLE CVD RISK FACTORS
Luc Van Gaal, Belgium
9
14:50-16:40
ROLE OF LIPASES IN LIPID AND LIPOPROTEIN METABOLISM
Chairpersons:
Sander Kersten
Matti Jauhiainen
Time
14:50
REGULATION OF PLASMA TRIGLYCERIDE CLEARANCE BY
ANGIOPOIETIN-LIKE PROTEINS
Sander Kersten, The Netherlands
15:15
THE COMPLEXITY OF LPL ACTION IN TG METABOLISM
Geesje Dallinga-Thie, The Netherlands
Abstract No
15:40
LOSS-OF-FUNCTION MUTATION IN THE ANGPTL3 GENE IS
ASSOCIATED WITH INCREASED LPL ACTIVITY AND DECREASED
SERUM FREE FATTY ACIDS
Matti Jauhiainen, M. Robciuc, A. Lahikainen, A. Bensadoun, D. Rader, M.
Maranghi, K. Öörni, I. Minicocci, M. Arca, C. Ehnholm, Finland, USA, Italy
56
15:55
NOVEL SMALL MOLECULE LIPOPROTEIN LIPASE ACTIVATOR LP071
IMPROVES PLASMA LIPID PARAMETERS IN VIVO
M. Eriksson, M. Larsson, R. Caraballo, P.-A. Enquist, M. Elofsson, G.
Olivecrona, Stefan K Nilsson, Sweden
304
16:10
EXPRESSION OF GROUP IIA SECRETORY PHOSPHOLIPASE A2
(SPLA2) INHIBITS CHOLESTERYL ESTER TRANSFER PROTEIN (CETP)
ACTIVITY IN TRANSGENIC MICE
E. Hurt-Camejo, T. Gautier, B. Rosengren, M. Behrendt, D.S. Grass, D.J.
Rader, Uwe J.F. Tietge, Sweden, France, USA, The Netherlands
235
16:25
MULTIPLE MOLECULAR DEFECTS ASSOCIATED TO NOVEL APOA5
MUTATIONS FOUND IN PATIENTS WITH SEVERE
HYPERCHYLOMICRONEMIA
Josep Julve1,2, E. Mendoza-Barberà, S.K. Nilsson, A. Lookene, J.M. MartínCampos, R. Roig2,5, A.M. Lechuga-Sancho, J.J. Sloan, P. Fuentes-Prior, F.
594
Blanco-Vaca2,5,8, Spain, Sweden, Estonia, USA
10
14:50-16:40
CELLULAR GROWTH, DEATH, TRAFFICKING, AND MICROVESICULATION IN
ATHEROGENESIS
Chairperson: Wolfgang Schneider
Edward Fisher
Time
14:50
MACROPHAGE PHENOTYPIC DIVERSITY DURING ATHEROSCLEROSIS
REGRESSION
Edward Fisher, USA
15:15
MATRIX VESICLES RELEASED BY SMOOTH MUSCLE CELLS: KEY
INITIATORS OF VASCULAR CALCIFICATION
Catherine. M. Shanahan, UK
Abstract No
15:40
CARTILAGENOUS METAPLASIA IN ATHEROSCLEROSIS IS
ASSOCIATED WITH TRAIL-DEFICIENCY AND ALTERED EXPRESSION
OF GENES INVOLVED IN CALCIFICATION
B. Di Bartolo, S. Cartland, H. Harith1,2, M. Schoppet, Mary Kavurma1,2,
Australia, Germany
938
15:55
TARGETING CHONDROITIN SULFATE NACETYLGALACTOSAMINYLTRANSFERASE 2 IN THE
MODIFICATION OF SUBENDOTHELIAL LIPOPROTEIN RETENTION
AND FOAM CELL FORMATION
Dyah Samti Mayasari, N. Emoto1,2, K. Yagi, K. Nakayama, N. Arfian, H.
Ali, K.-I. Hirata, Japan
16:10
16:25
NOTCH PATHWAY POLARIZES MONOCYTES INTO M2
MACROPHAGES AND INHIBITS ATHEROSCLEROSIS IN APOE
KNOCKOUT MICE
Dinender Singla, B. Yan, L. Abdeli, S. Parthasarathy, USA
+
904
1091
NULL
T CELLS FROM PATIENTS WITH MYOCARDIAL
CD4 CD28
INFARCTION HAVE DEREGULATED APOPTOSIS PATHWAYS AND
ARE RESISTANT TO APOPTOTIC CELL DEATH
Ingrid Elena Dumitriu, E. Kovalcsik, R. Antunes, J.C. Kaski, UK
11
1464
15:45-16:30
EAS INITIATIVES UPDATE
OVERVIEW OF CURRENT STATUS AND FORTHCOMING DEVELOPMENTS IN THE
SOCIETY’S KEY INITIATIVES
Chairpersons: Alberico L. Catapano
Lale Tokgozoglu
Time
15.45
INTRODUCTION BY SESSION CHAIRS
Alberico L. Catapano, Lale Tokgozoglu
15.50
EAS GUIDELINES AND CONSENSUS PAPERS INITIATIVE
15.55
EAS CONSENSUS POSITION PAPER INITIATIVE – FOCUS ON FH
Børge Nordestgaard
16.15
GLOBAL GUIDELINES
Olov Wiklund
12
17:00-18:30
ON THE FOREFRONT OF CHOLESTEROL MANAGEMENT: CLINICAL CONSIDERATIONS
AND PRACTICAL APPROACHES BEYOND STATINS
SPONSORED BY MSD
Chairperson: Alberico L. Catapano
Time
17:00
WELCOME AND OPENING REMARKS
17:05
UNMET MEDICAL NEEDS IN DYSLIPIDEMIA
17:25
ACHIEVING SUPERIOR EFFICACY BY INTENSIVE LDL-C LOWERING;
ARGUMENTS FOR THE USE OF A CHOLESTEROL ABSORPTION
INHIBITOR
17:45
IMPROVING CLINICAL OUTCOMES IN STATIN TREATED PATIENTS
John E. Deanfield, UK
18:05
PANEL DISCUSSION
A.L. Catapano; P. Barter; M. Farnier; J.E. Deanfield, Italy, Australia,
France, UK
18:25
CLOSING REMARKS
17:00-17:45
SPECIAL LECTURE SPONSORED BY KOWA
Chairperson: Yasushi Saito
Time
17:00
INTRODUCTION TO KOWA SPECIAL LECTURE
Yasushi Saito, Japan
17:05
NORMALISING DYSLIPIDEMIA AND REVERSING ATHEROSCLEROSIS
IN CARDIO-METABOLIC DISEASE: INSIGHTS FROM STATIN
PHARMACOTHERAPY
13
17:00-17:50
THE ROLE OF PLANT STANOLS/STEROLS IN THE MANAGEMENT OF DYSLIPIDAEMIAS
JOINTLY SPONSORED BY BASF, DANONE, RAISIO, UNILEVER
Chairpersons:
Henry Ginsberg
Petri Kovanen
Time
17:00
INTRODUCTION AND OPENING REMARKS
Henry Ginsberg, USA
17:05
BASIC SCIENCE OF PLANT STEROLS/STANOLS
Jogchum Plat, The Netherlands
17:25
CLINICAL APPLICATION & SAFETY OF PLANT STEROLS/STANOLS
Henry Ginsberg, USA
17:45
SUMMARY AND CLOSING REMARKS
Petri Kovanen, Finland
14
TUESDAY, JUNE 4, 2013
Tuesday, June 4, 2013
08:30-10:30
PUSHING THE FRONTIERS IN CARDIOVASCULAR BIOLOGY
Chairpersons:
Philippe Moulin
Olov Wiklund
Time
08:30
GUT-LIVER INTERACTION IN TRIGLYCERIDE RICH LIPOPROTEIN
METABOLISM
Gary Lewis, Canada
09:00
MICRO-RNA AND EPIGENETIC CONTROL OF ATHEROGENESIS
Kathryn Moore, USA
09:30
THERAPEUTIC OPTIONS TO INDUCE REGRESSION OF CORONARY
ATHEROSCLEROSIS
Steven Nissen, USA
10:00
PHARMACOLOGICAL TARGETS IDENTIFIED BY GENETIC
APPROACHES
François Cambien, France
10:30-10:50
Exhibition Area
10:50-12:40
ADVANCED CLINICAL SEMINAR: WHEN STATINS ARE NOT TOLERATED OR ARE NOT
SUFFICIENT ALONE: HOW TO HANDLE THE PROBLEM?
Time
10:50
PATIENTS NOT AT GOAL: WHAT ARE THE CAUSES?
11:15
WHAT IS THE ROOM FOR THE ASSOCIATION THERAPY
Marcello Arca, Italy
11:40
LOWERING LDL-CHOLESTEROL -BEYOND STATIN THERAPY
Frederick Raal, South Africa
15
10:50-12:40
HEPATIC REGULATION OF LIPID AND LIPOPROTEIN METABOLISM IN
CARDIOMETABOLIC DISORDERS
Chairpersons:
Marten Hofker
Maurizio Averna
Time
10:50
DERANGEMENT OF HEPATIC LIPID METABOLISM
Jan Boren, Sweden
11:15
MACROPHAGES LINK FATTY LIVER DISEASE AND
ATHEROSCLEROSIS
Marten Hofker, The Netherlands
Abstract No
11:40
P2Y13 RECEPTOR DEFICIENCY DECREASES HEPATOBILIARY AND
FAECAL LIPID EXCRETIONS AND PROMOTES ATHEROSCLEROSIS IN
APOE KNOCKOUT MICE
Laeticia Lichtenstein, N. Serhan, B. Perret, M. Laffargue, L.O. Martinez,
France
1486
11:55
NAFLD AND CARDIOVASCULAR DISEASE: MAY A SUFFERING LIVER
BE A PREDICTOR MARKER OF CARDIOVASCULAR RISK?
Carmela Viscomi1,2, A. Minutolo, M. Arciello, B. Conti, R. Maggio, A. Longo,
609
E. Scarpellini, C. Balsano2,4, Italy
12:10
EXENDIN-4 REDUCES THE DEVELOPMENT OF NON-ALCOHOLIC
STEATOHEPATITIS IN ADDITION TO ATHEROSCLEROSIS IN APOE*3LEIDEN.CETP MICE
Yanan Wang, E.T. Parlevliet1,2, J.J. Geerling, S.J.L. van der Tuin, V. Bieghs,
A.H.M. Jawad, H. Zhang, R. Shiri-Sverdlov, L.M. Havekes1,4,5, J.A. Romijn1,2,
524
K. Willems van Dijk1,6, P.C.N. Rensen, The Netherlands
16
10:50-12:40
LIFESTYLE FACTORS AND CARDIOVASCULAR DISEASES
Chairpersons:
Adrian JB Brady
Zeljko Reiner
Time
10:50
DIET AND CARDIOVASCULAR RISK: EVIDENCE AND POSSIBLE
MECHANISMS
11:15
DIET AND EXERCISE - JUST A BIG WASTE OF TIME?
Adrian J. Brady, UK
Abstract No.
11:40
CHROMOSOME 9P21 VARIANT INTERACTS WITH DIETARY
VEGETABLE AND WINE INTAKE ON THE RISK OF CARDIOVASCULAR
DISEASE
George Hindy, V. Hamrefors, U. Ericson, I. Drake, E. Wirfält, O. Melander,
M. Orho-Melander, Sweden
1361
11:55
EFFECT OF DIFFERENT EXERCISE MODALITIES IN EXPERIMENTAL
PERIPHERAL ARTERY DISEASE AND ASSESSMENT OF POTENTIAL
UNDERLYING MECHANISMS
Maxime Pellegrin, K. Bouzourene, C. Poitry-Yamate, V. Mlynarik, J.-F.
Aubert, C. Amstutz, R. Gruetter, L. Mazzolai, Switzerland
12:10
INCREASING LONG-CHAIN N-3PUFA CONSUMPTION IMPROVES
SMALL PERIPHERAL ARTERY FUNCTION IN PATIENTS AT
INTERMEDIATE-HIGH CARDIOVASCULAR RISK
Jordi Merino, A. Sala-Vila, R. Kones, R. Ferré, N. Plana, J. Girona, D.
Ibarretxe, M. Heras, E. Ros, L. Masana, Spain, USA
17
617
1318
10:50-12:40
INFECTION, INFLAMMATION AND IMMUNITY IN ATHEROGENESIS
Chairpersons:
Eicke Latz
Michal Vrablík
Time
10:50
MOLECULAR REGULATION OF MACROPHAGES: IMPLICATIONS FOR
ATHEROSCLEROSIS
Menno P.J. De Winther, The Netherlands
11:15
CHOLESTEROL CRYSTALS AS A DANGER SIGNAL IN
ATHEROSCLEROSIS
Eicke Latz, Germany
Abstract No.
+
11:40
CYTOTOXIC CD8 T CELLS PROMOTE VULNERABLE
ATHEROSCLEROTIC PLAQUE DEVELOPMENT IN APOE-/- MICE
T. Kyaw, C. Tay, A. Winslop, P. Kanellakis, H. Hosseini, A. Cao, A. Bobik, P.
Tipping, Ban-Hock Toh, Australia
175
11:55
METAGENOMICS REVEALS GUT SIGNATURES IN ATHEROSCLEROSIS
MICROBIOME
Emi Kozarov1,2, S. Kalachikov, A. Morozov, N. Chalmers4,5, M. Chien, Spain,
USA
758
12:10
THE NEUTROPHIL ACTIVATION MARKER MRP8/14 CORRELATES
WITH CAROTID PLAQUE AREA AND PREDICTS CARDIOVASCULAR
EVENTS IN HEALTHY INDIVIDUALS
O. Cotoi, N. Ko, P. Dunér, H. Björkbacka, J. Nilsson, Alexandru Schiopu2,3,
Romania, Sweden
1068
12:25
OPTIMIZING NATURAL OCCURRING IGM ANTIBODIES FOR
THERAPEUTIC USE: INFLAMMATORY VASCULAR DISEASE
TREATMENT WITH ANTI-PHOSPHORYLCHOLINE IGG
M.M. Ewing, J.C. Karper, M.R. De Vries, R.C.M. de Jong, I. Dahlbom, J.
Kuiper, S. Karabina, E. Ninio, J.W. Jukema, K. Pettersson, Paul Quax, The
Netherlands, Sweden, France
1023
12:40-14:45
Exhibition Area
LUNCH BREAK, EXHIBITION AND POSTER PRESENTATIONS
12:40 – 13:40 MODERATED POSTER SESSION B (See page 37)
13:40 – 14:40 MODERATED POSTER SESSION C (See page 47)
18
13:00-14:30
CONTEXT AND FUTURE CHALLENGES IN THE EFFECTIVE MANAGEMENT OF
DYSLIPIDAEMIA
SPONSORED BY ROCHE
Chairpersons:
Chris Packard
Terje Pedersen
Time
13:00
INTRODUCTION
Terje Pedersen, Norway
13:05
LDL CHOLESTEROL AND CARDIOVASCULAR RISK REDUCTION SUCCESSES AND CHALLENGES
13:30
PCSK9 INHIBITION, A SAFE AND EFFICIENT STRATEGY TO LOWER
LDL CHOLESTEROL?
Gilles Lambert, France
13:55
TRANSLATING NEW APPROACHES TO REDUCE LDL CHOLESTEROL
INTO FUTURE THERAPIES
Evan Stein, USA
14:20
SUMMARY AND CLOSE
Chris Packard, UK
19
14:50-16:40
CARDIOVASCULAR DISEASE AND ITS PREVENTION IN PATIENTS WITH CHRONIC
INFLAMMATORY OR CHRONIC KIDNEY DISEASE
Chairpersons:
Eric Bruckert
Naveed Sattar
Time
14:45
CARDIOVASCULAR DISEASE AND IT'S PREVENTION IN PATIENTS
WITH CHRONIC INFLAMMATORY MUSCULOSKELETAL DISEASES
George D. Kitas, UK
15:10
CARDIOVASCULAR DISEASE AND IT'S PREVENTION IN PATIENTS
WITH CHRONIC INFLAMMATORY MUSCULOSKELETAL DISEASES
Naveed Sattar, UK
Abstract No.
15:35
IMPACT OF MILD CHRONIC KIDNEY DISEASE ON CORONARY
ATHEROSCLEROSIS, CARDIAC SYSTOLIC FUNCTION AND
MORTALITY
Andrea Natali, B. Boldrini, S. Baldi, M. Rossi, A. L'Abbate, E. Ferrannini,
Italy
561
15:50
INHIBITION OF MATRIX METALLOPROTEINASE-9 ATTENUATES
DIABETIC NEPHROPATHY BY MODULATING PODOCYTE FUNCTIONS
AND DOWNREGULATION EPITHELIAL-MESENCHYMAL TRANSITION
Po-Hsun Huang, S.-Y. Li, S.-J. Lin, Taiwan R.O.C.
352
16:05
ATHEROPROTECTIVE CHANGES IN HDL COMPOSITION IN
RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TNF-INHIBITORS
Johannes Levels, A. Jamnitski, I. van den Oever, M.T. Nurmohamed, The
Netherlands
1404
16:20
LIPOPROTEIN(a) IS CAUSALLY ASSOCIATED WITH TYPE 2 DIABETES
1177
Pia R. Kamstrup1,2, B.G. Nordestgaard1,2, Denmark
20
14:50-16:40
JOINT ESC/EAS SYMPOSIUM: BEHIND ENEMY LINES: IMMUNOMODULATION IN
ATHEROSCLEROSIS
Chairpersons:
Christoph Binder
Jan Nilsson
Time
14:50
ANTIBODIES TO OXIDIZED LIPIDS
15:15
CD31 PEPTIDES
Giuseppina Caligiuri, France
15:40
ARTERY TERTIARY LYMPHOID ORGANS (ATLOS) CONTROL KEY
STEPS OF ATHEROSCLEROSIS T CELL RESPONSES IN APOE-/- MICE
DURING AGING
Andreas Habenicht, Germany
16:05
VACCINES
Jan Nilsson, Sweden
21
14:50-16:40
LATE BREAKING SESSION
Chairpersons:
Geesje Dallinga-Thie
Time
Abstract No.
14:50
THE SUSCEPTIBILITY OF LDL TO AGGREGATION DEPENDS ON LDL
COMPOSITION
Katariina Öörni, H. Lähteenmäki, T. Aittokallio, M. Jauhiainen, L. Rudel,
P.T. Kovanen, Finland, USA
1650
15:05
VALIDATION OF A NEAR-INFRARED SPECTROSCOPIC SIGNATURE OF
LIPID LOCATED AT CULPRIT LESIONS IN ST-SEGMENT ELEVATION
MYOCARDIAL INFARCTION
David Erlinge, J.E. Muller, R. Puri, J. Harnek, M. Götberg, R. McNamara, D.
Wohns, S. Vanoosterhout, K. Wolski, S. Madden, S. Nicholls, R.D. Madder,
Sweden, USA, Australia
1637
15:20
PROTECTIVE EFFECTS OF PLANT STEROL AND STANOL ESTERS IN
DIET-INDUCED NONALCOHOLIC STEATOHEPATITIS IN
HYPERLIPIDEMIC MICE
Jogchum Plat, V. Bieghs, T. Hendrikx, M. Jeurissen, S. Walenbergh, P.J.
van Gorp, E.D. de Smet, M. Konings, A.C.E. Vreugdenhil, Y.D. Guichot, D.
Lutjohann, R.P. Mensink, R. Shiri-Sverdlov, The Netherlands, Germany
1628
15:35
EFFECT OF Ω-3 FATTY ACID ETHYL ESTERS ON POSTPRANDIAL
APOLIPOPROTEIN B-48 KINETICS IN OBESE SUBJECTS ON A WEIGHT
LOSS DIET
Dick C. Chan, A.T.Y. Wong, P.H.R. Barrett, G.F. Watts, Australia
1634
15:50
FIRST REPORT OF ENZYME REPLACEMENT THERAPY IN A PATIENT
WITH FAMILIAL LCAT DEFICIENCY: RAPID IMPROVEMENT OF LIPID
AND CLINICAL MANIFESTATIONS
Robert Shamburek, R. Bakker-Arkema, B. Krause, B. Auerbach, L.
Freeman, R. Homan, B. Asztalos, E. Schaefer, C. Schwartz, M. Amar, A.
Remaley, USA
1635
16:05
NEW INSIGHTS INTO STATIN ACTION ON THE DYSLIPIDEMIA OF
METABOLIC SYNDROME: NORMALISATION OF BIOACTIVE
PLASMALOGENS AND SPHINGOLIPIDS IN HDL
Peter J. Meikle, G. Wong, A.R. Tan, B.A. Kingwell, A.K. Orsoni, N.
Hounslow, P. Giral, M.J. Chapman, Australia, France, UK
1643
TRIAL EVALUATING AMG 145, A PCSK9 ANTIBODY, IN PATIENTS
WITH HOMOZYGOUS FH: RESULTS OF AN INITIAL DOSESCHEDULING STUDY
Evan A. Stein, N. Honarpour, S.M. Wasserman, F. Xu, R. Scott, F. Raal,
USA, South Africa
1625
16:20
22
14:50-15:35
YOUNG INVESTIGATOR AWARD SESSION
Chairpersons:
Petri Kovanen
Danilo Norata
Time
14:50
,
15:10
WINNER IN BASIC RESEARCH
STEM CELL MOBILIZATION AND CHOLESTEROL EFFLUX
WINNER IN CLINICAL RESEARCH
Y-CHROMOSOME AND CARDIOVASCULAR DISEASE
15:40-16:40
CLINICAL EXPERIENCE OF LOMITAPIDE THERAPY IN PATIENTS WITH HoFH DURING
CLINICAL TRIALS
SPONSORED BY AEGERION
Chairperson: Raul D. Santos
Time
15:40
SELECTING THE RIGHT PATIENTS WHO MAY BE SUITABLE FOR
LOMITAPIDE THERAPY
M. Averna; D. Blom, Italy, South Africa
16:00
PRACTICALITIES OF DRUG ADMINISTRATION INCLUDING DOSE
TITRATION AND DRUG INTERACTIONS
16:20
MANAGEMENT AND MONITORRING OF ADVERSE EFFECTS
17:00-19:00
REVIEWER, AUTHOR WORKSHOP
SPONSORED BY ELSEVIER
23
24
WEDNESDAY, JUNE 5, 2013
Wednesday, June 5, 2013
08:30-10:30
LIPIDS AND LIPOPROTEINS: EMERGING RISK FACTORS AND THERAPIES
Chairpersons:
Marja-Riitta Taskinen
M John Chapman
Time
08:30
TAILORING TREATMENT ACCORDING TO LIPID PHENOTYPE
Anton Stalenhoef,, The Netherlands
09:00
NEW INSIGHTS OBTAINED FROM LIPIDOMICS AS RISK MARKERS
Robert Gerszten, USA
09:30
LIPID SIGNALING AND LIPOTOXICITY
Rudolf Zechner, Austria
10:00
EMERGING THERAPEUTIC APPROACHES TO TREAT DYSLIPIDEMIAS
Chris Packard, UK
10:30-10:50
Exhibition Area
10:50-11:40
ADVANCED CLINICAL SEMINAR: CLINICAL UTILITY OF NON-INVASIVE IMAGING IN CVD
RISK ASSESSMENT
Chairperson: Jacques Bonnet
Time
10:50
ASSESSMENT OF CORONARY ARTERY DISEASE BY COMPUTED
TOMOGRAPHY IS BETTER
11:10
ASSESSMENT OF CAROTID ARTERY DISEASE BY ULTRASOUND AND
MAGNETIC RESONANCE IMAGING IS BETTER
Henrik Sillesen, USA
25
10:50-12:40
PRIMARY AND FAMILIAL DYSLIPIDEMIAS
Chairpersons:
Vincent Durlach
Jan A. Kuivenhoven
Time
10:50
DYSLIPIDEMIA IN CHOLESTERYL ESTER STORAGE DISEASE
11:15
MOLECULAR GENETIC STUDIES IN PATIENTS WITH FAMILIAL
HYPERCHOLESTREOLEMIA
Jan A. Kuivenhoven, The Netherlands
Abstract No.
11:40
A FOURTH TYPE OF AUTOSOMAL DOMINANT
HYPERCHOLESTEROLEMIA CHARACTERIZED BY AN ALTERATION
OF THE LDL ENDOSOMAL TRANSPORT
Mathilde Varret, E. Girard, B. Védie, K. Ouguerram, A. Marques-Pinheiro,
S. Lestavel, M. Guerin, Y. Zair, M. Devillers, M. Krempf, M. Abifadel, J.-P.
Rabès, C. Lamaze, C. Boileau, France, Lebanon
1101
11:55
FAMILIAL HYPERCHOLESTEROLEMIA IS NOT RELATED TO BRAIN
WHITE MATTER DAMAGE BUT ACCENTUATES CORTICAL ATROPHY
IN AGE-RELATED REGIONS
C. Valls-Pedret, D. Vidal-Piñeiro, N. Bargalló, D. Bartrés-Faz, Emilio Ros,
Spain
1503
12:10
GENETICS IN FAMILIAL HYPERCHOLESTEROLEMIA AND THE RISK
OF CARDIOVASCULAR EVENTS
Joost Besseling, B. Sjouke, B. Hutten, J. Kastelein, K. Hovingh, The
Netherlands
1595
12:25
NATURAL HISTORY OF AUTOSOMAL DOMINANT
HYPERCHOLESTEROLEMIA CAUSED BY GAIN-OF-FUNCTION
MUTATIONS IN PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE
9 (PCSK9) (FUNDED BY REGENERON/SANOFI)
Joep C. Defesche, S.W. Fouchier, B. Sjouke, J. Mendoza, S. Mellis, K.
Miller, G.D. Swergold, on behalf of the PCSK9 Natural History Study (NHS)
Group, The Netherlands, USA
147
26
10:50-12:40
Room René Leriche A
METABOLIC REGULATION OF APOLIPROTEIN A-I-CONTAINING LIPOPROTEINS
Chairpersons:
Xavier Collet
Time
10:50
CONSTITUTIVE INHIBITION OF PLASMA CHOLESTERYL ESTER
TRANSFER PROTEIN (CETP): FUNCTIONALITY AND
DYSFUNCTIONALITY IN ANIMAL MODELS AND HUMAN POPULATIONS
11:15
ROLE OF THE ENDOTHELIUM IN HDL METABOLISM
Arnold von Eckardstein, Switzerland
Abstract No
11:40
APOA-I INCREASES INSULIN SECRETION FROM PANCREATIC BETA
CELLS VIA A CAMP-PKA-FOXO1 DEPENDANT MECHANISM
Blake J. Cochran, R.J. Bisoendial, K.-A. Rye, Australia
1312
11:55
THE ROLE OF HIGH DENSITY LIPOPROTEINS IN HUMAN
MACROPHAGE POLARIZATION
X.L. Moore, M.K. Lee, Y. Fu, J.Y. Wong, L. Fang, A.M. Dart, D. Sviridov,
Jaye Chin-Dusting, Australia, China
403
12:10
HIGH-DENSITY LIPOPROTEINS ASSOCIATED MICRORNAS: ORIGINS
AND FUNCTION
Fatiha Tabet, K.C. Vickers, L.F. Cuesta Torres, P.J. Barter, A.T. Remaley,
K.-A. Rye, Australia, USA
946
12:25
GLYCATION OF APOLIPOPROTEIN C1 LEADS TO A LOSS OF ITS
ABILITY TO INHIBIT CHOLESTERYL ESTER TRANSFER PROTEIN
ACTIVITY DURING DIABETES
Benjamin Bouillet1,2, T. Gautier, D. Blache, J.-P. Pais de Barros, L.
Duvillard, J.-M. Petit1,2, L. Lagrost, B. Verges1,2, France
27
435
10:50-12:40
Room René Leriche B
ADVENTITIA AND PERIVASCULAR FAT
Chairpersons:
Patricia Iozzo
Steven B. Feinstein
Time
10:50
UPDATE ON ARTERIAL VASA VASORUM: DIAGNOSIS MONITORING
AND POTENTIAL THERAPIES
Steven.B. Feinstein, USA
11:15
PERIVASCULAR AND EPICARDIAL FAT
Patricia Iozzo, Italy
Abstract No
11:40
AUTOCRINE PRODUCTION OF SONIC HEDGEHOG ENHANCES PDGF
BB-MEDIATED MIGRATION AND PERICYTE RECRUITMENT TO
NEOVESSELS
Q. Yao1,2, M.-A. Renault, C. Chapouly, S. Vanderdionck, I. Belloc, B.
Jaspard-Vinassa, C. Desgranges, Alain-Pierre Gadeau, France
1330
11:55
ROLE OF THE TUMOR SUPPRESSOR CDKN2A/P16INK4A IN THE
DEVELOPMENT OF PERIVASCULAR ADIPOSE TISSUE
K. Wouters, S.A. Hannou, C. Cudejko, J. Vanhoutte, A. Lucas, K.
Bantubungi, E. Vallez, E. Bouchaert, A. Tailleux, B. Staels, Réjane
Paumelle, France
12:10
12:25
PERIVASCULAR ADIPOSE TISSUE AND CORONARY
ATHEROSCLEROSIS
Rudolf Poledne, Z. Tonar, D. Kautznerova, I. Malek, J. Pirk, V. Lanska, J.
Pitha, Czech Republic
1015
284
MACROPHAGES BULLYING T CELLS IN TYPE-A STANFORD ACUTE
AORTIC DISSECTION
Livia Ferri, M. Proietta, C. di Gioia, L. Tritapepe, M. Leopizzi, C. Fantozzi, C.
Chiappetta, I. Nofroni, C. Della Rocca, E. Marinari, A.P. Mitterhofer, A.
Negro, A. Koverech, M. Taurino, F. Del Porto, Italy
699
11:40-12:40
ADVANCED CLINICAL SEMINAR: DO NEW BIOMARKERS HAVE ANY ADDED VALUE IN
CLINICAL DECISION MAKING?
Chairperson: Jan Boren
Time
11:40
LIPIDS AND LIPOPROTEINS
Borge Nordestgaard, Denmark
12:05
INFLAMMATION AND IMAGING
Wolfgang Koenig, Germany
28
POSTER
PRESENTATIONS
Written by top experts in the field
Cardiology
Advances in
er
Editor: J.S. Bor
Vol. 47
Therapy in
Antiplatelet
ib
ACS and A-F
Editors
ny
V.L. Serebrua
D. Atar
(Advances in Cardiology, Vol. 47)
TXA2
ADP
TRAP
Thrombin
Editors:
TPɲ
Ticlopidine
Clopidogrel
Prasugrel
Ticagrelor
TXAS
Aspirin
Antiplatelet Therapy
in ACS and A-Fib
PGH 2
COX
Platelet
acƟvaƟon
AA
ɲ IIbɴ3
Fibrinogen
GP IIb/IIIa
inhibitors
PLA2
Serebruany, V.L. (Towson, Md.);
Atar, D. (Oslo)
Over the last several decades, a better understanding of the pathogenesis of coronary heart
disease and atrial fibrillation has led to refinements in antithrombotic strategies and clinical
outcomes. With this in mind, some of the issues outlined in this book are:
• New insights in genetic testing
• Modification of individualized antiplatelet therapy based on rapid bedside platelet analyzers
• Current update of pros and cons of novel antiplatelet agents (such as prasugrel and ticagrelor)
• Conventional antiplatelet strategies with aspirin and clopidogrel
• Experimental antiplatelet agents like PAR-1 thrombin receptor antagonists or aptamers
Get your copy at the Wisepress booth!
ki13248
Please visit www.karger.com/adcar and read
free chapter excerpts, more details and full table of contents.
13:40-14:40
Moderated Poster Area
MODERATED POSTER SESSION A
Session 1: ENDOTHELIUM AND ATHEROTHROMBOSIS
Moderator: Yiannis Chatzizisis, Greece
Poster Board No.
M1
HOMOCYSTEINE REDUCES PROTEIN S-NITROSYLATION IN
ENDOTHELIAL CELLS
Y. Chen, Enqi Liu, J. Fan, China, Japan
Abstract No
170
M2
CILOSTAZOL ENHANCES CIRCULATING ENDOTHELIAL PROGENITOR
CELLS AND COLLATERAL FORMATION MEDIATED BY MODIFYING
VASCULO-ANGIOGENIC BIOMARKERS IN PATIENTS WITH
PERIPHERAL ARTERIAL DISEASE
I-Chih Chen, T.-H. Chao , S.-Y. Tseng, Y.-S. Tsai, Y.-Y. Huang, P.-Y. Liu,
H.-Y. Ou, Y.-H. Li, G.-Y. Shi, H.-L. Wu, J.-H. Chen, Taiwan R.O.C.
214
M3
TAMOXIFEN ELICITS ATHEROPROTECTION THROUGH ESTROGEN
RECEPTOR ALPHA AF-1 BUT DOES NOT ACCELERATE
REENDOTHELIALIZATION
Coralie Fontaine, A. Abot, A. Billon-Gales, G. Flouriot, E. Grunenwald, A.
Vinel, M.-C. Valéra, P. Gourdy, J.-F. Arnal, France
356
DELETION OF FHL2 GENE IMPAIRED ISCHEMIA-INDUCED BLOOD
FLOW RECOVERY
Pao-Hsien Chu, P.-H. Huang, S.-J. Lin, Taiwan R.O.C.
459
M4
M5
OXIDIZED-HDL3 MODULATES THE EXPRESSION OF T-PA IN HUMAN
ENDOTHELIAL CELLS
Feng Tao Liu, Z.Y. Yu, Z. Ren, Z.H. Tang, R. Wang, L.S. Liu, Z. Wang, Z.S.
Jiang, China
725
M6
ENDOTHELIAL CELL-SPECIFIC ROLE OF THE CHEMOKINE RECEPTOR
CXCR4 IN WIRE INJURY-INDUCED ATHEROSCLEROSIS
Baixue Zhou, Germany
1155
M7
RED BLOOD CELL INFILTRATION OF ATHEROMATOUS LESIONS
INDUCE A VICIOUS CYCLE LEADING TO ENDOTHELIAL ACTIVATION
AND CYTOTOXICITY
Viktória Jeney1,2, L. Potor, M. Soares, G. Balla1,2, J. Balla, Hungary,
Portugal
1323
M8
REMODELING AND ENDOTHELIAL SHEAR STRESS EXHIBIT
SIGNIFICANT LONGITUDINAL VARIATION IN HUMAN CORONARY
ARTERIES: IMPACT ON PLAQUE PROGRESSION
Antonios P. Antoniadis, M.I. Papafaklis, S. Takahashi, M. Tsuda, S.
Mizuno, Y. Makita, T. Domei, T. Ikemoto, A.U. Coskun, J. Honye, S.
Nakamura, S. Saito, C.L. Feldman, P.H. Stone, USA, Japan
29
1526
13:40-14:40
MODERATED POSTER SESSION A (contd.)
Session 2: REGULATION OF CELLULAR LIPID METABOLISM IN ATHEROGENESIS
Moderator: Bart Staels, France
Poster Board No.
Abstract No
M59
ADIPOCYTE ENHANCER-BINDING PROTEIN 1 OVER-EXPRESSION
PROMOTES AND ABLATION ATTENUATES ATHEROSCLEROSIS IN
APOE-/- AND LDLR-/- MICE
Amin Majdalawieh, O. Bogachev, X. Pan, L. Zhang, H.-S. Ro, United Arab
Emirates, Canada
315
M60
AUTOPHAGY IS NOT INVOLVED TO PROVIDE FREE CHOLESTEROL
FOR ABCA1-MEDIATED EFFLUX IN CHOLESTEROL-LOADED HUMAN
MONOCYTE-DERIVED MACROPHAGES
512
Natalie Fournier1,2, M. Passet, E. Girard, B. Vedie, J.-L. Paul1,2, France
M61
CHOLESTEROL EFFLUX IS ASSOCIATED WITH PLASMA
TRIACYLGLYCEROL SPECIES CONTAINING SATURATED FATTY
ACIDS
Peter J. Meikle, T.W. Ng, R. Tan, K. Huynh, G. Wong, C.K. Barlow, J.M.
Weir, A.J. White, B.A. Kingwell, Australia
640
M62
ACUTE EFFECT OF PLANT STANOL ESTERS ON HEPATIC STEROL
METABOLISM IN MICE
Els De Smet, R. Mensink, M. Konings, G. Brufau, B. Groen, R. Havinga, M.
Schonewille, A. Kerksiek, D. Lütjohann, J. Plat, The Netherlands, Germany 801
M63
GENETIC DETERMINATION OF PLASMA CHOLESTEROL EFFLUX
CAPACITY IS GENDER-SPECIFIC AND INDEPENDENT OF HDLCHOLESTEROL LEVELS
Elise Florence Villard, P. El Khoury, E. Frisdal, E. Bruckert, K. Clement, D.
Bonnefont-Rousselot, R. Bittar, W. Le Goff, M. Guerin, France
973
M64
GLOBAL NRF2 DEFICIENCY ALLEVIATES DIET-INDUCED
ATHEROSCLEROSIS IN LDL RECEPTOR DEFICIENT MICE
Anna-Kaisa Ruotsalainen, E. Tapper, J. Lappalainen, S. Ylä-Herttuala, A.L. Levonen, Finland
984
M65
PHYTOSTEROL FEEDING DOWNREGULATES MOUSE PERITONEAL
MACROPHAGE ABCG1 MRNA AND PREVENTS ATHEROSCLEROSIS IN
LDL-RKO MICE
Renata Bombo, R. Machado, M. Afonso, M.S. Lavrador, E. Nakandakare, V.
Nunes, C. Lin, M. Koike, E. Quintao, A.M. Lottenberg, Brazil
1053
M66
CHOLESTEROL CRYSTALS IN EARLY HUMAN ATHEROMA
B. Ho-Tin-Noé, V. Ollivier, J.-B. Michel, Sophie Vo, France
30
1461
13:40-14:40
Session 3: ROLE OF LIPASES IN LIPID AND LIPOPROTEIN METABOLISM
Moderator: Geesje Dallinga-Thie, Netherlands
Poster Board No.
M67
Abstract No
THE EFFECTS OF VEGF-A ON ATHEROSCLEROSIS, LIPOPROTEIN
PROFILE AND LIPOPROTEIN LIPASE IN HYPERLIPIDEMIC MOUSE
MODELS
Annukka Kivelä, S. Heinonen, M. Dijkstra, E. Gurzeler, J. Huusko, P.
Mäkinen, P. Leppänen, V. Olkkonen, U. Eriksson, M. Jauhiainen, S. YläHerttuala, Finland, Sweden
229
M68
AAV-DRIVEN OVEREXPRESSION OF HANGPTL4 IN APOE-/- MICE
AGGRAVATES PLASMA TG LEVELS BUT DOES NOT AFFECT POSTHEPARIN PLASMA LIPOPROTEIN LIPASE ACTIVITY
Madelene Eriksson, S.K. Nilsson, C. Schlein, J. Heeren, Sweden, Germany517
M69
RELATIONSHIP OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2
MASS AND ACTIVITY WITH TRADITIONAL LIPOPROTEIN
BIOMARKERS IN A TUNISIAN STUDY
Mazen Belhabib, M. Caslake, A. Bekir, H. Chahed, J. Cooney, A. Lewis, D.
Bedford, T. Trimech, F. Maatouk, S. Ferchichi, A. Miled, Tunisia, UK
518
M70
LIPOPROTEIN LIPASE MASS IS A PREDICTIVE MARKER OF
CARDIOVASCULAR AND CEREBROVASCULAR EVENT IN FUTURE
Haruki Imamura, K. Endo, A. Saiki, T. Murano, Y. Sato, T. Yamaguchi, N.
Ban, H. Kawana, D. Nagayama, A. Nagumo, M. Ohira, S. Yamamura, K.
Shirai, I. Tatsuno, Japan
M71
A NEW POSSIBLE ROLE FOR ANGIOPOIETIN LIKE 3, A REGULATOR
OF TRIGLYCERIDE METABOLISM, IN MODULATING INSULIN
RESISTANCE
Marianna Maranghi, I. Minicocci, G. Tiseo, A. Montali, P. Coletta, D.
Pergolini, G. Pigna, E. Ciociola, C. Durante, G. Labbadia, M. Arca, Italy
1017
M72
APOA5 DOWN-REGULATION THROUGH MIRNA INTERACTION WITH
POLYMORPHIC 3'UTR
Cyrielle Caussy1,2, S. Charrière1,2, C. Marçais2,3, M. Di Filippo2,4, A.
1090
Sassolas2,4, E. Lefai, S. Rome, P. Moulin1,2, France
M73
HUMAN POLYMORPHISMS OF ENDOTHELIAL LIPASE DISPLAY
IMPAIRED HYDROLYSIS OF HIGH-DENSITY LIPOPROTEINS
Kate Shearston, D. Marais, K.-A. Rye, G. Lambert, Australia, South Africa,
France
1316
M74
ANGPTL4 MEDIATES THE SHORT-POSTER BOARD NO. EFFECTS OF
TNF-ALPHA ON THE LPL SYSTEM IN 3T3-L1 ADIPOCYTES
Evelina Vorrsjö, E. Makoveichuk, T. Olivecrona, G. Olivecrona, Sweden 1378
31
652
13:40-14:40
Session 4: EVALUATION AND TREATMENT OF CARDIOVASCULAR RISK FACTORS IN
THE YOUNG AND THE ELDERLY
Moderator: George D. Davey-Smith, UK
Poster Board No.
Abstract No
M117
ENDOGENOUS SEX HORMONES, ISCHEMIC HEART DISEASE AND
EARLY DEATH IN WOMEN FROM THE GENERAL POPULATION
Marianne Benn, S.S. Voss, G.B. Jensen, B.G. Nordestgaard, Denmark
977
M118
HIGH PREVALENCE OF ATHEROSCLEROSIS IN ARTERIES OF
ANCIENT MUMMIES DETERMINED BY NEAR INFRARED
SPECTROSCOPY
Mohammad Madjid, N. Fuenffinger, K. Stutler, R. Lodder, USA
328
M119
LIPOPROTEIN(A): FASTING AND NONFASTING LEVELS,
INFLAMMATION, AND CARDIOVASCULAR RISK PREDICTION
Anne Langsted, P.R. Kamstrup, B.G. Nordestgaard, Denmark
1175
M120
INCREASE IN THE INCIDENCE OF ACUTE CORONARY SYNDROME
AFTER THE 2011 EAST JAPAN NATURAL DISASTER: CONCORDANCE
WITH SEQUENTIAL QUAKE SHOCKS
Masanobu Niiyama, F. Tanaka, K. Sato, T. Takahashi, T. Onoda, T.
Segawa, M. Onodera, M. Kawakami, M. Ogawa, H. Endoh, T. Matsumoto, K.
Sakata, M. Nakamura, Japan
1413
M121
FIBROBLAST GROWTH FACTOR 23, PARATHYROID HORMONE AND
RISK OF HEART FAILURE IN A MIDDLE-AGED GERMAN POPULATION
Romina di Giuseppe, B. Buijsse, F. Hirche, J. Wirth, M. Arregui, H.W.
Hense, J. Dierke, H. Boeing, G.I. Stangl, C. Weikert, Germany, Norway
1475
M122
LABORATORY VS. NON-LABORATORY YOUTH RISK MEASURES FOR
PREDICTING CAROTID INTIMA-MEDIA THICKNESS IN ADULTHOOD:
THE INTERNATIONAL CHILDHOOD CARDIOVASCULAR COHORT
CONSORTIUM
Costan G. Magnussen1,2, M. Juonala, J.S.A. Viikari, G.S. Berenson, T.
Dwyer, A. Venn, O.T. Raitakari, Finland, Australia, USA
1477
M123
USE OF FIBRATES IN PRIMARY PREVENTION IN TYPE 2 DIABETIC
PATIENTS AT HIGH CARDIOVASCULAR RISK
Ronan Roussel1,2, C. Chaignot, A. Weill, B. Hansel, F. Travert, P.
Ricordeau, F. Alla, H. Allemand, France
1514
M124
NAFLD IS INCREASED IN PATIENTS WITH CV RISK FACTORS AND IS
CORRELATED WITH ATHEROSCLEROSIS AND THE FRAMINGHAM
SCORE
R. Pais, D. Rosenbaum, P. Lebray, D. Thabut, M. Rudler, V. Ratziu, Philippe
Giral, France
1242
M125
EFFECT OF SHIFTWORK ON BODY MASS INDEX AMONG FEMALE
NURSES IN KOREA: NURSES' HEALTH STUDY
Min-Ju Kim, H.-Y. Park, K.-H. Son, M.-C. Cho, D.-J. Choi, the Nurses Health
Study(NHS) Group, Republic of Korea
1435
32
13:40-14:40
Session5: INFLAMMATION AND HDL
Moderator: Dimitris Kardassis, Greece
Poster Board No.
Abstract No
M75
EVIDENCE FROM AN INTEGRATED ANALYSIS COMBINING
GENOMICS, TRANSCRIPTOMICS, AND LIPIDOMICS HIGHLIGHTS THE
ROLE OF INFLAMMATION IN LOW HDL-C STATE
Pirkka-Pekka Laurila, I. Surakka, A.-P. Sarin, J. Tang, T. Hyötyläinen, S.
Söderlund, J. Naukkarinen, J. Kettunen, D. Mirel, J. Soronen, T. Lehtimäki,
A. Ruokonen, C. Ehnholm, J. Eriksson, V. Salomaa, A. Jula, O. Raitakari, M.R. Järvelin, A. Palotie, M. Oresic, S. Ripatti, M. Jauhiainen, M.-R. Taskinen,
Finland, USA
429
M76
HUMAN APOA-I AFFECTS THE INFLAMMATORY RESPONSE
MEDIATED BY CD4+ T-LYMPHOCYTES DURING ATHEROSCLEROSIS
PROGRESSION
Marco Busnelli, F. Sala, L. Arnaboldi, C. Parolini, S. Manzini, D. Norata, G.
Chiesa, Italy
1497
M77
GENETIC ABLATON OF THE P2Y2 NUCLEOTIDE RECEPTOR REDUCES
VASCULAR INFLAMMATION AND ATHEROSCLEROSIS IN MICE
Cheikh Seye, S. Qian, USA
1360
M78
PREVALENCE OF CLASSICAL CD14++/CD16- BUT NOT OF
INTERMEDIATE CD14++/CD16+ MONOCYTES IN HYPOALPHALIPOPROTEINEMIA
Fabrizia Bonacina, L. Cutuli, F. Sala, L. Grigore, S. Fiorelli, K. Garlaschelli,
1533
G. Chiesa, A.L. Catapano1,3, G.D. Norata1,2, Italy
M79
RESVERATROL ADMINISTRATION OR SIRT1 OVEREXPRESSION DOES
NOT INCREASE LXR SIGNALING AND MACROPHAGE-TO-FECES
REVERSE CHOLESTEROL TRANSPORT IN VIVO
J.C. Escolà-Gil, J. Julve, G. Llaverias, M. Urpi-Sarda, R. Silvennoinen, M.
Lee-Rueckert, C. Andres-Lacueva, Francisco Blanco-Vaca, Spain, Finland1288
M80
OXLIG-1, A NOVEL PPAR GAMMA AGONIST, INCREASE ABCA1
EXPRESSION AND PROMOTE CHOLESTEROL EFFLUX FROM THP-1
MACROPHAGES
Yan Chi, R. Wang, F. Zhang, X. Han, Z. Liu, Q. Liu, China
1379
M81
ASSOCIATION BETWEEN REVERSE CHOLESTEROL TRANSPORT
RATE AND LIPOPROTEIN BIOMARKERS USING A NOVEL IN SILICO
MODEL OF LIPOPROTEIN METABOLISM AND KINETICS
James Lu, K. Hϋbner, E.A. Brinton, M.N. Nanjee, N.A. Mazer, Switzerland,
Germany, USA
1108
33
13:40-14:40
Session 6: THROMBOSIS AND HEMOSTASIS: RELATION TO ATHEROTHROMBOSIS AND
LIPOPROTEINS
Moderator: Pierre Morange, France
Poster Board No.
Abstract No
M9
HIGH CONCENTRATIONS OF LOW DENSITY LIPOPROTEINS (LDL)
INCREASE TISSUE FACTOR-DEPENDENT PROCOAGULANT ACTIVITY
IN PLATELETS
Susana Contreras-Duarte, C. González, P. Hidalgo, A. Rigotti, D. Mezzano,
O. Panes, Chile
227
M10
ANTAGONIZING THE EP3 RECEPTOR FOR PGE2 WITH DG-041
PREVENTED THROMBOSIS WITH NO IMPACT ON HEMOSTASIS
P. Tilly, A.-L. Charles, S. Ludwig, J.-B. Michel, B. Geny, Jean-Etienne
Fabre, France
682
M11
IS PLATELET MEDIATED LEUKOCYTE RECRUITMENT A DRUGABLE
TARGET IN ATHEROSCLEROSIS?
Matthew James Harrison, G. Nash, S. Watson, E. Rainger, UK
988
M12
M13
M14
OXIDIZED HDL INHIBIT HUMAN PLATELET AGGREGATION
Catherine Calzada, E. Véricel, Q.-H. Le, M. Lagarde, P. Moulin, France
HDL-BASED THERAPY REDUCES THE HEMORRHAGIC
COMPLICATIONS ASSOCIATED WITH TISSUE PLASMINOGEN
ACTIVATOR TREATMENT IN EXPERIMENTAL STROKE
Bertrand Lapergue, B.Q. Dang, J.P. Desilles, G. Ortiz, S. Delbosc, S.
Loyau, L. Louedec, P.O. Couraud, M. Mazighi, J.B. Michel, O. Meilhac, P.
Amarenco, France
PENTRAXIN 3 DEFICIENCY IS ASSOCIATED WITH INCREASED
ARTERIAL THROMBOSIS IN ANIMAL MODELS
Fabrizia Bonacina, S.S. Barbieri, L. Cutuli, P. Amadio, M. Sironi, B.
Bottazzi, C. Garlanda, E. Tremoli1,2, A. Mantovani, G.D. Norata1,4, A.L.
Catapano1,5, Italy
34
1041
301
1553
13:40-14:40
Session 7: FATTY ACIDS INFLUENCE ATHEROSCLEROSIS AND ITS RISK FACTORS:
THE DOUBLE BONDS DECIDE
Moderator: Michel Lagarde, France
Poster Board No.
Abstract No
M126
IMPACT OF N-3 TO N-6 POLYUNSATURATED FATTYACID RATIO ON
VASCULAR FUNCTION IN ISCHEMIC HEART DISEASE PATIENTS WITH
IDEAL LDL LEVEL
Hitoshi Adachi, H. Takamatsu, J. Tomono, S. Oshima, Japan
241
M127
MEDITERRANEAN DIET AND 2.4-YEAR CHANGES IN ULTRASOUNDASSESSED CAROTID INTIMA-MEDIA THICKNESS AND PLAQUE: A
SUB-STUDY OF THE PREDIMED TRIAL
Aleix Sala-Vila, E.S. Romero-Mamani, R. Gilabert, I. Núñez, E. Toledo, V.
Ruiz-Gutiérrez, R.M. Lamuela-Raventós, X. Pintó, F. Arós, M. Fiol, M.I.
Covas, M.Á. Martínez-González, R. Estruch, E. Ros, Spain
981
M128
OMEGA 3 FATTY ACIDS PROMOTE MACROPHAGE REVERSE
CHOLESTEROL TRANSPORT IN HAMSTER FED HIGH FAT DIET
Fatima Kasbi Chadli1,2, E.-H. Nazih, M. Krempf, P. Nguyen, K. Ouguerram,
France
421
M129
VASCULAR FUNCTION AFTER N-3 POLYUNSATURATED FATTY ACIDS
SUPPLEMENTATION IN AN ANIMAL MODEL OF EXPERIMENTAL
MENOPAUSE
Andrea Grillo, P. Losurdo, E. Panizon, M. Jevnikar, L. Macaluso, M. Zanetti,
B. Fabris, R. Carretta, Italy
450
M130
IMPACT OF DIFFERENT DIETARY TREATMENTS ON THE MOLECULAR
LIPID PROFILE OF AORTIC PLAQUES DEVELOPED IN APOE-/- MICE
C. Parolini, M. Busnelli, Stefano Manzini, G. Ganzetti, M. Jänis, K. Tarasov,
R. Hurme, K. Ekroos, R. Laaksonen, G. Chiesa, Italy, Finland
1509
Session 8: INSULIN-RESISTANT STATES: MODULATORS OF LIPID METABOLISM
AND CARDIOVASCULAR DISEASE
Moderator: Klaus Parhofer, Germany
M131
M132
INFLUENCE OF LIPIDS AND APOLIPOPROTEINS ON INSULIN
SENSITIVITY: A CROSS-SECTIONAL ANALYSIS OF THE RISC STUDY
Simona Baldi, F. Bonnet, M. Laville, C. Morgantini, E. Ferrannini, A. Natali,
on behalf of the RISC Investigators, Italy, France
419
HETEROZYGOUS GLUCOKINASE KNOCKOUT MICE IN APOE
DEFICIENT BACKGROUND REPRESENT A NOVEL DISEASE MODEL
FOR TYPE 2 DIABETES AND ATHEROSCLEROSIS
Suvi E. Heinonen, A.-C. Andréasson, M. Brusberg, L. Hägerstrand, K.
Jennbacken, A. Ahnmark, B. Leighton, A.-C. Jönsson-Rylander, Sweden, UK632
35
13:40-14:40
Session 8: INSULIN-RESISTANT STATES: MODULATORS OF LIPID METABOLISM
AND CARDIOVASCULAR DISEASE (contd.)
Poster Board No.
Abstract No
M133
ASSOCIATION OF FASTING GLUCOSE LEVEL 6 MONTHS AFTER PCI
WITH THE DEVELOPMENT OF MACE IN DES-IMPLANTED PATIENTS
ON STATIN THERAPY
Dong Oh Kang, H.S. Seo, B. Choi, C. Choi, E.M. Lee, S.I. Lim, S.W. Kim,
J.O. Na, C.U. Choi, H.E. Lim, J.W. Kim, E.J. Kim, S.-W. Rha, C.G. Park, D.J.
Oh, Republic of Korea
661
M134
PCSK9 CIRCULATING LEVELS ARE INCREASED IN TYPE 2 DIABETIC
PATIENTS REGARDLESS OF METABOLOMIC DIFFERENCES IN LIPID
PROFILE
Anna Cabré, N. Plana, D. Ibarretxe, M. Heras, S. Guaita, J. Merino, J.
Ribalta, L. Masana, Spain
979
M135
LIPID PROFILES IN DIABETIC SUBJECTS - ASSOCIATIONS WITH
CARDIOVASCULAR DISEASE
O. Piksasova, V. Schnecke, F. Agakov, P. McKeigue, K. Leander, U.
deFaire, I. Brady, H. Looker, H. Colhoun, A. Hamsten, John Öhrvik,
SUMMIT Consortium, Sweden, UK
1057
CHARACTERIZATION OF ATHEROGENIC DYSLIPIDEMIA USING A
NOVEL NMR-BASED ADVANCED LIPOPROTEIN TEST IN TYPE 2
DIABETIC SUBJECTS
Roger Mallol1,2,3, A. Cabré1,2,3, M.A. Rodríguez1,2,3, N. Amigó1,2,3, M.
Vinaixa1,2,3, N. Plana, M. Heras1,2,3, L. Masana1,2,3, X. Correig1,2,3, Spain
1502
M136
M137
PREVALENCE AND DETERMINANTS OF FATTY LIVER IN NORMAL
WEIGHT AND OVERWEIGHT YOUNG ADULTS. THE CARDIOVASCULAR
RISK IN YOUNG FINNS STUDY
Mervi Oikonen, M. Kähönen, J. Viikari, M. Juonala, O.T. Raitakari1,4, The
Young Finns Study Group, Finland
1537
M138
VANCOMYCIN DECREASES INSULIN SENSITIVITY AND IS
ASSOCIATED WITH ALTERATIONS IN INTESTINAL MICROBIOTA
AND BILE ACID COMPOSITION IN METABOLIC SYNDROME
SUBJECTS
Ruud Kootte, C. Out, S. Fuentes, L. Jonker, A. Vrieze, E. Van Nood, F.
Holleman, G. Dallinga-Thie, H. Romijn, M. Soeters, E. Blaak, D.
Reijnders, M. Ackermans, M. Serlie, F. Knop8,9, J. Holst, E. Stroes, E.
Zoetendal, W. De Vos3,10, J. Hoekstra, B. Groen, M. Nieuwdorp1,4, The
Netherlands, Denmark
M139
ISCHEMIC HEART DISEASE IN OVERWEIGHT AND OBESITY WITH AND
WITHOUT THE METABOLIC SYNDROME
M. Thomsen, Børge Nordestgaard, Denmark
1472
36
1546
12:40-13:40
MODERATED POSTER SESSION B
Session 9: CELL DYSFUNCTIONS IN ATHEROGENESIS
Moderator: Catherine Shanahan, UK
Poster Board No.
Abstract No
M15
AUTOPHAGY AND ER STRESS ARE INDUCED BY OXIDIZED LDL:
ROLE IN VASCULAR ENDOTHELIAL CELLS APOPTOSIS AND
ATHEROGENESIS
C. Muller, M. Bisserier, A. Swiader, A. Nègre-Salvayre, F. Lezoualc'h, R.
Salvayre, Cécile Vindis, France
478
M16
SPHINGOSINE-1-PHOSPHATE (S1P) INHIBITS TNFA-STIMULATED
MMP-9 EXPRESSION IN MACROPHAGES AND SMOOTH MUSCLE
CELLS VIA DIFFERENT S1P RECEPTORS
Petra Keul, G. Heusch, B. Levkau, Germany
619
M17
IN VIVO IMAGING OF APOPTOSIS AT ATHEROSCLEROTIC PLAQUE
USING APOPTOSIS-TARGETED PEPTIDE PROBE
Byung-Heon Lee, Republic of Korea
731
M18
SP1, ACETYLATED HISTONE-3 AND P300 REGULATE TRAIL TO
PROMOTE PDGF-BB-MEDIATED VASCULAR SMOOTH MUSCLE CELL
PROLIFERATION AND MIGRATION
936
N.S. Azahri, B. Di Bartolo, L. Khachigian, Mary Kavurma1,2, Australia
M19
DISSECTION OF ACTIVATION FUNCTIONS (AF-1 AND AF-2) OF
ESTROGEN RECEPTOR ALPHA IN VIVO: UNCOUPLING VASCULAR
AND SEXUAL EFFECTS
Anne Abot, C. Fontaine, I. Raymond-Letron, G. Flouriot, M. Adlanmerini,
M. Buscato, P. Gourdy, F. Lenfant, J.-F. Arnal, France
1021
M20
EFFECT OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9
(PCSK9) ON SMOOTH MUSCLE CELL PROLIFERATION AND
MIGRATION
Nicola Ferri, G. Tibolla, F. Maglione, P. Costet, A. Corsini, A.L. Catapano1,3,
Italy, France
1209
M21
MACROPHAGE PHENOTYPIC DIVERSITY DURING
ATHEROSCLEROSIS REGRESSION
J.E. Feig, Y. Vengrenyuk, B. Hewing1,2, K.J. Moore, Edward A.
Fisher, USA, Germany
1424
MICRORNAS 143/145 DEFICIENCY LIMITS ATHEROSCLEROSIS IN
ANIMAL MODELS
Federica Sala, L. Elia, G. Condorelli1,2, A.L. Catapano1,3, G.D. Norata1,4,
Italy
1468
M22
37
12:40-13:40
MODERATED POSTER SESSION B (contd.)
Session 10: ANGIOGENESIS
Moderator: Jan Nilsson, Sweden
Poster Board No.
Abstract No
M23
NOGO B EXPRESSION AND THE ADVENTITIAL LYMPHANGIOGENESIS
IN HUMAN DONOR'S ARTERIES
Katarzyna Magdalena Drożdż, I. Grzegorek, M. Chmielewska, A.
Gomułkiewicz, K. Jabłońska, A. Piotrowska, D. Janczak, M. PodhorskaOkołów, P. Dzięgiel, A. Szuba, Poland
152
M24
ANTI-ATHEROSCLEROTIC EFFECT OF AN ANTIBODY THAT BINDS TO
EXTRACELLULAR MATRIX GLYCOSAMINOGLYCANS
Ana María Vázquez, Y. Soto, E. Acosta, L. Delgado, A. Pérez, V. Falcón,
M.A. Becquer, A. Fraga, V. Brito, I. Alvarez, T. Griñán, Y. FernándezMarrero, A. López-Requena, M. Noa, E. Fernández, Cuba
238
M25
QA-1-RESTRICTED CD8+ T REGULATORY CELLS CONTROL THE
DEVELOPMENT OF PRO-ATHEROGENIC ADVENTITIAL TERTIARY
LYMPHOID ORGANS IN APOLIPOPROTEIN E KO MICE
Marc Clement1,2, K. Guedj1,2, M. Morvan, J. Khallou-Laschet1,2, A.-T. Gaston,
386
H.-J. Kim3,4, H. Cantor3,4, G. Caligiuri, A. Nicoletti1,2, France, USA
M26
ELASTASE INHIBITOR TREATMENT PREVENTS ABDOMINAL AORTIC
ANEURYSM GROWTH
Sandrine Delbosc1,2, J.-M. Alsac1,3, M. Rouer, L. Louedec1,2, M. Philippe1,2,
610
O. Meilhac1,2, C. Whatling, J.B. Michel1,2, France, Sweden
M27
NON-INVASIVE ASSESSMENT OF NEOANGIOGENESIS AND
INFLAMMATION IN INTERMEDIATE LESIONS OF HUMAN CAROTID
ARTERIES
Maria Drakopoulou, K. Toutouzas, G. Benetos, C. Aggeli, C. Nikolaou, I.
Felekos, H. Grassos, A. Synetos, K. Stathogiannis, A. Karanasos, E.
Tsiamis, E. Siores, C. Stefanadis, Greece, UK
M28
M29
M30
837
-/-
TRAIL MICE DISPLAY REDUCED NEOVASCULARISATION AFTER
HIND-LIMB ISCHEMIA: IMPLICATIONS FOR TRAIL IN REGULATING
PROANGIOGENIC GENES
Belinda Ann Di Bartolo, L.P. Lourenco, N.S. Azahri1,2, L.M. Khachigian,
M.M. Kavurma2,3, Australia
924
SIRT1 SUPPRESSES HYPOXIA-INDUCED HIF-1Α EXPRESSION AND
ATTENUATES NEOINTIMA FORMATION VIA INHIBITION OF
NEOVASCULARIZATION AFTER ARTERIAL INJURY IN MICE
Jinung Bae, S.J. Lee, K.W. Hong, S.Y. Park, C.D. Kim, Republic of Korea
933
ESSENTIAL ROLE FOR SPHINGOSINE-1-PHOSPHATE IN OXIDIZED
LOW DENSITY LIPOPROTEIN-INDUCED ANGIOGENESIS. PREVENTION
BY ANTI-S1P ANTIBODY
Caroline Camaré, M. Trayssac, B. Garmy-Susini, R. Sabbadini, R. Salvayre,
A. Nègre-Salvayre, France, USA
1257
38
12:40-13:40
Session 11: LIFESTYLE
Moderator: Angela Rivellese, Italy
Poster Board No.
Abstract No
M140
GENETIC VARIATION IN FADS MODIFIES THE ASSOCIATION
BETWEEN ALA/LA AND INCIDENCE OF CARDIOVASCULAR DISEASE
Sophie Hellstrand, E. Sonestedt, U. Ericson, B. Gullberg, E. Wirfält, M.
Orho-Melander, Sweden
411
M141
TRANS-FATTY ACID ACCELERATES THROMBUS FORMATION IN VIVO
THROUGH INHIBITING ENDOTHELIAL ANTI-THROMBOGENIC ACTIONS
Kensuke Kondo, T. Yasuda, J. Yamamoto, T. Monguchi, K. Mori, M.
Hasokawa, H. Haraguchi, H. Nakajima, M. Shinohara, R. Toh, T. Ishida, K.
Hirata, Japan
414
M142
CARBOHYDRATE-RICH FOODS AND RISK OF CARDIOVASCULAR
DISEASE IN THE MALMÖ DIET AND CANCER COHORT
Emily Sonestedt, S. Hellstrand, M. Orho-Melander, Sweden
M143
THE EFFECTS OF DARK CHOCOLATE ON ENDOTHELIAL FUNCTION
AND PULSE-WAVE SHAPE IN HEALTHY PERSONS
Oxana Dikur, A. Parfenov, Y. Ashikhmin, Russia
810
M144
THE DECREASE IN CARDIORESPIRATORY FITNESS IS RELATED TO
THE RISK OF ACUTE MYOCARDIAL INFARCTION AND ALL-CAUSE
MORTALITY IN MEN
Jari Laukkanen, S. Kurl, R. Rauramaa, KIHD, Finland
853
M145
REPLACING A SFA DIET WITH DIETARY PUFA REDUCES HEPATIC
PCSK9 MRNA AND PLASMA LIPIDS IN RATS
Sara Straniero, L. Persson, B. Angelin, M. Rudling, Sweden
597
1225
M146
EFFECTS OF OMEGA-3 POLYUNSATURATED FATTY ACIDS ON
ADIPOKINE LEVELS IN PATIENTS UNDERGOING PERCUTANEOUS
CORONARY INTERVENTION
Grzegorz Gajos, M. Mostowik, J. Zalewski, J. Nessler, A. Undas, Poland 1235
M147
EFFECTS OF LIFESTYLE MODIFICATION PROGRAM IN REDUCTION OF
RISK FACTORS IN PATIENTS WITH CORONARY HEART DISEASE
Solmaz Aminpour, M. Shahamfar, J. Shahamfar, Iran
704
M148
THE FREQUENCY OF ALCOHOL CONSUMPTION IS ASSOCIATED WITH
THE INCREASED RISK OF STROKE MORTALITY
Sanna Helena Rantakömi, S. Kurl, J. Sivenius, J. Kauhanen, J.A.
Laukkanen, Finland
1345
39
12:40-13:40
Session 12: CV RISK FACTORS 1
Moderator: Jacques Bonnet, France
Poster Board No.
Abstract No
M149
ASSOCIATIONS BETWEEN SERUM URIC ACID AND MARKERS OF
SUBCLINICAL ATHEROSCLEROSIS. THE CARDIOVASCULAR RISK IN
YOUNG FINNS STUDY
Mervi Oikonen, M. Wendelin-Saarenhovi, L.-P. Lyytikäinen3,4, O.T.
Raitakari, Cardiovascular Risk in Young Finns Study, Finland
444
M150
OUTCOMES FOLLOWING CORONARY REVASCULARIZATION IN
CHINESE, SOUTH ASIAN AND WHITE PATIENTS WITH ACUTE
MYOCARDIAL INFARCTION
D. Gasevic1,2, N. Khan, H. Qian, S. Karim, G. Simkus, H. Quan, M. Mackay,
Amir Ayyobi, Canada
514
M151
SKIN CANCER AS A MARKER OF SUN EXPOSURE AND RISK OF
MYOCARDIAL INFARCTION, HIP FRACTURE, AND EARLY DEATH
Peter Brøndum-Jacobsen, B.G. Nordestgaard, S.F. Nielsen, M. Benn,
Denmark
573
M152
MAXIMAL BLOOD PRESSURE RESPONSE TO EXERCISE IS
ASSOCIATED WITH SUBCLINICAL ATHEROSCLEROSIS IN
NORMOTENSIVE ADOLESCENTS
Egle Silva, J.J. Villasmil, L. Chacin, G. Bermudez, M. Bracho, A. Gonzalez,
Venezuela
638
M153
HIGH LEVEL OF TRIGLYCERIDES IN CHILDREN OF PATIENTS WITH
EARLY CORONARY ARTERY DISEASE: RELATION TO OWN AND
PARENTAL RISK FACTORS
Mikhail Konnov, L. Dobordzhginidze, N. Gratsiansky, Russia
919
M154
PROGNOSTIC ROLE OF EOSINOPHILIC CATIONIC PROTEIN IN
PATIENTS WITH ST-ELEVATION MYOCARDIAL INFARCTION TREATED
BY PRIMARY PERCUTANEOUS CORONARY INTERVENTION
A. Imaeva, F. Fracassi, N. Cosentino, L. Cataneo, M. Roberto, D. Schiavino,
G. Niccoli, F. Crea, Giorgia Copponi, Russia, Italy
1183
M155
FACTOR V LEIDEN AND PROTHROMBIN G20210A MUTATION IN
ISCHEMIC STROKE PATHOGENESIS: ESH STROKE SURVEY
Alena Krajcoviechova, P. Wohlfahrt, O. Mayer, J. Vanek, J. Kvasnicka, T.
Kvasnicka, J. Filipovsky, R. Cifkova, Czech Republic
1473
M156
METABOLOMIC PROFILES IN LEAN AND OBESE ADOLESCENTS
Yun Chen, M. Peitzsch, G. Eisenhofer, P. Friberg, Sweden, Germany
M157
1483
THE RELATION OF ALCOHOL CONSUMPTION LEVELS WITH THE
CARDIO-ANKLE VASCULAR INDEX (CAVI) IS J-SHAPED IN HEALTHY
MIDDLE-AGED JAPANESE MEN
Masatsune Ogura, T. Kobayashi, K. Ikewaki, Japan
494
40
12:40-13:40
Poster Board No.
Abstract No
Session 13: ATHEROSCLEROSIS-REGULATING FACTORS IN MOUSE AND MAN 2
Moderator: Christoph Binder, Austria
M31
LACK OF NICOTINE ALPHA 7 RECEPTOR ACCELERATES
ATHEROSCLEROSIS IN LDLR-/- MICE
Maria E. Johansson1,2, M.A. Ulleryd, A.M. Lundberg, L. Fogelstrand, Z.-Q.
Yan, G.K. Hansson, Sweden
591
M32
LOW DOSE ASPIRIN REDUCES PLASMA CHEMERIN LEVELS IN
CORONARY ARTERY DISEASE PATIENTS THROUGH REDUCTION OF
ADIPOSE TISSUE INFLAMMATION
Magdalena Herová1,2, C. Loretz, M. Schmid, M. Hersberger1,2, Switzerland 1027
M33
CROSS-TALK BETWEEN ACTIVATED MONOCYTES AND SMOOTH
MUSCLE CELLS UP-REGULATES RESISTIN EXPRESSION BY
ACTIVATION OF STAT3 TRANSCRIPTION FACTOR
A.M. Gan, M. Pirvulescu, D. Stan, V. Simion, M. Calin, I. Manduteanu, Elena
Butoi, Romania
1326
M34
THE EXTRACELLULAR TOLL LIKE RECEPTOR 4 REGULATOR RP105
(CD180) AMELIORATES ATHEROSCLEROSIS VIA ITS ROLE ON BCELLS
J.C. Karper, S.C.A. de Jager, M.M. Ewing, M.R. De Vries, I. Bot, R. Arens,
J.W. Jukema, Z. Mallat, C.J. Binder6,7, J. Kuiper, Paul H.A. Quax, The
Netherlands, France, Austria
987
M35
THERAPEUTIC TARGETING OF JAK/STAT/SOCS PATHWAY REDUCES
ATHEROSCLEROSIS IN DIABETIC MICE
Carlota Recio, A. Oguiza, I. Lazaro, B. Mallavia, J. Egido, C. GomezGuerrero, Spain
509
M36
TWEAK/FN14 INTERACTION PROMOTES OXIDATIVE STRESS
THROUGH NADPH OXIDASE ACTIVITY IN MACROPHAGES
J. Madrigal-Matute1,2, Valvanera Fernández-Laso, C. Sastre, J. Egido, J.L.
Martín-Ventura, G. Zalba, L.M. Blanco-Colio, Spain, USA
268
M37
MOLECULAR MECHANISMS INVOLVED IN RESISTIN DEPENDENT
ENHANCED MONOCYTES INFILTRATION IN THE VESSEL WALL
Monica Madalina Pirvulescu, A.M. Gan, E. Butoi, D. Stan, V. Simion, M.
Calin, I. Manduteanu, Romania
1400
M38
CANNABINOIDS INCREASE ENDOGENOUS HYDROGEN SULFIDE (H2S)
SIGNALING IN PERIVASCULAR ADIPOSE TISSUE BY IMPAIRING
MITOCHONDRIAL BIOGENESIS
Jerzy Bełtowski, A. Jamroz-Wiśniewska, Poland
1511
41
12:40-13:40
Session 14: MULTIPLE ROLES OF HDL AND ITS TRANSPORTERS IN
ATHEROSCLEROSIS AND RELATED DISEASES
Moderator: Arie van Tol, Netherlands
Poster Board No.
M82
M83
Abstract No
HDL IMPROVES GLUCOSE HOMEOSTASIS AND REDUCES
ATHEROSCLEROSIS IN TRAIL-/-APOE-/- MICE
Belinda Di Bartolo, S.P. Cartland, K.-A. Rye, M.M. Kavurma1,3, Australia
LOWER ADRENAL STEROID PRODUCTION IN MICE AND HUMANS
WITH LOW HDL-CHOLESTEROL DUE TO MUTATIONS IN LCAT
Andrea Bochem, A. Holleboom, J.A. Kuivenhoven, M. van Eck, G.K.
Hovingh, E. Stroes, M. Hoekstra, The Netherlands
941
1305
M84
HIGH-DENSITY LIPOPROTEINS INHIBIT CHEMOKINE EXPRESSION
AND PROLIFERATION OF VASCULAR SMOOTH MUSCLE CELLS
Christina Bursill, E. van der Vorst, L. Vanags, L. Dunn, H. Prosser, K.-A.
Rye, Australia, The Netherlands
1315
M85
APOLIPOPROTEIN A- I INHIBITS LPS-INDUCED ATHEROSCLEROSIS IN
APOE-/- MICE
K. Yin, Chao-Ke Tang, China
1329
M86
WHAT HAPPENS TO HDL PARTICLE FUNCTIONALITY FOLLOWING
ACUTE MYOCARDIAL INFARCTION?
Fabiana Hanna Rached1,2, L. Camont, M. Lhomme, M. Miname, R.D.
Santos, C.V. Serrano Jr, M.J. Chapman, A. Kontush, Brazil, France
1415
EFFECTS OF THE CETP INHIBITOR DS-1442 ON REVERSE
CHOLESTEROL TRANSPORT AND ATHEROSCLEROSIS
Naoki Terasaka, Japan
1277
M87
M88
PARAOXONASE 1 (PON1) REGULATES THE CHOLESTEROL EFFLUX
VIA THE PPARΓ-LXRΑ-ABCA1 PATHWAY
Souade Ikhlef, H. Berrougui, P. Camponova, S. Loued, A. Khalil, Canada 1250
M89
THE CELL SURFACE-RESIDENT ATP-BINDING CASSETTE
TRANSPORTER A1 (ABCA1) IS UBIQUITINATED AND SORTED TO
LYSOSOME FOR DEGRADATION
Tadahaya Mizuno, H. Hayashi, S. Naoi, Y. Sugiyama, H. Kusuhara, Japan 1399
42
12:40-13:40
M ODERATED POSTER SESSION B (contd.)
Session 15: NOVEL INSIGHTS INTO THE ROLE OF MICRONUTRIENTS IN
CARDIOVASCULAR RISK AND DISEASE
Moderator: Eric Bruckert, France
Poster Board No.
Abstract No
M158
VITAMIN D SUPPLEMENTATION REDUCES RESTENOSIS FOLLOWING
CORONARY INTERVENTION IN HYPERCHOLESTEROLEMIC SWINE
Devendra K. Agrawal, G.K. Gupta, M.G. Delcore, W.J. Hunter, USA
843
M159
CONSUMPTION OF PLANT STEROL-ENRICHED FOODS MODESTLY
INCREASES PLASMA/SERUM PLANT STEROL CONCENTRATIONS - A
META-ANALYSIS
Rouyanne T. Ras, H. Hiemstra, Y. Lin, M. Vermeer, G.S.M.J.E. Duchateau,
E.A. Trautwein, The Netherlands
1022
M160
EFFECTS OF DIETARY POLYPHENOLS AND/OR N-3 FATTY ACIDS ON
OXIDATIVE STRESS IN PEOPLE AT HIGH CARDIOVASCULAR RISK:
THE ETHERPATHS PROJECT
Giuseppina Costabile, G. Annuzzi, L. Bozzetto, G. Della Corte, A. Giacco,
M. Vitale, E. Griffo, S. Cocozza, G. Della Pepa, L. Di Marino, F. Pasanisi, G.
Riccardi, A.A. Rivellese, Italy
1495
M161
IS TAKING HEALTH FUNCTIONAL FOOD BENEFICIAL FOR
CARDIOVASCULAR SYMPTOMS?
Mi-Seung Shin, B.R. Kim, I.-M. Chung, D.-J. Choi, Republic of Korea
1559
M162
PHYTOSTEROL SUPPLEMENTATION AFFECTS STEROL PLASMA
LEVELS IN PATIENTS UNDER LIPID-LOWERING THERAPIES
Livia Nascimento Matos, D.M. Tegani, F.A. Fonseca, S.A. Barbosa, S.H.
Kasmas, R.M. Povoa, M.C. Izar, Brazil
145
M163
FLAVANOL METABOLITES REDUCE MONOCYTE ADHESION AND
MODULATE GENE EXPRESSION INVOLVED IN ATHEROSCLEROSIS
DEVELOPMENT THROUGH MAPK-P38 OR NFKB-P65 SIGNALING
PATHWAYS
S. Claude, Dragan Milenkovic, C. Boby, C. Morand, France
438
M164
DIETS RICH IN POLYPHENOLS AND/OR N-3 FATTY ACIDS REDUCE
FASTING AND POSTPRANDIAL TRIGLYCERIDE- RICH LIPOPROTEINS:
THE ETHERPATHS PROJECT
Lutgarda Bozzetto, G. Annuzzi, R. Giacco, P. Cipriano, A. Mangione, G.
Costabile, G. Anniballi, C. Vetrani, F. Conte, A. Rivieccio, L. Patti, G.
Riccardi, A.A. Rivellese, Italy
1576
43
12:40-13:40
Session 16: TREATMENT OF DYSLIPIDEMIA: FROM GUIDELINES TO GOALS AND
MECHANISMS
Moderator: Anders G. Olsson, Sweden
Poster Board No.
Abstract No
M90
BRIDGED NUCLEIC ACID (BNA)-BASED ANTISENSE THERAPEUTICS
TARGETING PCSK9
Mariko Harada-Shiba, T. Yamamoto1,2, H. Yasuhara1,2, S. Wada1,2, F.
331
Wada1,2, M.-A. Shibata, S. Obika, Japan
M91
CHANGES IN BIOMARKER LEVELS WITH ROSUVASTATIN OR
SIMVASTATIN IN COMBINATION WITH EZETIMIBE: RESULTS FROM
GRAVITY
Christie M. Ballantyne1,2, R. Hoogeveen1,2, V.A. Cain, M.K. Palmer, B.W.
Karlson5,6, on behalf of the GRAVITY Study Investigators, USA, UK, Sweden1054
M92
EFFECTS OF 12 WEEKS OF TREATMENT WITH RN316 (PF-04950615), A
HUMANIZED MONOCLONAL ANTIBODY BINDING PCSK9, IN
HYPERCHOLESTEROLEMIC SUBJECTS ON STATINS
B. Gumbiner, T. Joh, C. Udata, P. Forgues, C. Baum, Pamela D Garzone,
USA
1271
M93
MIPOMERSEN, AN APOLIPOPROTEIN B SYNTHESIS INHIBITOR,
REDUCES LDL-C IN HoFH PEDIATRIC PATIENTS
Frederick J. Raal, S. Selvey, South Africa, USA
1368
M94
INHIBITION OF PCSK9 WITH AMG 145, A MONOCLONAL ANTIBODY,
REDUCES LP(A): INSIGHTS FROM THE POOLED PROFICIO STUDY
Evan A. Stein, R.P. Giugliano, M.S. Sabatine, M.J. Koren, G. Langslet, H.
Bays, D. Blom, M. Eriksson, R. Dent, S.M. Wasserman, F. Huang, T. Liu, M.
Albizem, R. Scott, F. Raal, USA, Norway, South Africa, Sweden
1621
M95
RAMIPRIL INCREASES WALKING ABILITY IN PERIPHERAL ARTERY
DISEASE PATIENTS WITH CLAUDICATION; POTENTIAL ROLE OF
INFLAMMATION, ADHESION, COAGULATION AND ANGIOGENESIS
A.A. Ahimastos, A.K. Natoli, C. Latouche, M. Reddy-Luthmoodoo, J.
Golledge, Bronwyn A. Kingwell, Australia
M96
M97
THE IMPACT OF LOW DENSITY LIPOPROTEIN RECEPTOR (LDLR)
GENE MUTATION ON THE RESPONSE TO THERAPY IN PATIENTS
WITH FAMILIAL HYPERCHOLESTEROLEMIA
Vasiliki Metaxa, C. Pitsavos, I. Skoumas, E. Oikonomou, A. Miliou, C.
Masoura, L. Papadimitriou, C. Stefanadis, Greece
719
1135
GUIDELINES EAS/ESC AND VERY HIGH RISK TYPE 2 DIABETIC
PATIENTS IN A FRENCH REGISTRY: HOW FARE TO LDL-C GOAL?
Michel Krempf, B. Cariou, M. Le Bras, N. Fuertes, E. Nobecourt, France 1608
44
12:40-13:40
Session 16: TREATMENT OF DYSLIPIDEMIA: FROM GUIDELINES TO GOALS AND
MECHANISMS (contd.)
Moderator: Anders G. Olsson, Sweden
Poster Board No.
Abstract No
M98
EFFECTS OF STATINS ON LIPID PROFILE IN CHRONIC KIDNEY
DISEASE PATIENTS: A META-ANALYSIS OF RANDOMIZED
CONTROLLED TRIALS
D. Nikolic, S. Nikfar, P. Salari, M. Rizzo, K.K. Ray, M.J. Pencina, D.P.
Mikhailidis, P.P. Toth, S.J. Nicholls, J. Rysz, M. Abdollahi, Maciej Banach,
Lipid and Blood Pressure Meta-Analysis Collaboration Group, Italy, Iran,
USA, UK
1414
M99
EFFECTS OF HIGH-DOSE ATORVASTATIN MONOTHERAPY ON
CIRCULATING PCSK9 LEVELS IN HETEROZYGOUS FAMILIAL
HYPERCHOLESEROLEMIA
Kouji Kajinami, E. Ueno, K. Tanabe, N. Fujioka, H. Akao, T. Tsuchiya, Y.
Kawai, M. Kitayama, Japan
247
Session 17: IMAGING OF THE ARTERIAL WALL AS A DIAGNOSTIC AND
PROGNOSTIC INDICATOR OF ATHEROSCLEROTIC DISEASE
Moderator: Lale Tokgozoglu, Turkey
M165
DIFFERENCES IN CULPRIT RUPTURED PLAQUE MORPHOLOGY IN
STEMI AND NSTEMI BY OPTICAL COHERENCE TOMOGRAPHY
Konstantinos Toutouzas, A. Karanasos, E. Tsiamis, M. Riga, M.
Drakopoulou, A. Synetos, A. Papanikolaou, K. Stathogiannis, D. Tousoulis,
C. Stefanadis, Greece
557
M166
THE EFFECT OF AGING ON ATHEROSCLEROTIC PLAQUE
INFLAMMATION AND MOLECULAR CALCIFICATION: A PET CT
IMAGING STUDY
Björn Alexander Blomberg, A. Thomassen, J.A. Simonsen, M. Hildebrandt,
A.C.P. Diederichsen, H. Mickley, A. Alavi, P.F. Høilund-Carlsen, Denmark,
USA
1107
M167
CONTRAST-ENHANCED ULTRASOUND: EARLY DIAGNOSIS METHOD
FOR CAROTID ATHEROSCLEROSIS
1131
Adelina Baleanu-Curaj1,2, Germany
45
12:40-13:40
Session 17: IMAGING OF THE ARTERIAL WALL AS A DIAGNOSTIC AND
PROGNOSTIC INDICATOR OF ATHEROSCLEROTIC DISEASE (contd.)
Moderator: Lale Tokgozoglu, Turkey
Poster Board No.
Abstract No
M168
CLINICAL AND ECHOCARDIOGRAPHIC FACTORS RELATED TO FALSE
RESULTS OF EXERCISE TOLERANCE TEST
Hakimeh Sadeghian, E. Hakki Kazazi, A. Zoroufian, M. Sahebjam, A. Jalali,
M. Pashang, Iran
116
M169
18
F-FLUOROMETHYLCHOLINE PET IMAGING OF INFLAMED
ATHEROSCLEROTIC PLAQUES IN MICE
Sanna Hellberg, A. Roivainen1,2, J. Silvola, H. Liljenbäck1,2, P. Saukko, J.
Knuuti, A. Saraste1,4, Finland
993
M170
PROGNOSTIC VALUE OF CORONARY CALCIFICATION USING 64SLICE CORONARY CT ANGIOGRAPHY FOR PREDICTING CORONARY
DISEASE EXTENT AND CARDIAC EVENTS
Y.-C. Liu, Zhonghua Sun, T. Chan, P.-K. Tsay, I.-C. Hsieh, C.-C. Chen, M.S. Wen, Y.-L. Wan, Taiwan R.O.C., Australia, Canada
310
M171
MULTILEVEL ASSESSMENT OF ATHEROSCLEROTIC BURDEN USING
64-SLICE MULTI-DETECTOR CT IN ACUTE STROKE PATIENTS:
COCASE STUDY, PART TWO
Laura Mechtouff, L. Boussel, S. Cakmak, J.-L. Lamboley, A.-M. Schott, T.H. Cho, L. Derex, N. Nighoghossian, P.-C. Douek, France
422
46
13:40-14:40
MODERATED POSTER SESSION C
Session 18: IMMUNITY AND ATHEROSCLEROSIS
Moderator: Menno De Winther, Netherlands
Poster Board No.
Abstract No
M39
THE BALANCE OF T-REGULATORY AND T-HELPER 1 AND 17
LYMPHOCYTE SUBSETS IN BLOOD OF PATIENTS WITH CORONARY
ATHEROSCLEROSIS
Alexandra Potekhina, E. Pylaeva, K. Raskina, A. Kuranova, S. Provatorov,
E. Noeva, T. Arefieva, Russia
958
M40
ROLE OF HIF1Α IN IMMUNE REGULATION OF ATHEROSCLEROSIS
Sweena M. Chaudhari, J.C. Sluimer, M. Koch, H.D. Manthey, M. Busch,
H.M. Hermanns, A. Zernecke1,3, Germany, The Netherlands
1454
M41
ROLE OF PSGL-1 EXPRESSING CD4 T CELLS IN ACUTE CORONARY
SYNDROME
Kayoko Sato, K. Kitamura, K. Gomita, N. Hagiwara, Japan
1310
M42
INDUCTION OF DENDRITIC-CELL MEDIATED T-CELL ACTIVATION BY
MODIFIED BUT NOT NATIVE LDL: HEAT SHOCK PROTEINS AS
POSSIBLE T-CELL ANTIGENS
A. Liu, J. Ming, Y. He, R. Fiskesund, A. Frostegård, E. Ninio, S.-A. Karabina,
Johan Frostegård, Sweden, France
1505
M43
IMMUNOSENESCENCE CHARACTERIZED BY A RESTRICTED T CELL
RECEPTOR REPERTOIRE IN ACUTE CORONARY SYNDROMES
Roland Klingenberg, C. Brokopp, A. Grives, A. Courtier, N. Pasqual, E.
Vlaskou, L.A. Altwegg, O. Gämperli, C.A. Wyss, S. Hoerstrup, W. Maier, R.
Corti, U. Landmesser, T.F. Lüscher, C.M. Matter, Switzerland, France
961
M44
T-CELL CO-STIMULATION BY CD28-CD80/86 AND ITS NEGATIVE
REGULATOR CTLA-4 STRONGLY INFLUENCE ACCELERATED
ATHEROSCLEROSIS DEVELOPMENT
M.M. Ewing, R.C.M. de Jong, J.C. Karper, M.R. De Vries, R. Arens, J.W.
Jukema, J. Kuiper, Paul H.A. Quax, The Netherlands
1020
Session 19: METABOLIC REGULATION OF APOLIPROTEIN A-I-CONTAINING LIPOPROTEINS
Moderator: Laurent Lagrost, France
M100
AUTOANTIBODIES TO APOLIPOPROTEIN A-1 AND
MYLEOPEROXIDASE AS PREDICTORS OF MAJOR ADVERSE
CARDIOVASCULAR EVENTS AFTER CAROTID ENDARTERECTOMY
Nicolas Vuilleumier, F. Montecucco, G. Spinella, S. Pagano, M. Bertolotto,
B. Pane, A. Pende, P. Roux-Lombard, C. Combescure, F. Dallegri, F. Mach,
D. Palombo, Switzerland, Italy
55
47
13:40-14:40
MODERATED POSTER SESSION C (contd.)
Session 19: METABOLIC REGULATION OF APOLIPROTEIN A-I-CONTAINING LIPOPROTEINS
Moderator: Laurent Lagrost, France
Poster Board No.
Abstract No
M101
HDLS PREVENT HEMORRHAGE INDUCED BY NEUTROPHIL
ELASTASE
Lourdes Maria Varela Perez, C. Hoteit, J.-B. Michel1,2,3, B. Ho-Tin-Noé1,2, O.
589
Meilhac1,2,4, France
M102
ADDITION OF S1P TO RECONSTITUTED HDL ENHANCE POSTISCHEMIC PROTECTION IN VIVO
M. Frias, V. Braunersreuther, F. Montecucco, S. Lecour, F. Mach, Richard
William James, Switzerland, South Africa
475
M103
INTRAPERITONEAL ADMINISTRATION OF 2S, APOA-I MIMETIC
PEPTIDE, INHIBITS THE ATHEROSCLEROTIC LESION DEVELOPMENT
IN HIGH FAT HIGH CHOLESTEROL-FED APOE-/- MICE
B.-S. Lee, S.H. Han, Y. Kim, J. Yu, Jeong Euy Park, Republic of Korea
960
M104
ARE EXTREMELY AND MODERATELY INCREASED LEVELS OF HDL
CHOLESTEROL PROTECTIVE AGAINST ALL-CAUSE MORTALITY IN
THE JAPANESE GENERAL POPULATION?
Tomonori Okamura, Y. Murakami, H. Iso, A. Tamakoshi, M. Yamada, K.
Miura, H. Ueshima, for the EPOCH-JAPAN Research Group, Japan
213
M105
OXIDATIVE STRESS AND IMPAIRED HIGH-DENSITY LIPOPROTEIN
ANTI-OXIDANT CAPACITY IN HUMAN ABDOMINAL AORTIC
ANEURYSM
Sandrine Delbosc1,2, T. Dejouvencel1,2, D. Diallo1,2, L. Louedec1,2, P.
Rossignol3,4, G. Leseche1,5, J.B. Michel1,2, O. Meilhac1,2, France
673
M106
THE ROLE OF APOA-I VS HDL-C AS A DETERMINANT OF CAROTID
INTIMA-MEDIA-THICKNESS
Sanni Söderlund, M. Jauhiainen, C. Ehnholm, M.-R. Taskinen, Finland
1258
Session 20: CARDIOVASCULAR DISEASE AND ITS PREVENTION IN PATIENTS WITH
CHRONIC INFLAMMATORY AND CHRONIC RENAL DISEASE
Moderator: Naveed Sattar, UK
M172
M173
USEFULNESS OF NEW STAGING SYSTEM FOR PREDICTING
CARDIOVASCULAR RISK AND ALL-CAUSE DEATH IN CHRONIC
KIDNEY DISEASE: A VALIDATION STUDY
Yorihiko Koeda, T. Segawa, F. Tanaka, M. Ohsawa, K. Tanno, K. Sakata,
M. Nakamura, Iwate KENCO, Japan
ACCELERATED ADIPOSE TISSUE DYSFUNCTION AND
CARDIOVASCULAR RISK IN INDIVIDUALS OF SOUTH ASIAN
ETHNICITY
Shirya Rashid, P. Power, M. Melone, Canada
48
28
198
13:40-14:40
CHRONIC INFLAMMATORY AND CHRONIC RENAL DISEASE (contd.)
Poster Board No.
Abstract No
M174
ANACETRAPIB DOSE-DEPENDENTLY DECREASES
ATHEROSCLEROSIS DEVELOPMENT AND ADDS TO THE BENEFICIAL
EFFECTS OF ATORVASTATIN IN APOE*3LEIDEN.CETP MICE
S. Kühnast1,2, Sam J.L. van der Tuin3,4, L.M. Havekes1,2,3, P.C.N. Rensen,
K. Willems van Dijk3,4, J.W.A. Van der Hoorn1,2, J.W. Jukema, H.M.G.
Princen, The Netherlands
382
M175
HIGH-DENSITY LIPOPROTEIN CHOLESTEROL EFFLUX CAPACITY
PREDICTS GRAFT FAILURE BUT NOT CARDIOVASCULAR AND ALLCAUSE MORTALITY IN RENAL TRANSPLANT RECIPIENTS
Wijtske Annema, A. Dikkers, J.F. de Boer, R.P.F. Dullaart, J.-S.F. Sanders,
S.J.L. Bakker, U.J.F. Tietge, The Netherlands
484
M176
DIFFERENT ASSOCIATIONS BETWEEN VISCERAL AND
SUBCUTANEOUS ADIPOSITY AND CORONARY ARTERY
CALCIFICATION
Sophie Eastwood, T. Tillin, J. Heasman, A. Wright, P. McKeigue, A.
Hughes, N. Chaturvedi, UK
1099
M177
THE EFFECT OF MAXIMUM BODY WEIGHT IN LIFEPOSTER BOARD
NO. ON THE DEVELOPMENT OF CORONARY ARTERY DISEASE IN
TYPE 2 DIABETES: MAXWEL-CAD STUDY
Soo Lim, J.-W. Suh, S.M. Kang, M.K. Moon, H.C. Jang, S.H. Choi, Republic
of Korea
1171
M178
ESTROGENS CONTROL THE STROMA-VASCULAR FRACTION OF
ADIPOSE TISSUE AND PREVENT HIGH-FAT DIET-INDUCED
INFLAMMATION
Elodie Riant, S. Handgraaf, A. Fabre, M. Guillaume, A. Zakaroff, D. Teixeira,
1373
A. Bouloumié, R. Burcelin, J.-F. Arnal, P. Gourdy1,3, France, Portugal
M179
DYSFUNCTIONAL HIGH-DENSITY LIPOPROTEIN AS A NOVEL
CARDIOVASCULAR RISK FACTOR AFTER KIDNEY
TRANSPLANTATION
Chantal Kopecky, M. Haidinger, C. Kaltenecker, M. Antlanger, G. Marsche,
M. Holzer, J. Kovarik, J. Werzowa, M. Hecking, M.D. Säemann, Austria
1383
M180
EFFECTS OF STATINS ON CARDIOVASCULAR ENDPOINTS IN
CHRONIC KIDNEY DISEASE PATIENTS: A META-ANALYSIS OF
RANDOMIZED CONTROLLED TRIALS
D. Nikolic, S. Nikfar2,3, P. Salari, D.P. Mikhailidis, M. Rizzo1,6, P.P. Toth, J.
Rysz, M. Abdollahi, Maciej Banach, Italy, Iran, UK, USA, Poland
1409
49
13:40-14:40
CHRONIC INFLAMMATORY AND CHRONIC RENAL DISEASE (contd.)
Poster Board No.
M181
Abstract No
RENAL OUTCOMES OF USE OF STATINS IN CHRONIC KIDNEY
DISEASE PATIENTS: A META-ANALYSIS OF RANDOMIZED
CONTROLLED TRIALS
Maciej Banach, D. Nikolic, S. Nikfar, P. Salari, D.P. Mikhailidis, M. Rizzo,
P.P. Toth, M. Abdollahi, J. Rysz, Poland, Italy, Iran, UK, USA
1410
Session 21: PRIMARY DYSLIPIDEMIA
Moderator: Sebastiano Calandra, Italy
M107
HIGH FREQUENCY AND MILD PHENOTYPE IN TRUE HOMOZYGOUS
OR DOUBLE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
CAUSED BY PCSK9 MUTATION (E32K) IN JAPAN
Hiroshi Mabuchi, A. Nohara, T. Noguchi, J. Kobayashi, M.-A. Kawashiri, H.
Tada, M. Mori, T. Inoue, C. Nakanishi, M. Yamagishi, A. Inazu, Hokuriku FH
Research Group, Japan
307
M108
ELEVATED MONOCYTE-DERIVED MICROPARTICLES IN PATIENTS
WITH FAMILIAL HYPERCHOLESTEROLEMIA: A POTENTIAL
ATHEROSCLEROSIS RISK MARKER
Morten Hjuler Nielsen, H. Irvine, S. Vedel, B. Raungaard, H. Beck-Nielsen,
A. Handberg, Denmark
457
M109
AFTER LDLR, APOB AND PCSK9, APOE IS ANOTHER MAJOR GENE
OF AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA
Mathilde Varret1,2, M. Marduel, K. Ouguerram, V. Serre2,4, D. BonnefontRousselot, K.E. Berge, M. Devillers, G. Luc, J.-M. Lecerf, L. Tosolini, M.
Abifadel1,9, T.P. Leren, J.-P. Rabès1,10,11, C. Boileau1,10,11, The French
Research Network on ADH, France, Norway, Lebanon
562
M110
FAMILIAL HYPERCHOLESTEROLEMIA AND EXOME SEQUENCING:
IDENTIFICATION OF THE FIRST COMPOUND HETEROZYGOTE FOR
APOB AND PCSK9 MUTATIONS
Marianne Abifadel1,2, G. Peloso3,4, J.-P. Rabès1,5,6, J.P. Pirruccello3,4,7, M.
Varret, V. Carreau, N. Stitziel3,4, L. Tosolini, Y. Ghaleb, N. Gupta, S. Gabriel,
A. Carrié, E. Bruckert8,9, S. Kathiresan3,4, C. Boileau1,5,6, France, Lebanon,
USA
636
M111
CIRCULATING PCSK9 IS A STRONG DETERMINANT OF PLASMA
TRIGLYCERIDES, BUT NOT OF LDL CHOLESTEROL IN FAMILIAL
DYSBETALIPOPROTEINEMIA
Martijn Brouwers, M. van Greevenbroek, R. Konrad, J. Troutt, N. Schaper,
C. Stehouwer, The Netherlands, USA
845
50
13:40-14:40
Session 21: PRIMARY DYSLIPIDEMIA (contd.)
Moderator: Sebastiano Calandra, Italy
Poster Board No.
Abstract No
M112
PREVALENCE AND CLINICAL CHARACTERISTICT OF PATIENTS WITH
HOMOZYGOUS AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA
IN THE NETHERLANDS
Barbara Sjouke, D.M. Kusters, I. Kindt, J. Besseling, J. Defesche, E.J.
Sijbrands, J.E. Roeters van Lennep, A. Stalenhoef, S.W. Fouchier, J.J.P.
Kastelein, G.K. Hovingh, The Netherlands
865
M113
PCSK9 IN HETEROZYGOUS FH (HEFH) PATIENTS
Mathias Chatelais, F. Petrides, D. Marais, G. Lambert2,4, France, Australia,
South Africa
903
M114
FAMILIAL COMBINED HYPERLIPIDEMIA: IDENTIFICATION OF LDLR
MUTATIONS IN A POPULATION FROM SOUTHERN ITALY
Maria Nicoletta D'Agostino1,2, M.D. Di Taranto, A. D'Angelo, A. Ruotolo, C.
1093
Giacobbe, G. Marotta, M. Gentile, P. Rubba, G. Fortunato1,2, Italy
M115
IDENTIFICATION OF NOVEL ANGPTL3 MUTATIONS ASSOCIATED
WITH SEVERE HYPOBETALIPOPROTEINEMIA
Patrizia Tarugi, R. Spina, E. Pinotti, A.B. Cefalù, D. Noto, E. Di Leo, I.
Crisci, R. Miccoli, M. Averna, Italy
M116
LDL-CHOLESTEROL ASSOCIATED GWAS SNPS INTERFERE WITH THE
CLINICAL PHENOTYPE OF FAMILIAL HYPERCHOLESTEROLEMIA
Sigrid W. Fouchier, G.M. Dallinga-Thie, J.C. Defesche, J.J.P. Kastelein, S.
Kathiresan, G.K. Hovingh, The Netherlands, USA
1493
1263
Session 22: INFLAMMATION AND INFECTION IN EXPERIMENTAL AND CLINICAL
ATHEROSCLEROSIS
Moderator: Giuseppina Caligiuri, Italy
M45
NLRP3 INFLAMMASOME ACTIVATION IN MONOCYTES OF PATIENTS
WITH ACUTE CORONARY SYNDROME
Kai Yin1,2, J.-F. Li, D. Xie, J.-Y. Peng, J.-J. Zhang, G. Wang, Q.-J. Gui2,3, Y.L. Tu, Z.-S. Jiang, C.-K. Tang, China
97
M46
MICRORNA-1264 UPREGULATES SUPPRESSOR OF CYTOKINE
SIGNALING 3 EXPRESSION UNDER INFLAMMATORY CONDITIONS IN
HUMAN CORONARY ARTERY SMOOTH MUSCLE CELLS
Devendra K. Agrawal, K. Dhar, D. Pankajakshan, USA
836
M47
CORRELATION BETWEEN ACTIVATION OF T LYMPHOCYTES AND
HERPES VIRUSES IN ATHEROSCLEROTIC PLAQUES
Jean-Charles Grivel, O. Ivanova, N. Pinegina, A. Lebedeva, E. Nikitskaya,
A. Shpektor, L. Margolis, E. Vasilieva, USA, Russia
974
51
13:40-14:40
Session 22: INFLAMMATION AND INFECTION IN EXPERIMENTAL AND CLINICAL
ATHEROSCLEROSIS (contd.)
Moderator: Giuseppina Caligiuri, Italy
Poster Board No.
Abstract No
M48
HIV INFECTION AND LONG TERM PROGNOSIS OF ACUTE CORONARY
SYNDROME. FINAL RESULTS FROM THE PACS-HIV STUDY
Franck Boccara1,2,3, M. Mary-Krause, E. Teiger, S. Lang, P. Lim, K. Wahbi,
P.G. Steg, C. Funck-Brentano, M. Slama, D. Costagliola, A. Cohen, France 1239
M49
MYXOMAVIRUS-DERIVED SERPIN REDUCES VASCULAR
INFLAMMATION AND PROLONGS SURVIVAL IN UNRELATED LETHAL
HEMORRHAGIC MOUSE VIRAL SEPSIS
H. Chen, D. Zheng, J. Davids, Alexandra Lucas, USA
1423
M50
ELASTIN-DERIVED PEPTIDES POTENTIATE ATHEROSCLEROSIS
THROUGH IMMUNE PI3KΓ
Stephanie Gayral, R. Garnotel, A. Castaing-Berthou, S. Blaise, E. Berge, N.
Malet, P. Maurice, L. Martiny, L. Martinez, L. Duca, M. Laffargue, France 1241
M51
THE PRESENCE OF EXTRA DOMAIN A IN FIBRONECTIN INFLUENCES
THE ACUTE INFLAMMATORY RESPONSE
Vivek Krishna Pulakazhi Venu, P. Uboldi, A. Muro, A.L. Catapano1,3, G.D.
1299
Norata1,4, Italy
M52
CROSSROAD BETWEEN INFLAMMATION, IRON AND LIPIDS IN
ATHEROGENESIS
Liliana Marques1,2,3, L. Robert, A. Auriac, F. Canonne-Hergaux, L. Costa1,2,
Portugal, France
1333
M53
PHOSPHOINOSITIDE 3-KINASE GAMMA DRIVES CD4+ T CELLS
INDUCED INTIMAL HYPERPLASIA
N. Smirnova, S. Gayral, C. Pedros, N. Malet, A.P. Gadeau, M. Wymann, E.
Hirsch, A. Sahoudi, L. Martinez, Muriel Laffargue, France, Switzerland, Italy1567
Session 23: REGULATION OF ISCHEMIA REPERFUSION INJURY
Moderator: Jean-Francois Arnal, France
M54
M55
THIOREDOXIN AND THIOREDOXIN REDUCTASE CONTROL TISSUE
FACTOR ACTIVITY BY THIOL-REDOX-DEPENDENT MECHANISM
P. Wang, Y. Wu, X. Li, X. Ma, Liangwei Zhong, China
1419
DAILY ISCHEMIC PRECONDITIONING PROVIDES SUSTAINED
PROTECTION FROM ISCHEMIA AND REPERFUSION: A HUMAN STUDY
Mary Clare Luca, K. McLaughlin, A. Liuni, J.D. Parker, Canada
778
52
13:40-14:40
Session 23: REGULATION OF ISCHEMIA REPERFUSION INJURY (contd.)
Moderator: Jean-Francois Arnal, France
Poster Board No.
Abstract No
M56
HIGH ESTROGEN LEVELS DURING THE LATE FOLLICULAR PHASE OF
THE MENSTRUAL CYCLE PROVIDE PROTECTION FROM ISCHEMIA
AND REPERFUSION INJURY
Mary Clare Luca, A. Liuni, S. Mak, T. Gori, H. Paula, J. Parker, Canada,
Germany
914
M57
RELATION BETWEEN LOCAL AND SYSTEMIC LEVELS OF OXIDATIVE
STRESS AND NO-REFLOW IN MYOCARDIAL INFARCTION
Karim Stamboul, J. Lorin, A. Kahli, M. Zeller, L. Rochette, Y. Cottin1,2, L.
1375
Lorgis1,2, C. Vergely, France
M58
INCREASED OEDEMA AND DECREASED CARDIAC FUNCTION IN RIP2DEFICIENT MICE AFTER MYOCARDIAL ISCHEMIA
Annika Lundqvist, M. Scharin Täng, M. Lindbom, B. Redfors, K. Skålén, M.
Heyden, J. Borén, M. Levin, Sweden
1442
Session 24: EXERCISE AND CARDIOVASCULAR HEALTH: BOTH QUANTITY AND
QUALITY COUNT
Moderator: Matti Jauhiainen, Finland
M182
ASSESSMENT OF PHYSICAL SELF-EFFICACY IS PREDICTIVE FOR
CARDIOVASCULAR EVENTS DURING 13-YEARS OF FOLLOW-UP IN
INITIALLY HEALTHY 58-YEAR-OLD MEN
Caroline Schmidt, G. Bergström, Sweden
202
M183
EXERCISE TRAINING REDUCES VISCERAL FAT INFLAMMATION IN
OBESE WOMAN: F-18 FDG TOF (POSTER BOARD NO. OF FLIGHT)
PET/CT STUDY
Sungeun Kim, H.S. Seo, E.J. Kim, J.H. Na, J.H. Park;, C.U. Choi, H.E. Lim,
J.W. Kim, S.-W. Rha, C.-G. Park, D.J. Oh, Republic of Korea
413
M184
ENDURANCE EXERCISE LOWERS AORTAL PLAQUE FORMATION IN
YOUNG APOE-/- MICE AND LEADS TO AN INCREASE IN TREGS
Bojana Jakic, M. Carlsson, C. Grundtman, G. Wick, Austria
888
M185
MODULATING EFFECT OF CARDIAC REHABILITATION ON
AUTONOMIC NERVOUS SYSTEM FUNCTION IN CORONARY ARTERY
DISEASE PATIENTS
T. Pereira-da-Silva, Marta Nogueira, A. Abreu, P. Rio, N. Santos, T. Alves,
S. Silva, R. Cruz Ferreira, Portugal
895
53
13:40-14:40
Session 24: EXERCISE AND CARDIOVASCULAR HEALTH: BOTH QUANTITY AND
QUALITY COUNT (contd.)
Moderator: Matti Jauhiainen, Finland
Poster Board No.
M186
M187
Abstract No
AEROBIC EXERCISE TRAINING IS THE BEST TREATMENT TO
INCREASE THE HIGH-DENSITY LIPOPROTEIN CHOLESTEROL IN
PATIENTS WITH DYSLIPIDEMIA
Hiroaki Tanaka, R. Michishita, H. Kumahara, M. Ayabe, T. Tobina, E.
Yoshimura, T. Matsuda, Y. Higaki, A. Kiyonaga, Fukuoka University
Randomized Control Trial (FURCT), Japan
918
THE ROLE OF PHYSICAL ACTIVITY AND BROWN ADIPOSE TISSUE IN
THE AMELIORATION OF METABOLIC SYNDROME DISORDERS IN
HEREDITARY HYPERTRIGLYCERIDEMIC RATS
Vojtech Skop, H. Malinska, J. Trnovska, M. Huttl, L. Kazdova, Czech
Republic
1025
Session 25: CV RISK FACTORS 2
Moderator: Anne Tybjaerg-Hansen, Denmark
M188
ANALYSIS OF THE BASAL DATA ON INTIMA-MEDIA THICKNESS OF
THE SPANISH MULTICENTER PROSPECTIVE OBSERVATIONAL STUDY
OF ATHEROMATOSIS IN CKD (NEFRONA)
Àngels Betriu, M. Borràs, M. Martinez, J.M. Valdivielso, E. Fernández, and
the Investigators of the Nefrona Study, Spain
498
M189
ARTERIAL STIFFNESS AND LP(A) LEVELS AS PROGNOSTIC FACTORS
FOR FIRST-EVER ISCHEMIC STROKE IN A GREEK POPULATION
SAMPLE
Christina Voulgari, S. Tesfaye, C. Karagiannis, S. Paximadas, S. Pagoni,
Greece, UK
312
M190
REDUCED 25-HYDROXYVITAMIN D CONCENTRATIONS AND
INCREASED RISK OF VENOUS THROMBOEMBOLISM, MYOCARDIAL
INFARCTION, AND ISCHEMIC STROKE
Peter Brøndum-Jacobsen, M. Benn, A. Tybjærg-Hansen, B.G.
Nordestgaard, Denmark
571
M191
MULTIMARKER APPROACH COMBINING BIOMARKERS OF
HAEMOSTASIS, INFLAMMATION AND ENDOTHELIAL ACTIVATION,
CHEMOKINES AND ADIPOCYTOKINES TO PREDICT ISCHAEMIC
STROKE
Christof Prugger, G. Luc, B. Haas, P.-E. Morange, J. Ferrieres, P. Amouyel,
F. Kee, P. Ducimetiere, J.-P. Empana, France, UK
1261
54
13:40-14:40
Session 25: CV RISK FACTORS 2 (contd.)
Moderator: Anne Tybjaerg-Hansen, Denmark
Poster Board No.
Abstract No
M192
GENETICALLY REDUCED NONFASTING TRIGLYCERIDES AND
REDUCED ALL-CAUSE MORTALITY
M. Thomsen, A. Varbo, A. Tybjærg-Hansen, Børge Nordestgaard, Denmark1501
M193
IL-18 +183 A/G POLYMORPHISM, SINGLE AND IN COEXISTENCE WITH
THE MMP-9 -1562 C/T POLYMORPHISM, ASSOCIATES WITH CLINICAL
EVENTS IN CAD
Trine Baur Opstad1,2, A.Å. Pettersen1,2, H. Arnesen2,3,4, I. Seljeflot1,2,4,
Norway
555
M194
GENETIC DEFECTS IN PROTEIN GLYCOSYLATION AS CAUSE OF
DYSLIPIDEMIA
Adriaan G. Holleboom, G.K. Hovingh, M.M. Motazacker, G.M. DallingaThie, J.A. Kuivenhoven, H. Aerts, R. Wevers, E.S.G. Stroes, D.J. Lefeber,
The Netherlands
M195
896
THE NATURAL HISTORY OF CORONARY OBSTRUCTIONS IS
INFLUENCED BY THE PRESENCE OF ADJACENT PROXIMAL
OBSTRUCTIONS
Masaya Tsuda, S. Takahashi, M.I. Papafaklis, A.P. Antoniadis, S. Mizuno,
Y. Makita, S. Nakamura, S. Gohara, M. Shibata, A. Namiki, T. Matsumura, S.
Tanaka, A.U. Coskun, S. Saito, C.L. Feldman, P.H. Stone, PREDICTION
Study Investigators, USA, Japan
1521
55
Monday, June 3 – Wednesday, June 5, 2013
10:00-17:00
Poster Area Track 1
POSTERS TRACK 1: VASCULAR BIOLOGY OF THE ARTERIAL WALL
Poster Board No.
Abstract No
Endothelial cells and function
1
BLOOD FLOW INVESTIGATION AT THE BOUNDARY LAYER IN
ATHEROSCLEROSIS
Merab Beraia, E. Beraia, Georgia
156
2
ASSOCIATION BETWEEN CIRCULATING ENDOTHELIAL PROGENITOR
CELLS AND TRADITIONAL CARDIOVASCULAR RISK FAKTORS IN
PATIENTS WITH CORONARY ARTERY DISEASE
Alexander E. Berezin, A.A. Kremzer, Ukraine
267
3
RAPAMYCIN ATTENUATES ENDOTHELIAL CELL OXIDATIVE
APOPTOSIS INDUCED BY LOW SHEAR STRESS THROUGH
PROMOTION OF SESTRIN1 EXPRESSION VIA MTORC2 INHIBITION
Junxia Zhang, Z. Wang, S. Chen, China
4
CLINICAL FEATURES OF PATIENTS WITH CRITICAL LIMB ISCHEMIA
WHO RESPONDED TO AUTOLOGOUS MONONUCLEAR CELL
TRANSPLANTATION FOR THERAPEUTIC ANGIOGENESIS
Naoyoshi Aoyama, M. Nishinari, O. Shinichi, A. Kanai, N. Chiharu, M.
Hirata, T. Izumi, Japan
318
5
HIGH DENSITY LIPOPROTEINS LIMIT NEUTROPHIL-INDUCED DAMAGE
TO THE BLOOD BRAIN BARRIER IN VITRO
Bao Quoc Dang, B. Lapergue1,2,3, A. Tran-Dinh1,2,3, D. Diallo, J.-A.
Moreno1,4, M. Mazighi1,2,3, J.-B. Michel1,5, P. Amarenco1,2,3, O. Meilhac1,2,3,
France, Spain
508
6
THE ROLE OF THE GLYCOCALYX IN ENDOTHELIAL CELL RESPONSE
TO WALL SHEAR STRESS
Karli McDonald, S. Cooper, P. Jonak, R.L. Leask, Canada
618
7
SEX DIFFERENCES IN MESENTERIC NITRIC OXIDE PRODUCTION AND
NADPH OXIDASE MRNA EXPRESSION OF STREPTOZOTOCININDUCED DIABETIC RATS
R. Zhang, X. Han, L. Anderson, Roshanak Rahimian, USA
639
8
RESEARCHING OF THE ENDOTHELIAL DYSFUNCTION MARKERS AND
THE APOPTOSIS OF ENDOTHELIOCYTES DURING EXPERIMENTAL
ATHEROSCLEROSIS IN A RAT MODEL
Svetlana Kryvorot, T. Vladimirskaya, I. Sved, N. Moskaleva, Belarus
754
9
L-ARGININE INHIBITS ENDOTHELIAL CELL APOPTOSIS IN RABBIT
MODEL OF HYPERCHOLESTEROLEMIA
Shaghayegh Haghjooy Javanmard, M. Nematbakhsh, Iran
56
277
1032
POSTERS TRACK 1 VASCULAR BIOLOGY OF THE ARTERIAL WALL (contd.)
Poster Board No.
Abstract No
10
SYNDECAN-4 INTRACELLULAR DOMAIN ORCHESTRATES
RANTES/CCL5-INDUCED ENDOTHELIAL CELL MIGRATION BY
MODULATION OF PKC ACTIVATION
Loic Maillard, V. Friand, N. Suffee, H. Hlawaty, O. Haddad, F. Chmilewsky,
O. Oudar, N. Saito, L. Martin, D. Letourneur, N. Charnaux1,5, A. Sutton1,5,
France, Japan
1052
11
MNA-INDUCED PGI2 RELEASE IN THE ISOLATED, PRESSURIZED AND
PERFUSED CAROTID ARTERY
Magdalena Sternak, B. Sitek, T. Wójcik, A. Broniec, B. Proniewski, A.
1072
Fedorowicz, S. Chłopicki1,2, Poland
12
ENDOTHELIAL SR-B1 LIMITS CEREBRAL INFARCTION IN A STROKE
MODEL
Alexy Tran-Dinh1,2,3, L. Varela-Perez, S. Gilibert4,5,6, B. Lapergue1,3, D.
Diallo, L. Louedec, S. Delbosc, J.-B. Michel1,2,7, P. Amarenco1,2,3, T. Huby4,5,6,
1078
O. Meilhac1,2,3, France
13
UNCOUPLING OF ENOS IS RELATED TO ADMA ACCUMULATION IN
THE ENDOTHELIUM ADJACENT TO ATHEROSCLEROTIC LESIONS
Leszek Kalinowski, M. Stepnowska, A. Siekierzycka, M. Wozniak, A.
Szeffler, L.W. Dobrcucki, J. Wojciechowski, J. Rogowski, I.T. Dobrucki,
Poland, USA
1127
14
ENDOTHELIAL EXPRESSIONS OF ENDOGLIN AND ENOS DIFFER
BETWEEN C57BL/6J AND C3H/HEJ MICE AFTER CHOLESTEROL DIET IMPLICATIONS IN ENDOTHELIAL DYSFUNCTION?
Jana Pfeiferova, Z. Strasky, K. Jezkova, P. Nachtigal, Czech Republic
1213
15
ENDOTHELIAL RESPONSE TO SUNITINIB TREATMENT IN
NORMOTENSIVE AND HYPERTENSIVE RATS - PILOT STUDY
Ivana Nemeckova, O. Lencova, M. Sterba, P. Nachtigal, Czech Republic 1289
16
CHANGE OF CONCEPT ABOUT THE REGULATION OF MONOCYTE
CHEMOATTRACTANT PROTEIN-1 PRODUCTION IN HUMAN
ENDOTHELIAL CELLS STIMULATED WITH ANGIOTENSIN II
María Isabel Castiñeiras-Landeira, B.K. Rodiño-Janeiro, B. ParadelaDobarro, S. Raposeiras-Roubín, M. González-Peteiro, R. Ucieda-Somoza,
J.R. González-Juanatey, E. Alvarez, Spain
1372
17
DIFFERENTIAL EFFECTS OF EARLY GLYCATED PROTEINS AND
ADVANCED GLYCATION END-PRODUCTS ON ENDOTHELIAL
RESPONSES INVOLVED IN DIABETIC VASCULAR COMPLICATIONS
Beatriz Paradela-Dobarro, B.K. Rodiño-Janeiro, J. Alonso, M.I. CastiñeirasLandeira, S. Raposeiras-Roubín, M. González-Peteiro, R. Ucieda-Somoza,
J.R. González-Juanatey, E. Alvarez, Spain
1388
18
EFFECT OF ENDOTHELIAL PROGENITOR CELLS ON PLATELET
ACTIVATION IN VITRO
Vasilios Chantzichristos, F. Gkrozou, M. Paschopoulos, A. Tselepis,
Greece
57
1460
Poster Board No.
Abstract No
19
EFFECTS OF PURE TOCOTRIENOLS ON ENDOTHELIAL ACTIVATION
IN PREVENTING EXPERIMENTALLY INDUCED SEVERE
ATHEROSCLEROSIS
Nurmazni Zulkafli, T.H. Abdul Rahman, N.K. Mohd Kornain, N.F. Hassim,
A. Mohd Ismail, H. Mohd Nawawi, Malaysia
1491
20
LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY IN MICE
ALTERS ENDOTHELIAL FUNCTION
Stefano Manzini, P. Cinquanta, C. Pinna, C. Parolini, M. Busnelli, L.
Calabresi, G. Chiesa, G. Franceschini, Italy
1504
Endothelial dysfunction clinical assessment
21
INCREASED ASYMMETRIC DIMETHYLARGININE LEVEL IS THE MOST
POWERFUL FACTOR ASSOCIATED WITH LOW HDL LEVELS IN
PATIENTS WITH ACUTE MYOCARDIAL INFARCTION
Julie Lorin, J.-C. Guilland, C. Korandji, Y. Cottin1,2, L. Rochette, C. Vergely,
M. Zeller, France
17
22
SYMMETRIC DIMETHYLARGININE SERUM LEVEL AS A NEW MARKER
OF LEFT VENTRICULAR EJECTION FRACTION IN PATIENTS WITH
ACUTE MYOCARDIAL INFARCTION
Julie Lorin, J.-C. Guilland, C. Korandji, P. Gambert, Y. Cottin1,3, L. Rochette,
C. Vergely, M. Zeller, France
24
23
DYSLIPIDEMIA, ARTERIAL STIFFNESS AND ENDOTHELIAL
DYSFUNCTION; UTILITY OF THE RADIAL ARTERY PULSE WAVE
ANALYSIS
Pablo Corral, F. Clara, G. Blanco, Argentina
41
24
ANALYSIS OF ARTERIAL FUNCTION IN ADULTS WITH A HISTORY OF
KAWASAKI DISEASE
Hisako Tobayama, H. Fukunaga, K. Takahashi, T. Furukawa, H. Oda, K.
Akimoto, M. Kishiro, T. Shimizu, Japan
786
25
ENDOTHELIAL DYSFUNCTION AND AUTONOMIC NERVOUS SYSTEM
ACTIVITY IN THE DEVELOPMENT OF CORONARY ARTERY DISEASE
Tonka Kurteva, D. Somleva, N. Spasova, E. Kinova, A. Goudev, Bulgaria 959
26
FMD TEST RESULTS CAN PREDICT SPONTANEOUS AND EFFECTIVE
PHARMACOLOGICAL REPERFUSION IN STEMI PATIENTS
Anna Kalinskaya, I. Urazovskaya, E. Vasilieva, A. Shpektor, Russia
975
27
NON-INVASIVE DETECTION OF ENDOTHELIAL PERMEABILITY AND
FUNCTION BY MRI
Alkystis Phinikaridou, M.E. Andia, A. Protti, R.M. Botnar, UK
1014
28
SMALL LDL CHOLESTEROL CONCENTRATION IS A DETERMINANT OF
ENDOTHELIAL DYSFUNCTION BY PERIPHERAL ARTERY TONOMETRY
IN JAPANESE MEN
Ryotaro Takahashi, K. Okumura, N. Taguchi, M. Suzuki, N. Ikeda, T.
Murohara, Japan
1607
58
Poster Board No.
29
Abstract No
THE EFFECT OF ENDOTHELIAL DYSFUNCTION BIOCHEMICAL
MARKERS AND FLOW-MEDIATED DILATION ON THE PREDICTIVITY OF
EXERCISE ECG
Muhammed Sait Toprak, H. Sonmez, Z. Ozturk, H. Ekmekci, O.B. Ekmekci,
H.A. Cakmak, B. Ikitimur, B. Karadag, B. Ilerigelen, Turkey
1610
Smooth muscle cells
30
NEUROPILIN ROLE IN THE DEVELOPMENT OF NEOINTIMAL
HYPERPLASIA
Caroline Pellet-Many, V. Mehta, I. Evans, J. Ruivo, I. Zachary, UK
446
31
EFFECTS OF A NOVEL BIOISOSTER OF FLAVONOIDS ON AORTIC
SMOOTH MUSCLE CELL PROLIFERATION AND INFLAMMATION
Cassandra Sentieri, C. Saponaro, S. Del Turco, S. Sartini, C. La Motta, G.
Basta, Italy
482
32
S100A12 PROTEIN INDUCES THE PROLIFERATION AND
CALCIFICATION OF VASCULAR SMOOTH MUSCLE CELLS
Eiko Matsuoka, Y. Mori, A. Kosaki, Japan
542
33
TRANSCRIPTOME ANALYSIS IDENTIFIES NOVEL MECHANISMS OF
CAMP-MEDIATED GROWTH ARREST IN VSMC: PKA AND EPAC
SYNERGISE TO SUPPRESS EGR-1 EXPRESSION
Tomomi Kimura-Wozniak, C. Hindmarch, M. Bond, UK
807
34
MECHANICAL STRETCH-INDUCED MMP-2 PRODUCTION REQUIRES
ACTIVATION OF PDGFR-Β AND AKT IN VASCULAR SMOOTH MUSCLE
Kyo Won Seo, J.U. Bae, Y.H. Kim, S.Y. Park, S.J. Lee, C.D. Kim, Republic
of Korea
929
35
PLATELET ACTIVATING FACTOR ENHANCES MMP-2 PRODUCTION IN
RAT AORTIC VASCULAR SMOOTH MUSCLE CELLS VIA Β-ARRESTIN2DEPENDENT ERK SIGNALING PATHWAY
Yun Hak Kim, J. Bae, K.W. Seo, S.J. Lee, S.Y. Park, C.D. Kim, Republic of
Korea
930
36
EXTRACELLULAR S100A4 PROMOTES ARTERIAL SMOOTH MUSCLE
CELL PHENOTYPIC TRANSITION: IMPLICATION IN
ATHEROSCLEROSIS AND RESTENOSIS
Chiraz Chaabane, C.W. Heizmann, M.-L. Bochaton-Piallat, Switzerland
1013
37
NUCLEAR TARGETING OF APELIN IN VASCULAR SMOOTH MUSCLE
CELLS: IMPLICATIONS IN CELL PROLIFERATION AND
ATHEROSCLEROTIC PLAQUE FORMATION?
Chiraz Chaabane, C. Brun, A. Roatti, Y. Audigier, A.J. Baertschi, M.-L.
Bochaton-Piallat, Switzerland, France
1043
38
PARADOXICAL STIMULATION OF MATRIX METALLOPROTEINASE
EXPRESSION BY BISPHOSPHONATES IN RAT VASCULAR SMOOTH
MUSCLE CELL CULTURE
Mehmet Zuhuri Arun, B. Reel, G.B. Sala-Newby, M. Bond, A.C. Newby,
Turkey, UK
1048
59
Poster Board No.
Abstract No
39
CALMODULIN EXPRESSION DISTINGUISHES THE SMOOTH MUSCLE
CELL POPULATION OF THE HUMAN CAROTID PLAQUE
Matteo Coen, G. Marchetti, P.M. Palagi, C. Zerbinati, G. Guastella, T.
Gagliano, F. Bernardi, F. Mascoli, M.-L. Bochaton-Piallat, Switzerland, Italy 1082
40
INFLUENCE OF THE PHENOTYPE OF VASCULAR SMOOTH MUSCLE
CELLS ON THE RENIN-ANGIOTENSIN SYSTEM IN RAT
Sabrina Bennia, O. Lohez, G. Bricca, France
1528
41
EPAC 2 IS INVOLVED IN THE INFLAMMATORY RESPONSE OF TRANSDIFFERENTIATED AC8-EXPRESSING VASCULAR SMOOTH MUSCLE
CELLS
Amélie Vromman, N. Clément, K. Blirando, I. Limon, France
1570
42
HEAT SHOCK PROTEIN-60 MEDIATED INDUCTION OF VASCULAR
SMOOTH CELL PROLIFERATION THROUGH NUCLEOCYTOPLASMIC
TRAFFICKING
Justin F. Deniset1,2, M. Hlaváčková, T.E. Hedley, M.N. Chahine, E. Dibrov,
1627
G.N. Pierce1,2, Canada
43
INTRINSIC SEROTONERGIC SYSTEM IN HUMAN CORONARY ARTERY
SMOOTH MUSCLE CELLS: POTENTIAL IMPLICATION IN CORONARY
ARTERY DISEASE
Vithya Selvaraj, K. Baskar, S. Sur, D.K. Agrawal, USA
1642
44
THE EFFECTS OF ALENDRONATE ON CONTRACTILE RESPONSES IN
HUMAN LEFT INTERNAL MAMMARY ARTERY
Buket Reel, M. Arun, M. Guzeloglu, G. Albayrak, E. Hazan, Turkey
1220
Extracellular matrix and calcification
45
WALL PROPERTIES OF THE APOLIPOPROTEIN E-DEFICIENT MOUSE
AORTA
Aristotelis Agianniotis, N. Stergiopulos, Switzerland
182
46
PREVENTION OF CARDIAC EVENTS IN PATIENTS WITH
ATHEROSCLEROSIS UNDERGOING VASCULAR OPERATIONS
Elena Medvedeva, Y. Shchukin, E. Seleznev, Russia
272
EFFECT OF DIFFERENT TYPES OF PLAQUE ON HEMODYNAMIC
CHANGES TO THE LEFT CORONARY ARTERY
T. Chaichana, Zhonghua Sun, Australia
313
47
48
CHRONIC ANGIOTENSIN II INFUSION CHANGES MICRORNA PROFILE
IN MURINE AORTAS
Maria Gabriela Dulak, M. Siedlinski, T. Mikolajczyk, R. Nosalski, R. Korbut,
A. Jozkowicz, T.J. Guzik, Poland
399
49
VITRONECTIN EXPRESSION IN AORTIC VALVES FROM SUBJECTS
WITH SEVERE AORTIC STENOSIS
M. Ledesma, L.M. Salazar-Pelaez, M. Correa, J.S. Jaramillo, S. Franco, Lina
Maria Yassin-Norena, A.M. Herrera, Colombia
627
60
Poster Board No.
Abstract No
50
DIFFERENTIAL GENE EXPRESSION IN CAROTID PLAQUES WITH
CALCIFICATION
Hiroyuki Katano1,2, K. Yamada, Japan
51
INTERPLAY OF INFLAMMATION AND OXIDATIVE STRESS IN HUMAN
ABDOMINAL AORTIC ANEURYSMS
Agnieszka Sagan, W. Mrowiecki, T. Mikolajczyk, K. Urbanski, G. Filip, B.
Kapelak, T. Mrowiecki, R. Korbut, T. Guzik, Poland
868
52
ATHEROSCLEROSIS AND FIBRO-DYSPLASIA: TWO
PATHOPHYSIOLOGICAL STREAMS INTO THE CALCIFIC AORTIC
VALVE DISEASE. HOW COULD WE STEM THE DISEASE
PROGRESSION?
A. Vianello, S. Perlini, S. Cappelli, G. Palladini, A. Cerillo, D. della Latta, D.
Chiappino, P. Tanganelli, M. Glauber, S. Berti, Annamaria Mazzone, Italy 884
53
ELASTIN PEPTIDES, NEW REGULATORS OF INSULIN RECEPTOR
B. Romier-Crouzet, C. Kawecki, S. Baud, P. Maurice, L. Duca, L. Debelle, V.
Durlach, Sebastien Blaise, France
948
54
CORONARY CALCIFICATION CORRELATES WITH VALVE AND ROOT
CALCIFICATION IN ISOLATED AORTIC STENOSIS: AN EVIDENCE FOR
CARDIAC-BASE CALCIFICATION DISEASE
P. Hällgren, A. Holmgren, K. Sörensen, U. Näslund, K. Riklund, Michael
Henein, Sweden
967
55
DEREGULATION OF SMOOTH MUSCLE CELL CYTOSKELETON WITHIN
THE HUMAN ATHEROSCLEROTIC CORONARY MEDIA LAYER
Fernando Vivanco, Spain
976
56
TLR ACCESSORY MOLECULE RP105 (CD180) IS INVOLVED IN POSTINTERVENTIONAL VASCULAR REMODELING AND SOLUBLE RP105
MODULATES NEOINTIMA FORMATION
J.C. Karper, M.M. Ewing, M.R. De Vries, S.C.A. de Jager, E.G. Huizinga, J.
Kuiper, J.W. Jukema, Paul Quax, The Netherlands
997
57
THE EFFECT OF PROLONGED SYSTEMIC DOXYCYCLINE THERAPY
ON SERUM TISSUE DEGRADING PROTEINASES IN CORONARY
BYPASS PATIENTS
Hatem Alfakry, I. Kormi, P. Pussinen, J. Sinisalo, T. Sorsa, Finland
1036
58
ROLE OF S100A4 IN EARLY STAGE OF ATHEROSCLEROSIS AND
ANEURYSM OF THE AORTA
Ziad Touat, V. Ollivier, L. Louedec, K. Guedj, J.-B. Michel, G. Jondeau1,2,
France
1096
59
ATHEROSCLEROTIC PLAQUES IN EX VIVO SYSTEM
Anna Lebedeva, J.-C. Grivel, O. Ivanova, A. Shpektor, E. Vasilieva, L.
Margolis, O. Ivanova, Russia, USA
60
687
1125
ZOLEDRONATE ATTENUATES ANGIOTENSIN II-INDUCED ABDOMINAL
AORTIC ANEURYSM THROUGH INACTIVATION OF RHO/ROCK
DEPENDENT JNK AND NF-KB PATHWAY
Po-Hsun Huang, S.-H. Tsai, S.-J. Lin, Taiwan R.O.C.
1227
61
Poster Board No.
Abstract No
61
FGF-23 AND CAROTID ATHEROSCLEROSIS: A DANGEROUS AFFAIR
Angela Koverech, F. Del Porto, L. Ferri, C. Fantozzi, L. Rizzo, M. Taurino,
M. Proietta, Italy
1259
62
PROTEOMIC ANALYSIS OF THE ELASTIC ARTERIAL MEDIA IN AGING
Motoji Sawabe, S. Yoshida, A. Hamamatsu, T. Toda, T. Arai, M. Iwamoto, T.
Endo, Y. Miura, Japan
1207
63
ROLE OF FIBRONECTIN EXTRA DOMAIN A IN CARDIOVASCULAR
DISEASE: EVIDENCES FROM ANIMAL MODELS OF
ATHEROSCLEROSIS
V.K. Pulakazhi Venu, Giuseppe Danilo Norata1,2, P. Uboldi, A. Muro, L.
Arnaboldi, A. Corsini, A.L. Catapano1,4, Italy
1300
64
WHOLE TRANSCRIPTOME SEQUENCING OF APOE-KO MOUSE AORTA
REVEALS DIFFERENTIALLY EXPRESSED GENES IN ADVANCED
ATHEROSCLEROSIS
Stefano Manzini, M. Chiara, M. Busnelli, C. Parolini, G. Ganzetti, C.R.
Sirtori, D.S. Horner, G. Chiesa, Italy
1522
65
EXTRACELLULAR MATRIX PROTEINS FROM PIG ARTERIES: FROM
TISSUE TO BLOOD MARKERS OF ATHEROGENESIS
Silvia Rocchiccioli, G. Pelosi, A. Cecchettini1,2, F. Viglione, M. Puntoni, L.
Citti, O. Parodi, M.G. Trivella, Italy
1540
66
REGULATION OF ELASTIN SYNTHESIS IN AORTA THROUGH A CA2+ERK-DEPENDANT PATHWAY
M. Lannoy, C. Choqueux, L. Louedec, Marie-Paule Jacob, France
1571
67
MMP-13 PREDOMINATES OVER MMP-8 AS THE FUNCTIONAL
INTERSTITIAL COLLAGENASE IN MOUSE ATHEROMATA
Thibaut Quillard, H.A. Araújo, Y. Tesmenitsky, P. Libby, USA
1647
Gene expression
68
MIR-21, -133B, -146A, -150, -155, -181B AND LET-7A ARE UPREGULATED IN ATHEROSCLEROTIC CORONARY VALVES FROM
PATIENTS WITH AORTAL STENOSIS
Jana Borucka1,2, J. Petrkova2,3, V. Lonsky, T. Tomankova, M. Petrek, Czech
Republic
344
69
GENE EXPRESSION RESPONSES TO AORTAL ATHEROGENESIS
T.A. Shchelkunova, I.A. Morozov, P.M. Rubtsov, L.M. Samokhodskaya, Igor
322
A. Sobenin4,5, A.N. Orekhov5,6, A.N. Smirnov, Russia
70
COORDINATION BETWEEN GENES EXPRESSION DURING
ATHEROGENESIS
T.A. Shchelkunova, I.A. Morozov, P.M. Rubtsov, L.A. Samokhodskaya, I.A.
Sobenin4,5,6, Alrexander N. Orekhov5,6, A.N. Smirnov, Russia
323
62
Poster Board No.
Abstract No
71
GENOME-WIDE EXPRESSION PROFILING HIGHLIGHTS THE ROLE
PLAYED BY COMPLEMENT SYSTEM AND WNT PATHWAY DURING
EARLY-STAGE ATHEROSCLEROSIS IN APOEKO MICE
Marco Busnelli, S. Manzini, M. Chiara, C. Parolini, G. Ganzetti, C.R. Sirtori,
D.S. Horner, G. Chiesa, Italy
1513
72
TRANSFORMING GROWTH FACTOR-BETA (TGF-ß)
TRANSCRIPTIONAL REGULATION IN HUMAN CAROTID ATHEROMA:
IN SILICO STUDY
Nedra Dhaouadi, C. Paultre, P. Feugier, M.-P. Gustin, K. Kacem, J.-Y. Li, G.
Bricca, C. Cerutti, France, Tunisia
1516
73
TRANSCRIPTIONAL ORGANIZATION AND FUNCTIONAL
INTERACTIONS BETWEEN CORTICOIDS AND ANGIOTENSIN II
SYSTEMS IN HUMAN ATHEROMA AND VASCULAR SMOOTH MUSCLE
CELLS
Hanene Ayari, L. Legedz, S. Barrot, P. Lantelme, P. Feugier, G. Bricca, O.
Lohez, J.Y. Li, C. Cerutti, M.-P. Gustin, France
1519
74
ANNEXIN A5 INHIBITS ATHEROGENIC AND PRO-INFLAMMATORY
EFFECTS OF LYSOPHOSPHATIDYLCHOLINE
H. Domeij, X. Hua, J. Su, A. Bäcklund, Z. Yan, A. Frostegård, J. Haeggström,
T. Modéer, Johan Frostegård, Sweden
1520
Infection and atherosclerosis
75
ASSOCIATION OF CHLAMYDIA PNEUMONIAE INFECTION WITH
ATHEROGENIC LIPID PROFILE
Hosseinali Habibinejad, A. Riahin, Iran
664
76
PERIODONTITIS IS CLOSELY ASSOCIATED WITH CAROTID ARTERIAL
INFLAMMATION
Sungeun Kim, H.-S. Seo, E.J. Kim, J.H. Na, J.H. Park, C.U. Choi, H.E. Lim,
J.W. Kim, S.-W. Rha, C.-G. Park, D.J. Oh, Republic of Korea
689
77
MONO- AND POLYMICROBIAL PERIODONTAL PATHOGEN-INDUCED
INFLAMMATORY CYTOKINE PROFILES IN HYPERLIPIDEMIC APOENULL
MICE
I. Velsko, S. Chukkapalli, M. Rivera, A. Lucas, Lakshmyya Kesavalu, USA1092
78
HIV INFECTION REDUCES THE CAPACITY OF HDL PARTICLES TO
MEDIATE CHOLESTEROL EFFLUX FROM HUMAN MACROPHAGES
Petra El Khoury, E.F. Villard, C. Legeai, G. Catalano, P. Yeni, C. Goujard,
M. Guerin, France
1104
79
INDUCTION OF TOLL-LIKE RECEPTOR-2 MEDIATED INFLAMMATION
IN HUMAN ATHEROMA DERIVED SMOOTH MUSCLE CELLS BY ORAL
BACTERIA AND CHLAMYDIA PNEUMONIAE
Tanja Pessi, L. Viiri, N. Astola, M. Pyysalo, K. Lounatmaa, A.H. Davies, T.
Lehtimäki, P.J. Karhunen, C. Monaco, Finland, UK
1282
63
Poster Board No.
Abstract No
80
MOLECULAR DETECTION OF BACTERIAL RNA IN ATHEROMATOUS
PLAQUES OF PATIENTS WITH STROKE
Macarena Gomez Lira, S. Ferronato, S. Olivato, A. Bertoncelli, S.
Mazzucco, C. Signoretto, Italy
1353
81
DETECTION OF PERIODONTAL BACTERIA DNA IN CAROTID
ATHEROSCLEROTIC PLAQUES. ASSOCIATION WITH THE
HAPTOGLOBIN GENOTYPE
Hélène Rangé1,2,3, M. Varret1,4, S. Delbosc, J.-B. Michel1,2,5, P. Bouchard2,3,6,
1455
O. Meilhac1,2,7, France
82
DETECTION OF HUMAN HERPES VIRUSES IN ATHEROSCLEROTIC
LESION IN PATIENTS WITH CORONARY ARTERY DISEASE
J.-C. Grivel, Elizaveta Nikitskaya, O. Ivanova, N. Ryazankina, N. Pinegina,
A. Lebedeva, A. Shpektor, L. Margolis, E. Vasilieva, USA, Russia
1485
Inflammation
83
NADPH OXIDASE/ROS-DEPENDENT PYK2 ACTIVATION IS INVOLVED
IN TNF-A-INDUCED MATRIX METALLOPROTEINASE-9 EXPRESSION IN
RAT HEART-DERIVED H9C2 CELLS
Chuen-Mao Yang, Taiwan R.O.C.
119
84
HIGH-CHOLESTEROL DIET STIMULATES 11Β-HYDROXYSTEROID
DEHYDROGENASE TYPE 1 IN ATHEROSCLEROTIC LESIONS OF
APOE-DEFICIENT MICE
L. Rehakova, P. Ergang, F. Kolar, R. Poledne, Jiri Pacha, Czech Republic 249
85
FLUVASTATIN SIGNIFICANTLY REDUCES LPS-STIMULATED
INTERLEUKIN-6, BUT NOT INTERLEUKIN-1, IN THE STANDARD
VASCULAR SMOOTH MUSCLE - MONOCYTE COCULTURE
Harald Loppnow, C. Jaschke, H. Fu, K. Schlecht, S. Gielen, U. MüllerWerdan, H. Ebelt, M. Buerke, K. Werdan, Germany
298
86
ULTRASOUND EVIDENCE OF ATHEROGENESIS IN MOUSE LEMUR
PRIMATES
Fabien Chauveau, A. Sérusclat, E. Canet-Soulas, M. Wiart, J.-B. Langlois,
R. Bolbos, F. Aujard, M. Perret, M. Dhenain, N. Nighoghossian, France
369
87
ACTIVATION OF Α7 NICOTINIC ACETYLCHOLINE RECEPTOR
SUPPRESSES ATHEROSCLEROSIS
Toshihiro Ichiki, T. Hashimoto, K. Sunagawa, Japan
474
88
MAPKAP 2/3: A NOVEL DRUG TARGET FOR CHOLESTEROL INDUCED
CARDIOVASCULAR DISEASES IN VIVO?
Naveed Akbar, M. Gaestel, J.J.F. Belch, F. Khan, UK, Germany
500
89
TRANSCRIPTIONAL LEUKOTRIENE PATHWAY ACTIVATION IN
APOLIPOPROTEIN-E DEFICIENT MICE EXPOSED TO INTERMITTENT
HYPOXIA: ROLE IN ATHEROSCLEROSIS PROGRESSION
E. Gautier1,2, M. Bäck, C. Arnaud, M. Petri, P. Levy1,4,5, Françoise StankeLabesque1,2,5, France, Sweden
515
64
Poster Board No.
90
91
Abstract No
ROLE OF INTERLEUKIN-6 IN АCUTE CORONARY SYNDROME
Azizjon Abdumatlubovich Nizomov, Uzbekistan
523
DIETARY NITRATE REDUCES LEUKOCYTE ACTIVATION IN THE
APOLIPOPROTEIN E KNOCKOUT MOUSE
Rayomand S. Khambata, S.M. Ghosh, A. Ahluwalia, UK
574
92
LIPID BIOMARKERS PREDICT MONOCYTE POLARISATION AND
CYTOKINE RELEASE IN HEALTHY CONTROLS
John Fletcher, H. Williams, G. Cassorla, C. Wang, K. Hitos, N. Marmash, H.
Medbury, Australia
684
93
TGFΒ BUT NOT BMPS ACTIVATES SMAD1/5 PATHWAY IN PRIMARY
HUMAN MACROPHAGES AND INDUCES EXPRESSION OF
PROATHEROGENIC GENES
D. Nurgazieva, W. Ming, I. Ovsyi, A. Popova, N. Wang, Julia
Kzhyshkowska3,4, A. Gratchev2,4, Russia, Germany
952
94
INCREASED INTERLEUKIN 9 IN ATHEROSCLEROTIC DISEASE
Ida Gregersen, K. Holven2,3, M. Skjelland, S. Holm, L. Gullestad3,5, K. Krogh980
Sørensen3,6, P. Aukrust1,3,7, B. Halvorsen1,3, Norway
95
EMPHYSEMA ALONE DOES NOT EXPLAIN THE HIGHER RISK OF
DEVELOPING ATHEROSCLEROSIS IN COPD PATIENTS: A ROLE FOR
CHRONIC PULMONARY INFLAMMATION?
P.P.S.J. Khedoe1,2, M.C. Wong1,2, I. Meurs, J.J. Plomp, G.T.M. Wagenaar, M.
van Eck, L.M. Havekes1,6,7, P.C.N. Rensen, P.S. Hiemstra, Jimmy Berbée1,8,
The Netherlands, Greece
1040
96
NLRP1-INFLAMMASOME, A KEY IN THE TURN OFF OF THE
ENDOTHELIAL CELL TO THE PROINFLAMMATORY STATE OF THE
Silvia Bleda, J. De Haro, C. Varela, I. Lopez de Maturana, J. Rodriguez, F.
Acin, Spain
1081
97
LYSINE RICH CATIONIC PEPTIDES MAY ATTENUATE INFLAMMATION
AND ATHEROSCLEROSIS
Sampath Parthasarathy, A.N. Chandrakala, K. Selvarajan, USA
1148
98
POXYTRINS, A NEW FAMILY OF LIPOXYGENASE PRODUCTS FROM
POLYUNSATURATED FATTY ACIDS, ARE DOTED OF ANTIATHEROTHROMBOTIC POTENTIAL
Miao Liu, P. Chen, E. Véricel, T. Boussetta, F. Driss, M. Lagarde, M.
Guichardant, France, China
1178
99
THE ANTIATHEROSCLEROTIC POTENTIAL OF VILDAGLIPTIN: THE
CONCEPT OF ANTIINFLAMMATORY AND ANTIOXIDANT PROPERTIES
Najah R. Hadi, S. Majeed, H. Abdelkadhem, A. Al-Jenabi, Iraq
1204
100
HIGH LEVELS OF COX-2 GENE EXPRESSION IN PERIPHERAL BLOOD
OF CARDIOEMBOLIC COMPARED TO ATHEROTHROMBOTIC STROKE
PATIENTS
S. Ferronato, S. Olivato, C. Patuzzo, A. Scuro, P.F. Pignatti, S. Mazzucco,
Macarena Gomez Lira, Italy
1322
65
Poster Board No.
Abstract No
101
HIGH EXPRESSION OF ARACHIDONATE 15-LIPOXYGENASE AND
PROINFLAMMATORY MARKERS IN HUMAN ISCHEMIC HEART TISSUE
L.M. Hultén, Annika Lundqvist, L.U. Magnusson, C. Hermansson, A.
Jeppsson, Sweden
1354
102
THEAFLAVINS-RICH FRACTION INHIBITS LIPOPOLYSACCHARIDESTIMULATED NUCLEAR FACTOR- ҠB ACTIVATION IN HUMAN
ENDOTHELIAL CELLS
Nur Hidayah Mohd Ishak, A. Mohd Ismail, G.R.A. Froemming, T.H. Abdul
Rahman, H. Mohd Nawawi, Malaysia
1450
103
PERIVASCULAR INFLAMMATION IN HYPERTENSIVE RATS
Ryszard Nosalski, T.P. Mikolajczyk, J. Maciag, T.J. Guzik, Poland
1582
Innate immunity
104
ASSOCIATION OF TOLL-LIKE RECEPTOR 4 WITH LUMINAL STENOSIS
IN PATIENTS WITH STABLE ANGINA
Bahador Bagheri, A. Garjani, B. Sohrabi, S. Mashayekhi, A. Movassaghpur,
Iran
57
105
HYDROCORTIOSNE REDUCES MONOCYTE EXPRESSION AND
RESPONSE OF TOLL-LIKE RECEPTOR 4 IN PATIENTS UNDERGOING
PERCUTANEOUS CORONARY INTERVENTION
Bahador Bagheri, A. Garjani, B. Sohrabi, S. Mashayekhi, A. Movassaghpur,
Iran
127
106
NOD2 INDUCES COX2-MPGES-1-PGE2 AS PROXIMAL INNATE IMMUNE
SIGNALING IN ATHEROSCLEROSIS
H.-Q. Liu1,2, Xiao-Ying Zhang1,3, K. Edfeldt, M.M.O. Nijhuis, H. Idborg, M.
Bäck, J. Roy, U. Hedin, P.-J. Jakobsson, J.D. Laman, D.P.V.D. Kleijn, G.
Pasterkamp, G.K. Hansson, Z.-Q. Yan, Sweden, China, Netherlands Antilles 303
107
RECOVERY OF NATURAL KILLER CELLS IN PATIENTS WITH
CORONARY ARTERY DISEASE. A ONE YEAR FOLLOW-UP STUDY
Karin Backteman, J. Ernerudh, L. Jonasson, Sweden
332
5-LIPOXYGENASE PLAYS A CENTRAL ROLE IN TLR4-MEDIATED
MONOCYTE ADHESION TO VASCULAR ENDOTHELIAL CELLS
Chi Dae Kim, S.J. Lee, E.K. Choi, S.Y. Park, Republic of Korea
463
108
109
DIFFERENTIAL EXPRESSION OF GM1, A MARKER OF LIPID RAFTS, IN
HUMAN MONOCYTE SUBPOPULATIONS MAY BE INVOLVED THE
PATHOGENESIS OF ATHEROSCLEROSIS
Valentina Shishkina, T. Pavlunina, M. Chelombitko, E. Gracheva, A.
Kaminnyi, Y. Romanov, N. Samovilova, N. Prokazova, Russia
565
110
MODIFIED LIPOPROTEINS MODULATE DENDRITIC CELL IMMUNE
FUNCTION
Laure Perrin-Cocon1,2, O. Diaz1,2, P. André1,2,3, V. Lotteau1,2, France
992
SPLENIC DENERVATION ACCELERATES ATHEROSCLEROSIS IN
APOE-/- MICE
Marcus A. Ulleryd, P.A. Micallef, L.J. Yang, S. Hua, M.E. Johansson,
Sweden
1003
111
66
Poster Board No.
Abstract No
112
MACROPHAGIC VERSATILE OUTCOME IN CRITICAL CAROTID
STENOSIS AND ACUTE AORTIC DISSECTION
Livia Ferri, M. Proietta, C. di Gioia, L. Tritapepe, M. Leopizzi, C. Fantozzi, C.
Chiappetta, I. Nofroni, C. Della Rocca, E. Marinari, A.P. Mitterhofer, A.
Negro, A. Koverech, M. Taurino, F. Del Porto, Italy
1111
113
NATURAL KILLER CELL APOPTOSIS IN CORONARY ARTERY
DISEASE: IS IT REFLECTED BY SOLUBLE APOPTOTIC MARKERS?
Anna Lundberg, C. Evaldson, W. Li, K. Backteman, J. Ernerudh, L.
Jonasson1,2, Sweden
1139
114
THE ROLE OF IKKΑ IN ATHEROSCLEROSIS
Pathricia Tilstam, H. Noels, M. Gijbels, B. Zhou, W. Theelen, M. de Winther,
C. Weber, Germany, Netherlands Antilles
1159
115
CHARACTERIZATION OF INVARIANT NATURAL KILLER CELL
SUBSETS IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA
Sergey Alexandrovich Bondarenko, A. Baragetti1,2, F. Pellegatta, A.L.
1269
Catapano1,3, G.D. Norata1,2, Italy
116
TLR4 -2604G>A VARIANT CONFERS DNA BINDING CAPACITY TO
GATA FAMILY TRANSCRIPTION FACTORS, MODIFYING GENE
EXPRESSION IN ATHEROSCLEROTIC PATIENTS PERIPHERAL BLOOD
S. Ferronato, S. Olivato, M. Menegazzi, A. Scuro, M.G. Romanelli, E. Diani,
S. Mazzucco, Macarena Gomez Lira, Italy
1283
117
THE NEURON-DERIVED ORPHAN RECEPTOR1 (NOR1) IS INDUCED IN
HUMAN ALTERNATIVE MACROPHAGES AND CONTROLS THE
EXPRESSION OF ALTERNATIVE POLARIZATION MARKERS
Federica De Paoli, C. Copin, J. Vanhoutte, C. Zawadzki, B. Jude, S. Haulon,
J. Eeckhoute, P. Lefebvre, B. Staels, G. Chinetti-Gbaguidi, Nuclear
Receptors, Cardiovascular Diseases, Diabet, France
1291
118
PHENOTYPE CHANGES OF CIRCULATING BLOOD MONOCYTES (MN)
IN THE HYPERCHOLESTEROLEMIC SWINE MODEL OF CORONARY
ARTERY DISEASE (CAD)
S. Sbrana, M.R. Puntoni, F. Viglione, G. Pelosi, Federico Vozzi3,4, M.G.
Trivella, O. Parodi, Italy
1369
119
DISTRIBUTION OF M1 AND M2 MACROPHAGES SUBPOPULATIONS IN
DIFFERENT TYPES OF CAROTID ATHEROSCLEROTIC PLAQUES
Valentina S. Shishkina, M.A. Chelombitko, O.P. Ilyinskaya, E.M. Tararak,
Russia
1391
120
INCREASING SURVIVAL OF MACROPHAGES DELAYS PROGRESSION
OF ESTABLISHED ATHEROSCLEROTIC LESIONS
Laura Bouchareychas, J. Pirault, F. Saint-Charles, E. Gautier, P. Giral, T.
Huby, P. Lesnik, France
1402
67
Poster Board No.
Abstract No
Adaptive immunity
121
122
ACTIVE IMMUNIZATION AGAINST SULFATED
GLYCOSAMINOGLYCANS AS A NOVEL THERAPEUTIC AVENUE IN
ATHEROSCLEROSIS
Katia Mellal, V. Brito, S.G. Portelance, A. Pérez, Y. Soto, D. deBlois, H.
Ong, A.M. Vázquez, S. Marleau, Canada, Cuba
628
ROLE OF PI3K-C2BETA IN T LYMPHOCYTES DEVELOPMENT AND
ATHEROSCLEROSIS
Gianpaolo Tibolla1,2, S. Bertoni, F. Sala, G.D. Norata1,2, A.L. Catapano1,3,
Italy
695
123
ATTENUATION OF EARLY ATHEROSCLEROSIC LESIONS IN A MURINE
MODEL BY IMMUNOTOLERANCE WITH BETA-2-GLYCOPROTEIN AND
THE IMMUNOMODULATORY EFFECTORS IL-2 AND IL-10
Joaquín De Haro, L. Esparza, C. Varela, S. Bleda, I. López-Maturana, J.
Rodríguez, C. González, F. Acin, Spain
722
124
METHOTREXATE AND ETOPOSIDE, BOTH ASSOCIATED WITH LIPID
NANOEMULSIONS, INCREASES FOXP3 T LYMPHOCYTES IN THE
INTIMA OF HYPERCHOLESTEROLEMIC RABBITS
Antonio Carlos de Arruda Leite Jr1,2, A. Bulgarelli, E.R. Tavares, R.C.
Maranhão1,2, Brazil
901
125
LOSS OF B-CELL FUNCTION IN MRAS- KNOCK-OUT MOUSE AND
REDUCED INFLAMMATION IN ATHEROSCLEROTIC PLAQUES AT THE
AORTIC ROOT
Jennifer Freyer1,2, M. Behrensen1,2, Z. Aherrahrou1,2, J.F.P. Berbée, H.
1133
Schunkert4,5, J. Erdmann1,2, Germany, The Netherlands
126
MCS-18 INHIBITS THE PROGRESSION OF ATHEROSCLEROSIS IN
APOE-DEFICIENT MICE BY MODULATING THE IMMUNE RESPONSE
Barbara Dietel, R. Münch, R. Altendorf, I. Cicha, A. Steinkasserer, E. Zinser,
S. Achenbach, C. Garlichs, F. Kerek, Germany
1157
127
CD137 SIGNALING IN THE PATHOGENESIS OF ATHEROSCLEROSIS
1427
I.-H. Jung1,2, J. Jin, D.-Y. Kim, Goo Taeg Oh, Republic of Korea
128
CHARACTERIZATION OF MEMORY T CELL SUBSETS IN PATIENTS
Federica Sala, F. Pellegatta, A. Baragetti, G.D. Norata1,2, A.L. Catapano1,3,
Italy
1462
68
Poster Board No.
Abstract No
Hormones and atherosclerosis
129
MEN WITH POOR CARDIORESPIRATORY FITNESS COMBINED WITH
LOWER TESTOSTERONE HAVE HIGH OXIDIZED LDL LIPIDS - BEING
FIT PREVENTS THIS RELATIONSHIP
Jussi Kosola, M. Ahotupa, H. Kyrolainen, M. Santtila, T. Vasankari, Finland 117
130
THE THYROID HORMONE RECEPTOR TRΑ PROTECTS AGAINST
ATHEROSCLEROSIS DEVELOPMENT: AN NEW ROLE FOR TRΑ AS AN
ANTI-INFLAMMATORY FACTOR
C. Billon, L. Canaple, J. Samarut, Karine Gauthier, France
224
131
EFFECT OF ESTRADIOL ON ATHEROSCLEROSIS OF THE COMMON
CAROTID ARTERY IN WOMEN: A POSTMORTEM ANALYSIS
Ho-Dirk Kim, Republic of Korea
467
132
INCREASED NEOINTIMAL FORMATION AFTER VASCULAR INJURY IN
ANDROGEN RECEPTOR KNOCKOUT MICE
Anna S. Wilhelmson, J. Bourghardt-Fagman, M.E. Johansson, K. De
Gendt, G. Verhoeven, P. Fogelstrand, Å. Tivesten, Sweden, USA, Belgium 774
133
INVOLVEMENT OF P27 IN THE PROGESTERONE-INDUCED MIGRATION
INHIBITION IN RAT AORTIC SMOOTH MUSCLE CELLS
Hui-Jane Wang, S.-P. Hsu, S.-F. Chang, C. Hsu, W.-S. Lee, Taiwan R.O.C. 910
134
THE ROLE OF DISCOIDIN DOMAIN RECEPTOR SIGNALLING AND
EFFECT OF ALENDRONATE IN CAROTID ARTERY LIGATION-INDUCED
INTIMAL THICKENING IN MICE
Buket Reel, S. Ozbal, B.U. Ergur, O. Yilmaz, D. Keles, G. Oktay, G. Sevin,
Z. Kerry, Turkey
1228
69
POSTERS TRACK 2 LIPID AND LIPOPROTEIN METABOLISM: FROM ALTERATIONS TO
TREATMENTS
Poster Board No.
Abstract No
apoB-Containing lipoproteins / Modified lipoproteins
135
PROTEIN DISULFIDE ISOMERASE MODIFICATION BY OXIDIZED LDL
IMPAIRS ITS FUNCTION AND CONTRIBUTES TO APOPTOSIS. A ROLE
IN ATHEROSCLEROSIS?
C. Muller, J. Bandemer, C. Vindis, R. Salvayre, Anne Negre-Salvayre,
France
1123
136
ANTAGONISTIC EFFECTS OF IL-10 AND IL-6 ON LDL OXIDATION;
PROBABLE EVIDENCE FOR A CYTOKINIC MODULATORY MECHANISM
IN ATHEROGENESIS
Adel Abedpour Dehkordi1,2, G.A. Naderi, H. Nayeri, M. Boshtam, N. Jafari
Dinanai, Iran
415
137
MODIFIED ATHEROGENIC LDL INDUCES OVEREXPRESSION OF BOTH
PRO-INFLAMMATORY CYTOKINE TNFA AND ANTI-INFLAMMATORY
CHEMOKINE CCL18
Nikita G. Nikiforov1,2, Y.V. Bobryshev1,3,4, V. Aladinsky, E.N. Borodachev, O.
Gorlova, A. Temchenko, N. Pervushina, I.A. Sobenin1,2,3, A.N. Orekhov1,3,
Russia, Australia
674
apoB-Containing lipoproteins / Lp(a)
138
ELEVATED LIPOPROTEIN(A) IS ASSOCIATED WITH WORSE
PROGNOSIS IN DIABETIC PATIENTS WITH CORONARY ARTERY
DISEASE
Sung Woo Kwon, J.-J. Cha, B.K. Lee, J.-Y. Kim, E.-Y. Choi, P.-K. Min, Y.W.
Yoon, B.-K. Hong, S.-J. Rim, H.M. Kwon, Republic of Korea
71
139
EVALUATION OF HOMOCYSTEINE AND LIPOPROTEIN(A) PLASMA
LEVELS CAN REVEAL ADVANCED SYSTEMIC ATHEROSCLEROTIC
BURDEN IN ACUTE CORONARY SYNDROME PATIENTS
Gabriele Cioni, R. Marcucci, A.M. Gori, S. Fedi, A. Galassini, E. Ganugi, A.
Rogolino, C. Giglioli, S. Valente, G.F. Gensini, R. Abbate, M. Boddi, Italy 1083
140
LIPOPROTEIN (A) ANALYSES IN A FAMILY WITH PREMATURE
Reyhana Yahya, R. Vongpromek, L. van der Zee, J. Touw, E. Sijbrands, A.
Verhoeven, J. Roeters van Lennep, M. Mulder, The Netherlands
1469
HDL / CETP
141
HOW ANACETRAPIB INHIBITS THE ACTIVITY OF THE CHOLESTERYL
ESTER TRANSFER PROTEIN? INSIGHT GAINED THROUGH ATOMISTIC
SIMULATIONS
Tarja Äijänen, A. Koivuniemi, T. Rog, I. Vattulainen, Biological Physics and
Soft Matter Group, Finland
1436
142
ENDOGENOUS CETP ACTIVITY AS A PREDICTOR OF
CARDIOVASCULAR RISK
E.F. Villard, M.-C. Federspiel, V. Fesel-Fouquier, C. Cherfils, E. Bruckert, K.
Clement, D. Bonnefont-Rousselot, W. Le Goff, R. Bittar, P. Couvert, Maryse
Guerin, France
1046
70
POSTERS TRACK 2: LIPID AND LIPOPROTEIN METABOLISM: FROM ALTERATIONS TO
TREATMENTS (contd.)
Poster Board No.
Abstract No
143
PLASMA CHOLESTERYL ESTER TRANSFER PROTEIN: A BIOMARKER
FOR HEPATIC MACROPHAGES IN MICE AND HUMANS
Yanan Wang, S.J.L. van der Tuin1,2, V. Bieghs, R. Shiri-Sverdlov, H.M.G.
Princen, J.A. Romijn, M.G.M. Wolfs, S. Rensen, L.M. Havekes 1,4,7, M.H.
Hofker, K. Willems van Dijk, P.C.N. Rensen, The Netherlands
847
144
ELEVATED CETP ACTIVITY IS ASSOCIATED WITH LOW,
DYSFUNCTIONAL HDL IN SOUTH ASIANS
145
195
HIGH CETP ACTIVITY IN MYOCARDIAL INFARCTION PREDICTS
SHORT-TERM MORTALITY BY INDUCING ENDOTHELIAL
DYSFUNCTION, POOR CORONARY FLOW AND MICROVASCULAR
HYPOPERFUSION
L.S. Carvalho, S. Santos, V.W. Virginio, F. Alexandre, Natalia B. Panzoldo,
O. Nobrega, E.C. de Faria, J.C.Q. Silva, A.C. Sposito, Brazilian Heart Study,
Brazil
1421
HDL / Cholesterol efflux
146
REGULATION OF ATP-BINDING CASSETTE TRANSPORTER A1
EXPRESSION IN RAW264.7 MACROPHAGES UNDER HYPERGLYCEMIC
STRESS
Anna Chiang, Y.-C. Chang, W.H.-H. Sheu, Y.-S. Chien, P.-C. Tseng,
Taiwan R.O.C.
122
147
METABOLIC PHENOTYPING OF AN ENDOTHELIAL SPECIFIC ABCA1
KNOCKOUT MOUSE MODEL IN A NORMAL CHOW AND A HIGH
CHOLESTEROL DIET
Reda Hasballa, L. Rohrer, A. von Eckardstein, Switzerland
148
PI-3 KINASE- BUT NOR ERK1/2-MEDIATED SIGNALING PATHWAY IS
INVOLVED IN BERBERINE-INDUCED ABCA1 MODULATION
Francesca Zimetti, M.P. Adorni, S. Costa, N. Ronda, F. Bernini, E. Favari,
Italy
1007
149
EFFECT OF ARECOLINE IN ATP-BINDING CASSETTE TRANSPORTER
A1 EXPRESSION IN RAW 264.7 MACROPHAGE-DERIVED FOAM CELLS
X.-P. Ouyang, Chao-Ke Tang, China
1328
150
EFFECT OF MUTANT APOA-I FORMS BOUND TO RECONSTITUTED
HDL ON ABCG1-DEPENDENT CHOLESTEROL EFFLUX
Georgios Daniil, V.I. Zannis, A. Chroni, Greece, USA
1366
ATHEROSCLEROTIC CELLS FOR ESTIMATION OF CHOLESTEROL
EFFLUX
Alrexander N. Orekhov1,2, I.A. Sobenin1,2,3, A.A. Melnichenko1,2, V.A.
Orekhova1,3, Y.V. Bobryshev1,2,4, Russia, Australia
325
151
152
A SIMPLE METHOD TO MEASURE THE ABILITY OF PLASMA
LIPOPROTEINS TO ACCEPT CHOLESTEROL FROM PLASMA
MEMBRANES
Antonio Carlos de Arruda Leite Jr1,2,3, D.L. Bispo, T.B. Moreira, J.C. dos
Santos, R.C. Maranhão1,3, Brazil
71
385
821
TREATMENTS (contd.)
Poster Board No.
Abstract No
HDL / Function and metabolism
153
FUNCTIONAL LIPID-PROTEIN CLUSTERS IN HUMAN PLASMA HDL: A
SYSTEMS BIOLOGY APPROACH
Ekaterina Chernova1,2, M. Lhomme, L. Camont, S. Chantepie, W. Le Goff,
M.J. Chapman, A. Orekhov, W.S. Davidson, A. Kontush, France, Russia,
USA
1550
154
A NOVEL HIGH-DENSITY LIPOPROTEIN ANTIOXIDANT CAPACITY
ASSAY AND ITS APPLICATION TO HIGH-DENSITY LIPOPROTEIN
FRACTIONS
Krisztina Gaál, H. Lőrincz, I. Seres, M. Harangi, A.V. Oláh, G. Paragh,
Hungary
832
155
LOW NORMAL FREE T4 CONFERS DECREASED HIGH DENSITY
LIPOPROTEIN ANTI-OXIDATIVE FUNCTIONALITY IN THE CONTEXT OF
HYPERGLYCEMIA
Michela Triolo, J.F. de Boer, W. Annema, A. Kwakernaak, U. Tietge, R.
Dullaart, The Netherlands
612
156
THE INVERSE RELATIONSHIP OF HDL ANTI-OXIDATIVE
FUNCTIONALITY WITH SERUM AMYLOID IS ABSENT IN METABOLIC
SYNDROME
Robin P. Dullaart, J.F. de Boer, W. Annema, U.J. Tietge, The Netherlands
157
HDL-BINDING ANTIBODIES SELECTED FROM PHAGE ANTIBODY
LIBRARY
Janita Lövgren, N. Elonen, E.-C. Brockmann, T. Huovinen, K. Pettersson,
M. Jauhiainen, U. Lamminmäki, Finland
1456
158
HIGH DENSITY LIPOPROTEINS FROM PATIENTS WITH LIPID
TRANSFER ALTERATIONS AND CORONARY ARTERY DISEASE ARE
ASSOCIATED WITH INCREASED PLATELET AGGREGATION
Antonio Carlos de Arruda Leite Jr1,2,3, T.B. Moreira2,3, D.L. Bispo2,3, J.C.
dos Santos2,3, M.C.O. Sprandel, A. Casella-Filho, W. Hueb, R.C.
Maranhão1,3,4, Brazil
159
ENHANCED OXIDATIVE STRESS STATUS IN SUBJECTS WITH LOW
HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) IS NOT
ASSOCIATED WITH LECITHIN CHOLESTEROL ACYLTRANSFERASE
(LCAT)
Farah Hanis Sakri, N.A. Mohd Mokhsin, T.H. Abdul Rahman, B.P. Hoh, A.
Mohd Ismail, H. Mohd Nawawi, Malaysia
1448
160
WEARING THE HAT OF HIGH HDL CHOLESTEROL?
Shamanna S. Iyengar, S. Chavan, N. Basha, India
161
96
820
190
HIGH PARAOXONASE 1 ACTIVITY STRENGTHENS HDL'S IN VITRO
ANTI-OXIDANT FUNCTION IN STATIN TREATED DYSLIPIDEMIC
PATIENTS AND IN HEALTHY SUBJECTS
Rahul Yadav, Y. Liu, S. Kwok, V. Charlton-Menys, M. France, R. Eatough,
S. Hama, N. Younis, B. Issa, B.J. Ammori, H. Soran, UK
1141
72
TREATMENTS (contd.)
Poster Board No.
Abstract No
162
LP A-I, LP A-II AND LP A-I/A-II IN THE PRE-BETA MOBILITY FRACTION,
ARISING BY THE INTERACTION BETWEEN HDL AND LIPOSOMES
Anna Wolska, M. Bednarek, K. Domitrz, A. Szutowicz, M. Wróblewska,
Poland
123
163
ARE SMALL HDL PARTICLES PROTECTIVE IN CAROTID
ATHEROSCLEROSIS ?
D. Diallo, S. Delbosc, G. Lambert, Olivier Meilhac, France
1056
164
REGRESSION OF LUMINAL STENOSIS AT THE SITE OF SILENT
PLAQUE DISRUPTION AND HIGH-DENSITY LIPOPROTEIN
CHOLESTEROL
Takayoshi Nemoto, K. Matsuo, Y. Ueda, Japan
1564
HDL / apoA1 functions
165
BOVINE APOLIPOPROTEIN (APO) A-I DEMONSTRATE ENHANCED
ANTI-OXIDANT ACTIVITY WITH DIFFERENT STRUCTURE-FUNCTION
CORRELATIONS RELATIVE TO HUMAN APOA-I
G.-Y. Park1,2, S.-M. Kim1,2, Kyung-Hyun Cho1,2, Republic of Korea
308
166
SHORT TERM EFFECTS OF MDCO-216 (APOA-I MILANO WITH POPC)
ON LIPIDS AND (APO)LIPOPROTEIN LEVELS IN CYNOMOLGUS
MONKEYS
Herman Kempen, M. Gomaraschi, L. Calabresi, S.E. Bellibas, P.L.
Wijngaard, Switzerland, Italy, USA
181
167
STRUCTURAL PROPERTIES OF FUNCTIONAL HDL AND MILANO
VARIANT OF APOA-I
Jitka Petrlova, J. Dalla-Riva, L. Zhu, M. Mörgelin, H. Hebert, C.
Jegerschöld, J.C. Voss, J.O. Lagerstedt, Sweden, USA
168
A PROTEOLIPOSOME CONTAINING V156K-APOA-I ENHANCES RAPID
TUMOR REGRESSION ACTIVITY OF ONCOLYTIC ADENOVIRUS IN
TUMOR-BEARING ZEBRAFISH AND MICE
676
J. Kim1,2, Kyung-Hyun Cho1,2, Republic of Korea
270
Intracellular metabolism
169
PHARMACOLOGICAL EVIDENCE FOR THE DOMINANT ROLE OF
NEUTRAL CE HYDROLASE 1 IN THE HYDROLYSIS OF CE IN MURINE
MACROPHAGES
Kent Sakai, S. Nagashima, M. Takahashi, D. Yamamuro, H. Yagyu, J.-I.
Osuga, S. Ishibashi, Japan
677
170
FARNESOID X RECEPTOR UP-REGULATES EXPRESSION
FIBROBLASTGROWTH FACTOR 21 IN HEPG2 AND THE STUDY OF ITS
MECHANISM*
Yongchao Wang, H. Liu, J. Peng, Y. Zhang, J. Dong, X. Liu, Y. Jiang**,
China
1214
73
TREATMENTS (contd.)
Poster Board No.
Abstract No
171
INTESTINAL RE-EXPRESSION OF APOA5 TROUGH DEMETHYLATION
WITH 5-AZA-2′-DEOXYCYTIDINE OF ITS PROMOTER AND CPG ISLAND
Montse Guardiola, A. Guillaumet, I. Oliva, R. Rosales, J.C. Vallvé, F.
Sabench, D. Del Castillo, M. Esteller, D. Monk, J. Ribalta, Spain
1002
172
BIS(MONOACYLGLYCERO)PHOSPHATE PROTECTS FROM OXIDIZED
LDL-INDUCED APOPTOSIS IN MACROPHAGES
Maud Arnal, C. Costaz, I. Vandenbroucke, France
698
173
REGULATION OF LIPOGENIC PATHWAY BY LXR AGONISTS IN
VASCULAR SMOOTH CELLS OF PSAMMOMYS OBESUS
Nadjiba Hamlat Khennaf, S. Neggazi, S. Aouichat Bouguerra, M. Beylot,
Algeria, France
1237
174
LIVER X RECEPTOR ACTIVATION DECREASES CHYLOMICRON
ASSEMBLY AND IMPROVES POST-PRANDIAL TRIGLYCERIDEMIA VIA
INTESTINAL SR-BI DOWNREGULATION
Olivier Briand, S. Colin, V. Touche, A. Tailleux, V. Clavey, B. Staels, S.
Lestavel, France
191
175
PREPONDERANT ROLE OF LXRΑ IN CHOLESTEROL EFFLUX FROM
HUMAN FOAM CELLS THROUGH A SPECIFIC ABCA1-DEPENDENT
PATHWAY
Alexandre Superville, E. Frisdal, C.M. Quinn, M.-J. Kim, W. Jessup, M.
Guerin, W. Le Goff, France, Australia
598
176
OXYPHYTOSTEROL FORMATION IN HUMANS; IDENTIFICATION OF
HIGH AND LOW OXIDIZERS
Sabine Baumgartner, R.P. Mensink, G. den Hartog, A. Bast, O. Bekers, U.
Diczfalusy, C. Husche, D. Lütjohann, J. Plat, The Netherlands, Sweden,
Germany
433
177
NATIVE LDL TRAFFICKING AND EFFECTS ON PRIMARY HUMAN
MONOCYTE DERIVED MACROPHAGES
N. Nikiforov, F. Li, N. Wang, M. Moisenovich, A.N. Orekhov1,4, Julia
Kzhyshkowska2,4, Russia, Germany
859
Lipases and lipoprotein metabolism
178
A NEW ROUTINE ASSAY FOR REPRODUCIBLE LPL ACTIVITY
MEASUREMENT IN POST HEPARIN PLASMA
Mathilde Di Filippo1,2, C. Marçais2,3, M. Broyer, M. Merlin, A. Nollace, M.
Delay, O. Marmontel, S. Charrière2,4, P. Moulin2,4, A. Sassolas1,2, France
1094
179
INCREASES OF SERUM MASS OF ENDOTHELIAL LIPASE IMPACT
PLASMA HIGH-DENSITY LIPOPROTEIN-CHOLESTEROL
CONCENTRATIONS IN ACUTE MYOCARDIAL INFARCTION
Kenta Mori, T. Ishida, K. Miyashita, N. Kinoshita, H. Nakajima, T.
Yasuda, R. Toh, M. Kawata, S. Sakamoto, K. Nakajima, K.-I. Hirata,
Akashi KOBE study (AKB study) Group, Japan
1276
74
TREATMENTS (contd.)
Poster Board No.
Abstract No
180
HDL METABOLISM BY HTGL, EL AND LPL
Katsuyuki Nakajima, K. Miyashita, N. Kinoshita, S. Imamura, T. Ishida, K.
Hirata, T. Machida, H. Sumino, M. Nara, M. Murakami, Japan
1301
181
LOCALIZATION AND FUNCTION OF THE LIPOPROTEIN LIPASE
SYSTEM IN MOUSE KIDNEY
Rakel Nyrén, E. Vorrsjö, M. Ericsson, S. Nilsson, S. Kersten, G. Olivecrona,
Sweden, The Netherlands
1466
182
CONTROL OF POSTPRANDIAL LIPEMIA BY CEREBRAL GLP-1
Thibault Deblache, C. Cabou, F. Reichardt, A. Colom, F. Tercé, R. Burcelin,
X. Collet, France
1248
183
ROLE OF ENDOTHELIAL LIPASE IN HIGH-DENSITY LIPOPROTEIN
METABOLISM IN HUMANS
Tatsuro Ishida, K.-I. Hirata, Japan
1523
Lp-PLA2
184
A STUDY OF LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A2
(LPPLA2) AS AN EMERGING BIOMARKER IN CORONARY ARTERY
DISEASE
Saswati Das, S.K. Gupta, G. M.P., P.C. Ray, India
52
185
TREATMENT WITH BETABLOCKERS IS ASSOCIATED WITH LOWER
LEVELS OF LP-PLA2 AND SUPAR IN CAROTID PLAQUES
Giuseppe Asciutto, A. Edsfeldt, N.V. Dias, J. Nilsson, C. Prehn, J.
Adamski3,4, I. Gonçalves2,5, Sweden, Germany
186
LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 LEVELS IS
INFLUENCED BY CARDIAC DISEASE, EXTENSION OF
ATHEROSCLEROSIS AND TREATMENTS
Jean-Paul Charniot, R. Bittar, J.-P. Albertini, P. Giral, C. Cherfils, C.
Cosson, E. Guillerm, P. Leprince, I. Gandjbakhch, D. Bonnefont Rousselot,
France
416
187
INTEREST OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 IN
THE PREOPERATIVE STATUS PRIOR AORTIC STENOSIS SURGICAL
VALVE REPLACEMENT
Jean-Christophe Charniot, R. Bittar, J.-P. Albertini, P. Giral, C. Cherfils, C.
Cosson, E. Guillerm, P. Leprince, I. Gandjbakhch, D. Bonnefont Rousselot,
France
420
188
PROGNOSTIC ROLE OF LIPOPROTEIN-ASSOCIATED
PHOSPHOLIPASE A2 ASSAYS IN PATIENTS WITH CARDIOGENIC
SHOCK SYNDROME. A PILOT STUDY
Jean-Christophe Charniot, R. Bittar, J.-P. Albertini, C. Cherfils, C. Cosson,
E. Guillerm, D. Bonnefont Rousselot, France
437
189
COMPARING OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2
SERUM LEVELS IN CORONARY ARTERY DISEASE PATIENTS
DEPENDING ON DIABETES MELLITUS PRESENCE
Anna Semenova, D. Nozadze, I. Sergienko, T. Vlasik, I. Rybalkin, Russia
75
359
559
TREATMENTS (contd.)
Poster Board No.
Abstract No
190
DECREASED ACTIVITY OF THE ANTI-ATHEROGENIC HDLASSOCIATED LPPLA2 AND INCREASED PROPORTION OF SMALL
HDL3 PARTICLES IN SUBJECTS WITH IMPAIRED FASTING GLUCOSE
T.D. Filippatos, E.C. Rizos, V. Tsimihodimos, A.D. Agouridis, E. Tzavella, Z.
Mitrogianni, A.D. Tselepis, Moses S. Elisaf, Greece
696
191
ELEVATED LEVELS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE
A2 AMONG DIABETIC PATIENTS WITH CORONARY ARTERY DISEASE
Aymen Bekir, M. Belhabib, M. Caslake, J. Cooney, A. Lewis, D. Bedford, H.
Chahed, T. Trimech, K. Ben Hamda, F. Maatouk, S. Ferchichi, A. Miled,
Tunisia, UK
709
192
PLASMA LP-PLA2 ACTIVITY IS RELATED TO PLAQUE STABILITY AS A
POTENTIAL BIOMARKER FOR ACUTE CORONARY SYNDROME
Byoung Kwon Lee, H. Chung, H.M. Kwon, Y. Yoon, E.-Y. Choi, Republic of
Korea
797
193
THE USE OF LP-PLA2 MEASUREMENT AS A CARDIOVASCULAR
„FINETUNER“
Ursula Kassner, T. Grenkowitz, E. Steinhagen-Thiessen, Germany
1113
194
EVEROLIMUS THERAPY IS ASSOCIATED WITH REDUCED
LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) ACTIVITY
AND OXIDATIVE STRESS IN HEART TRANSPLANT RECIPIENTS
Jerzy-Roch Nofer, K. Rosing, M. Fobker, F. Kannenberg, J. Stypmann,
Germany
1163
195
CORONARY CALCIUM SCORE IS RELATED TO POLYMORPHISMS OF
GENES OF PHOSPHOLIPASE A2 AND OF CHROMOSOME 9
A. Bertolami, C. Gonzaga, M. Sulzbach, D.B. Araujo, H. Zatz, Y. Nakamura,
L. Wang, P. Lima, M. Hirata, A. Garofaro, A.A. Faludi, Marcelo Chiara
Bertolami, Brazil
1167
Biomarkers / Lipid metabolism
196
MONITORING OF DIET-RELATED CHANGES OF THE PLASMA
LIPIDOMICS PROFILE IN YOUNG HYPERCHOLESTEROLEMIC
PATIENTS USING A MALDI-TOF-MS/MS APPROACH
Gerald Stübiger, L. Hedjazi, M. Wuczkowski, O. Belgacem, K. Widhalm,
Austria, France, UK
798
197
PLASMA PCSK9 IS A BIOMARKER OF SEVERITY IN PATIENTS WITH
SEVERE TRAUMA INJURY
Bertrand Cariou, M. Le Bras, A. Roquilly, F. Feuillet, V. Deckert, L. Lagrost,
K. Asehnoune, P. Costet, France
869
198
CIRCULATING PCSK9 DISTRIBUTION IN RELATION TO AGE AND
GENDER,AND ITS RELATION TO MARKERS OF CHOLESTEROL
METABOLISM IN A SWEDISH COHORT
Moumita Ghosh1,2, B. Angelin1,2, M. Rudling1,2, Sweden
76
999
TREATMENTS (contd.)
Poster Board No.
199
Abstract No
CHANGES IN THE FATTY ACID PROFILE OF ARTERIAL WALL AND
BLOOD PLASMA IN PATIENTS WITH ATHEROSCLEROSIS
Alexander Nikolaevich Osipenko, A.N. Osipenko, N.V. Akulich, Belarus 1389
Dyslipidaemia: epidemiology, biomarkers / HDL
200
201
DEVELOPMENT OF A NOVEL HOMOGENEOUS ASSAY FOR HDL
SUBCLASSES
Yasuki Ito, N. Sato, Japan
409
VALIDATION OF "BRINTON´S RATIO" FOR ESTIMATING HDL SIZE
USING NMR-SPECTROSCOPY DATA FROM THE HIFUN STUDY
Norman A. Mazer, E. Damonte, S. Rossomanno, M. Abt, R. Benghozi,
Switzerland
691
202
HIGH DENSITY LIPOPROTEIN CHOLESTEROL, ANGIOGRAPHIC
CORONARY ARTERY DISEASE, AND CARDIOVASCULAR MORTALITY
Günther Silbernagel1,2, T.B. Grammer, H. Scharnagl, M.E. Kleber5,6, A.
Ritsch, B.O. Boehm, U. Landmesser, W. März3,4,10, Germany, Austria,
Switzerland
1165
203
RECENT HDL-C LEVEL OF JAPANESE GENERAL POPULATION
INCREASED BY THE INTENSIVE LIFESTYLE MODULATION
Koki Takata, Japan
1304
204
LOW CHOLESTEROL AND PHOSPHATIDYLCHOLINE PLASMA
CONCENTRATIONS OF HDL SUBCLASSES IN SUBJECTS WITH HIGH
CORONARY CALCIUM SCORE
Oscar Pérez-Méndez, C. García-Sánchez, G. Vargas-Alarcón, C. PosadasRomero, Mexico
1418
205
CALCULATED LDL CHOLESTEROL BY FRIEDEWALD SUBSTANTIALLY
UNDERESTIMATES LDL-C BELOW 70 MG/DL
Evan Stein, S.M. Wasserman, I. Bridges, USA, UK
10
Dyslipidaemia: epidemiology, biomarkers
206
PREVALENCE OF SEVERE HYPERCHOLESTEROLEMIA IN A
PREVENTIVE CARDIOLOGY CLINIC
Jean Ferrières, D. Taraszkiewicz, J. Fourcade, S. Lemozy, D. Allemandou,
V. Bongard, France
50
207
LIPID METABOLISM IN PERIMENOPAUSAL WOMEN WITH LOW TO
MODERATE CARDIOVASCULAR RISK
Anna Isayeva, M. Vovchenko, V. Volkov, I. Komir, Ukraine
208
RISK OF HYPERCHOLESTEROLEMIA ON CARDIOVASCULAR DISEASE
AND POPULATION ATTRIBUTABLE FRACTION IN A 24-YEAR COHORT
STUDY OF JAPANESE GENERAL POPULATION
Daisuke Sugiyama, T. Okamura, T. Ohkubo, K. Miura, A. Okayama, H.
Ueshima, NIPPON DATA 80/90 Research Group, Japan
465
77
319
TREATMENTS (contd.)
Poster Board No.
209
Abstract No
OXLDL TO OXLDL-AB RATIO - THE NEW BIOMARKER ASSOCIATED
WITH CAROTID ATHEROSCLEROSIS AND CARDIOVASCULAR
COMPLICATIONS IN DIALYZED PATIENTS
Krystyna Pawlak, M. Mysliwiec, D. Pawlak, Poland
477
210
TRIGLYCERIDE/HDL RATIO, APOLIPOPROTEIN B, NON-HDL
CHOLESTEROL ARE USEFUL PREDICTORS FOR LDL PARTICLE SIZE
WITH STATIN TREATMENT IN CORONARY ARTERY DISEASE
Sang-Hyun Kim, H.-L. Lee, D.-G. Park, K. Hack-Ryoung, J.-B. Seo, W.-Y.
Chung, J.-H. Zo, M.-A. Kim, Republic of Korea
615
211
AGE AND SEXUAL ASPECTS OF THE HYPERCHOLESTEROLEMIA
I.G. Leschenko, V.A. Leschenko, Roman Iosifovich Vorobyev, E.N.
Vorobyeva, Russia
212
TRIGLYCERIDE IS A PREDICTOR OF HYPERTENSION IN AN 8-YEAR
COHORT STUDY IN THE JAPANESE WORKERS
Naomi Miyamatsu, A. Shima1,2, Y. Kawatsu, T. Nishikawa, D. Sugiyama, A.
Kadota, A. Morimoto, Y. Tatsumi1,6, N. Sonoda, A. Morino, T. Okamura,
Japan
705
213
A NON-RADIOMETRIC METHOD FOR ESTIMATION OF CHOLESTERYL
ESTERS
Hardik Gandhi, P. Pal, R. Giridhar, M.R. Yadav, India
1636
214
APOLIPOPROTEIN B:A1 RATIO IS INDEPENDENTLY ASSOCIATED
WITH SUB-CLINICAL AND INCIDENT CORONARY HEART DISEASE IN
BRITISH SOUTH ASIAN AND EUROPEAN MEN
Therese Tillin, J. Heasman, A. Wright, P. McKeigue, A.D. Hughes, N.
Chaturvedi, UK
739
215
IMPACT OF SEASONALITY ON THE PREVALENCE OF DYSLIPIDEMIA:
A LARGE POPULATION STUDY
E.S. Parra, A.C. Sposito, F. Moura, M.S. Dutra-Rodrigues, A. Cassol,
V.H.D.S. Zago, F. Alexandre, I.V. Calanca, F. Vendrame, V.W. Virginio, F.K.
Saraiva, O.R. Coelho, E. Naknadakare, E.C.R. Quintao, Eliana C. de Faria,
Brazil
816
216
PREVALENCE OF DYSLIPIDEMIA IN OUTPATIENT CLINIC OF SAMARA
CITY
Mikhail A. Kachkovskii, V.V. Simerzin, I.M. Nazarkina, L.S. Fedoseeva, I.H.
Sytdykov, E.R. Bulatova, O.A. Rubanenko, Russia
829
217
SMALL DENSE LDL AND OXIDIZED LDL ARE DIFFERENTLY
ASSOCIATED WITH PROGRESSING ATHEROSCLEROSIS
M. Budkhashvili, A. Sapegin, A. Titkov, S. Urazgildeeva, L. Vasina, Victor
Gurevich, Russia
218
655
830
NOT ALL QUIET ON THE EASTERN FRONT. FAVORABLE CHANGES IN
THE LIPID LEVELS OF PATIENTS WITH HIGH RISK IN HUNGARY
Istvan Reiber, I. Mező, L. Márk, G. Paragh, G. Pados, I. Karádi, Z. Kiss,
Hungary
863
78
TREATMENTS (contd.)
Poster Board No.
219
Abstract No
PROGNOSTIC VALUE OF APOLIPOPROTEIN B LEVEL IN PATIENTS
WITH HEART FAILURE WHO SUFFERED ACUTE CORONARY
SYNDROME
Natalya Koziolova, E. Polyanskaya, Russia
935
LOW DENSITY LIPOPROTEIN SUBFRACTIONS IN PATIENTS WITH
DIFFERENT GRADE OF CORONARY ATHEROSCLEROSIS
Victoria A. Metelskaya, I.N. Ozerova, N.V. Perova, N.E. Gavrilova, O.I.
Chernushevich, Russia
966
221
MARKERS OF SUBCLINICAL ATHEROSCLEROSIS - OXIDIZED LOW
DENSITY LIPOPROTEINS
Loreta Bagdonaite, Z.A. Kucinskiene, Lithuania
1006
222
ATHEROGENIC LIPID DISORDERS IN SIBERIAN ADOLESCENT
POPULATION: PREVALENCE, TRENDS AND ASSOCIATIONS
Diana Denisova, L. Zavyalova, Russia
1217
220
223
DEVELOPEMENT OF A REFERENCE METHOD FOR LDL-P AND
PRODUCTION OF NEW REFERENCE STANDARDS IN LIPID TESTING:
THE BIO-SITRACE PROJECT
Vincent Delatour, M. Heuillet, B. Lalere, S. Vaslin-Reimann, H. Parkes,
France, UK
1362
224
ESTIMATION OF SMALL DENSE LDL LEVEL USING THE SIMPLE
PRECIPITATION METHOD IN TUNISIAN PATIENTS WITH CORONARY
ARTERY DISEASE
H. Aoua, A. Ben Khalfallah, Y. Nekaies, K. Charradi, M. Sakly, Nebil Attia,
Tunisia
1376
225
DIFFERENT LIPOPROTEIN PROFILES IN EXAMINED INDIVIDUALS
WITH DYSLIPOPROTEINEMIA IDENTIFIED BY LIPOPRINT SYSTEM
Stanislav Oravec, J. Bulas, Ľ. Gašpar, A. Dukát, I. Vacula, Slovak Republic1499
226
HIGH SERUM REMNANT-LIKE LIPOPROTEIN PARTICLE
CHOLESTEROL LEVELS ARE INDEPENDENTLY ASSOCIATED WITH
INCREASED NECROTIC COMPONENTS IN CORONARY PLAQUES IN
STATIN-TREATED PATIENTS
Tetsuro Matsuoka, T. Matsuoka, A. Kato, Y. Makino, S. Kihara, Japan
1508
227
EXTENDED CHARACTERIZATION OF LIPIDIC PROFILE: EVALUATION
OF LIPOPROTEIN SUBFRACTIONS
F. Leitão, S. Berguete, S. Tania, G. Alexandra, Bourbon Mafalda1,2,
Portugal
1568
Familial hypercholesterolaemia
229
ATYPIC ISOLATED GIANT XANTHOMAS ASSOCIATED WITH SEVERE
MIXED DYSLIPIDEMIA WITHOUT FAMILIAL
Jean-Christophe Charniot, R. Bittar, A. Carrié, P. Couvert, R. Kidouche, O.
Verola, E. Brucker, D. Bonnefont Rousselot, France
423
79
TREATMENTS (contd.)
Poster Board No.
Abstract No
230
PREVALENCE AND CHARACTERISTICS OF AUTOSOMAL DOMINANT
HYPERCHOLESTEROLEMIA IN PERSONS SCHEDULED FOR
CORONARY ANGIOGRAPHY. LUDWIGSHAFEN RISK AND
CARDIOVASCULAR HEALTH STUDY (LURIC)
Hubert Scharnagl, T.B. Grammer, M.E. Kleber, T. Stojakovic, U. Kassner,
431
E. Steinhagen-Thiessen, W. März1,2,4, Austria, Germany
231
SUBJECTS WITH FAMILIAL HYPERCHOLESTEROLEMIA ARE
CHARACTERIZED BY A PRO-INFLAMMATORY PHENOTYPE DESPITE
LONG-TERM INTENSIVE CHOLESTEROL-LOWERING TREATMENT
Ingunn Narverud, P. Aukrust, H.W. Lindvig, B. Halvorsen, G. Langslet, L.
Ose, K. Retterstøl, K.B. Holven, Norway
449
232
GENETIC DIAGNOSIS OF FAMILIAL HYPERCHOLESTEROLEMIA (FH)
BY DIFFERENT NEXT GENERATION SEQUENCING PLATFORMS
Marianne Stef, D. Arteta, E. Olano-Martin, N. Aizpuru, L. Grandoso, L.
Alonso, J. Nieves, B. Sanz, X. Ugarte-Pedrero, X. Cantero, P. Galán-Garcia,
I. Santos, L. Osaba, D. Tejedor, L. Palacios, Spain
576
233
PCSK9 GENETIC HETEROGENEITY IN FAMILIAL
HYPERCHOLESTEROLEMIA (FH) PATIENTS
L. Palacios, L. Grandoso, D. Arteta, A. Etxebarria2,3, C. Martin2,3, N. Aizpuru,
L. Alonso, L. Osaba, D. Tejedor, Marianne Stef, Spain
586
234
DEFINING PATIENTS AT EXTREMELY HIGH RISK FOR CORONARY
ARTERY DISEASEIN HETEROZYGOUS FAMILIAL
Mariko Harada-Shiba, H. Makino, T. Okamura, I. Kishimoto, Y. Miyamoto,
H. Tomoike, S. Yokoyama, Japan
643
235
BENEFICIAL EFFECT OF LDL-APHERESIS AND PLASMAPHERESIS ON
PARAOXONASE CONCENTRATION AND LDL SUBCLASSES IN A
PATIENT WITH SEVERE TYPE III HYPERLIPIDEMIA
Mariann Harangi, I. Seres, M. Katkó, J. Padra, H. Lőrincz, G. Paragh,
Hungary
667
236
NOVEL PCSK9 GENE VARIANT IN A FAMILIAL
HYPERCHOLESTEROLAEMIA FAMILY FROM POLAND
Malgorzata Walus-Miarka, M. Futema, B. Idzior-Waluś, M. Sanak, R.A.
Whittall, K.W. Li, S.E. Humphries, Poland, UK
1500
237
COMMON PCSK9 VARIANT AS GENETIC BACKGROUND OF FAMILIAL
COMBINED HYPERLIPIDEMIA IN JAPAN
Atsushi Nohara, T. Noguchi, M.-A. Kawashiri, T. Inoue, S. Katsuda, M. Mori,
C. Nakanishi, K. Yagi, A. Inazu, M. Yamagishi, H. Mabuchi, Japan
880
238
WOLMAN DISEASE: THE IMPORTANCE OF EARLY DIAGNOSIS. A
REVIEW OF 6 CASES WITH COMPLETE LYSOSOMAL ACID LIPASE
DEFICIENCY
Pascale Benlian, A. Pagnier, K. Mention, F. Feillet, T. Levade, D. Plantaz,
P. De Lonlay, V. Valayannopoulos, France
905
80
TREATMENTS (contd.)
Poster Board No.
Abstract No
239
AMINOTRANSFERASE ELEVATIONS OBSERVED IN A PHASE 3 STUDY
OF PATIENTS WITH HOMOZYGOUS FAMILIAL
HYPERCHOLESTEROLEMIA TREATED WITH LOMITAPIDE WERE
CLINICALLY MANAGEABLE
Marina Cuchel, E.A. Meagher, D.J. Blom, H.D.T. Theron, A.D. Marais, R.A.
Hegele, M.R. Averna, C.R. Sirtori, P.K. Shah, D. Gaudet, C. Stefanutti, G.B.
Vigna, A.M. Du Plessis, L.T. Bloedon, D.J. Rader, USA, South Africa,
Canada, Italy
915
240
CLINICAL VERSUS MOLECULAR DIAGNOSIS OF FAMILIAL
Mahtab Sharifi, A. Nair, D. Harvey, S.E. Humphries, D. Nair, UK
1150
241
A LARGE PROPORTION OF PATIENTS WITH FAMILIAL
HYPERCHOLESTEROLEMIA ARE UNDER-TREATED: RESULTS OF A
CROSS SECTIONAL STUDY IN 1757 FRENCH PATIENTS
Sophie Béliard, V. Carreau, A. Carrié, P. Giral, E. Duchêne, M. Farnier, J.
Ferrières, A. Fredenrich, M. Krempf, G. Luc, P. Moulin, E. Bruckert, France 1211
242
PREGNANCY IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
- WHEN THE THINGS ARE GOING WELL
M. Blaha, M. Lanska, Vladimir Blaha, L. Boudys, I. Zimmerova, Czech
Republic
1387
243
SECRETORY PHOSPHOLIPASE A2 ACTIVITY IN CHILDREN WITH
HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AND TWOYEAR EFFICACY OF PRAVASTATIN
Marjet Braamskamp, S. Tsimikas, A. Wiegman, J. Kastelein, B. Hutten, The
Netherlands, USA
1538
244
PATHOGENICITY ASSESSMENT OF LDLR VARIANTS IN PATIENTS
Ana Margarida Medeiros1,2, A.C. Alves1,2, A. Extebarria, C. Martin, Portugal,
Spain
1541
245
APOB: OLD GENE, NEW PERSPECTIVE FOR FAMILIAL
HYPERCHOLESTEROLAEMIA
Ana Catarina Alves1,2, A. Extebarria, C. Martin, M. Bourbon1,2, Portugal,
Spain
246
1542
P450 OXIDOREDUCTASE (POR) *28 ALLELE IS ASSOCIATED WITH
LIPID LOWERING RESPONSE TO ATORVASTATIN IN CHILDREN AND
ADOLESCENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA
G. Ragia, E. Drogari, V. Kolovou, L. Elens, V. Mollaki, A. Tavridou 1,5, R. van
Schaik, G. Kolovou, Vangelis George Manolopoulos1,5, Greece, The
Netherlands
1569
Primary dyslipidaemia
247
FAMILIAL COMBINED HYPERLIPIDEMIA: SHOULD WE CONSIDER IT IN
PEDIATRICS?
Francesca Abello, P. Cagliero, O. Guardamagna, Italy
1026
81
TREATMENTS (contd.)
Poster Board No.
Abstract No
248
OCCURRENCE OF TYPE V HYPERCHYLOMICRONEMIA IN
DYSBETALIPOPROTEINEMIC PATIENTS: A CASE CONTROL STUDY
Audrey Garon, C. Marcais, M. Di-Filippo, S. Charriere, A. Sassolas, P.
Moulin, France
1087
249
TREATMENT OF EXTREME HYPERTRIGLYCERIDEMIA IN ZIEVE´S
SYNDROME. A CASE REPORT
Ioannis Terzis, T. Bitsis, I. Mallias, E. Papastefanou, T. Milidis, Greece
1234
LIPOPEROXIDATION IN CHRONIC PANCREATITIS - PRELIMINARY
DATA
Marek Vecka1,2, A. Žák1,2, L. Vávrová1,2, J. Kodydková1,2, J. Macášek, M.
Urbánek, T. Krechler, B. Staňková1,2, Czech Republic
1577
250
251
MTTP MUTATIONS Y528H, R540C AND N649S ARE ASSOCIATED WITH
ABETALIPOPROTEINEMIA AND REDUCE IN VITRO MICROSOMAL
TRIGLYCERIDE TRANSFER PROTEIN ACTIVITY
S.A. Miller, J.R. Burnett1,2, F.M. van Bockxmeer1,2, Amanda J. Hooper1,2,
Australia
402
252
A NEW CASE OF FAMILIAL COMBINED HYPOLIPIDEMIA (FHBL2) WITH
NEW HOMOZYGOUS ANGPTL3 MUTATION AND ABNORMAL ORAL
FAT LOAD
Mathilde Di Filippo1,2, O. Marmontel1,2, P. Moulin2,3, S. Charrière2,3, A.
Sérusclat, L. Perrot, S. Nony, S. Dumont, D. Bozon, A. Sassolas1,2, France 1089
253
A CASE OF TANGIER DISEASE RESTRICTED TO VERY LOW HDL-C
AND CHD
Diana Muačević-Katanec, A. Merkler, A. Carrié, M. Barešić, M. Vučić, Ž.
Reiner, P. Couvert, Croatia, France
1638
254
CLINICAL AND BIOCHEMICAL ASPECTS OF
PSEUDOHYPERTRIGLYCERIDEMIA RESULTING FROM
HYPERGLYCEROLEMIA
P. Giral1,2, Randa Khani Bittar2,3, V.F. Fouquier, D. Rosenbaum, C. Vatier,
1059
B. Hansel, D.B. Rousselot3,5, France
Secondary dyslipidaemia
256
OXIDIZED LOW DENSITY LIPOPROTEIN CONCENTRATION IS
ASSOCIATED WITH THYROTROPIN LEVELS IN EUTHYROID
NORMOCHOLESTEROLEMIC SUBJECTS
Gustavo Giunta, G. Duaip, D. Rojo, G. Yannarelli1,2, N. Pacienza1,2, L.
Maggi, L. Cuniberti1,2, Argentina
772
257
SUBCLINICAL THYROID DYSFUNCTION AS A PROGNOSTIC FACTOR
FOR FIRST-EVER ISCHEMIC STROKE
Christina Voulgari, L. Moulopoulos, A. Kanellou, V. Giannopoulou, A.
Anagnostopoulos, S. Pagoni, Greece
1317
258
EARLY MARKERS OF ATHEROSCLEROSIS IN HYPOTHYROID WOMEN
WITH ARTERIAL HYPERTENSION
O. Mitchenko, Maksym Gvozdyk, V. Romanov, Ukraine
1145
82
TREATMENTS (contd.)
Poster Board No.
Abstract No
259
STIMULATION OF HUMAN CHOLESTEROL AND LIPOPROTEIN
METABOLISM IN HYPERTHYROIDISM: IMPORTANCE OF LIVERSPECIFIC HORMONE ACTIONS
Ylva Bonde1,2, O. Breuer, D. Lütjohann, S. Sjöberg, B. Angelin1,2, M.
Rudling1,2, Sweden, Germany
260
HIV PROTEASE INHIBITORS INDUCE PREMATURE SENESCENCE AND
CALCIFICATION OF VASCULAR SMOOTH MUSCLE CELLS IN VITRO
Pauline Afonso, M. Auclair, C. Vigouroux, M. Caron-Debarle, France
1545
261
LIPID PROFILE AND ACHIEVEMENT OF LIPIDS GOALS AMONG HIVINFECTED PATIENTS COMPARED TO HIV-UNINFECTED PATIENTS
AFTER ACUTE CORONARY SYNDROME
Franck Boccara1,2, J. Miantezila Basilua, M. Mary-Krause, S. Lang, D.
Costagliola, M. Guiguet, A. Cohen, France
1240
262
PSORIASIS ALTERS HDL COMPOSITION AND FUNCTION
Gunther Marsche, P. Wolf, M. Holzer, Austria
396
1279
Genetics / HDL metabolism
263
ABCA1 GENE POLYMORPHISMS IN CORONARY ARTERY DISEASE
Arzu Ergen, S. Isbir, H. Karagedik, T. Isbir, Turkey
131
264
ASSOCIATION OF THE G30S MUTATION OF LECITHIN: CHOLESTEROL
ACYLTRANSFERASE (LCAT) WITH AN INCREASE OF CORONARY
STENOSIS IN A TUNISIAN POPULATION
J. Rejeb, Asma Omezzine, I. Boumaiza, L. Rebhi, A. Moussa, S. Kacem, N.
Ben Rejeb, A. Ben Abdelaziz, E. Boughzala, A. Bouslama, Tunisia
490
265
ASSOCIATIONS OF ABCA1, CETP, APOAI, SCARB1, PON1, PON2 AND
LCAT POLYMORPHISMS WITH CORONARY STENOSIS IN A TUNISIAN
POPULATION
J. Rejeb, Asma Omezzine, I. Boumaiza, L. Rebhi, A. Moussa, N. Ben Rejeb,
A. Ben Abdelaziz, E. Boughzala, A. Bouslama, Tunisia
496
266
INFLUENCES OF ABCG1, ABCG5 AND ABCG8 SINGLE NUCLEOTIDEPOLYMORPHYSMS ON PLASMA LIPIDS AND LIPOPROTEINS OF A
REPRESENTATIVE BRAZILIAN POPULATION
Vanessa Helena De Souza Zago, E.S. Parra, N.B. Panzoldo, D.Z. Scherrer,
J.H.G. Colletes, E.I.L. Gomes, V.S. Nunes, E. Nakandakare, E.C.R. Quintao,
E.C. de Faria, Brazil
826
Genetics / Lipid metabolism
267
SMOKING, APOLIPOPROTEIN E GENOTYPES AND MORTALITY (THE
LUDWIGSHAFEN RISK AND CARDIOVASCULAR HEALTH STUDY)
Tanja Grammer, M.M. Hoffmann, H. Scharnagl, M.E. Kleber, G. Silbernagel,
S. Pilz, A. Tomaschitz, E. Lerchbaum, R. Siekmeier, W. März 1,3,8, Germany,
Austria
234
83
TREATMENTS (contd.)
Poster Board No.
Abstract No
268
THE INFLUENCE OF CETP, LPL AND APO CIII POLYMORPHISMS ON
POSTPRANDIAL LIPEMIA
Katherine Anagnostopoulou, C. Mihas, V. Kolovou, D. Manolopoulou, K.
Sorontila, S. Lekka, P. Kostakou, D. Damaskos, D.V. Cokkinos, G. Kolovou,
Greece
451
269
APOLIPOPROTEIN E GENOTYPE AND PROTEIN LEVEL, DEMENTIA
AND CEREBROVASCULAR DISEASE - A STUDY OF 76,000
INDIVIDUALS FROM THE GENERAL POPULATION
Katrine L. Rasmussen, A. Tybjærg-Hansen, B.G. Nordestgaard, R. FrikkeSchmidt, Denmark
564
270
THE RELATIONSHIP BETWEEN THE LEVELS OF SPLA2-IIA,
VARIATION IN THE SPLA2-IIA GENE AND THE SEVERITY OF
CORONARY ATHEROSCLEROSIS
Tatyana Olegovna Pavlunina, Y.A. Shuvalova, Z. Khasanova, E.V.
Samoylova, A.A. Korotaeva, V.V. Kukharchuk, A.I. Kaminnyi, Russia
271
ASSOCIATION OF PCSK9 GENE POLYMORPHISMS WITH THE RISK OF
CORONARY ARTERY DISEASE IN THAI
Parnsak Pitivej Thurakit, C. Settasatian, N. Settasatian, N. Komanasin, P.
Intharapetch, U. Kukongwiriyapan, K. Tantipanichteerakul, V. Senthong,
Cardiovascular Research Group, Khon Kaen University, Thailand
831
272
ASSOCIATION OF GENETIC VARIABILITY AT LDLR PROMOTER AND
PRIMARY HYPERCHOLESTEROLEMIA
Isabel De Castro-Orós1,2, J. Pérez-López, R. Mateo-Gallego2,4, M.
Ledesma5,6,7, M. León6,7, M. Cofán, J.A. Casasnovas6,7, E. Ros, J.C.
Rodríguez-Rey, F. Civeira, M. Pocoví1,7, Spain
986
273
THE PNPLA3 I148M VARIANT IS ASSOCIATED WITH HIGHER
PREVALENCE OF TYPE 2 DIABETES IN SUBJECTS WITH METABOLIC
SYNDROME
Laura D'Erasmo, L. Polimeni, F. Baratta, A. Di Costanzo, N. Virga, M.
Maranghi, M. Del Ben, F. Angelico, M. Arca, Italy
994
274
THE POLYMORPHISM OF APOLIPOPROTEIN CIII GENE AND LIPID
PROFILE IN CAUCASIAN POPULATION OF WEST SIBER
E. Shakhtshneider, I. Kulikov, V. Maksimov, Y. Nikitin, S. Malyutina, Mikhail
Voevoda, Russia
1110
275
THE POLYMORPHISM OF APOLIPOPROTEIN E GENE AND LIPID
PROFILE IN CAUCASIAN POPULATION OF WEST SIBERIA
Mikhail Voevoda, E. Shakhtshneider, I. Kulikov, V. Maksimov, M. Ivanova,
Y. Nikitin, S. Malyutina, Russia
1114
276
HPA1 GENE POLYMORPHISM IN APOLIPOPROTEIN C1 GENE IS
ASSOCIATED WITH TYPE II DIABETES IN CAD PATIENTS
Yann Pucheu, X. Pillois, A. Horovitz, A. Reynaud, J. Bonnet, France
84
567
1121
TREATMENTS (contd.)
Poster Board No.
Abstract No
277
GENOTYPIC INTERACTIONS OF GENES IMPLICATED IN LIPOPROTEIN
METABOLISM WITH TYPE 2 DIABETES IN TUNISIAN POPULATION
Raja Chaaba, S. Mehri, N. Attia, S. Hammami, M. Smaoui, K. Ben Hamda,
A. Nakbi, N. Koubaa, M. Hammami, Tunisia
1185
278
ASSOCIATION OF HEPATIC LIPASE -514T ALLELE WITH CAD AND
ANKLE-BRACHIAL INDEX, DEPENDENCE ON THE LIPOPROTEIN
PHENOTYPE: THE GENES STUDY
Céline Verdier, J.-B. Ruidavets, V. Bongard, D. Taraszkiewicz, L. Martinez,
1231
M. Elbaz1,3, J. Ferrières2,3, B. Perret, France
279
LDL RECEPTOR EXPRESSION AND FUNCTIONAL POLYMORPHISMS
OF MMP 1 GENE IN CORONARY ARTERY DISEASE
Kodapalli Mrudula Spurthi, G. Rajesh Kumar, G. Kishor Kumar, K. Sanjib
Sahu, N. Prathiba, H. Surekha Rani, India
1626
280
ASSOCIATION OF HAPLOTYPES IN THE 3'UTR OF THE LDLR GENE
WITH LOW-DENSITY LIPOPROTEIN LEVELS IN A BLACK SOUTH
AFRICAN POPULATION
Tertia Van Zyl, G.W. Towers, K.R. Conradie, J.C. Jerling, South Africa
1644
Lipid-lowering therapy / Ezetimibe
283
EFFECTS OF EZETIMIBE (EZE), SIMVASTATIN (SIMVA) AND
EZETIMIBE/SIMVASTATIN (EZE/SIMVA) ON APOB, LDL-C AND NONHDL-C TARGETS IN PATIENTS WITH PRIMARY
Michel Farnier, J.R. Guyton, E. Jensen, A.B. Polis, A.O. Johnson-Levonas,
P. Brudi, France, USA
120
284
EFFECTS OF EZETIMIBE, EZETIMIBE COADMINISTERED WITH
STATINS AND STATIN THERAPIES ON FASTING GLUCOSE CHANGES
IN PATIENTS WITH HYPERCHOLESTEROLEMIA
P.P. Toth, A. Catapano, M. Farnier, J. Foody, Joanne E. Tomassini, E.
Jensen, A.B. Polis, T. Musliner, A.M. Tershakovec, USA, Italy, France
196
285
VARIABILITY OF THE LDL-C LOWERING RESPONSE TO STATINS AND
EZETIMIBE + STATIN THERAPY IN HYPERCHOLESTEROLEMIC
PATIENTS
O Descamps, J. Lin, J.E. Tomassini, A.B. Polis, A. Shah, P. Brudi, A.M.
Tershakovec, Belgium, USA
201
286
EZETIMIBE IMPAIRS ENDOTHELIAL TURNOVER IN STABLE PATIENTS
AT HIGH CARDIOVASCULAR RISK WITH ELEVATED C-REACTIVE
PROTEIN
L.C. Lins, C.N. França, F.A. Fonseca, S.P. Barbosa, A.C. Aguirre, H.T.
Bianco, J.B. Amaral, L.N. Matos, Maria Cristina de Oliveira Izar, Brazil
357
287
LOW DOSE SIMVASTATIN PLUS EZETIMIBE TREATMENT REDUCE
INFLAMMATORY CYTOKINES WITHOUT MODIFICATION OF HSPCR
LEVELS IN HYPERCHOLESTEROLEMIC PATIENTS
A. Cerda, C.M. Fajardo, E.S. Guimaraes, E.L. Dorea, M.C. Gosukuma, G.A.
Pinto, Mario Hiroyuki Hirata, R.D.C. Hirata, Brazil
921
85
TREATMENTS (contd.)
Poster Board No.
Abstract No
288
COMPARISON OF LIPID LOWERING EFFECTS BETWEEN EZETIMIBE
AND PRAVASTATIN: RESULTS FROM A PILOT CROSSOVER STUDY
1311
Noriaki Kume1,2, Japan
289
DO SERUM LIPID CHANGES WITH STATIN/EZETIMIBE DIFFER
SUBSTANTIVELY BY BMI CATEGORY? AN ACT II STUDY ANALYSIS
Dominik Lautsch1,2, H. Toplak, C. Saely1,4, M. Pichler, P. Brudi,
Liechtenstein, Austria, USA
1639
290
EZETIMIBE AND ATORVASTATIN COADMINISTRATION VERSUS
ATORVASTATIN UP-TITRATION OR SWITCHING TO ROSUVASTATIN IN
PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND HIGH
CARDIOVASCULAR RISK
Michel Farnier, M. Averna, C. Majul, D. Muller-Wieland, A. De Pellegrin, H.
Giezek, R. Lee, R.S. Lowe, P. Brudi, J. Triscari, H.E. Bays, France, Italy,
Argentina, Germany, Belgium, USA
1640
Lipid-lowering therapy / Miscellaneous
291
DIFFERENCES IN THE ATHEROGENIC RISK OF PATIENTS TREATED
BY LIPOPROTEIN APHERESIS ACCORDING TO THEIR LDL
CHOLESTEROL AND LIPOPROTEIN(A) LEVELS
Ulrich Julius, M. von Dryander, S. Fischer, G. Müller, Germany
107
292
BEZAFIBRATE IMPROVES POSTPRANDIAL LIPEMIA AND
POSTPRANDIAL ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH
METABOLIC SYNDROME
Toru Miyoshi, H. Oe, Y. Ohno, K. Nakamura, H. Morita, K. Kusano, H. Ito,
Japan
337
293
COLESEVELAM WITH LOW-DOSE STATIN IS ASSOCIATED WITH A
FAVORABLE EFFECT ON MARKERS OF INSULIN RESISTANCE
COMPARED WITH A HIGHER-DOSE STATIN
M. Florentin, Evangelos N. Liberopoulos, A.A. Kei, C.V. Rizos, M.S. Elisaf,
Greece
361
294
LIPOPROTEIN APHERESIS DURING THE FIRST-YEAR AFTER CABG IN
PATIENTS WITH HYPERLIPIDEMIA
Marat Ezhov, L. Ilìna, R. Adzhiev, O. Afanasieva, M. Safarova, E. Vlasova,
I. Adamova, G. Konovalov, S. Pokrovsky, Russia
991
295
THE PPAR AGONIST TETRADECYLTHIOACETIC ACID REDUCES
ATHEROSCLEROSIS PROGRESSION IN APOE-/- MICE BEYOND
PLASMA LIPID LOWERING
Rita Vik, M. Busnelli, C. Prolini, B. Bjørndal, S. Holm, T. Brattelid, S.
Manzini, G. Banzetti, P. Aukrust, G. Chiesa, R.K. Berge, Norway, Italy
296
UNITED STATES TRENDS IN THE USE AND COST OF LIPID LOWERING
MEDICATIONS FROM 2004 THROUGH 2012
L. Goldman Rosas, M. Shahbaz, S. Thiyagarajan, Randall Stafford, USA 1273
86
1038
TREATMENTS (contd.)
Poster Board No.
Abstract No
Lipid-lowering therapy / Nicotinic acid
297
PHENOTYPIC DETERMINANTS OF LIPID RESPONSES TO TREATMENT
WITH NICOTINIC ACID AND LAROPIPRANT IN HONG KONG CHINESE
PATIENTS WITH DYSLIPIDAEMIAV
Y.L. Yang, Miao Hu, B. Tomlinson, Hong Kong S.A.R.
738
298
EFFECT OF EXTENDED-RELEASE NIACIN/ LAROPIPRANT
COMBINATION ON FASTING LIPIDS, GLUCOSE, INSULIN AND
ADIPONECTIN LEVELS IN CHINESE PATIENTS WITH DYSLIPIDAEMIA
Y.L. Yang, M. Hu, S. Yamashita, D. Masuda, Brian Tomlinson, Hong Kong
S.A.R., Japan
746
299
NIACIN EFFICACY AND SAFETY IN APPARENTLY HEALTHY MEN WITH
LIPOPROTEIN(A) EXCESS
Nadezhda Artemeva, M. Safarova, M. Ezhov, O. Afanasieva, O. Dmitrieva,
S. Pokrovsky, Russia
818
Lipid-lowering therapy / PCSK9
300
AFFITOPE®-BASED ANTI-PCSK9 VACCINES - AN INNOVATIVE
APPROACH FOR LONG TERM CHOLESTEROL MANAGEMENT
Gergana Galabova, C. Juno, W. Kirchstetter, E. Bilcikova, M. Edjlalipour, G.
Winsauer, S. Brunner, F. Mattner, W. Schmidt, A. von Bonin, G. Staffler,
Austria
371
301
DYNAMICS BETWEEN THE MONOCLONAL ANTIBODY
SAR236553/REGN727, PROPROTEIN CONVERTASE SUBTILISIN/KEXIN
TYPE 9 (PCSK9) AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL
(LDL-C) LEVELS (FUNDING: REGENERON/SANOFI)
James M. McKenney, G.D. Swergold, T. DiCioccio, P. Belomestnov, C.
Hanotin, A. Brunet, W.J. Sasiela, E.A. Stein, USA, France
485
302
THE EFFECTS OF SINGLE DOSE ADMINISTRATION OF RN316 (PF04950615), A HUMANIZED MONOCLONAL ANTIBODY BINDING PCSK9,
IN HYPERCHOLESTEROLEMIC SUBJECTS
B. Gumbiner, C. Udata, T. Joh, H. Liang, H. Wan, D. Shelton, P. Forgues, S.
Billotte, J. Pons, C. Baum, Pamela D Garzone, USA
1268
303
THE EFFECTS OF MULTIPLE DOSE ADMINISTRATION OF RN316 (PF04950615), A HUMANIZED MONOCLONAL ANTIBODY BINDING PCSK9,
IN HYPERCHOLESTEROLEMIC SUBJECTS
B. Gumbiner, C. Udata, T. Joh, H. Liang, H. Wan, D. Shelton, P. Forgues, S.
Billotte, J. Pons, C. Baum, Pamela D Garzone, USA
1270
Lipid-lowering therapy / Statins
305
ROSUVASTATIN EVALUATION PROGRAM FOR ESTABLISHING
EFFICACY AND SAFETY IN INDIAN HYPERLIPIDEMIA PATIENTS
ROSUVEES
Navneet Wadhwa, B. Kotak, C. Shah, ROSUVEES Study Group, India
87
1016
TREATMENTS (contd.)
Poster Board No.
Abstract No
306
PREOPERATIVE STATIN TREATMENT IN CARDIAC SURGERY IS MORE
EFFECTIVE IN PATIENTS WITH PREVIOUS ACTIVATION OF THE
INFLAMMATORY SYSTEM
Jose Rubio Alvarez, J.M. Martinez Comendador, J. Sierra Quiroga, E.
Teijeira Fernandez, B. Adrio Nazar, Spain
21
307
EFFECT OF SIMVASTATIN/EZETIMIBE 10/10 MG VERSUS
SIMVASTATIN 40 MG ON SERUM VITAMIN D LEVELS
S.E. Makariou1,2, E.N. Liberopoulos, E. Moutzouri, M. Kostapanos, I.
Panagopoulou, A. Challa, Moses Elisaf, Greece
26
308
ROSUVASTATIN SIGNIFICANTLY IMPROVES ARTERIAL STIFFNESS
PARAMETERS BY PULSE-WAVE ANALYSIS IN HIGH RISK PATIENTS
WITH ARTERIAL HYPERTENSION AND DYSLIPIDEMIA
Olga N. Korneeva, O.M. Drapkina, L. Palatkina, E. Zyatenkova, N.
Balachonova, V. Ivashkin, Russia
118
309
ROSUVASTATIN INFLUENCE ON CAROTID ATHEROSCLEROSIS.
DADA
Nataliya Gamletovna Dadamyants, F. Djalalov, Uzbekistan
237
310
EFFECTS OF ROSUVASTATIN VERSUS PROBUCOL ON LIPID
ABNORMALITIES IN PATIENTS WITH CHRONIC KIDNEY DISEASE
STAGE 3 AND ABOVE
Gen Yasuda, K. Yatsu, S. Saka, N. Hirawa, Japan
244
311
NO PHARMACOGENETIC PRAVASTATIN EFFECT ON
CARDIOVASCULAR EVENTS IN THE PROSPER/PHASE STUDY. IS
PERSONALIZED MEDICINE WITH REGARD TO STATINS STILL
REALISTIC?
Iris Postmus1,2, S. Trompet1,2,3, A.J.M. de Craen1,2, D. Shiffman, J.J. Devlin,
I. Ford, P.E. Slagboom2,6, R.G.J. Westendorp1,2, J.W. Jukema3,7,8, The
Netherlands, USA, UK
283
312
LONG-TERM EFFECT OF STATIN ON FASTING BLOOD GLUCOSE
LEVELS IN ASIAN HYPERCHOLESTEROLEMIC PATIENTS
Chee Jeong Kim, M.-A. Kim, Republic of Korea
88
333
TREATMENTS (contd.)
Poster Board No.
Abstract No
313
STATIN USE IS ASSOCIATED WITH DEPRESSION IN MINORITY ETHNIC
GROUPS IN UK
Emily D. Williams, R. Stewart, T. Tillin, N. Chaturvedi, A.D. Hughes, UK
554
314
ROSUVASTATIN CAN REDUCE AORTIC STIFFNESS IN
HYPERCHOLESTEROLEMIC PATIENTS BY FAVORABLE
HEMODYNAMIC CHANGES, INDEPENDENT OF LIPID LOWERING AND
ANTI-INFLAMMATORY EFFECTS
P.C. Oh, Seung Hwan Han, J. Seo, K.K. Koh, T.H. Ahn, E.K. Shin, Republic
of Korea
644
315
EFFECTS OF TWO DIFFERENT STATINS ON VASCULAR
INFLAMMATION MARKERS IN ACUTE CORONARY SYNDROMES
DURING IN-HOSPITAL FOLLOW-UP
Ali Çoner, A. Aydınalp, V. Çamkıran, K. Okyay, U.A. Bal, A. Yıldırır, H.
Müderrisoğlu, Turkey
708
PRAVASTATIN COMBINED WITH VALSARTAN SHOWS ADDITIVE
BENEFICIAL VASCULAR EFFECTS IN PATIENTS WITH
Kwang Koh, M. Quon, Republic of Korea, USA
727
316
317
COMBINATION THERAPY WITH PRAVASTATIN AND VALSARTAN HAS
ADDITIVE EFFECTS TO IMPROVE METABOLIC PHENOTYPES OVER
MONOTHERAPY IN HYPERCHOLESTEROLEMIC PATIENTS
Kwang Koh, M. Quon, Republic of Korea, USA
728
318
EFFECT OF ROSUVASTATIN ON ATHEROSCLEROSIS OF CAROTID
ARTERIES
M. Kenjaev, Azizjon Nizomov, M.B. Urinov, Uzbekistan
873
EFFICACY OF ROSUVASTATIN ON INFLAMMATORY MARKERS IN
PATIENTS WITH ACUTE CORONARY SYNDROME
Azizjon Abdumatlubovich Nizomov, Uzbekistan
893
319
320
ATORVASTATIN INDUCES ENDOGLIN AND ENOS EXPRESSION IN
ENDOTHELIAL CELLS
Lenka Zemankova, M. Varejckova, Z. Strasky, P. Nachtigal, Czech Republic1011
321
EFFECT OF PRAVASTATIN ON ATHEROSCLEROSIS IN
BRAHIOCEPHALIC ARTERY IN APOE/LDL R-/- MICE FED LOW
CARBOHYDRATE HIGH PROTEIN DIET
Magdalena Anna Franczyk-Zarow, E. Maslak, I. Czyzynska, A. Drahun, A.
Jasztal, L. Mateuszuk, S. Chlopicki, R.B. Kostogrys, Poland
1050
89
TREATMENTS (contd.)
Poster Board No.
Abstract No
322
PROTECTION BY L-CARNITINE OF STATIN INDUCED MUSCLE
MITOCHONDRIAL DYSFUNCTION
P.G. La Guardia, L.C. Alberici, F.G. Ravagnani, R.R. Catharino, Anibal E.
Vercesi, Brazil
1063
323
EFFECT OF ROSUVASTATIN ON MICRORNAS EXPRESSION IN HUMAN
ATHEROSCLEROTIC PLAQUES: RESULTS FROM QUASAR STUDY
Pamela Marcantonio, D. Santovito, D. Mastroiacovo, C. Mandolini, V. De
Nardis, G. De Blasis, A. Mezzetti, G. Desideri, F. Cipollone, Italy
1064
324
STATIN IS ASSOCIATED WITH LOWER DEEP VEIN THROMBOSIS
INCIDENCE CONFIRMED BY CT ANGIOGRAPHY IN PATIENTS
UNDERGOING TOTAL KNEE REPLACEMENT ARTHROPLASTY
Sang-Ho Jo, H.-S. Kim, Republic of Korea
325
CUMULATIVE MORTALITY DUE TO HIGH DOSES OF ATORVASTATIN
GIVEN TO HYPERCHOLESTEROLEMIC MICE
Juan C. Diaz-Zagoya, I.E. Juárez-Rojop, A.E. Castell-Rodríguez, J.L. BléCastillo, R. Miranda-Zamora, Mexico
1302
326
EFFECTS OF PITAVASTATIN ON HIGH DENSITY LIPOPROTEIN
CHOLESTEROL IN ELDERLY PATIENTS WITH DIABETES
Hyang-Lim Lee, S.-H. Kim, D.-G. Park, Republic of Korea
1253
1494
327
ATORVASTATIN AND THE RISK TO DEVELOP DIABETES MELLITUS
Renato Alves, G. Paranhos, N. Scalissi, J. Salles, Brazil
1589
328
PITAVASTATIN HAS NEUTRAL EFFECTS ON GLYCAEMIC
PARAMETERS IN METABOLIC SYNDROME: THE CAPITAIN AND
PREVAIL US TRIALS
N. Hounslow, P. Giral, C.A. Sponseller, P. Robillard, A. Orsoni, M John
Chapman, UK, France, USA
1615
329
NEUTRAL EFFECT OF PITAVASTATIN ON GLYCAEMIC PARAMETERS
IN METABOLIC SYNDROME : THE CAPITAIN TRIAL
M John Chapman, N. Hounslow, A. Orsoni, M. Suzuki, P. Robillard, P. Giral,
France, UK
1616
330
NEW INSIGHTS INTO STATIN ACTION ON THE DYSLIPIDEMIA OF
METABOLIC SYNDROME: NORMALISATION OF BIOACTIVE
PLASMALOGENS AND SPHINGOLIPIDS IN HDL
Peter J. Meikle, G. Wong, A.R. Tan, B.A. Kingwell, A.K. Orsoni, N.
Hounslow, P. Giral, M.J. Chapman, France, UK
90
1643
POSTERS TRACK 3: RISK FACTORS, EPIDEMIOLOGY, PREVENTION, AND TREATMENT
OF CARDIOVASCULAR DISEASES
Poster Board No.
Abstract No
Cardiovascular epidemiology
331
DYNAMICS OF ATHEROSCLEROTIC LOADING OF CAROTID ARTERIES
IN MOSCOW POPULATION UNDER TWO-YEAR OBSERVATION
Olga Pogorelova, M. Tripoten, A. Rogoza, V. Kukharchuk, Y. Karpov, S.
Boytsov, T. Balakhonova, Russia
1128
332
ESTIMATION OF CORONARY ARTERY DISEASE ACCORDING TO
CARDIAC RISK FACTORS IN IRANIAN URBAN POPULATION
Sepideh Sokhanvar, S.A.N. Kazemi, S.N. Mousavinasab, Iran
1358
333
LONG TERM MORTALITY FOLLOWING CAROTID ENDARTERECTOMY
IS GOOD
Gareth Harrison, G. Lawrence, A. Stead, C. Chan, UK
1606
334
PREVALENCE OF HEART DISEASE RISK FACTORS IN THE AZORES
Rita Ferin, E. Schaefer, K. Horvath, J. Baptista, M.L. Pavão, Portugal, USA 139
335
MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULT
CONGENITAL HEART DISEASE: AN ASIA POPULATION-BASED LONGTERM STUDY
Pao-Hsien Chu, Y.-S. Lin, C.-J. Chang, Taiwan R.O.C.
458
336
CAROTID ATHEROSCLEROSIS AMONG GENERAL JAPANESE WITH
ESTIMATED 10-YEAR ABSOLUTE RISK OF CAD DEATH ACCORDING
TO THE JAPAN ATHEROSCLEROSIS SOCIETY GUIDELINE2012
Aya Kadota, K. Miura, T. Okamura, A. Fujiyoshi, T. Ohkubo, T. Kadowaki, N.
Takashima, T. Hisamatsu, Y. Nakamura, F. Kasagi, H. Maegawa, A.
Kashiwagi, H. Ueshima, the SESSA Research Group and the NIPPON
DATA80/90 Research Group, Japan
469
337
ASSOCIATION OF ELECTROPHYSIOLOGICAL MARKERS OF SUDDEN
CARDIAC DEATH INCREASED RISK WITH LIPID METABOLISM AND
INFLAMMATION BIOMARKERS IN CORONARY ATHEROSCLEROSIS
Sergei Ponkin, A. Kuznetsov, Y. Ragino, A. Chernyavskiy, M. Voevoda,
Russia
470
338
RISK FACTORS FOR HEART DISEASE IN MIDDLE-AGED WOMEN
DRIVING CAR
A.V. Petrischeva, Natalya Koryagina, Russia
563
339
THE ESTIMATED RISK OF FATAL CARDIOVASCULAR DISEASE IN
ASYMPTOMATIC ROMANIAN AERONAUTICAL PERSONNEL
ACCORDING TO ESC CRITERIA
Mirela Anghel, Romania
614
ENDOTHELIUM FUNCTION MARKERS AT CARDIOVASCULAR
DISEASES
Roman Iosifovich Vorobyev, E.N. Vorobyeva, Russia
654
340
91
OF CARDIOVASCULAR DISEASES (contd.)
Poster Board No.
341
Abstract No
CONTROL OF CORONARY RISK WITH USE OF THE COMPUTER
PROGRAMS
Roman Iosifovich Vorobyev, E.N. Vorobyeva, Russia
656
342
ESTIMATION OF THE GLOBAL CARDIOVASCULAR RISK IN THE HSHS
“HAMMAM-SOUSSE SAHLOUL HEART STUDY” AND COMPARISON OF
4 FORMULAS
A. Moussa, K. Rouis, Asma Omezzine, I. Boumaiza, J. Rejeb, L. Rebhi, L.
Bouacida, S. Neffati, N. Ben Rejeb, A. Ben Abdelaziz, A. Bouslama, Tunisia 666
343
LIPID, HEMOSTASIS AND HEMODYNAMIC ASPECTS OF PREDICTING
THE RISK OF CARDIOVASCULAR DEATH IN PATIENTS OF HIGH AND
VERY HIGH RISK
Mikhail A. Kachkovskii, V.V. Simerzin, O.A. Rubanenko, N. Kirichenko,
Russia
669
344
CARDIOVASCULAR RISK FACTORS FOR MULTIVESSEL DISEASE
Marina Fernandes, V.H. Pereira, J. Português, J. Guardado, F. CanárioAlmeida, F. Ferreira, I. Quelhas, A. Pereira, A. Lourenço, Portugal
802
CORONARY HEART DISEASE RISK FACTOR CONTROL AND
TREATMENT IN REPUBLIC OF SRPSKA PATIENTS WITH KNOWN
CORONARY HEART DISEASE( ROSCOPS)
Dusko Vulic, D. Djekic, M. Krneta, A. Lazarevic, L. Sormaz, R. Skrbic,
Bosnia-Herzegovina
822
345
346
RISK FACTORS FOR MULTIVESSELS CORONARY HEART DISEASES
IN BOSNIAN POPULATION
Belma Pojskic, A. Macic Dzankovic, A. Rosic, D. Mehinagic, M. Pojskic,
Bosnia-Herzegovina
835
347
COMBINATION OF HEARTSCORE- AND SHAPE (SOCIETY FOR HEART
ATTACK PREVENTION AND ERADICATION)-BASED ALGORITHMS IN
CARDIOVASCULAR RISK ASSESSMENT
Frederic Kontny, B. Selseth, T. Fjornes, U. Gisletun, A. Paus, M. Fortun, M.
Hamre, G. Kjoelsnes, P. Tillander, Norway
965
348
THE CORRELATION IN PATIENTS WITH ACUTE CORONARY
SYNDROMES BETWEEN HYPERTENSION, OXIDATIVE STRESS,
PLATELETS HYPERACTIVITY, ENDOTHELIAL DYSFUNCTION AND
PROGNOSIS
Elena Bobescu1,2, A. Covaciu, D. Dobreanu, N. Aldulea, Romania
1147
INFLUENCE OF VASCULAR RISK FACTORS IN THE MEDIUM-TERM
EVOLUTION OF PERCUTANEOUS REVASCULARIZATION OF
Luisa Cabeza Letrán, R. Toro, M. Sobrino, M.C. Durán, I. Tinoco, C.
Rodríguez, D. Corrales, J.M. Ibañez, A. Mangas, Spain
1306
349
92
Poster Board No.
Abstract No
350
COMBINED EFFECTS OF BLOOD PRESSURE AND SERUM
CHOLESTEROL LEVEL IN CARDIOVASCULAR DISEASE: AN ELDERLY
TAIWANESE COHORT STUDY
Kuo-Yang Wang, W.-W. Lin, W.-H. Yin, Taiwan R.O.C.
1308
351
HIGHER CARDIOVASCULAR RISK PROFILE IN PATIENTS WITH
DEGENERATIVE AORTIC VALVE STENOSIS AND ASSOCIATED
CORONARY ARTERY DISEASE
D. Gilmanov, A. Vianello, A. Miceli, G. Bianchi, S. Bevilacqua, S. Berti, M.
Glauber, Annamaria Mazzone, Italy
1598
Woman and cardiovascular risk
352
MINIMUM VALUE OF THYROID FAILURE TO STRUCTURE AND
FUNCTION HEART WOMAN OF REPRODUCTIVE AGE
Natalya Koryagina, A. Petrischeva, Russia
549
353
CV RISK SELF-ASSESSMENT FOR PERIMENOPAUSAL WOMEN
Ljiljana Trtica Majnaric, A. Vcev, M. Zulj, Croatia
603
354
EFFECT OF DIFFERENTS COMBINED ORAL CONTRACEPTIVES IN THE
VASCULAR ENDOTHELIUM
Bianca Stocco, H.F. Fumagalli, F.J. Bianchini, S.A. Franceschini, C.M.
Marzocchi-Machado, M.R. Torqueti, Brazil
866
355
NEGATIVELY AFFECTED ARTERY WALL LAYER DIMENSIONS IN
WOMEN WITH PREVIOUS PREECLAMPSIA - AN INVESTIGATION BY
NON-INVASIVE HIGH-FREQUENCY ULTRASOUND
Tansim Akhter, M. Larsson, A.-K. Wikström, T. Naessen, Sweden
356
887
ISCHEMIA MODIFIED ALBUMIN IN POSTMENOPAUSAL WOMEN WITH
CORONARY DISEASE IN RELATION TO NT-PROBNP AND HSCRP: A
BIOMARKER OF ATHEROSCLEROSIS BURDEN?
K. Kazanis, M. Dalamaga, E. Kassi, I. Vagionas, G. Jullien, Amalia
Dionyssiou-Asteriou, Greece
1393
Biomarkers
357
A NOVEL ANTI-INFLAMMATORY ADIPOKINE, SECRETED FRIZZLEDRELATED PROTEIN 5, IS ASSOCIATED WITH CORONARY ARTERY
DISEASE IN NON-ELDERLY POPULATION
Masayuki Doi, T. Miyoshi, M. Iwamoto, M. Kajiya, K. Nosaka, K. Ohkawa, R.
Nakayama, W. Takagi, K. Takeda, S. Hirohata, S. Kusachi, H. Ito, Japan
378
358
DEVELOPMENT OF A FULLY AUTOMATED LATEX ENHANCED TIA
FOR ADIPONECTIN
Yosuke Meguro, Y. Ito, Y. Minakawa, H. Mizue, Japan
93
408
Poster Board No.
Abstract No
359
INCREMENTAL VALUE OF CIRCULATING ADIPONECTIN LEVELS IN
PREDICTING THE EXTENT OF CORONARY ATHEROSCLEROSIS
ASSESSED BY COMPUTED TOMOGRAPHY ANGIOGRAPHY
Morihiro Matsuda, R. Tamura, O. Nishimoto, K. Kanno, T. Segawa, K.
Nakamoto, H. Nishiyama, T. Kawamoto, Japan
360
A PRELIMINARY STUDY ABOUT NT-PROBNP AS A SCREENING TEST
FOR HEART FAILURE IN A HEALTH CHECK
Jiro Suwa, Japan
128
361
PROGNOSTIC SIGNIFICANCE OF LONG PENTRAXIN-3 LEVEL IN
PATIENT WITH ACUTE CORONARY SYNDROME
S. Altay, Huseyin Altug Cakmak, T. Kemaloglu, A. Turer, B. Erer, G. Can, I.
Keles, M. Eren, Turkey
436
362
1
H-NMR SPECTROMETRIC IDENTIFICATION OF BIOMARKERS OF
ATHEROSCLEROSIS IN THE APOLIPOPROTEIN-E KNOCKOUT MOUSE
Peshang Abdulhannan1,2, S. Saha, N. Yuldasheva, S. Wheatcroft, D.
592
Russell1,3, S. Homer-Vanniasinkam1,3, J. Fisher, UK
363
CIRCULATING ANTI-BETA2-GLYCOPROTEIN-I ANTIBODIES OF
PERIPHERAL ARTERIAL DISEASE PATIENTS TRIGGERS A GENOMIC
OVER-EXPRESSION OF TOLL-LIKE RECEPTOR 4 IN ENDOTHELIAL
CELLS
Cesar Varela, J. De Haro, S. Bleda, L. Esparza, A. Ferruelo, F. Acin, Spain 681
364
THE MONITORING OF EFFECTS OF LIPOIC ACID FOCUSING ON CELL
PROLIFERATION AND THE DETERMINATION OF ITS CONCENTRATION
IN PLASMA
Soňa Bencová, P. Žáková, K. Královec, L. Geryk, Czech Republic
735
365
THE RELATIONSHIP BETWEEN PLASMA LONG PENTRAXIN-3 LEVEL
AND RENAL FUNCTIONS IN ACUTE CORONARY SYNDROME
Ibrahim Keles, S. Altay, H.A. Cakmak, T. Kemaloglu, A. Turer, F.O.
Karadeniz, G. Can, B. Erer, M. Eren, Turkey
783
366
TOTAL BILIRUBIN IN YOUNG MEN AND WOMEN : ASSOCIATION WITH
RISK MARKERS FOR CARDIOVASCULAR DISEASES
Marina Stojanov, A. Stefanovic, G. Dzingalasevic, J. Ivanisevic, M.
Miljkovic, S. Mandic-Radic, M. Prostran, Serbia
1190
367
SERUM CALPROTECTIN LEVELS IN APPARENTLY HEALTHY
JAPANESE SUBJECTS
Yukio Ikeda, Y. Kumon, T. Ohguro, N. Hisakawa, J. Nishiuchi, S.
Yamanaka, T. Sugiura, Japan
368
899
1232
FIBRONECTIN EXTRA DOMAIN-A AND CARDIOVASCULAR DISEASE:
EVIDENCES FROM ANIMAL MODELS
Vivek Krishna Pulakazhi Venu, R. Baetta, P. Uboldi, N. Ferri, A. Muro, A.
1254
Corsini, G.D. Norata1,3, A.L. Catapano1,4, Italy
94
Poster Board No.
369
370
Abstract No
TMAO: A NEW MARKER OF ATHEROSCLEROSIS?
Samira De Oliveira1,2, V. Ferchaud-Rouchet, K. Bach, Y. Goueffic, K.
Ougerram1,2, M. Krempf1,2, France
1265
HAIR SELENIUM CONCENTRATION OF HYPERLIPIDEMIC PATIENTS
WITH VARIOUS RISK FACTORS OF ATHEROSCLEROSIS
Péter Fülöp, I. Seres, I. Juhász, Z. Jenei, G. Paragh, Hungary
1267
Functional assessment of arterial wall
371
ARTERIAL STIFFNESS IS INDEPENDENTLY ASSOCIATED WITH INHOSPITAL EARLY CLINICAL OUTCOME AFTER ISCHEMIC STROKE
Christina Voulgari, E. Jude, S. Avgeri, S. Paximadas, S. Pagoni, Greece,
UK
311
372
EVALUATION OF ULTRASOUND ASSESSED FLOW-MEDIATED
VASODILATION IN THE GÖTTINGEN MINIPIG
Trine Pagh Ludvigsen, N. Wiinberg, B.Ø. Christoffersen, S.G. Moesgaard,
H.D. Pedersen, L.H. Olsen, Denmark
400
373
COLOR DOPPLER ULTRASOUND (CDUS) ANALYSIS OF TURBULENT
FLOW IN THREE DIFFERENT ANIMAL MODELS
J.J. Elias, K. Mata, C.R. Fernandes, Simone Gusmão Ramos, Brazil
511
374
NON-INVASIVE DETECTION OF CORONARY ARTERY DISEASE USING
COMPUTERIZED ANALYSIS OF DIASTOLIC HEART SOUNDS
Samuel Emil Schmidt, S. Winther, N.R. Holm, E. Toft, J.J. Struijk, M.
Bøttcher, Denmark
547
375
ASSOCIATION BETWEEN PULSE WAVE VELOCITY AND CORONARY
ARTERY CALCIFICATION IN A GENERAL JAPANESE MALE
POPULATION: SESSA
Sayuki Torii, T. Ohkubo, A. Fujiyoshi, A. Kadota, N. Takashima, S.
Kadowaki, T. Hisamatsu, Y. Saitoh, N. Miyagawa, M. Zaid, Y. Murakami, K.
Miura, H. Ueshima, Shiga Epidemiological Study of Subclinical
Atherosclerosis (SESSA) Research Group, Japan
551
376
SOUTH ASIANS HAVE REDUCED LEFT VENTRICULAR SYSTOLIC
LONGITUDINAL FUNCTION THAT IS NOT EXPLAINED BY THEIR
EXCESS CARDIOVASCULAR DISEASE RISK
Chloe May Park, K. March, T. Tillin, N. Chaturvedi, A.D. Hughes, UK
566
377
ABNORMAL METABOLIC PARAMETERS ARE INDEPENDENT
FACTORS FOR INCREASED AORTIC STIFFNESS IN HEALTHY, NO
DRUG TREATMENTS SUBJECTS
Seung Hwan Han, H.S. Hwang, J. Moon, S.Y. Suh, K.H. Lee, K.K. Koh, T.H.
Ahn, I.S. Choi, E.K. Shin, Republic of Korea
646
378
EVALUATION OF INTIMA MEDIA THICKNESS AND VASCULAR
COMPLIANCE AT COMMON CAROTID AND FEMORAL ARTERIES IN
ATHLETES AND YOUNG CONTROLS
Gabriele Cioni, R. Marcucci, A.M. Gori, A. Rogolino, G.F. Gensini, R.
Abbate, M. Boddi, Italy
1085
95
Poster Board No.
Abstract No
379
ATTENUATED VASCULAR ENDOTHELIAL FUNCTION ASSESSED BY
PERIPHERAL ARTERIAL TONOMETRY IS ASSOCIATED WITH
CARDIOVASCULAR RISK FACTORS IN MIDDLE-AGED FEMALE
WORKERS
Jussi Konttinen, H. Lindholm, J. Sinisalo, J. Uitti, Finland
1152
380
THE CLINICAL SIGNIFICANCE OF CONDITIONS PRESENTED BY ECG
CHANGES MIMICKING ACUTE MYOCARDIAL INFARCTION
1294
Malka Yahalom, N. Roguin, Y. Turgeman1,2, Israel
381
DIFFERENCES IN ARTERIAL STIFFNESS BETWEEN ISCHEMIC
STROKE SUBTYPES
Peter Wohlfahrt, A. Krajcoviechova, O. Mayer, J. Vanek, J. Filipovsky, R.
Cifkova, Czech Republic
1335
382
ADDITIVE VALUE OF LOWER EXTREMITY ARTERIAL STIFFNESS TO
AORTIC STIFFNESS FOR PREDICTING TARGET ORGAN DAMAGE
Peter Wohlfahrt1,2, A. Krajcoviechova, J. Seidlerova, O. Mayer, J. Filipovsky,
S. Laurent, R. Cifkova, Czech Republic, France
1339
383
REACTIVE HYPEREMIC INDEX MEASURED BY PERIPHERAL ARTERY
TONOMETRY ASSOCIATES WITH RADIAL ARTERY INTIMA-MEDIATHICKNESS, PATIENTS WITH SUSPECTED CORONARY ARTERY
DISEASE
1371
Charlotte Eklund, L.-M. Gan1,2, Sweden
Imaging / IMTc
384
PREVALENCE AND CARDIAC RISK FACTORS PREDICTORS OF
SUBCLINICAL ATHEROSCLEROSIS, INCREASED CAROTID INTIMAMEDIA THICKENING AND CARDIOVASCULAR DISEASE IN MORBID
OBESITY
Julio Oscar Bono, R. Chiosso, R. Del Valle, J.M. Foscarini, C. Esquivel, L.
Ahuad, E. Moreyra, A. Surur, Argentina
864
385
CAROTID INTIMA MEDIA THICKNESS AS A RISK FACTOR FOR
INCREASED CORONARY CALCIUM SCORE
A. Bertolami, C. Gonzaga, M. Sulzbach, D.B. Araujo, H. Zatz, R. Gonçalves,
A.A. Faludi, Marcelo Chiara Bertolami, Brazil
1164
386
IMAGING METHODS OF CAROTID ARTERIES STENOSIS
Nataliya Dadamyants, Uzbekistan
387
1266
CA-IMT AND QT PARAMETERS IN DYSLIPIDEMIC PATIENTS IN
PRIMARY PREVENTION AT DIFFERENT ESC/EAS CARDIOVASCULAR
RISK LEVELS
G. Mombelli, Barbara Terraneo, F. Pazzucconi, C. Pavanello, R. Bosisio, M.
1340
Triolo, V. Barbieri, P. Magni, S. Castelnuovo, C.R. Sirtori 1,2, Italy
96
Poster Board No.
Abstract No
Imaging / Calcifications assessment
388
PATHOGENESIS OF CALCIFIED AORTIC VALVE STENOSIS: A
SPECTROSCOPIC STUDY
Ioannis E. Mmamarelis, K. Pissaridi, E. Koutoulakis, V. Dritsa, C. Kotoulas,
V. Mamareli, J. Anastassopoulou, Greece
61
389
THE STATE OF CALCIUM METABOLISM AND LIPID PROFILE FOR
PATIENTS WITH CORONARY ARTERY DISEASE DEPENDING ON THE
SMOKING STATUS
Irina Grebenshchikova, S. Levashov, E. Volkova, Russia
384
390
MARKER OF CALCIFIED ATHEROSCLEROSIS AT CARDIOVASCULAR
DISEASES
I.G. Leschenko, V.A. Leschenko, Roman Iosifovich Vorobyev, E.N.
Vorobyeva, Russia
649
391
CORONARY CALCIFICATION IS SUPERIOR TO EXERCISE TOLERANCE
TESTING IN PREDICTING SIGNIFICANT CORONARY ARTERY
STENOSIS IN SYMPTOMATIC PATIENTS
Tarek Bengrid, R. Nicoll, A. Schmermund, M. Henein, Sweden, Germany 762
392
CORONARY CALCIFICATION CORRELATES WITH THE PRESENCE
AND SEVERITY OF VALVE CALCIFICATION IN ANGINA PATIENTS
WITH NO AORTIC STENOSIS
George Koulaouzidis, R. Nicoll, P. Jenkins, M. Henein, Sweden, UK
765
393
SCREENING OF ASYMPTOMATIC PATIENTS WITH TYPE 2 DIABETES
AND HIGH CVD-RISKS FOR SILENT CHD: BENEFIT OF CORONARY
ARTERY CALCIUM SCORING
Maria Karlinskaya, Y. Poteshkin, I. Glinkina, A. Zilov, S. Ternovoy, G.
Melnichenko, Russia
850
394
ATHEROSCLEROTIC EVALUATION WITH WHOLE-BODY CTA (WB-CTA)
IN PATIENTS WITH CV RISK FACTORS: ARE CORONARY ARTERIES
AND EXTRA-CORONARY VESSELS EQUALLY INVOLVED?
Fulvio Zaccagna, A. Napoli, G. Cartocci, V. Noce, F. Boni, C. Catalano, Italy877
395
IN VIVO QUANTIFICATION OF ATHEROSCLEROTIC BURDEN: CTA´S
PROGNOSTIC ACCURACY IN RELATION TO TRADITIONAL
CARDIOVASCULAR RISK INDEX AND 5-YEAR FOLLOW-UP
Fulvio Zaccagna, A. Napoli, G. Cartocci, V. Noce, F. Boni, C. Catalano, Italy878
396
EVALUATION OF PATIENTS PRIOR TO NON CORONARY CARDIAC
SURGERY BY CARDIAC CT
Sara Casquero Dominguez, N. Romero Rodriguez, M. Romero
Vazquianez, M. Villa Gil-Ortega, M. Fernandez Quero, A. Guisado Rasco, A.
Martinez Martinez, Spain
1566
97
Poster Board No.
Abstract No
Imaging / Miscellaneous
397
THE ROLE OF QUANTITATIVE CORONARY ARTERIOGRAPHY IN
ANALYSIS IN PROGRESSION OF CORONARY STENOSIS TO A TOTAL
OCCLUSION, NEW WAY
Jovica Saponjski, B. Beleslin, V. Vukcevic, Serbia
169
398
MYOCARDIAL PERFUSION IMAGING USING 99MTC-SESTAMIBI SPECT:
A CARDIAC PHANTOM STUDY
Mansour Almoudi, Z. Sun, Australia
206
399
QUANTIFICATION OF CORONARY VESSEL WALL ENHANCEMENT:
REPRODUCIBILITY OF METHODS AND FEASIBILITY OF
QUANTIFICATION IN HEALTH AND DISEASE
Niharika Varma, R. Botnar, D. D'Cruz, A. Indermuehle, S. Peel, G. Greil, T.
Hussain, E. Nagel, V. Puntmann, UK
890
400
ASSESSMENT OF INTEGRATED MULTIMODAL BASED NANO-IMAGING
FOR EARLY DIAGNOSIS OF CAROTID ATHEROSCLEROSIS
ASSOCIATED WITH NEUROLOGICAL DISORDERS
Lina H. Machtoub, Austria
947
401
GEOMETRIC APPROACH IN EVALUATING ATHEROSCLEROSIS IN
LEFT CORONARY ARTERY
Young Ho Choi, S.-H. Suh, H.-H. Kim, Republic of Korea
402
NON-INVASIVE ASSESSMENT OF BYPASS GRAFTS AND NATIVE
CORONARY VERSUS INVASIVE CORONARY ANGIOGRAPHY BY
CADIAC CT
Sara Casquero Dominguez, N. Romero Rodriguez, M. Romero
Vazquianez, M. Fernandez Quero, A. Guisado Rasco, M. Villa Gil-Ortega, A.
Martinez Martinez, Spain
1575
1474
Imaging / Vulnerability
403
CORONARY CT ANGIOGRAPHY OF CORONARY PLAQUES: AN
INVESTIGATION OF INTRALUMINAL APPEARANCES AND
CORRELATION OF LEFT BIFURCATION ANGULATION WITH PLAQUE
FORMATION
Zhonghua Sun, M. Almoudi, Australia
207
404
IMAGING VULNERABLE ATHEROSCLEROTIC PLAQUES BY
TARGETING CO-STIMULATORY MOLECULES
Adrienne Müller, L. Mu, K. Beck, R. Meletta, Z. Rancic, K. Drandarov, P.A.
548
Kaufmann, R. Schibli1,2, S.M. Ametamey, S.D. Krämer, Switzerland
405
MORPHOLOGICAL PLAQUE FEATURES SUGGEST CONTRALATERAL
CAROTID VULNERABILITY IN SYMPTOMATIC BUT NOT
ASYMPTOMATIC PATIENTS
Fisnik Jashari, P. Ibrahimi, E. Johansson, C. Gronlund, G. Bajraktari, P.
Wester, M. Henein, Sweden
605
98
POSTERS TRACK 3: RISK FACTORS, EPIDEMIOLOGY, PREVENTION, AND
TREATMENT OF CARDIOVASCULAR DISEASES (contd.)
Poster Board No.
Abstract No
406
SYMPTOMATIC PATIENTS WITH CAROTID DISEASE HAVE MORE
VULNERABLE CONTRALATERAL PLAQUES THAN ASYMPTOMATIC
Pranvera Ibrahimi, F. Jashari, E. Johansson, C. Gronlund, G. Bajraktari, P.
Wester, M. Henein, Sweden
611
407
RISK ASSESSMENT OF ATHEROSCLEROTIC PLAQUES BASED ON
GLOBAL BIOMECHANICS
Simone Melchionna, H.-E. Lee, G. Amati, M. Bernaschi, M. Bisson, S.
Succi, Italy, Republic of Korea
408
769
EVALUATION OF [18F]-FLUORODEOXYGLUCOSE UPTAKE IN THE
AORTIC ARCH OF APOLIPOPROTEIN E-DEFICIENT MICE
Jakub Toczek, A. Broisat, P. Perret, D. Fagret, L.M. Riou, C. Ghezzi, France1331
Genetics
409
ASSOCIATION STUDY OF 10 GENE VARIANTS WITH ANGIOGRAPHIC
SEVERITY OF CORONARY ARTERY DISEASE
Martin Javorsky1,2, V. Vitanov, L. Klimcakova, V. Habalova, J. Zidzik, E.
291
Babjakova1,2, J. Salagovic, B. Stancak, I. Tkac1,2, Slovak Republic
410
POSSIBLE GENE-GNDER INTERACTION BETWEEN THE SLCO1B1
POLYMORPHISM AND STATIN TREATMENT EFFICACY
Jaroslav Hubacek, D. Dlouha, V. Adamkova, V. Lanska, R. Ceska, M.
Vrablik, Czech Republic
345
411
LACK OF AN ASSOCIATION BETWEEN THE MRAS POLYMORPHISM
AND ACS RISK IN CZECH POPULATION
Jaroslav A. Hubacek, V. Adamkova, V. Lanska, R. Ceska, M. Vrablik, R.
Poledne, M. Gebauerova, V. Stanek, J. Pitha, Czech Republic
349
412
MCP1 POLYMORPHISMS ARE ASSOCIATED WITH SEVERAL
CARDIOMETABOLIC PARAMETERS BUT NOT WITH PREMATURE
CORONARY ARTERY DISEASE IN THE MEXICAN POPULATION
Gilberto Vargas-Alarcón, T. Villarreal-Molina, R. Posadas-Sánchez, E.
Alvarez-León, S. Canizales-Quinteros, E. Kimura-Hayama, S. RomeroHidalgo, J.G. Juárez-Rojas, E. Larrieta-Carrasco, V. Acuña-Alonzo, E. JorgeGalarza, C. Posadas-Romero, Mexico
525
413
ASSOCIATION BETWEEN THE A603G TISSUE FACTOR GEN
POLYMORPHISM, MARKERS OF ENDOTHELIAL DYSFUNCTION AND
INCIDENCE OF MYOCARDIAL INFARCTION IN RUSSIA
Elena Gennadyevna Sergeeva1,2, M.A. Karpenko, Z.I. Ionova, G.V.
Alekseeva, S. Saha, D. Saha, Russia
414
670
POLYMORPHISMS OF METHYLENETETRAHYDROFOLATE
REDUCTASE GENE (MTHFR), HOMOCYSTEINE LEVEL, AND RISK
FACTORS FOR CAD IN THAI
Ingkarat Sarutipaiboon, N. Settasatian, C. Settasatian, N. Komanasin, U.
Kukongwiriyapan, P. Intharapetch, K. Tantipanichteerakul, V. Senthong,
716
99
Poster Board No.
Abstract No
415
PROBABLE IMPACT OF POLYMORPHIC VARIANTS SOME
HAEMOSTATIC AND FOLATE SYSTEM GENES IN THE RISK OF
RESTENOSIS AFTER PERCUTANEOUS CORONARY INTERVENTION
Galina Chumakova1,2, A. Dashkova1,2, A. Momot, N. Veselovskaya2,4,
Russia
416
THE LEVEL OF HETEROPLASMY OF MITOCHONDRIAL GENOME IS AN
EXPLANATORY BIOMARKER FOR BOTH SUBCLINICAL AND
MANIFESTED ATHEROSCLEROSIS
Igor A. Sobenin1,2, M.A. Sazonova1,2, M.M. Chicheva-Ivanova, K.Y.
861
Mitrofanov, A.V. Zhelankin, Y.V. Bobryshev2,3, A.N. Orekhov2,3, Russia
417
GENETIC APPROACH TO CARDIOVASCULAR DISEASE PREVENTION:
POLYMORPHISMS IN CANDIDATE GENES INVOLVED IN RISK
FACTORS FOR CARDIOVASCULAR DISEASE
Chatri Settasatian, N. Settasatian, P. Intharapetch, P. Yongsakulchai, I.
Sarutipaiboon, P. Pitivej Thurakit, K. Tantipanichteerakul, V. Senthong,
934
418
GENETIC VARIATIONS IN PEROXISOME PROLIFERATOR-ACTIVATED
RECEPTORS (PPARS) AND THEIR RELATED GENES INFLUENCE
CARDIOVASCULAR DISEASE RISK IN THAI
Pratthana Yongsakulchai, C. Settasatian, N. Settasatian, N. Komanasin, U.
Kukongwiriyapan, P. Intharapetch, K. Tantipanichteerakul, V. Senthong,
956
419
THE ROLE OF +405G/C AND -2578C/A POLYMORPHISMS OF VEGF IN
Ignacio López de Maturana Carrasco, S. Bleda Moreno, J. de Haro
Miralles, L. Esparza Gómez, C. Varela Casariego, J. Rodriguez Padilla, F.
Acín García, Spain
1129
420
PPARΓ MUTATIONS RESPONSIBLE FOR LIPODYSTROPHY WITH
SEVERE HYPERTENSION ACTIVATE THE CELLULAR RENINANGIOTENSIN SYSTEM
Franck Boccara1,2, M. Auclair, C. Vigouroux, E. Capel, C. Vigeral, B. Guerci,
O. Lascols, J. Capeau, M. Caron-Debarle, France
1249
421
ASSOCIATION OF ADIPOQ GENE VARIANTS AND HEART FAILURE IN
AN ITALIAN POPULATION
Silvana Pileggi, S. Barlera, C. Casola, L. Crociati, S. Pietri, C. Specchia1,2,
M.G. Franzosi, Italy
1260
422
TERC RS12696304C ALLELE AND TRF1 RS2975843C ALLELE
SIGNIFICANTLY INCREASE THE RISK OF EARLY-ONSET ISCHEMIC
STROKE
Fang-I Hsieh, W.-Y. Lin, H.-J. Lin, L.-M. Lien3,4, C.-C. Yu, Y.-R. Chen, H.-Y.
Chiou, Taiwan R.O.C.
1443
100
759
Poster Board No.
Abstract No
423
OPERATIONAL REDEFINITION OF THE TISSUE ANGIOTENSIN SYSTEM
FROM GENE CO-EXPRESSION IN ATHEROGENESIS
Catherine Cerutti, S. Barrot, M.-P. Gustin, H. Ayari, C. Paultre, P. Feugier,
L. Legedz, G. Bricca, France
1465
424
INTERACTION BETWEEN I148M IN THE ADIPONUTRIN GENE (PNPLA3)
AND DIETARY INTAKES OF CARBOHYDRATES AND N-6/N-3POLYUNSATURATED FATS ON FASTING TRIGLYCERIDE LEVELS
I.A. Stojkovic, U. Ericson, G. Rukh, Marju Orho-Melander, Sweden
1548
425
GENOME-WIDE ASSOCIATION STUDY IDENTIFIES THREE GENOMIC
LOCI SIGNIFICANTLY ASSOCIATED WITH SERUM LEVELS OF
HOMOARGININE - THE ATHEROREMO CONSORTIUM
Marcus Edi Kleber1,2, I. Seppälä, S. Pilz4,5, M.M. Hoffmann, A. Tomaschitz,
N. Oksala3,8, E. Raitoharju, L.-P. Lyytikäinen, K.-M. Mäkelä, R. Laaksonen,
M. Kähönen, O.T. Raitakari10,11, J. Huang, C. Drechsler, V. Krane, C.
Wanner, B.O. Böhm, W. König, T. Lehtimäki, W. März1,15,16, A. Meinitzer,
Germany, Finland, The Netherlands, Austria
1561
426
THE AGT M235T POLYMORPHISM ASSOCIATES WITH AMI RISK AND
INFLUENCES CAD SEVERITY
Sounira Mehri, R. Chaaba, M. Hammami, Tunisia
1602
Obesity and fat distribution
427
EFFECT OF VARIOUS BARIATRIC SURGICAL PROCEDURES ON
PLASMA APO-CIII LEVELS
N. Padilla, M. Maraninchi, B. Berthet, A. Bégu-Le Corroller, N. Dubois, R.
Grangeot, C. Mattei, B. Vialettes, René Valéro, France
970
428
OBESITY MODULATES THE IMMUNE RESPONSE TO OXIDIZED LDL
AND INFLAMMATORY MILIEU IN HYPERTENSIVE PATIENTS
H.A. Fonseca1,2, F.A. Fonseca, A.M. Monterio, H.T. Bianco, S.A. Brandão, M.
Gidlund, Maria Cristina Izar, Brazil
240
429
WEIGHT LOSS INDUCED IMPROVEMENTS IN LIPIDS IN
OVERWEIGHT/OBESE SUBJECTS TREATED WITH
PHENTERMINE/TOPIRAMATE EXTENDED-RELEASE (PHEN/TPM ER)
Hermann Toplak, S. Klein, W.W. Day, Austria, USA
391
430
BMI OR WAIST CIRCUMFERENCE - WHICH IS THE MORE RELIABLE
MARKER FOR PREDICTING CARDIOVASCULAR DISEASE?
Helen Marcoyannopoulou Fojas, E. Barrios, Philippines
480
431
REDUCTION OF P WAVE DISPERSION AFTER THERAPEUTIC WEIGHT
LOSS IN OVERWEIGHT AND OBESE PATIENTS
Anna Giulia Falchi, C. Muggia, C. Tinelli, Italy
522
432
CALORIC RESTRICTION INDUCES OBESITY AND DIABETES AND
AGGRAVATES SPONTANEOUS ATHEROSCLEROSIS DEVELOPMENT
IN HYPERCHOLESTEROLEMIC MICE
G.G. Dorighello, J.C. Rovani, C.J.F. Luhman, B.A. Paim, A.E. Vercesi,
Helena C F Oliveira, Brazil
620
101
Poster Board No.
Abstract No
433
LONG TERM STATUS OF METABOLIC PARAMETERS ARE RISK
FACTORS FOR ABNORMAL CORONARY ENDOTHELIAL FUNCTION IN
PATIENTS WITHOUT SIGNIFICANT CAD
Seung Hwan Han, J. Seo, P.C. Oh, W.J. Chung, K. Lee, S.Y. Suh, W.C.
Kang, K.K. Koh, T.H. Ahn, E.K. Shin, Republic of Korea
641
434
EPICARDIAL ADIPOSITY AS A MARKER OF SUBCLINICAL CORONARY
ATHEROSCLEROSIS
734
N. Veselovskaya1,2, Galina Chumakova1,3, A. Ott, Russia
435
RISK OF ATHEROSCLEROSIS AND WAIST CIRCUMFERENCE CUT-OFF
POINTS IN SIBERIAN POPULATION 45-69 YEARS OLD
(EPIDEMIOLOGICAL STUDY)
Galina Simonova, S. Mustafina, Russia
1001
436
BENEFICIAL EFFECTS OF PPARG ACTIVATION ON LIPID
METABOLISM IN LIPODYSTROPHIC BSCL2-/- MICE
X. Prieur, L. Dollet, M. Takhashi, J. Capeau, B. Feve, C. Le May, P. Costet,
J. Magrè, Bertrand Cariou, France
1009
437
MYELOPEROXIDASE, MATRIX METALLOPROTEASE-9 AND
PARAOXONASE-1 ACTIVITY IN OVERWEIGHT HYPERLIPIDEMIC
PATIENTS WITH AND WITHOUT VASCULAR COMPLICATIONS
Peter Koncsos, N. Zsíros, M. Harangi, H. Lőrincz, I. Seres, G. Paragh,
Hungary
1018
438
CORRELATION OF TRIGLYCERIDES AND TYPE OF FAT
ACCUMULATION INVESTIGATED BY COMPUTED TOMOGRAPHY IN
OBESE PATIENTS
Gabor Simonyi, M. Medvegy, R.J. Bedros, Hungary
1028
439
MORBID OBESITY IS A INDEPENDENT RISK FACTOR FOR
DEVELOPING SUBCLINICAL ATHEROSCLEROSIS?
Julio Oscar Bono, R. Del Valle, R. Chiosso, J.M. Foscarini, C. Esquivel, L.
Ahuad, E. Moreyra, Argentina
1160
440
HYPOXIA INDUCES A HIF-1ALPHA DEPENDENT SIGNALLING
CASCADE TO MAKE A COMPLEX METABOLIC SWITCH IN SGBSADIPOCYTES
Andreas Leiherer1,2, K. Geiger, S. Geller-Rhomberg, A. Mündlein1,2, H.
Drexel1,2,3, Austria, Liechtenstein
1176
441
METABOLICALLY HEALTHY OBESE INDIVIDUALS HAVE AVERAGE
SUBCLINICAL ATHEROSCLEROSIS PARAMETERS COMPARED WITH
METABOLICALLY UNHEALTHY INDIVIDUALS
Jordi Merino, R. Ferré, D. Pedrico, M. Llort, J.P. Lonzi, N. Plana, D.
Ibarretxe, L. Masana, Spain
1319
442
ASSOCIATION BETWEEN OBESITY INDICES AND SERUM LIPIDS IN
OBESE NON-DIABETIC PATIENTS
A. Stępień, M. Stępień, R.N. Wlazeł, M. Paradowski, Maciej Banach, J.
Rysz, Poland
1324
102
Poster Board No.
Abstract No
443
SERUM PHOSPHOLIPIDS AS A MARKER OF ABDOMINAL OBESITY IN
POSTMENOPAUSAL OBESE WOMEN
K. Charradi1,2, A. Trimeche, F. Ben Hassine, E. Aouani1,2, M. Sakly2,5, Nebil
Attia2,5, Tunisia
1458
444
RELATIONSHIP BETWEEN INTRAABDOMINAL FAT DISTRIBUTION,
PLASMA BIOMARKER LEVELS AND ENDOTHELIAL FUNCTION IN
HYPERCHOLESTEROLEMIC SUBJECTS
Peteris Tretjakovs, G. Krievina, I. Skuja, A. Jurka, I. Stukena, G. Bahs,
Latvia
445
1529
PLASMA APOLIPOPROTEIN B-48 TRANSPORT IN OBESE MEN: AN IN
VIVO STABLE-ISOTOPE STUDY IN POSTPRANDIAL STATE
Dick C. Chan, A.T.Y. Wong, J. Pang, G.F. Watts, P.H.R. Barrett, Australia 1633
Metabolic syndrome
446
ADIPONECTIN INHIBITS ANGIOTENSIN II-MEDIATED VASCULAR
INFLAMMATION AND ACCELERATED ATHEROSCLEROSIS
C.V. Stijn, J. Kim, D. Bacerra, U.J. Tietge, Rajendra K. Tangirala, USA,
Netherlands Antilles
1280
447
RESISTIN, AN ADIPOCYTOKINE, PROMOTES ANGIOGENESIS AND
VASCULAR PERMEABILITY
Hyun-Joung Lim, H. Kim, H.-Y. Park, M.-C. Cho, Republic of Korea
1426
448
TRIGLYCERIDE IS A PREDICTOR OF DIABETES MELLITUS
IRRESPECTIVE OF BMI IN AN 8-YEAR COHORT STUDY IN THE
JAPANESE WORKERS
Tomofumi Nishikawa, T. Okamura, A. Shima3,4, Y. Kawatsu, D. Sugiyama,
A. Kadota, A. Morimoto, Y. Tatsumi4,6, A. Morino, N. Sonoda, N. Miyamatsu,
Japan
743
449
ATHEROGENIC DYSLIPIDEMIA IN METABOLIC SYNDROME AS A
PREDICTOR OF COMPLICATIONS AFTER CORONARY ARTERY
BYPASS GRAFTING
Olesya Gritsenko1,2, G. Chumakova1,2, N. Veselovskaya2,3, E.
Vahromeeva1,3, Russia
748
450
ANTIOXIDATIVE FUNCTION OF HDL IN METABOLIC SYNDROME:
IMPACT OF A LIFESTYLE PROGRAM
Boris Hansel, A. Orsoni, S. Chantepie, R. Bittar, D. Bonnefont-Rousselot, P.
Giral, E. Bruckert, M.J. Chapman, A. Kontush, France
1407
451
ASSOCIATION OF LIPOPROTEIN SUBCLASS DISTRIBUTION WITH
METABOLIC RISK FACTORS IN JAPANESE MEN
Ryotaro Takahashi, K. Okumura, N. Taguchi, M. Suzuki, N. Ikeda, T.
Murohara, Japan
452
1604
EFFECTCS OF DERANGED GLUCOSE HOMEOSTASIS ON ARTERIAL
STIFFNESS IN PATIENTS WITH PRE-DIABETES MELLITUS
Chang-Hua Chou, J.-Y. Chen2,3, M.-C. Wang, C.-S. Ho, W.-C. Tsai, Taiwan
R.O.C.
13
103
Poster Board No.
Abstract No
453
THE EFFECT OF 25(OH)VITD ADMINISTRATION ON URINE 8ISOPROSTANE LEVELS IN PATIENTS WITH METABOLIC SYNDROME
S.E. Makariou1,2, E.N. Liberopoulos, A. Challa, K. Tellis, A. Tselepis, Moses
Elisaf, Greece
25
454
THE EFFECT OF MOLYBDENO-ENZYMES ON ATHEROSCLEROTIC
HYPERURICAEMIC PATIENTS
Ioannis E. Mamarelis, K. Pissaridi, E. Koutoulakis, V. Dritsa, C. Kotoulas, V.
Mamareli, J. Anastassopoulou, Greece
62
455
RELATIONSHIP ENDOTHELIAL DYSFUNCTION-CHRONOBIOLOGY TO
OVERWEIGHT AND OBESE PATIENTS
Teodora Gabriela Alexescu, A.V. Sitar-Taut, A. Cozma, O. Mislea, V.
Negrean, M. Motocu, Romania
163
456
IMBALANCE BETWEEN ENDOTHELIAL DAMAGE AND REPAIR IN
CHILDHOOD OBESITY: USE OF NOVEL BIOMARKERS
Luc Bruyndonckx1,2,3, H. Franckx, E. Basslé, S. van Ierssel1,2, A. Van
Craenenbroeck1,2, E. Van Craenenbroeck1,2,5, V. Hoymans1,2, C. Vrints1,2,5, D.
184
Vissers, J. Ramet, V. Conraads1,2,5, Belgium
457
METABOLIC SYNDROME AND SEVERITY OF CORONARY ARTERY
DISEASE IN WEST OF IRAN
Shila Berenjy, Iran
278
458
DECREASED HIGH DENSITY LIPOPROTEIN-INDUCED NO SYNTHESIS
IN TYPE 2 DIABETES, TYPE 1 DIABETES AND OBESITY
Laurence Duvillard1,2, S. Monier, L. Perségol, I. Robin, M.-C. Brindisi2,3, J.346
M. Petit2,3, B. Vergès2,3, France
459
THE IMPAIRED GLUCOSE REGULATION IN NON-DIABETIC SUBJECTS
IN SECONDARY PREVENTION OF CARDIOVASCULAR EVENT
Fouzia Kessal, R. Guermaz, A. Mammeri, A. Hatri, S. Taharboucht, S. Zekri,
M. Brouri, Algeria
376
460
ASSOCIATION BETWEEN PLASMA LEPTIN CONCENTRATIONS AND
DYSLIPIDEMIA IN OBESITY WITH AND WITHOUT METABOLIC
SYNDROME IN A TUNISIAN POPULATION
Fadoua Gannar, F. Marzougui, L. Khanfir, M. Sakly, N. Attia, Tunisia
424
461
PREVALENCE OF METABOLIC SYNDROME IN HAMMAM-SOUSSE
SAHLOUL HEART STUDY ACCORDING THREE DEFINITIONS
I. Boumaiza, Asma Omezzine, M. Romdhane, J. Rejeb, L. Rebhi, L.
Bouacida, S. Neffati, N. Ben Rejeb, A. Ben Abdelaziz, A. Bouslama, Tunisia 495
462
THE CHANGES IN VARIOUS HYDROXYPROLINE FRACTIONS IN
AORTIC TISSUE OF RABBITS ARE CLOSELY RELATED TO THE
PROGRESSION OF ATHEROSCLEROSIS
Mohamed Anwar K. Abdelhalim, M.M. Ghannam, Saudi Arabia
104
742
Poster Board No.
Abstract No
463
CARBOHYDRATE AND METABOLIC ABNORMALITIES IN ADULT
SURVIVORS OF YOUTH BRAIN TUMORS
Tatyana Y. Tselovalnikova, E.E. Gybernatorova, M.G. Pavlova, A.V. Zilov,
N.A. Mazerkina, A.V. Moshkin, Russia
862
464
INFLUENCE OF METABOLIC SYNDROME IN CRITICAL PATIENT
MORBIDITY
Jerusalen Villegas del Ojo, Spain
465
IMPACT OF OCCUPATIONAL FACTORS ON METABOLIC SYNDROME.
A PREVENTIVE STRATEGY FOR PRACTITIONERS?
Yolande Esquirol, V. Bongard, J.B. Ruidavets, J. Ferrieres, France
1285
466
THE RENAL RISK IN NON-DIABETIC SUBJECTS WITH METABOLIC
SYNDROM
Fouzia Kessal, R. Guermaz, S. Taharboucht, A. Hatri, F. Hamrour, N.
Teffahi, S. Zekri, M. Brouri, Algeria
467
1193
1406
THE ACCUMULATION OF RISK FACTORS OF METABOLIC SYNDROME
IS ASSOCIATED WITH THE INCREASE IN ARTERIAL STIFFNESS
AMONG MIDDLE-AGED FINNISH MALES
Janne Halonen, H. Lindholm, H. Sistonen, H. Gylling, Finland
1498
NASH and related disorders
468
CORRELATION OF HEPATIC ELASTICITY AND ARTERIAL STIFNESS IN
SUBJECTS WITH NORMAL BODY WEIGHT, OBESITY OR TYPE 2
DIABETES
Marinos Fysekidis, E. Cosson, Y. Jaber, E. Ngallhy, K. Ben Belkacem, D.
Roulot, C. Pillegand, S. Chiheb, I. Banu, P. Valensi, France
1149
469
HIGHER LEVELS OF WITHIN-NORMAL-LIMITS LIVER ENZYMES AND
THE PREVALENCE OF THE METABOLIC SYNDROME
Itzhak Shapira, A. Steinvil, O. Kliuk Ben-Bassat, M. Cohen, S. Berliner, O.
Rogowski, Israel
77
470
CONTROL OF HEPATIC GLUCONEOGENESIS THROUGH THE TUMOR
SUPPRESSOR P16INK4A
Sarah Hannou1,2,3, K. Bantubungi-Blum1,2,3, S. Caron-Houde1,2,3, E.
Vallez1,2,3, A. Lucas1,2,3, K. Wouters1,2,3, B. Staels1,2,3, A. Tailleux1,2,3, R.
192
Paumelle1,2,3, Diabetes, France
471
OBESE HUMAN SERUM STIMULATES APOLIPOPROTEIN B
OVERPRODUCTION BY HUMAN HEPATOCYTES
472
EFFECTS OF TUMOR-BEARING ON SERUM AND LIVER LIPID LEVELS
IN SATO LUNG CARCINOMA (SLC)-IMPLANTED RATS
Masashi Kawasaki, Japan
212
105
197
Poster Board No.
Abstract No
473
REDUCED EXPRESSION OF INTRACELLULAR LIPID TRANSPORTERS
ASSOCIATES WITH DYSLIPIDAEMIA AND STEATOSIS IN A RODENT
MODEL OF GENETIC OBESITY
Ugo Soffientini, S. Dolan, A. Graham, UK
430
474
ASSOCIATION OF NEUROMEDIN U WITH LIPID METABOLISM
Mika Hori, T. Mizuno, M. Harada-Shiba, Japan
540
475
SIGNIFICANT WEIGHT GAIN IN MICE EXPOSED TO THE POLLUTANT
BENZO[A]PYRENE IS ASSOCIATED WITH CHANGES IN HEPATIC
LIPOPROTEIN METABOLISM
Hamed Layeghkhavidaki1,2, M.-C. Lanhers, S. Akbar, N. Grova, B.
Appenzeller, C. Feidt, C. Corbier, F.T. Yen, France, Luxembourg
635
476
NICOTINIC ACID AMELIORATES DYSLIPIDEMIA AND PREVENTS
STEATOHEPATITIS IN MONOSODIUM GLUTAMATE-TREATED OBESE
MICE
Masumi Hara, M. Kurano, K. Tsuneyama, K. Kikuchi, A. Takai, T.
Matsushima, N. Ishizaka, K. Tsukamoto, Japan
680
477
ENDOTHELIAL DYSFUNCTION, INSULIN RESISTANCE AND OBESITY
IN MICE MODELS OF NAFLD
Edyta Maślak, A. Jasztal, B. Sitek, B. Proniewski, M. Sternak, A.
1071
Fedorowicz, T. Skórka, K. Jasiński, S. Chłopicki1,3, Poland
478
LIVER MARKERS AND METABOLIC SYNDROME-RELATED FACTORS
OVER 5 YEARS IN THE STANISLAS STUDY
Ndeye Coumba Ndiaye, B. Herbeth, G. Siest, S. Visvikis-Siest, France
1321
479
IS HOMOCYSTEINE ( HCY) A NEW MARKER OF THE
CARDIOVASCULAR RISK OF NON-ALCOHOLIC
STEATOHEPATITIS(NASH)?
Nicoleta Valentina Leach, M. Dronca, R. Tarau, R. Rusu, T. Alexescu,
Romania
1592
480
CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH
ASYMPTOMATIC NAFL
Ilze Skuja, I. Stukena, G. Krievina, A. Lejnieks, Latvia
1597
Sub inflammatory states
481
482
SUBCLINICAL HEART INVOLVEMENT IN PATIENTS WITH SYSTEMIC
SCLEROSIS
Charalampos Papagoras, K. Achenbach, N. Tsifetaki, S. Tsiouris, A.
Fotopoulos, A.A. Drosos, Greece
218
PROGRESSION OF SUBCLINICAL ATHEROSCLEROSIS OVER FIVE
YEARS IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS
Anna Södergren, K. Karp, E. Lundström, T. Smedby, B. Möller, S.
Rantapää-Dahlqvist, S. Wållberg-Jonsson, Sweden
232
106
Poster Board No.
483
Abstract No
VASCULAR INFLAMMATION MARKERS IN MEDIUM AND HIGH RISK
ACUTE CORONARY SYNDROMES
Ali Çoner, A. Aydınalp, K. Okyay, E. Özçalık, U.A. Bal, A. Yıldırır, H.
Müderrisoğlu, Turkey
347
484
POSSIBILITIES OF ENDOTELIAL DYSFUNCTION ASSESSMENT AT
WOMEN WITH RHEUMATOID ARTHRITIS BY DOPPLER LASER
FLUOMETRIA
Dmitrij Bublikov, E. Vorobjova, A. Andrienko, V. Lychov, O. Lapshataeva,
Russia
389
485
WHETHER WE CAN USE SCALE SCORE IN POPULATION OF
PATIENTS WITH RHEUMATOID ARTHRITIS
Dmitrij Bublikov, E. Vorobjova, A. Andrienko, V. Lychov, R. Vorobjov,
Russia
390
486
ORANGE JUICE AND HESPERIDIN CONSUMPTION ALTER
LEUKOCYTE GENE EXPRESSION TO AN ANTI-INFLAMMATORY AND
ANTI-ATHEROGENIC PROFILE IN HEALTHY VOLUNTEERS
Dragan Milenkovic, C. Dubray, A. Mazur, C. Morand, France
440
487
LIPID PROFILE AND INFLAMMATORY RESPONSE IN PATIENTS WITH
UNSTABLE ANGINA AFTER CORONARY STENTING: A PROSPECTIVE
STUDY
Natalia Musikhina, T. Petelina, L. Gapon, N. Dementjeva, V. Kuznetsov, A.
Takkand, Russia
539
488
CHRONIC INFLAMMATORY RHEUMATIC DISEASE INCREASES THE
RISK OF ARTERIOSCLEROSIS: CLINICAL-ULTRASOUND STUDY
Olga Malysheva, H. Barghan, K. Mühlberg, C. Klein, C. Baerwald, Germany675
489
HIGH SENSITIVITY C-REACTIVE PROTEIN LEVELS ARE ASSOCIATED
WITH TOTAL CORONARY ARTERY OCCLUSIONS
Gustavs Latkovskis1,2,3, M. Zabunova1,2, M. Berzina, D. Juhnevica, I.
750
Urtane, L. Zarakauska, A. Erglis1,2,3, Latvia
490
THE CORRELATION BETWEEN INFLAMMATORY SYNDROME AND
PRECLINICAL ATHEROSCLEROSIS IN OBESE PATIENTS
Vasile Negrean, I. Cheta, O. Mislea, T. Alexescu, Romania
855
491
IDENTIFICATION OF ESSENTIAL SIGNALING PATHWAYS IN SAAINDUCED MCP-1 PRODUCTION IN VASCULAR SMOOTH MUSCLE
CELLS
Nicole Prüfer, M. Schuchardt, T. Huang, J. Prüfer, M. Tölle, W. Zidek, M.
van der Giet, Germany
1044
492
TEMPORAL EVOLUTION OF INFLAMMATORY MARKERS AFTER BARE
METAL STENT OR DRUG-ELUTING STENT IMPLANTATION
A. Imaeva, S. Minelli, N. Cosentino, E. Falcioni, R. Antonazzo Panico, D.
Schiavino, G. Niccoli, F. Crea, Giorgia Copponi, Russia, Italy
1182
107
Poster Board No.
Abstract No
493
DIFFERENT PATTERN OF ACUTE SYSTEMIC INFLAMMATORY
RESPONSE IN YOUNG AND ELDERLY STEMI PATIENTS UNDERGOING
PRIMARY PCI
Annamaria Mazzone, N. Botto, U. Paradossi, E. Galli, A.R. De Caterina, C.
Palmieri, A. Clerico, S. Berti, A. Taddei, Italy
1245
494
INFLAMMATORY BIOMARKERS IN PATIENTS WITH TIA: CLINICAL
FEATURES AND STROKE RISK FOR PATIENTS WITH DIFFERENT TIA
SUBTYPES
1496
Olena Y. Fartushna1,2, Ukraine, UK
Diabetes macroangiopathy / Dyslipidaemia
495
LIPID PROFILE, GLUCOSE LEVEL AND WHITE BLOOD CELL
SUBTYPES IN TYPE 2 DIABETES MELLITUS PATIENTS
Nongnuch Settasatian, P. Singparu, C. Sumrit, C. Settasatian, Y.
Teerajetgul, P. Sanyanusin, Cardiovascular Research Group, Khon Kaen
University, Thailand
729
496
DIFFERENT PATTERN OF ATHEROGENIC DYSLIPIDAEMIA AMONG
NEWLY DIAGNOSED, UNTREATED PATIENTS WITH TYPE 2 DIABETES
MELLITUS
Andrej Dukat, P. Sabaka, L. Fabryova, J. Gajdosik, M. Zelina, S. Oravec,
Slovak Republic
846
497
POTENTIAL ROLE OF MITOCHONDRIAL DYSFUNCTION IN DIABETIC
HYPERTRIGLYCERIDEMIA
Sampath Parthasarathy, P. Mordhwaj, D. Litvinov, USA
1144
498
THE HYPOLIPIDEMIC EFFICACIES OF AN ESSENTIAL PHOSPHOLIPIDS
WITH METHIONINE AND ATORVASTATIN IN HYPERLIPIDEMIC
PATIENTS WITH TYPE 2 DIABETES MELLITUS
Marina Gennadievna Bubnova, D.M. Aronov, Russia
1367
499
DEFECTIVE HDL PARTICLES IN TYPE 2 DIABETES EXHIBIT AN
ALTERED LIPIDOME
L. Gomez Rosso1,2, M. Lhomme, T. Meroño, L. Camont, A. Dellepiane, P.
Robillard, S. Chantepie, A. Zerrad, F. Brites, J.M. Chapman, Anatol
Kontush, France, Argentina
1492
Diabetes macroangiopathy / Treatment
500
501
DECREASED CRP LEVELS IN RESPONSE TO A SIX-WEEK, ONCEDAILY ORAL INSULIN REGIMEN
R. Eldor, Miriam Kidron, Y. Miteva, E. Arbit, Israel, Switzerland
EFFECT OF DIPEPTIDLY PEPTIDASE-4 INHIBITOR TREATMENT ON
LEFT VENTRICULAR STIFFNESS BY TISSUE DOPPLER IMAGING IN
PATIENTS WITH TYPE 2 DIABETES
Hideto Sako, S. Miura, S. Furuyama, A. Matsunaga, K. Saku, Japan
108
47
178
Poster Board No.
502
Abstract No
EFFECT OF SITAGLIPTIN ON ENDOTHELIAL CELL FUNCTION IN
ISCHEMIC HEART DISEASE PATIENTS WITH DIABETES MELLITUS
Hitoshi Adachi, H. Takamatsu, J. Tomono, S. Oshima, Japan
401
503
INSULIN-SENSITIZING EFFECTS OF EMBELIA RIBES EXTRACT IN
HIGH FAT DIET- AND LOW DOSE STREPTOZOTOCIN-INDUCED TYPE 2
DIABETES IN WISTAR RATS
Uma Bhandari, H.S. Chaudhari, India
476
504
TREATMENT OF LINAGLIPTIN CAN ATTENUATE POSTPRANDIAL
HYPERLIPIDEMIA
Daisaku Masuda, T. Kobayashi, T. Okada, H. Nakaoka, R. Kawase, K.
Nakatani, T. Ohama1,2, M. Nishida1,2, A. Matsuyama, I. Komuro, S.
Yamashita, Japan
505
LAPAROSCOPIC SLEEVE GASTRECTOMY AND ROUX-EN-Y GASTRIC
BYPASS ARE EQUALLY EFFECTIVE IN CORRECTING INSULIN
RESISTANCE AND DIABETES
D. Benaiges, J.A. Flores Le-Roux, J.J. Chillarón, M. Renard, A. Parri, J.M.
Ramón, M. Pera, Juan Pedro-Botet, Spain
840
506
FROM THE GUIDES TO CLINICAL PRACTICE: PERCUTANEOUS
REVASCULARIZATION IN THE DIABETIC POPULATION WITH
Rocío Toro, M. Sobrino, L. Cabeza Letrán, C. Rodriguez, M.C. Durán, N.
Caro, I. Tinoco, E. Segura, A. Mangas, Spain
1307
507
ALOGLIPTIN REDUCES LOW-DENSITY LIPOPROTEIN CHOLESTEROL
IN PATIENTS TAKING STATINS
Takayoshi Nemoto, K. Kashiwase, Y. Ueda, Japan
1420
752
Diabetes macroangiopathy / Miscellaneous
508
USE OF ALPHALIPOIC ACID IN PREVENTION OF CONTRAST INDUCED
NEPHROPATHY IN DIABETIC PATIENTS
M. Cicek, A. Yildirir, Kaan Okyay, A.C. Yazici, A. Aydinalp, S. Kanyilmaz, H.
Muderrisoglu, Turkey
1552
509
CARDIO-ANKLE VASCULAR INDEX MIGHT REFLECT ENDOTHELIAL
FUNCTION IN TYPE 2 DIABETES
Kei Endo, A. Saiki, T. Yamaguchi, N. Kon, H. Imamura, H. Kawana, N. Ban,
A. Nagumo, D. Nagayama, M. Ohira, K. Shirai, I. Tatsuno, Japan
243
510
IMPAIRED ANTIOXIDANT ACTION OF HIGH DENSITY LIPOPROTEIN
FROM TYPE 1 DIABETIC PATIENTS WITH NORMOALBUMINURIA AND
MICROALBUMINURIA
E. Sampaio, D.S. Barbosa, T.L. Mazzuco, V.S. Nunes, M. Passarelli, E.
Nakandakare, Alexandre Carrilho, Brazil
317
109
Poster Board No.
Abstract No
511
NO IMPAIRED ENDOTHELIAL FUNCTION IN PATIENTS WITH DIABETES
MELLITUS ACCORDING TO A POPULATION-BASED PROPENSITY
SCORE MATCHING ANALYSIS
K. Empen, Roberto Lorbeer, H. Völzke, T. Reffelmann, S. Schipf, M. Nauck,
W. Kerner, H. Wallaschofski, S.B. Felix, M. Dörr, Germany
348
512
IS DIABETIC RETINOPATHY AN INDICATOR FOR PROGRESSIVE
ATHEROSCLEROSIS: INSIGHTS FROM A 5-YEAR OBSERVATIONAL
STUDY
Ayman El-Menyar, H. Al-Thani, A. Hussein, A. Sadek, A. Sharaf, V. Koshy,
Qatar
732
513
ICAM AND SELECTIN RECEPTOR EXPRESSION ON MONOCYTES IN
PATIENTS WITH CARDIOVASCULAR DISEASE AND DIABETIC
NEPHROPATHY
Ivan Topchii, P. Semenovykh, V. Galchinskaya, N. Yefimova, Ukraine
744
514
EARLY DIAGNOSIS OF COMPLICATED ATHEROSCLEROTIC PLAQUES
IN TYPE 2 DIABETES MELLITUS-BIOMARKERS AND IMAGING
Oana Vittos, B. Toana, F. Halici, D. Marta, A. Vittos, E. Moldoveanu,
Romania
753
515
SYNERGIC EFFECTS OF DIABETES AND HYPERTENSION IN THE
INCREASE OF PULSE WAVE VELOCITY OVER POSTER BOARD NO.
Paolo Meani, F. Cesana, C. Colombo, A. Fallanca, M. Stucchi, M. Baroni, F.
Soriano, C. Giannattasio, Italy
768
516
ATHEROSCLEROTIC PLAQUES IN SUBJECTS WITH DIABETES
BECOME SYMPTOMATIC AT A LOWER LEVEL OF INFLAMMATION
Andreas Edsfeldt, I. Goncalves1,2, H. Grufman1,2, M. Nitulescu, A.
Persson1,2, M. Nilsson1,2, C. Prehn, J. Adamski3,4,5, J. Nilsson, Sweden,
Germany
517
ROLE OF A1C IN THE POSTPARTUM SCREENING OF WOMEN WITH
GESTATIONAL DIABETES
D. Benaiges, J.J. Chillarón, J.A. Flores Le-Roux, A. Mas, J. Puig de Dou, E.
Segarra, M.J. Carrera, A. Goday, Juan Pedro-Botet, Spain
834
518
BIOCHEMICAL MARKERS OF INFLAMMATION AND
ATHEROSCLEROSIS IN PATIENTS WITH STABLE ANGINA AND
DIABETES MELLITUS OF TYPE 2
Tatiana Petelina, N. Musikhina, L. Gapon, N. Dementjeva, V. Kuznetsov, N.
Galeeva, N. Lystsova, T. Petrashevskaya, Russia
931
519
EFFECTS OF BODY WEIGHT REDUCTION ON BODY FAT AND PLASMA
LEPTIN IN OBESE PATIENTS WITH TYPE 1 DIABETES MELLITUS
Frantisek Musil, V. Blaha, A. Ticha, R. Hyspler, M. Haluzik, J. Lesna, A.
Smahelova, L. Sobotka, Czech Republic
971
520
ACUTE HEMODYNAMIC MODIFICATIONS AFTER A COLD PRESSURE
TEST IN HEALTHY SUBJECTS AND IN TYPE 2 DIABETIC PATIENTS
Marinos Fysekidis, K. Takbou, Y. Jaber, M.T. Nguyen, E. Cosson, P.
Valensi, France
1246
110
824
Poster Board No.
Abstract No
521
CLINICAL IMPACT OF FOLLOW-UP GLYCOSYLATED HEMOGLOBIN
ON CARDIOVASCULAR OUTCOMES IN DIABETIC PATIENTS WITH STSEGMENT ELEVATION MYOCARDIAL INFARCTION AFTER
SUCCESSFUL REVASCULARIZATION
J. Ahn, Taek Jong Hong, H.W. Lee, J.-H. Oh, J.H. Choi, H.C. Lee, K.S. Cha,
the Korea Working Group on Myocardial Infarction Investigators, Republic of
Korea
1320
522
PREDICTIVE VALUE OF GLYCOSYLATED HEMOGLOBIN ON
CARDIOVASCULAR OUTCOMES IN PREDIABETIC PATIENTS WITH STSEGMENT ELEVATION MYOCARDIAL INFARCTION UNDERGOING
PERCUTANEOUS CORONARY INTERVENTION
J. Ahn, Taek Jong Hong, H.W. Lee, J.-H. Oh, J.H. Choi, H.C. Lee, K.S. Cha,
the Korea Working Group on Myocardial Infarction Investigators, Republic of
Korea
1346
523
EXERCISE CAPACITY & HEART RATE VARIABILITY IN HEART
FAILURE WITH DIABETES MELLITUS
Teresita Corvera-Tindel1,2, L.V. Doering, F. Mody, USA
1429
Nephropathy
524
PROBUCOL SUPPRESSES INITIATION OF CHRONIC HEMODIALYSIS
THERAPY AND RENAL DYSFUNCTION-RELATED DEATH IN DIABETIC
NEPHROPATHY PATIENTS: SAKURA STUDY
Kei Endo, A. Saiki, T. Yamaguchi, K. Sakuma, H. Sasaki, H. Imamura, Y.
Sato, D. Nagayama, N. Ban, H. Kawana, A. Nagumo, M. Ohira, T. Murano,
S. Yamamura, K. Shirai, I. Tatsuno, Japan
239
525
HYPERHOMOCYSTEINEMIA AND THE PRESENCE OF CVD ARE
ASSOCIATED WITH KYNURENIC ACID LEVELS AND CAROTID
ATHEROSCLEROSIS IN PATIENTS UNDERGOING PERITONEAL
DIALYSIS
Dariusz Pawlak, M. Mysliwiec, K. Pawlak, Poland
479
526
A HIGHER SERUM ARSENIC LEVEL IS ASSOCIATED WITH A HIGHER
RISK FOR INCIDENT MYOCARDIAL INFARCTION IN HEMODIALYSIS
PATIENTS
Masaki Ohsawa, K. Tanno, K. Kato, Y. Fujishima, K. Itai, A. Okayama, T.
Onoda, K. Sakata, T. Fujioka, The KAREN Study, Japan
534
527
BIOCHEMICAL DISORDERS IN MILD CHRONIC RENAL IMPAIRMENT A
MODEL BUILDING APPROACH
Ljiljana Majnaric, A. Vcev, Croatia
624
528
CARDIOVASCULAR DISEASE RISK AND EVENTS IN HYPERTENSIVE
PATIENTS WITH CKD IN A RETROSPECTIVE COHORT IN A PRIMARY
CARE SETTING
944
Yook Chin Chia1,2, S.M. Ching, Malaysia, Australia
111
Poster Board No.
Abstract No
529
CONTROL OF CARDIOVASCULAR DISEASE RISK FACTORS AMONG
HYPERTENSIVE PATIENTS WITH OR WITHOUT CHRONIC KIDNEY
DISEASE IN PRIMARY CARE SETTING
1034
SiewMooi Ching, Y.C. Chia2,3, Malaysia, Australia
530
THE ENDOTHELIAL PROTECTIVE EFFECTS OF HIGH DENSITY
LIPOPROTEIN IS DIMINISHED USING HDL FROM PATIENTS WITH
CHRONIC RENAL FAILURE
Mirjam Schuchardt, N. Prüfer, S. Chebli, S. Schmid, L. Klöckl, M. Tölle, W.
Zidek, M. van der Giet, Germany
1045
531
THE 9P21 ALLELE AND CHRONIC ALLOGRAFT NEPHROPATHY
Jan Kvasnicka, J. Hajkova, Z. Krska, O. Viklicky, T. Kvasnicka, P.
Bobcikova, Czech Republic
1166
532
THE CLOPIDOGREL HYPO-RESPONSIVENESS RATE IN CHRONIC
KIDNEY DISEASE SUBJECTS
Ping-Yen Liu, L.-J. Hsu, Taiwan R.O.C.
1198
533
URINE ALBUMIN CREATININE RATIO COULD PREDICT CORONARY
HEART DISEASE RISK IN REAL WORLD KOREAN POPULATIONS
Seung Pyo Hong, Y.W. Park, S.W. Jeon, K.R. Bae, Y.S. Lee, J.B. Lee, J.K.
Ryu, J.Y. Choi, K.S. Kim, S.G. Chang, Republic of Korea
1222
534
LOW HDL CHOLESTEROL IS AN INDEPENDENT PREDICTOR OF
CHRONIC KIDNEY DISEASE PROGRESSION
Andrea Baragetti1,2, G.D. Norata1,2, C. Sarcina, F. Rastelli, L. Grigore, F.
Pellegatta, K. Garlaschelli, P. Uboldi, I. Baragetti, C. Pozzi, A.L. Catapano 1,4,
Italy
1434
535
ANDROID/GYNOID RATIO IS A MARKER OF VISCERAL ADIPOSITY IN
CHRONIC KIDNEY DISEASE
Andrea Baragetti1,2, K. Garlaschelli, C. Sarcina, L. Grigore, F. Pellegatta, C.
1437
Tidone, G.D. Norata1,2, I. Baragetti, C. Pozzi, A.L. Catapano1,4, Italy
536
PROGRESS OF STENOSIS IN ARTERIOVENOUS GRAFT FOR
HEMODIALYSIS
Young Ho Choi, H.-H. Kim, S.-H. Suh, Republic of Korea
1478
Thrombosis
537
ARTEFACTUAL ELEVATION OF PLASMA SOLUBLE CD40 LIGAND BY
RESIDUAL PLATELETS IN CARDIOVASCULAR DISEASE
Regent Lee, A.S. Antonopoulos, Z. Alexopoulou, M. Margaritis, R.K.
Kharbanda, R.P. Choudhury, C. Antoniades, K.M. Channon, UK
133
538
MEAN PLATELET VOLUME DECREASES AFTER EXTRACORPOREAL
LDL-CHOLESTEROL ELIMINATION
M. Blaha, M. Kostal, Vladimir Blaha, M. Lanska, S. Filip, P. Zak, Czech
Republic
112
88
Poster Board No.
539
540
Abstract No
VARYING EFFECTS OF DIFFERENT TYPES OF HEMODYNAMIC
FORCES ON TISSUE FACTOR (TF) EXPRESSION IN ENDOTHELIAL
CELLS (EC)
Bauer Sumpio, USA
226
PARTICIPATION OF THROMBOXANE A2 IN SEROTONIN AND
BRADYKININ EFFECTS ON RAT COMMON CAROTID AND FEMORAL
ARTERY
Marko Stojanović, M. Radenković, N. Skorupan, M. Prostran, Serbia
387
541
MACROPHAGES AND PLATELETS ARE THE MAJOR SOURCE OF THE
FACTOR SEVEN ACTIVATING PROTEASE IN HUMAN
ATHEROSCLEROTIC PLAQUES: IMPLICATIONS FOR
ATHEROTHROMBOSIS
Michael Worsch, M. Grebe, S. Kanse, B. Parviz, H. Tillmanns, H.
Hoelschermann, M. Parahuleva, Germany
568
542
IMAGING MURINE ATHEROTHROMBOSIS: VALIDATION OF SCANNING
ELECTRONY MICROSCOPY (SEM) FOR ASSESSING PLAQUE
RUPTURE IN MICE
A.-L. Charles, P. Tilly, S. Ludwig, A. Sayeh, P. Choquet, Jean-Etienne
Fabre, France
685
543
PREVALENCE OF DRUG-DRUG INTERACTION IN THE PRIMARY
HEALTH CARE DURING CLOPIDOGREL THERAPY
Inga Urtane, K. Pukite, A. Aitullina, A.S. Stokmane, Latvia
544
THE HOMEOSTATIC CHEMOKINE CCL21 PREDICTS MORTALITY IN
AORTIC STENOSIS PATIENTS AND IS NECESSARY FOR
DEVELOPMENT OF COMPENSATORY CONCENTRIC HYPERTROPHY
Trine Ranheim, A.V. Finsen1,2, T. Ueland, I. Sjåstad2,3, E.T. Askevold1,2, M.
Lipp, L. Gullestad1,2, G. Christensen2,3, P. Aukrust1,2, A. Yndestad1,2, Norway,
Germany
1189
545
A DOUBLE-BLIND RANDOMIZED PLACEBO PILOT STUDY
COMPARING AGGRENOX VERSUS PLACEBO IN HEART FAILURE
PATIENTS (ASAP-HF TRIAL)
Ping-Yen Liu, L.-M. Tsai, C.-H. Lee, J.K. Liao, J.-H. Chen, Taiwan R.O.C.,
USA
1199
546
DIFFERENTIAL RELATIONSHIPS BETWEEN CYSTEIN AND
HOMOCYSTEIN WITH HEMOSTASIS FACTORS IN DYSLIPIDEMIC
PATIENTS
Philippe Giral, D. Rosenbaum, N. Jacob, A. Carrié, X. Girerd, A. Ankri,
France
1298
INTERRELATIONSHIPS BETWEEN CARDIAC DYSFUNCTION,
ACTIVATED COAGULATION SYSTEM, PLATELET HYPERACTIVITY
AND ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH STABLE
CORONARY ARTERY DISEASE
Severina V. Golovach, I.V. Golovach, Belarus
1314
547
113
852
Poster Board No.
Abstract No
548
INTRINSIC PLATELET REACTIVITY AND THROMBUS BURDEN IN
PATIENTS WITH ST-ELEVATION MYOCARDIAL INFARCTION
Ioanna Xanthopoulou, G. Tsigkas, A. Damelou, K.C. Theodoropoulos, G.
Makris, V. Gizas, G. Kassimis, P. Davlouros, G. Hahalis, D. Alexopoulos,
Greece
1439
549
TICAGRELOR VS PRASUGREL ON THE CORONARY BLOOD FLOW
VELOCITY IN PATIENTS WITH ACUTE CORONARY SYNDROME
UNDERGOING PCI
Ioanna Xanthopoulou, N. Koutsogiannis, A. Moulias, A. Kakkavas, E.
Mavronasiou, P. Davlouros, G. Hahalis, D. Alexopoulos, Greece
550
ΕFFECTS OF TICAGRELOR ON PLATELET-MEDIATED THROMBOSIS
AND INFLAMMATORY RESPONSE IN PATIENTS WITH ACUTE
CORONARY SYNDROMES
Maria Tsoumani, P. Tatsidou, I. Ntalas, K. Kalantzi, I. Goudevenos, A.
Tselepis, Greece
1445
551
CIRCULATING MICRORNAS AS NOVEL BIOMARKERS FOR PLATELET
ACTIVATION
Anna Zampetaki, P. Willeit, K. Dudek, D. Kaudewitz, A. King, N.S. Kirkby,
H.S. Markus, T.D. Warner, S. Kiechl, M. Mayr, UK, Austria
1588
1441
Aneurysms
552
INTRACELLULAR CYCLOPHILIN A IN HUMAN ABDOMINAL AORTIC
ANEURYSM IS INFLUENCED BY SIMVASTATIN
A. Piechota-Polanczyk, S. Denyanets, M. Mittlboeck, C. Domenig, C.
Neumayer, J. Wojta, J. Nanobachvili, M. Klinger, O. Nykonenko, Ihor Huk,
Austria, Ukraine
236
553
554
ABDOMINAL AORTIC ANEURYSMS AND CORONARY ARTERY
DISEASE: A RETROSPECTIVE POPULATION-BASED STUDY
Hassan Al-Thani, A. El-Menyar, A. Tabib, M. AlSulaiti, A. Almalki, Qatar
ANGIOGENESIS IN HUMAN THORACIC AORTIC ANEURYSMS
Ketty Kessler, R. Vranckx, J.-B. Michel, France
736
1084
Arteriopathy
555
556
557
EFFECTS OF PERIPHERAL ARTERY COMPLIANCE ON EXERCISE
CAPACITY IN ELDERLY MALES
Wei-Chuan Tsai, C.-H. Chou, J.-Y. Chen, M.-C. Wang, C.-S. Ho, P.-Y. Liu,
L.-M. Tsai, C.-H. Wu, Taiwan R.O.C.
81
A CASE OF PSEUDO-XANTHOMA ELASTICUM PRESENTING WITH
ISCHAEMIC CLAUDICATION
Christopher Lamb, R. Johns, P. Gallagher, A. Odurny, C. Shearman, UK
804
THE COST OF TREATING END STAGE ATHEROSCLEROTIC LOWER
LIMB DISEASE IN THE NORTH WEST OF ENGLAND
Colin Chan, G. Harrison, G. Lawrence, UK
889
114
Poster Board No.
Abstract No
558
PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY (PTA) IN
PERIPHERAL ARTERY DISEASE: RESULTS OF A 5 YEARS FOLLOW
UP STUDY
Alessandro Cavarape, A. Da Porto, M.L. Casagrande, D. Gasparini, L.A.
Sechi, Italy
1355
559
PERIPHERAL ARTERIAL DISEASE RISK FACTORS IN RELATIONS TO
NEW BIOMARKERS OF INFLAMMATION AND ANGIOGENESIS
Sonja Perkov, M.M. Kardum Paro, V. Vidjak, Z. Flegar-Meštrić, Croatia
1447
560
FLOATING THROMBUS IN THE DESCENDING THORACIC AORTA A
RARE CAUSE OF SYSTEMIC THROMBOEMBOLIZATION
Hassan Al-Thani, A. El-Menyar, Qatar
561
ATHEROSCLEROSIS IN TAKAYASU'S ARTERITIS
Ahmed Hatri, F. Kessal, S. Taharboucht, A. Mameri, F. Hamrour, R.
Guermaz, S. Zekri, M. Brouri, Algeria
1601
157
Lifestyle and CV risk / Exercise
562
SHORT-TERM EXERCISE TRAINING CHANGES TRIGLYCERIDES
MOLECULAR CONTENT OF THE LDL AND HDL PARTICLES
AFFECTING THEIR FUNCTIONAL CHARACTERISTICS IN METABOLIC
SYNDROME
A. Casella-Filho, I.C. Trombetta, P.M. Dourado, Antonio Carlos de Leite Jr,
M.C. Sprandel, A. Segre, R.D. Santos, C.E. Negrao, R.C. Maranhao, A.C.P.
Chagas, Brazil
34
563
RELATIONSHIPS BETWEEN HDL FUNCTIONAL CHARACTERISTICS
AND ENDOTHELIAL VASCULAR FUNCTION AFTER SHORT-TERM
EXERCISE TRAINING IN PATIENTS WITH THE METABOLIC SYNDROME
A. Casella-Filho, I. Trombeta, P.M. Dourado, Antonio Carlos de Leite Jr, V.
Jonke, A. Segre, R.D. Santos, C.E. Negrao, R.C. Maranhao, A.C.P. Chagas,
Brazil
35
564
OVARIECTOMY IN RATS IS ASSOCIATED WITH A REDUCTION OF
HEPATIC LDLR, LRP1 AND PCSK9 GENE EXPRESSION; IMPACT OF
EXERCISE TRAINING
Emilienne Tudor Ngo Sock, J.-M. Lavoie, Canada
452
THE EXERCISE HAS DIFFERENT EFFECTS ON COLLAGEN AND
ELASTIC FIBERS OF THE AORTA IN NORMAL AND LDL KNOCKOUT
MENOPAUSED ANIMALS
C. Marchon, Ledimar Brianezi1,2, L. Maifrino3,4, R. Souza, Brazil
711
EFFECTS OF EXERCISES ON THE RIGHT VENTRICLE OF FEMALE
MICE SUBMITTED TO OVARIAN HORMONE DEPRIVATION
Ledimar Brianezi1,2, K. Ressureição2,3, L. Maifrino2,4, Brazil
713
565
566
567
INFLUENCE OF SHORT-TERM EXERCISE ON THE SIZE OF
LIPOPROTEIN PARTICLES AMONG YOUNG HEALTHY SEDENTARY
MALES
Peter Sabaka, S. Oravec, J. Gajdosik, M. Zelina, A. Dukat, Slovak Republic 757
115
Poster Board No.
Abstract No
568
COMPARED OUTCOME IN PATIENTS POST ACUTE CORONARY
SYNDROME WITH VERSUS WITHOUT CARDIAC REHABILITATION
FOLLOWING THE EVENT
Eliezer Klainman, D. Mossinson, R. Cohen, L. Valinsky, A. Yarmolovsky, G.
Fink, Israel
781
569
EFFECTS OF CARDIAC REHABILITATION ON ENDOTHELIAL
FUNCTION IN PATIENTS WITH CORONARY ARTERY DISEASE
Marta Nogueira, T. Silva, A. Abreu, N. Santos, P. Rio, C. Fundinho, S. Silva,
R. Ferreira, Portugal
791
570
DO LEISURE POSTER BOARD NO. PHYSICAL ACTIVITY AND
SEDENTARY BEHAVIOR AFFECT CARDIOVASCULAR RISK FACTORS
ONLY WEAKLY?
Gerda-Maria Haas, T. Bertsch, E. Liepold, P. Schwandt, Germany
811
571
DAILY PHYSICAL ACTIVITY RELATED TO COMPOSITE RISK FACTOR
SCORE FOR CVD IN CHILDREN
Magnus Dencker, T. Tahna, O. Thorsson, M.K. Karlsson, P. Wollmer, L.B.
Andersen, Sweden, Denmark
194
572
VISCERAL OBESITY, LIFESTYLE AND PHYSICAL ACTIVITY LEVELS OF
BRAZILIANS: TRYING TO CHANGE THE TENDENCY
Marcia Braz Rossetti, A.M. Girodo, C.C. Jardim, G.M. Diniz, Brazil
849
573
THE EFFECT OF CHRONIC SUPERVISED PHYSICAL TRAINING ON
INFLAMMATORY PARAMETERS IN PERIPHERAL BLOOD IN
PREHYPERTENSIVE SUBJECTS
Magdalena Filip, J. Głodzik, T. Mikołajczyk, A. Sałakowski, K. Rewiuk, T.
Grodzicki, T. Guzik, Poland
876
EXERCISE MEDIATES SELECTED MICRORNA EXPRESSION AND
PROMOTES PLAQUE REGRESSION
Mahdi Garelnabi, J. Jin, H. Mahini, F. Chai, USA
913
574
575
THE INFLUENCE OF GLYCEMIC CONTROL AND INSULIN RESISTANCE
ON EXERCISE CAPACITY IN PATIENTS WITH CORONARY ARTERY
DISEASE AND TYPE 2-DIABETES
Rune Byrkjeland1,2, E. Edvardsen3,4, I. Unhammer Njerve1,2, M. Aulie, L.A.
1065
Toftegaard, H. Arnesen1,2, I. Seljeflot1,2, S. Solheim1,2, Norway
576
THE ROLE OF TRANSPORTATION ACTIVITY IN IMPROVEMENT OF
HEALTHY LIFESTYLE IN THE POPULATION OF MEDICINE STUDENTS
Dariusz Kalka1,2, Z.A. Domagala, L. Rusiecki, M. Syrycki, P. Koleda, T.
Sebzda, L. Kipinski, A. Bielolus - Wilk, T. Szawrowicz-Pelka, W. Pilecki,
Poland
1565
577
INFLUENCE OF LEISURE POSTER BOARD NO. PHYSICAL ACTIVITY
ON FITNESS OF ELDERY PATIENS
Dariusz Kalka1,2, Z.A. Domagala, L. Rusiecki, A. Rakowska, J.
Wojcieszczyk, W. Marciniak, A. Skalska, K. Womperski, W. Pilecki, Poland 1578
116
Poster Board No.
Abstract No
Lifestyle and CV risk / Miscellaneous
578
ACUTE CORONARY SYNDROME IN COCAINE USERS. ALWAYS
VASOSPASM? THE IMPORTANCE OF CARDIOVASCULAR RISK
FACTORS
María Thiscal López Lluva, E. Marchan Carranza, M.D. Mañas García, M.
Marina Breysse, C. Llanos Guerrero, N. Pinilla Echeverri, J. Piqueras Flores,
M.C. Espinosa González, J.M. Arizón Muñoz, L. Ruiz-Valdepeñas Herrero,
Spain
637
579
SLEEP DISTURBANCES AND 16 YEARS RISK OF STROKE AND
BEHAVIORAL HABITS IN FEMALE POPULATION AGED 25-64 YEARS IN
RUSSIA
Valery Gafarov1,2, D. Panov1,2, E. Gromova1,2, I. Gagulin1,2, A. Gafarova1,2,
Russia
720
580
"EATING HABITS AND LIFE STYLE OF THE UNIVERSITARY STUDENTS
OF THE SCHOOL OF NURSING"
Hazel Ester Anderson Vasquez, C. Wanden-Berghe, E.C. Garrido
Zambrano, I.C. Pernalete Bustos, E. Rivera Bernardoni, Venezuela, Spain 794
Lifestyle and CV risk / Tobacco
581
LIPOPROTEINS FROM YOUNG SMOKERS WITH MODERATE EXTENT
CAUSED MORE CELLULAR SENESCENCE AND EXHIBITED MORE
ATHEROGENIC PROPERTIES
242
Ki-Hoon Park1,2, D.-G. Shin2,3, J.-R. Kim, K.-H. Cho1,2, Republic of Korea
582
FUNCTIONAL IN VITRO CHARACTERIZATION OF SASH1 GENE
LINKING SMOKING TO ATHEROSCLEROSIS
Henri Weidmann, C. Proust, R. Verdugo, D. Stengel, T. Zeller, S.
Blankenberg, L. Tiret, F. Cambien, E. Ninio, France, Germany
383
583
COMPARISON OF THE RESULTS OF EXERCISE TESTING IN SMOKERS
AND NON-SMOKERS PATIENTS
Haydeh Hashemizadeh, Iran
545
584
ESTIMATION OF SMOKING CESSATION BENEFITS ON
CARDIOVASCULAR RISK VIA LIPIDOMICS AND TRANSCRIPTOMICS
ANALYSIS OF APOE-/- MICE LIVER
Stephanie Boue, H. de Leon, S. Lebrun, M.C. Peitsch, J. Hoeng,
Switzerland
602
Lifestyle and CV risk / Therapeutic education
585
THE IMPORTANCE OF THERAPEUTIC EDUCATION IN PRIMARY
PREVENTION FOR REDUCING SOME RISK FACTORS OF
ATHEROSCLEROSIS
Marc Baudet, C. Daugareil, S. Caspar Bauguil, France
117
683
Poster Board No.
586
Abstract No
PATIENT COMPLIANCE IMPROVES LDL-CHOLESTEROL GOAL
ATTAINMENT IN THE HUNGARIAN MULTI GAP 2012 STUDY
Laszlo Mark, I. Reiber, G. Paragh, I. Karadi, G. Pados, I. Mező, Z. Kiss,
Hungary
874
587
IMPROVING DRUG ADHERENCE IS CORRELATED WITH BETTER LIPID
LOWERING EFFICACY IN HUNGARIAN MULTI GAP 2010-2012 STUDIES
Zoltán Kiss, I. Reiber, I. Mező, I. Karadi, G. Paragh, G. Pados, L. Mark,
Hungary
954
588
EFFECTS OF GROUP EDUCATION FOR SECONDARY PREVENTION TO
PATIENTS WITH ACUTE MYOCARDIAL INFARCTION BY MEDICAL
TEAM IN CARDIAC REHABILITATION
Chiharu Noda, T. Masuda, M. Kawano, Y. Ebina, A. Igarashi, K. Kamiya, N.
Hamazaki, N. Aoyama, S. Niwano, Japan
1233
Lifestyle and CV risk / Psychosocial factors
589
ANXIETY IN PATIENTS WITH METABOLIC SYNDROME BEFORE AND
AFTER CORONARY ARTERY BYPASS SURGERY
Galina Chumakova1,2, Y. Chugunova, N. Veselovskaya2,3, Russia
809
590
EFFECTS OF EMOTIONAL AND PHYSIOLOGICAL STRESS ON PLAQUE
INSTABILITY IN APOLIPOPROTEIN E KNOCKOUT MICE
Tao Zhang, H.B. Liu, Y.Z. Zhai, China
963
591
IMPACT OF ANXIETY AND DEPRESSION ON BIOCHEMICAL BLOOD
PARAMETERS IN GENERAL LITHUANIAN POPULATION
Dovilė Karčiauskaitė, A. Mažeikienė, N. Burokienė, Z.A. Kučinskienė,
Lithuania
1137
Nutrition and CV risk / Alcohol
592
VINEATROL AND CARDIOVASCULAR DISEASE: BENEFICIAL EFFECTS
OF A VINE-SHOOT PHENOLIC EXTRACT IN A HAMSTER
ATHEROSCLEROSIS MODEL
Cindy Romain, S. Gaillet, J. Vidé, J. Carillon, J. Ramos, J.-C. Izard, J.-P.
Cristol, J.-M. Rouanet, France
260
593
RED WINE EXTRACT OF ONION ON THE PREVENTION AND
IMPROVEMENT OF CARDIOVASCULAR DISEASES-A HUMAN
CLINICAL TRIAL
Chin-Kun Wang, Taiwan R.O.C.
1425
Nutrition and CV risk / Antioxidants
594
NUTRIGENOMICS REVEALS A COMMON MECHANISM OF ACTION OF
DIETARY POLYPHENOLS UNDERLYING THEIR ANTI-ATHEROGENIC
PROPERTIES
C. Morand, A. Mazur, Dragan Milenkovic, France
441
595
EFFECTS OF ONE-YEAR CONSUMPTION OF LUTEIN-ENRICHED EGG
YOLKS ON SERUM LIPID AND LIPOPROTEIN CONCENTRATIONS
Sanne M. van der Made, T.T.J.M. Berendschot, J. Plat, The Netherlands 556
118
Poster Board No.
Abstract No
596
PREVENTIVE EFFECTS OF LYCOPENE AGAINST CARDIOVASCULAR
DISEASES IN HIGH DOSE METHIONINE FEED RATS
Aicha Yefsah1,2, K. Othmani, R. Taghlit, N. Hamdis, Y. Benazzoug, Algeria 1394
597
RESVERATROL WINE POLYPHENOL RELAXES RAT RENAL ARTERY
IN DIABETIC RAT: THE ROLE OF SMOOTH MUSCLE VOLTAGESENSITIVE POTASSIUM CHANNELS
L. Gojkovic-Bukarica, J. Markovic-Lipkovski, S. Cirovic, R. Novakovic, H.
Heinle, Vladmiri Kanjuh, Serbia, Germany
1620
Nutrition and CV risk / Carbohydrates/fibres
598
HIGH-DENSITY LIPOPROTEINS MODIFIED BY ARTIFICIAL
SWEETENER, ASPARTAME AND SACCHARIN EXHIBIT LOSS OF ANTIATHEROSCLEROTIC ACTIVITY WITH EMBRYONIC TOXICITY
294
J.-M. Baek1,2, J.-Y. Kim1,2, Kyung-Hyun Cho1,2, Republic of Korea
599
IMPAIRED METABOLISM AND WORSENING OF ATHEROSCLEROTIC
LESIONS OBSERVED AFTER COLA BEVERAGES´ DRINKING IN APO-E
(-/-) MICE
M. Otero-Losada, S. Mc Loughlin, G. Rodríguez-Granillo, A. Muller, G.
Ottaviano, Juan C. Cutrin1,2, J. Milei, Argentina, Italy
1132
600
EFFECT OF CHIOS MASTIC GUM ADMINISTRATION ON LIPID AND
GLUCOSE METABOLISM IN STREPTOZOTOCIN-INDUCED DIABETIC
MICE
I. Georgiadis, T. Karatzas, G. Agrogiannis, Laskarina-Maria Korou, I.S.
Vlachos, I. Tzanetakou, I. Doulamis, A. Pantopoulou, N.L. Katsilambros 1,3,
D.N. Perrea, Greece
1555
Nutrition and CV risk / Fatty acids
601
CIRCULATING BIOMARKERS AND LIPID CLASSES INDICATIVE OF
CARDIOVASCULAR RISK: EFFECTS OF DAIRY FOOD CONSUMPTION
Paul Nestel, K. Croft, P. Meikle, T. Mori, Cardiovascular Nutrition, Australia 258
602
EFFECTS OF OLIVE OIL AND CANOLA OIL ON THE LIPID PROFILE IN
POSTMENOPAUSAL WOMEN
Hazel Ester Anderson Vasquez, P. Perez Martinez, J. Changarotti, I.
Fernandez, Y. Hernandez, Venezuela, Spain
771
603
SESAME OIL AND ITS ROLE IN OXIDATION OF ISOLATED LOWDENSITY LIPOPROTEINS AND OF TOTAL SERUM LIPOPROTEINS IN
VITRO
K. Makedou, S. Iliadis, M. Gogou, E. Kara, Areti Makedou, G.
Papageorgiou, Greece
604
TOTAL SERUM AND HDL-PHOSPHOLIPIDS ARE ASSOCIATED TO
DIETARY MONOUNSATURATED FATTY ACIDS IN CAD PATIENTS
FROM BIZERTA AREA, TUNISIA
Y. Nekaies, A. Ben Khalfallah, H. Aoua, K. Charradi, M. Sakly, Nebil Attia,
Tunisia
1103
119
803
Poster Board No.
605
Abstract No
IMPACT OF SERUM TRANS FATTY ACID LEVEL IN RISKS OF
CORONARY ARTERY DISEASE IN JAPAN
Kenta Mori, T. Ishida, N. Tanaka, T. Mori, T. Monguchi, M. Sasaki, K.
Kondo, M. Hasokawa, H. Nakajima, Y. Haraguchi, L. Sun, T. Yasuda, M.
Shinohara, R. Toh, K.-I. Hirata, Japan
1138
Nutrition and CV risk / Miscellaneous
606
607
A DIET-INDUCED ATHEROSCLEROSIS IN RABBIT MODEL PROVIDES
AN INSIGHT INTO ESSENTIAL ELEMENTS CONCENTRATIONS IN
Adeniran Sanmi Adekunle, T. Adelusi, J.O. Fatoki, B. Oyedokun, Nigeria
EFFECTS OF HYPERCHOLESTEROLEMIA ON TRACE ELEMENTS
LEVELS IN RABBIT TISSUES USING ATOMIC ABSORPTION
SPECTROSCOPY
Magdy Mohammed Ghannam, M.A.K. Abdelhalim, Medical Biophysics,
Saudi Arabia
64
703
608
INCREASED COFFEE CONSUMPTION IS ASSOCIATED WITH HIGHER
LIKELIHOOD OF ACUTE CORONARY SYNDROME AND ISCHEMIC
STROKE NON-FATAL EVENTS: A CASE/CASE-CONTROL STUDY
Christina-Maria Kastorini, H.J. Milionis, D. Kantas, V. Euthimiou, E. Trichia,
A. Litsardopoulou, V. Nikolaou, K.N. Vemmos, J.A. Goudevenos, D.B.
Panagiotakos, Greece
745
609
SPIRULINA PLATENSIS AND PHYCOCYANOBILIN MODULATE THE
ATHEROPROTECTIVE ENZYME HEME OXYGENASE (HMOX1)
Zbynek Strasky, L. Zemankova, I. Nemeckova, J. Pfeiferova, L. Muchova, I.
785
Subhanova, J. Vanikova, L. Vitek2,3, P. Nachtigal, Czech Republic
610
THE POTENTIAL OF LUPIN PROTEIN TO EXERT
ANTIATHEROSCLEROTIC EFFECTS
Melanie Bähr, A. Fechner, G. Jahreis, Germany
990
611
BIFIDOBACTERIUM SUPPLEMENTATION: EFFECTS ON PLASMA LIPID
PROFILE IN DYSLIPIDEMIC CHILDREN
Francesca Abello, P. Cagliero, O. Guardamagna, Italy
1030
612
EFFECT OF GRAPE SEED AND SKIN EXTRACT ON HIGH-FAT DIETINDUCED RENAL LIPOTOXICITY IN RAT
K. Charradi, Nebil Attia2,3, F. Limam, E. Aouani1,3, Tunisia
613
WATER INTAKE AND LDL CHOLESTEROL
Ronan Roussel1,2, O. Lantieri, B. Balkau, M. Marre, The D.E.S.I.R. Study
Group, France
1479
614
EFFECTS OF FENUGREEK AND SAPONINS ON THE BIOMARKERS OF
INFLAMMATION AND ENDOTHELIAL ACTIVATION IN STIMULATED
HUMAN CORONARY ARTERY ENDOTHELIAL CELLS
Radzi Ahmad1,2, T. Rahman, G.R.A. Froemming, H. Nawawi, Malaysia
1530
120
1452
Poster Board No.
Abstract No
615
GRAPE SEED AND SKIN EXTRACT MODULATES LIPASE ACTIVITY IN
WISTAR RATS FED A HIGH-FAT DIET
1547
K. Charradi1,2, Nebil Attia2,3, F. Limam, E. Aouani2,5, Tunisia
616
CHARACTERISATION OF ATHEROSCLEROSIS LESIONS IN
APOE/LDLR-/- MICE FED LOW CARBOHYDRATE, HIGH PROTEIN DIET
(LCHP)
R.B. Kostogrys, Magdalena Franczyk-Zarow, E. Maslak, I. Czyzynska, A.
Drahun, A. Jasztal, B. Sitek, L. Mateuszuk, M. Gajda, S. Chlopicki, Poland 1153
617
CHARACTERIZATION OF PROTEIN PROFILES RELATED TO DIET AND
EXERCISE AS MOLECULAR SIGNATURES OF VASCULAR WELLNESS
M.C. Duran, R. Toro, J. Alonso, Carmen Rodriguez Leal, I. Tinoco, M.L.
Cabeza-Letran, D. Corrales, N. Caro, E. Segura, A. Mangas, Spain
1303
618
CASE CONTROL STUDY OF THE EFFECT OF A NUTRITIONAL
STRATEGY «GOURMET NUTRITION» ON THE COMPLIANCE TO
CARDIOVASCULAR LIFESTYLES RECOMMENDATIONS
Francois Allaert, F. Paillard, T. Coutureau, France
285
EVOLUTION OF CARDIOVASCULAR LIFESTYLE BEHAVIOURS AND
LIPID PARAMETERS OCCURRING IN HYPERCHOLESTEROLEMIC
PATIENTS CONCOMITANTLY TO THE INTAKE OF PHYTOSTEROLSUPPLEMENTED YOGHURT
E. Bruckert, L. Massama, O. Descamps, E. Bosi, Francois Allaert, M.J.
Chapman, France, Spain, Belgium, Italy
937
619
Omega-3 fatty acids
620
CALORIC RESTRICTION AND POSTPRANDIAL STRESS MARKERS IN
HEALTHY AND OBESE PERSONS UNDER SUPPLEMENTATION WITH
N-3 POLYUNSATURATED FATTY ACIDS (PUFA)
Malgorzata Malczewska Malec, D. Siedlecka, J.S. Mozwillo, B.K. Wilk, M.
Malecki, A.D. Kiec, Poland
108
621
BENEFICIAL CARDIOVASCULAR EFFECTS OF FLAXSEED
SUPPLEMENTATION IN STZ- DIABETIC RATS
Nilay Tarhan, Y. Fidan, C. Tufan, B. Konuklugil, N. Arı, G. Ozansoy, Turkey 380
622
ASSOCIATION OF SERUM OMEGA-3 TO OMEGA-6
POLYUNSATURATED FATTY ACID RATIO WITH MICROALBUMINURIA
IN A POPULATION OF COMMUNITY-DWELLING JAPANESE
A. Fukami, Hisashi Adachi, Y. Hirai, M. Enomoto, A. Obuchi, A. Yoshimura,
T. Imaizumi, Japan
406
623
ASSOCIATION BETWEEN SERUM N-3/N-6 POLYUNSATURATED FATTY
ACID RATIO AND CORONARY AND AORTIC PLAQUE INSTABILITY
Yukihiko Momiyama, R. Ohmori, R. Kato, H. Taniguchi, F. Ohsuzu, Japan 497
121
Poster Board No.
Abstract No
624
OMEGA 3 FATTY ACIDS REDUCE CARDIOVASCULAR RISK BY
IMPROVING THE METABOLISMS OF SPHINGOLIPIDS AND
TRIGLYCERIDES IN VLDL
Veronique Ferchaud Roucher, C. Nael, A. Aguesse, M. Krempf, K.
Ouguerram, France
625
OMEGA-3 FATTY ACID DECREASES BOTH SYSTEMIC INFLAMMATION
OF RETICULO-ENDOTHELIAL SYSTEM AND INFLAMMATION AT
VASCULAR PLAQUE
Sungeun Kim, H.S. Seo, E.J. Kim, J.H. Na, J.H. Park, C.-G. Park, C.U.
Choi, H.E. Lim, J.W. Kim, S.-W. Rha, D.J. Oh, Republic of Korea
690
626
THE PARADOX OF OMEGA 3 PUFAS: ATHEROPROTECTIVE
ALTHOUGH HIGHLY SUSCEPTIBLE TO PEROXIDATION
Cecile Gladine, M. Zmojdzian, J. Newman, T. Durand, L. JoumardCubizolles, M.-A. Verny, J.-M. Galano, C. Demougeot, O. Berdeaux, E.
Pujos-Guillot, A. Mazur, B. Comte, France, USA
627
MARINE OIL EXTRACTED FROM THE COPEPODE CALANUS
FINMARCHICUS REDUCES AORTA ATHEROSCLEROSIS IN FEMALE
APOLIPOPROTEIN E-DEFICIENT MICE
Karl-Erik Eilertsen, H.K. Mæhre, I.-J. Jensen, H. Devold, E.O. Elvevoll, B.
Østerud, Norway
1446
628
DOCOSAHEXAENOIC ACID SUPPLEMENTATION IN APOLIPOPROTEINE DEFICIENT MICE EXPOSED TO INTERMITTENT HYPOXIA: EFFECT
ON ATHEROGENESIS PREVENTION
Laetitia Van Noolen1,2,3, M. Bäck, C. Arnaud, A. Rey, M.H. Petrii, P. Levy1,3,
1457
P. Faure1,2,3, F. Stanke-Labesque1,2,3, France, Sweden
629
DIETARY ENRICHMENT WITH MARINE OIL AND TAURINE REDUCE
HEPATIC EXPRESSION OF PROINFLAMMATORY GENES WITHOUT
AFFECTING ATHEROSCLEROSIS IN APOLIPOPROTEIN E-DEFICIENT
MICE
Ida Johanne Jensen, H. Mæhre, H. Devold, E. Elvevoll, B. Østerud, K.-E.
Eilertsen, Norway
1490
630
INCREASE IN THE SERUM LEVEL OF EICOSAPENTAENOIC ACID IS
ASSOCIATED WITH THE STABILIZATION OF CORONARY
VULNERABLE PLAQUE
Takayoshi Nemoto, A. Hirata, Y. Ueda, Japan
1560
631
YOUNGER PATIENTS WITH STABLE CORONARY ARTERY DISEASE
HAVE LOWER RATIO OF SERUM EICOSAPENTAENOIC ACID TO
ARACHIDONIC ACID
Takayoshi Nemoto, M. Nishio, Y. Ueda, Japan
1563
122
601
1438
Poster Board No.
Abstract No
Phytosterols
632
CARDIOVASCULAR PROFILE OF CONSUMERS OF A PHYTOSTEROLENRICHED YOGURT IN A REAL-LIFE SETTING: A FRENCH
OBSERVATIONAL TRANSVERSAL STUDY
J. Dallongeville, F. Paillard, Eric Bruckert, G. Naelten, P. Picard, E. Van
Ganse, France
604
634
GENETIC BASIS FOR HETEROGENEITY OF RESPONSE OF LDL
CHOLESTEROL TO PLANT STEROLS
Dylan Stapenhorst MacKay, D. Baer, P. Eck, P.J. Jones1,3, Canada, USA 1645
Treatment / Miscellaneous
635
RESVERATROL PROMOTES EXPRESSIONS OF SIRT1 AND LPL TO
INHIBIT TG ACCUMULATION IN DIFFERENTIATED 3T3-L1
PREADIPOCYTES
Haruki Imamura, T. Yamaguchi, Y. Sato, N. Ban, H. Kawana, D. Nagayama,
A. Nagumo, M. Ohira, K. Endo, A. Saiki, N. Ishihara, F. Watanabe, K. Shirai,
I. Tatsuno, Japan
653
636
IN VIVO PHARMACOLOGICAL ACTIVITY OF NOVEL 5-FLUORO-N-(9,10DIHYDRO-9,10-DIOXOANTHRACEN-8-YL)-1H-INDOLE-2-CARBOXAMIDE
DERIVATIVES ON PLASMA LIPID PROFILE OF TRITON-WR-1339INDUCED WISTAR RATS
Ghassan Shattat, T. Al-Qirim, G. Abu Sheikha, Y. Alhiari, K. Sweidan, R.
Alqirim, Jordan
86
637
ATHEROPROTECTION OF ANTI-LDL(-) SCFV CONJUGATED TO
NANOPARTICLES IN EXPERIMENTAL ATHEROSCLEROSIS
Marcela Frota Cavalcante, S.M. Kazuma, A.R. Pohlmann, S.S. Guterres,
E.A. Bender, M.D. Adorne, D.S.P. Abdalla, Brazil
150
PROBUCOL AND CILOSTAZOL EXERT A SYNERGISTIC ANTIATHEROGENIC EFFECT IN CHOLESTEROL-FED RABBITS
Enqi Liu, Y. Chen, S. Zhao, J. Fan, China, Japan
171
638
639
CSL112, A NOVEL FORMULATION OF HUMAN APOLIPOPROTEIN A-I,
IN HEALTHY SUBJECTS ENHANCES CHOLESTEROL EFFLUX
CAPACITY AND MOBILIZES CHOLESTEROL FROM TISSUES
Andreas Gille, R. Easton, S.D. Wright, C.L. Shear, Australia, USA
330
640
EFFECT OF MYRICETIN TREATMENT ON LIPOPROTEIN METABOLISM
IN 13-HODE EXPOSED HEPG2 CELLS
Mahdi Garelnabi, H. Mahini, USA
535
641
ADD-ON EFFECT OF PROBUCOL IN ATHEROSCLEROTIC,
CHOLESTEROL-FED RABBITS TREATED WITH ATORVASTATIN
Y. Keyamura1,2, C. Nagano, M. Kohashi, M. Niimi, M. Nozako, T. Koyama, R.
Okutsu, A. Fukuda, K. Mitani, H. Itabe, Tomohiro Yoshikawa, Japan
536
123
Poster Board No.
Abstract No
642
THE BOTANICAL PRODUCT XUEZHIKANG (XZK): ITS EFFICACY AND
SAFETY FOR LIPID-LOWERING THERAPY WHEN COMPARED TO
PLACEBO
Patrick M. Moriarty, Z. Duan, S. Guo, P. Liu, Y. Zhang, S. Li, WPU-201
Study Group, USA, China
630
643
EDARAVONE ATTENUATES ANGIOTENSIN II-INDUCED
ATHEROSCLEROSIS AND ABDOMINAL AORTIC ANEURYSMS IN
APOLIPOPROTEIN E DEFICIENT MICE
Haruhito Adam Uchida, H. Uchida, R. Umebayasi, K. Shikata, H. Makino,
Japan
1290
644
THE IMPACT OF STRATEGIC UK NATIONAL HEALTH SERVICE (NHS)
FUNDING ON THE PATIENT RECRUITMENT
TO“ATHEROTHROMBOSIS” RESEARCH STUDIES
Alistair S. Hall, D.E. Newby, C.P. Gale, R.G. Gillott, S. Scarlett, S.M. Wood,
J.D. Gower, B. Williams, M.J. Caulfield, UK NHS Atherothrombosis Research
Network, UK
1338
645
THE IMPACT OF COORDINATED NATIONAL SYSTEMS TO AID
PATIENT RECRUITMENT AND FOLLOW-UP IN “ATHEROTHROMBOSIS”
RESEARCH: THE EMMACE-3 STUDY
Christopher P. Gale, R.G. Gillott, R. Khatib, J.H. Barth, C. Forrest, R.E.
Maindonald, K.L. Willan, P.D. Batin, S. Scarlett, S.J. Howell, D. Lawson, J.D.
Gower, D.E. Newby, B. Williams, M.J. Caulfield, A.S. Hall, the UK NHS
Atherothrombosis Research Network, UK
1349
646
AMP-ACTIVATED PROTEIN KINASE ACTIVATION BY XANTHOHUMOL
AMELIORATES ATHEROSCLEROTIC PLAQUE FORMATION,
HYPERCHOLESTEROLEMIA AND HEPATIC STEATOSIS IN APOEDEFICIENT MICE
Branislav Radovic, P. Doddapattar, J.V. Patankar, S. Obrowsky, K. Jandl,
C. Nusshold, D. Kolb, N. Vujic, M. Goeritzer, H. Ahammer, G. Hoefler, W.
Sattler, D. Kratky, Austria
1463
647
ANTIBODIES AGAINST OXIDIZED BUT NOT NATIVE CARDIOLIPIN AND
PHOSPHATIDYLSERINE AS NOVEL PROTECTION MARKERS IN
ATHEROSCLEROSIS DEVELOPMENT
A. Frostegård, U. de Faire, Johan Frostegård, Sweden
1599
Treatment / Blood pressure treatment
648
HIGH-DOSE ARB VERSUS ARB PLUS CCB COMBINATION THERAPY
FOR SUPPRESSING CAROTID ATHEROSCLEROSIS IN HYPERTENSIVE
PATIENTS WITH HYPERCHOLESTEROLEMIA
Yasunori Sawayama, Japan
49
649
COMPARISON OF THE EFFECT OF M - AND N-CHOLINOBLOCKERS
AND VAGOTOMY ON PHYSICOCHEMICAL PROPERTIES OF
LIPOPROTEINS IN RAT BLOOD PLASMA
Nina Solomonovna Parfenova, A.S. Kuznetsov, Russia
124
87
Poster Board No.
650
Abstract No
EFFECTS OF ALISKIREN ON BLOOD PRESSURE, RENAL AND
CARDIAC FUNCTION, BAPWV AND CAROTID ARTERIAL ELASTIC
MODULUS IN HYPERTENSIVE PATIENTS
Toshio Yamagishi, K. Omata, H. Hasegawa, H. Kanai, Japan
299
651
EXTENDED RELEASE NIACIN LOWERS IN VITRO HDL OXIDIZABILITY
AND MEDIATORS OF VASCULAR INFLAMMATION IN STATIN TREATED
DYSLIPIDEMIC PATIENTS
R. Yadav, Y. Liu, S. Kwok, V. Charlton-Menys, M. France, R. Eatough, S.
Hama, N. Younis, B.J. Ammori, B. Issa, Handrean Soran, UK
1098
652
EFFECT OF ALISKIREN ON (PRO)RENIN RECEPTOR EXPRESSION
AND ACTIVITY IN CULTURED SMOOTH MUSCLE CELLS
Nicola Ferri, F. Panariti, G. Maiocchi, A. Corsini, Italy
653
LONG TERM EFFECT OF SPECIFIC TREATMENT OF PRIMARY
ALDOSTERONISM ON CAROTID INTIMA MEDIA THICKNESS
Robert Holaj, J. Rosa, T. Zelinka, B. Strauch, O. Petrak, D. Michalsky, K.
Novak, J. Widimsky, Czech Republic
1596
1255
654
SUSTAINED PHARMACOLOGIC PRECONDITIONING OF THE CONDUIT
ARTERY WITH SILDENAFIL: A HUMAN IN VIVO STUDY
K. McLaughlin, A. Liuni, John David Parker, Canada
906
655
LOW LEVEL LASER THERAPY PROTECT INFLAMMATION-INDUCED
ENDOTHELIALDYSFUNCTION
Yu-Jung Cheng, Taiwan R.O.C.
570
656
PREDICTORS OF THE ADVERSE OUTCOMES AFTER CORONARY
STENTING
Galina Chumakova1,2, N. Veselovskaya2,3, V. Elikomov1,3, O. Gritsenko1,2,
Russia
741
657
THE FEASIBILITY OF ENDOVASCULAR AORTIC BIOPSY DURING
ENDOVASCULAR INTERVENTIONS
Michał Stanisić, W. Majewski, J. Kulesza, P. Majewski, A. Marszałek, A.
Zarzecka, G. Oszkinis, Poland
766
658
PSEUDOANEURYSM OF THE ASCENDING AORTA FOLLOWING RIGHT
CORONARY STENTING
Jose Rubio Alvarez, J. Sierra Quiroga, B. Adrio Nazar, J. Garcia Carro, L.
Reija Lopez, A. Gandara, C. Rubio Taboada, Spain
22
659
NONINVASIVE IDENTIFICATION OF LEFT MAIN CORONARY
RESTENOSIS
Milana Zabunova, I. Mintale, I. Narbute, S. Jegere, I. Zakke, A. Erglis, Latvia 32
660
NON-INVASIVE FOLLOW-UP - A KEY POINT FOR PATIENTS AFTER
LEFT MAIN PERCUTANEOUS CORONARY INTERVENTION
I. Mintale, Milana Zabunova, I. Narbute, S. Jegere, I. Zakke, A. Erglis, Latvia 33
125
Poster Board No.
Abstract No
Miscellaneous
665
APOA-I DEPLETION AND ATHEROSCLEROSIS IN APOE-KO MICE: THE
RIGHT WAY TOWARDS A MURINE MODEL OF OCCLUSIVE CORONARY
ARTERY DISEASE?
G. Ganzetti, Marco Busnelli, C. Parolini, S. Manzini, F. Dellera, C.R. Sirtori,
G. Chiesa, Italy
1507
666
CURCUMIN MODULATION OF ATHEROSCLEROSIS AND
HEPATOSTEATOSIS IN LDLR-/- MICE
Mohsen Meydani, S.T. Hasan, J.-M. Zingg, P. Kwan, D. Smith, USA
916
667
ASPIRIN RESISTANCE OCCURS ALSO IN YOUNG HEALTHY MEN AND
IS ASSOCIATED WITH PREACTIVATION OF PLATELETS
Agnieszka Janus1,2, P. Ilnicka1,2, M. Jakubowski, E. Szahidewicz-Krupska1,2,
188
A. Szuba1,2, A. Doroszko1,2, Poland
668
ENDOTHELIAL DYSFUNCTION IN YOUNG HEALTHY MEN IS
ASSOCIATED WITH ASPIRIN RESISTANCE
Adrian Doroszko1,2, M. Jakubowski, A. Janus1,2, P. Ilnicka1,2, E.
Szahidewicz-Krupska1,2, A. Szuba1,2, Poland
1156
669
ENDOTHELIAL DYSFUNCTION AND ASPIRIN RESISTANCE IN YOUNG
HEALTHY MEN IS RELATED TO INCREASED ACTIVITY OF THE
RENNIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
A. Doroszko1,2, P. Ilnicka1,2, A. Janus1,2, Maciej Jakubowski, E.
Szahidewicz-Krupska1,2, A. Szuba1,2, Poland
187
670
DO LOW HDL CHOLESTEROL LEVELS PREDICT DIABETES MELLITUS
ONSET?
Alp Burak Catakoglu, V. Aytekin, E. Usta, M.G. Ercan, H. Kurtoglu, M.
Sener, H. Celebi, S. Aytekin, Turkey
707
671
CARDIOVASCULAR RISK PROFILE OF PATIENTS WITH
SPONDYLOARTHRITIS
Charalampos Papagoras, T.E. Markatseli, P. Margariti, A.K. Zikou, Y.
Alamanos, A.A. Drosos, Greece
672
RELATIONSHIP BETWEEN CETP AND CHOLESTEROL EFFLUX
Raja Chaaba, S. Mehri, N. Attia, S. Hammami, M. Smaoui, K. Ben Hamda,
A. Nakbi, N. Koubaa, M. Hammami, Tunisia
1173
673
CAROTID ATHEROSCLEROSIS IN ASYMPTOMATIC NEWLY
DIAGNOSED TYPE 2 DIABETIC SUBJECTS
Marta Catalan, Z. Herreras, M. Pinyol, A. Sala, R. Gilabert, E. Ortega, Spain998
674
PANORAMIC RADIOGRAPHY AND COLOR DOPPLER IN THE
DIAGNOSIS OF CALCIFIED CAROTID ATHEROMATOUS PLAQUES
T.Q. Abreu, Sebastião Barreto De Brito Filho, K.P.F.d. Sales, E.B.
Ferreira, A.E.F.D. Oliveira, Brazil
126
217
113
Poster Board No.
674
Abstract No
PANORAMIC RADIOGRAPHY AND COLOR DOPPLER IN THE
DIAGNOSIS OF CALCIFIED CAROTID ATHEROMATOUS PLAQUES
T.Q. Abreu, Sebastião Barreto De Brito Filho, K.P.F.d. Sales, E.B.
Ferreira, A.E.F.D. Oliveira, Brazil
113
675
FETUIN-A AND CARDIOVASCULAR MORBIDITY AND MORTALITY IN
PATIENTS WITH PERIPHERAL VASCULAR DISEASE IN NON-DIALYSED
PATIENTS
Zoltan Szeberin, M. Fehérvári, M. Krepuska, A. Apor, H. Sarkadi, L. Entz, B.
Merkely, Hungary
82
676
MULTIPLE RISK FACTORS AND CAROTID ATHEROSCLEROSIS IN
JAPANESE IN THE PRIME OF LIFE
Wakoh Takahashi, T. Uesugi, T. Ohnuki, S. Takizawa, Japan
677
BIOMARKERS OF ATHEROSCLEROTIC PLAQUES INSTABILITY AND
THEIR RELATION WITH LONG-TERM RESULTS OF SURGICAL
MYOCARDIAL REVASCULARIZATION
Yulia Ragino, A. Chernyavskiy, S. Tcimbal, L. Scherbakova, Y. Polonskaya,
M. Voevoda, Russia
468
678
INTRA-FAMILIAL ASSOCIATIONS OF CARDIOVASCULAR RISK
FACTORS IN 515 HEALTHY FAMILIES - THE PEP FAMILY HEART
STUDY 2007
Peter Schwandt, T. Bertsch, E. Liepold, G.-M. Haas, Germany
334
806
679
"LIFESTYLE AND HABITS FOOD OF STUDENTS NEW INCOME THE
SCHOOL OF NUTRITION AND DIETETICS"
Hazel Ester Anderson Vasquez, C. Wanden-Berghe, D.C. Araujo Castillo,
E.R. Labrador Aldana, K.D. Rodríguez Ortega, Venezuela, Spain
799
680
THE ROLE OF DRUGS WITH REDUCING EFFECTS ON OXIDATIVE
STRESS, PLATELETS HYPERACTIVITY AND ENDOTHELIAL
DYSFUNCTION IN CORONARY ARTERY DISEASE
Alexandru Covaciu, E. Bobescu1,2, N. Aldulea, Romania
1158
DEVELOPMENT OF NEW RAC1 INHIBITORS AS POTENTIAL
PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF
ATHEROSCLEROSIS
Sergio Kevin Bernini, A. Contini, A. Corsini, N. Ferri, Italy
1256
682
683
APO C-III CORRELATES WITH ARTERIAL STIFFNESS IN PATIENTS
WITH CLINICAL DIAGNOSIS OF FAMILIAL HYPERCHOLESTEROLEMIA
(FH)
Małgorzata Waluś-Miarka, B. Idzior-Waluś, D. Czarnecka, M. Sanak, P.
Miarka, W. Wojciechowska, M. Kloch-Badełek, M.T. Małecki, E.
Woźniakiewicz, J. Starzyk, Poland
724
127
Poster Board No.
Abstract No
684
LECITHIN CHOLESTEROL ACYLTRANSFERASE RS 5922 AND RS5923
SINGLE-NUCLEOTIDE POLYMORPHISMS AND INSULIN RESISTANCE:
A BRAZILIAN POPULATION STUDY
Eliane Soler Parra, N.B. Panzoldo, V.S. Nunes, J. Metso, M. Jauhiainen,
V.H.S. Zago, D.Z. Scherrer, F. Alexandre, E.R. Nakandakare, E.C.R.
Quintão, E.C. de Faria, Brazil, Finland
1649
685
PATIENT DETERMINANTS OF HYPERCHOLESTEROLEMIA
UNDERTREATMENT IN CENTRALIZED PAN-RUSSIAN SURVEY ON THE
UNDERTREATMENT OF HYPERCHOLESTEROLEMIA (CEPHEUS)
Yunona Khomitskaya. Eliane Soler Parra, Sergey Boytsov, Moscow,
Russia
838
686
INFLAMMATORY RESPONSE MODIFICATION AFTER CARDIAC
RESYNCHRONIZATION IN HEART FAILURE PATIENTS-PRELIMINARY
RESULTS
Ana Abreu, M. Mota Carmo, T. Pinheiro, H. Santa Clara, M. Selas, P.
Cunha, M. Oliveira, M. Nogueira Siva, R. Ferreira, Lisbon, Portugal
1382
687
MARKEDLY INCREASED FREQUENCY OF UNDETECTED PERIPHERAL
ARTERIAL DISEASE IN THE ELDERLY WITH DEMENTIA
Ilker Tasci, U. Safer, I., Naharci, E. Bozoglu, M. Gezer, O. Demir, H. Doruk,
Ankara, Turkey
823
128
INDEX
Arteriosclerosis, Thrombosis,
and Vascular Biology
The forum for publication of basic, translational, clinical, and population research in the
area of arteriosclerosis, thrombosis, and vascular biology
Download the iPad
app for a print-like,
full-text experience
Read and search
with ease on your Internetenabled smartphone
editOR-in-chief
Alan Daugherty, PhD, DSc, FAHA
atvb.ahajournals.org
A subscription includes access to ATVB online and on your iPad®.
Submit Your Manuscript
Join the aha*
http://atvb-submit.aha-journals.org
Call: 1-800-787-8984 (United States)
+1-301-223-2307 (Rest of World)
Visit my.americanheart.org/membership
6.368
With an Impact Factor of 6.368, ATVB ranks 3rd
among 68 journals in Peripheral Vascular Disease
and 7th among 68 journals in Hematology subject
categories. It is the #1 journal dedicated to the
study of atherosclerosis and thrombosis in relation
to vascular biology.
2011 Journal Citation Reports® (Thomson Reuters, 2012)
Rapid Online publicatiOn Within 5 tO 10 daYS Of acceptance
Subscribe†
Call: 1-800-638-3030 (United States)
+44 (0) 20 7981 0525 (Europe)
+1-301-223-2300 (Rest of World)
Visit http://lww.com/atvb
Premium Professional Plus Members receive full access to all 11 AHA journals online and for their iPad as a benefit of membership. Premium Professional, Early Career, and Student/Trainee Members have
limited access to journals and features as indicated by their selected level. Full-access options are available for each level of membership when you join. To have access to the iPad edition, Members with
online journal benefits must indicate ATVB as one of their online selections.
*
†
Non-member individual and resident subscriptions are ordered via LWW. Institutional print subscriptions are ordered via LWW, and institutional online access is available via Ovid. Visit www.ovid.com or
contact your Ovid Sales Representative directly.
Apple and iPad are trademarks of Apple Inc., registered in the U. S. and other countries. App Store is a service mark of Apple Inc.
L
Agianniotis, A. .................................... 60
Agouridis, A.D. ................................... 76
Agrawal, D.K. ..........................43, 51, 60
Agrogiannis, G. ................................ 119
Aguesse, A. ...................................... 122
Aguirre, A.C........................................ 85
Ahammer, H. .................................... 124
Aherrahrou, Z. .................................... 68
Ahimastos, A.A. ................................. 44
Ahluwalia, A. ...................................... 65
Ahmad, R.......................................... 120
Ahn, J. ............................................... 111
Ahn, T.H. ...............................89, 95, 102
Ahnmark, A. ....................................... 35
Ahotupa, M. ........................................ 69
Ahuad, L. .................................... 96, 102
Äijänen, T. .......................................... 70
Aittokallio, T........................................ 22
Aitullina, A. ....................................... 113
Aizpuru, N........................................... 80
Akao, H. .............................................. 45
Akbar, N. ............................................. 64
Akbar, S. ........................................... 106
Akhter, T. ............................................ 93
Akimoto, K. ......................................... 58
Akulich, N.V........................................ 77
Aladinsky, V. ...................................... 70
Alamanos, Y. .................................... 126
Alavi, A. ............................................... 45
Albayrak, G. ....................................... 60
Alberici, L.C. ....................................... 90
Albertini, J.-P...................................... 75
Albizem, M.......................................... 44
Aldulea, N. .................................. 92, 127
Alekseeva, G.V. ................................. 99
Alexandra, G. ..................................... 79
Alexandre, F. .........................71, 78, 128
Alexescu, T. ............................. 106, 107
Alexescu, T.G. ................................. 104
Alexopoulos, D................................. 114
Alexopoulou, Z. ................................ 112
Alfakry, H. ........................................... 61
Alhiari, Y. .......................................... 123
Ali, H.................................................... 11
A
Aalkjær, C. ............................................ 8
Abbate, R. ..................................... 70, 95
Abdalla, D.S.P. ................................. 123
Abdelhalim, M.A.K. .................. 104, 120
Abdeli, L. ............................................. 11
Abdelkadhem, H. ............................... 65
Abdollahi, M. ........................... 45, 49, 50
Abdul, Rahman, T.H. ............. 58, 66, 72
Abdulhannan, P. ................................ 94
Abedpour, Dehkordi, A. ..................... 70
Abello, F. ..................................... 81, 120
Abifadel, M. ................................... 26, 50
Abot, A........................................... 29, 37
Abreu, A. ..................................... 53, 116
Abreu, T.Q. ............................... 126, 127
Abt, M. ................................................. 77
Abu, Sheikha, G. .............................. 123
Achenbach, K. .................................. 106
Achenbach, S. .................................... 68
Acin, F. .................................... 65, 68, 94
Acín, García, F. ................................ 100
Ackermans, M. ................................... 36
Acosta, E. ............................................ 38
Acuña-Alonzo, V. ............................... 99
Adachi, H. ........................... 35, 109, 121
Adamkova, V. ..................................... 99
Adamova, I.......................................... 86
Adamski, J. ................................. 75, 110
Adekunle, A.S................................... 120
Adelusi, T. ......................................... 120
Adlanmerini, M. .................................. 37
Adorne, M.D. .................................... 123
Adorni, M.P. ........................................ 71
Adrio, Nazar, B. .......................... 88, 125
Adzhiev, R. ......................................... 86
Aerts, H. .............................................. 55
Afanasieva, O. .............................. 86, 87
Afonso, M. ........................................... 30
Afonso, P. ........................................... 83
Agakov, F. ........................................... 36
Aggeli, C.............................................. 38
129
Al-Jenabi, A. ....................................... 65
Alla, F. ................................................. 32
Allaert, F. ........................................... 121
Allemand, H. ....................................... 32
Allemandou, D. ................................... 77
Almalki, A. ......................................... 114
Almoudi, M. ......................................... 98
Alonso, J. .................................... 57, 121
Alonso, L. ............................................ 80
Alqirim, R. ......................................... 123
Al-Qirim, T. ........................................ 123
Alsac, J.-M. ......................................... 38
AlSulaiti, M. ....................................... 114
Altay, S. ............................................... 94
Altendorf, R. ........................................ 68
Al-Thani, H. ....................... 110, 114, 115
Altwegg, L.A. ...................................... 47
Alvarez, E............................................ 57
Alvarez, I. ............................................ 38
Alvarez-León, E.................................. 99
Alves, A.C. .......................................... 81
Alves, R. .............................................. 90
Alves, T. .............................................. 53
Amadio, P. .......................................... 34
Amar, M. .............................................. 22
Amaral, J.B. ........................................ 85
Amarenco, P. .......................... 34, 56, 57
Amati, G. ............................................. 99
Ametamey, S.M.................................. 98
Amigó, N. ............................................ 36
Aminpour, S. ....................................... 39
Ammori, B.J. ............................... 72, 125
Amouyel, P. ........................................ 54
Amstutz, C. ......................................... 17
Anagnostopoulos, A. ......................... 82
Anagnostopoulou, K. ......................... 84
Anastassopoulou, J. .................. 97, 104
Andersen, L.B................................... 116
Andersen, M.R. .................................... 8
Anderson, L. ....................................... 56
Anderson, Vasquez, H.E. 117, 119, 127
Andia, M.E. ......................................... 58
André, P. ............................................. 66
Andréasson, A.-C. ............................. 35
Andres-Lacueva, C. ........................... 33
Andrienko, A. ................................... 107
Angelico, F. ........................................ 84
Angelin, B. ...............................39, 76, 83
Anghel, M. .......................................... 91
Ankri, A. ............................................ 113
Annema, W. ................................. 49, 72
Anniballi, G. ........................................ 43
Annuzzi, G. ......................................... 43
Antlanger, M. ...................................... 49
Antonazzo, Panico, R. .................... 107
Antoniades, C. ................................. 112
Antoniadis, A.P. ........................... 29, 55
Antonopoulos, A.S. ......................... 112
Antunes, R.......................................... 11
Aoua, H. ...................................... 79, 119
Aouani, E. ..........................103, 120, 121
Aouichat, Bouguerra, S. ................... 74
Aoyama, N.................................. 56, 118
Apor, A. ............................................. 127
Appenzeller, B. ................................ 106
Arai, T. ................................................ 62
Araujo, Castillo, D.C........................ 127
Araujo, D.B. .................................. 76, 96
Araújo, H.A. ........................................ 62
Arbit, E. ............................................. 108
Arca, M. ............................. 10, 15, 31, 84
Arca, Marcello ...................................... 6
Arciello, M. .......................................... 16
Arefieva, T. ......................................... 47
Arens, R. ....................................... 41, 47
Arfian, N.............................................. 11
Arı, N. ................................................ 121
Arizón, Muñoz, J.M. ........................ 117
Arnaboldi, L. ................................. 33, 62
Arnal, J.-F. ...............................29, 37, 49
Arnal, M. ............................................. 74
Arnaud, C. .................................. 64, 122
Arnesen, H. ................................ 55, 116
Aronov, D.M. .................................... 108
Arós, F. ............................................... 35
Arregui, M. .......................................... 32
Artemeva, N. ...................................... 87
Arteta, D. ............................................ 80
Arun, M. .............................................. 60
Arun, M.Z. ........................................... 59
130
Asciutto, G. ......................................... 75
Asehnoune, K. .................................... 76
Ashikhmin, Y....................................... 39
Askevold, E.T. .................................. 113
Astola, N.............................................. 63
Asztalos, B. ......................................... 22
Attia, N...79, 85, 103, 104, 119, 120, 121,
126
Aubert, J.-F. ........................................ 17
Auclair, M. ................................... 83, 100
Audigier, Y. ......................................... 59
Auerbach, B. ....................................... 22
Aujard, F.............................................. 64
Aukrust, P. ...................... 65, 80, 86, 113
Aulie, M. ............................................ 116
Auriac, A.............................................. 52
Averna, M. ............................... 23, 51, 86
Averna, M.R. ....................................... 81
Averna, Maurizio ................................ 16
Avgeri, S.............................................. 95
Ayabe, M. ............................................ 54
Ayari, H........................................ 63, 101
Aydinalp, A........................................ 109
Aydınalp, A. ................................ 89, 107
Aytekin, S. ......................................... 126
Aytekin, V. ......................................... 126
Ayyobi, A. ............................................ 40
Azahri, N.S.................................... 37, 38
Baetta, R............................................. 94
Bagdonaite, L. .................................... 79
Bagheri, B........................................... 66
Bähr, M. ............................................ 120
Bahs, G. ............................................ 103
Bajraktari, G. ................................ 98, 99
Bakker, S.J.L...................................... 49
Bakker-Arkema, R. ............................ 22
Bal, U.A....................................... 89, 107
Balachonova, N. ................................ 88
Balakhonova, T. ................................. 91
Baldi, S. ........................................ 20, 35
Baleanu-Curaj, A. .............................. 45
Balkau, B. ......................................... 120
Balla, G. .............................................. 29
Balla, J. ............................................... 29
Ballantyne, C.M. ............................ 9, 44
Ballantyne, Christie ............................. 9
Balsano, C. ......................................... 16
Ban, N. ......................... 31, 109, 111, 123
Banach, M. ...................... 45, 49, 50, 102
Bandemer, J. ...................................... 70
Bantubungi, K. ................................... 28
Bantubungi-Blum, K. ....................... 105
Banu, I............................................... 105
Banzetti, G.......................................... 86
Baptista, J........................................... 91
Baragetti, A. ..........................67, 68, 112
Baragetti, I. ....................................... 112
Baratta, F. ........................................... 84
Barbieri, S.S. ...................................... 34
Barbieri, V........................................... 96
Barbosa, D.S.................................... 109
Barbosa, S.A. ..................................... 43
Barbosa, S.P. ..................................... 85
Barešić, M. ......................................... 82
Bargalló, N.......................................... 26
Barghan, H. ...................................... 107
Barlera, S.......................................... 100
Barlow, C.K. ....................................... 30
Baroni, M. ......................................... 110
Barrett, P.H.R. ........................... 22, 103
Barrett-Connor, E. ............................... 7
Barrios, E. ......................................... 101
Barrot, S. .................................... 63, 101
B
Babjakova, E. ..................................... 99
Bacerra, D. ........................................ 103
Bach, K. ............................................... 95
Bäck, M. ................................ 64, 66, 122
Bäcklund, A......................................... 63
Backteman, K. .............................. 66, 67
Badimon, L............................................ 6
Bae, J. ........................................... 38, 59
Bae, J.U. ............................................. 59
Bae, K.R. ........................................... 112
Baek, J.-M. ........................................ 119
Baer, D. ............................................. 123
Baertschi, A.J. .................................... 59
Baerwald, C. ..................................... 107
131
Barter, P. ......................................... 4, 13
Barter, P.J. .......................................... 27
Barth, J.H. ......................................... 124
Bartrés-Faz, D. ................................... 26
Basha, N. ............................................ 72
Baskar, K. ........................................... 60
Basslé, E. .......................................... 104
Bast, A. ................................................ 74
Basta, G. ............................................. 59
Batin, P.D. ......................................... 124
Baud, S................................................ 61
Baudet, M. ......................................... 117
Baum, C. ....................................... 44, 87
Baumgartner, S. ................................. 74
Bays, H. ............................................... 44
Bays, H.E. ........................................... 86
Beck, K. ............................................... 98
Beck-Nielsen, H. ................................ 50
Becquer, M.A. ..................................... 38
Bedford, D. .................................... 31, 76
Bednarek, M. ...................................... 73
Bedros, R.J. ...................................... 102
Beghin, L. .............................................. 7
Bégu-Le, Corroller, A....................... 101
Behrendt, M. ....................................... 10
Behrensen, M. .................................... 68
Bekers, O. ........................................... 74
Bekir, A. ......................................... 31, 76
Belch, J.J.F. ........................................ 64
Beleslin, B. .......................................... 98
Belgacem, O. ...................................... 76
Belhabib, M. .................................. 31, 76
Béliard, S. ........................................... 81
Bellibas, S.E. ...................................... 73
Belloc, I................................................ 28
Belomestnov, P. ................................. 87
Bełtowski, J. ........................................ 41
Ben, Abdelaziz, A. ............... 83, 92, 104
Ben, Belkacem, K. ........................... 105
Ben, Hamda, K. .................... 76, 85, 126
Ben, Hassine, F................................ 103
Ben, Khalfallah, A. ..................... 79, 119
Ben, Rejeb, N. ...................... 83, 92, 104
Benaiges, D. ............................. 109, 110
Benazzoug, Y. .................................. 119
Bencová, S. ........................................ 94
Bender, E.A. ..................................... 123
Benetos, G. ........................................ 38
Benghozi, R........................................ 77
Bengrid, T. .......................................... 97
Benlian, P. .......................................... 80
Benn, M. .............................. 7, 32, 40, 54
Bennia, S. ........................................... 60
Bensadoun, A. ................................... 10
Beraia, E. ............................................ 56
Beraia, M. ........................................... 56
Berbée, J. ........................................... 65
Berbée, J.F.P. .................................... 68
Berdeaux, O. .................................... 122
Berendschot, T.T.J.M. .................... 118
Berenjy, S. ........................................ 104
Berenson, G.S. .............................. 7, 32
Berezin, A.E. ...................................... 56
Berge, E. ............................................. 52
Berge, K.E. ......................................... 50
Berge, R.K. ......................................... 86
Berger, J.M. .......................................... 6
Bergström, G...................................... 53
Berguete, S. ....................................... 79
Berliner, S......................................... 105
Bermudez, G. ..................................... 40
Bernardi, F.......................................... 60
Bernaschi, M. ..................................... 99
Bernini, F. ........................................... 71
Bernini, S.K. ..................................... 127
Berrougui, H. ...................................... 42
Berthet, B.......................................... 101
Berti, S. ..................................61, 93, 108
Bertolami, A.................................. 76, 96
Bertolami, M.C. ............................ 76, 96
Bertolotto, M. ...................................... 47
Bertoncelli, A. ..................................... 64
Bertoni, S. ........................................... 68
Bertsch, T. .........................116, 127, 128
Berzina, M. ....................................... 107
Besseling, J. ................................. 26, 51
Betriu, À. ............................................. 54
Bevilacqua, S. .................................... 93
Beygui, F. ............................................. 8
Beylot, M. ............................................ 74
132
Bhandari, U. ...................................... 109
Bianchi, G. .......................................... 93
Bianchini, F.J. ..................................... 93
Bianco, H.T. ................................ 85, 101
Bieghs, V. ................................ 16, 22, 71
Bielolus, -, Wilk, A. ........................... 116
Bilcikova, E. ........................................ 87
Billon, C. .............................................. 69
Billon-Gales, A. .................................. 29
Billotte, S. ............................................ 87
Binder, C. ............................................ 21
Binder, C.J. ......................................... 41
Binder, Christoph ............................... 21
Bisoendial, R.J. .................................. 27
Bispo, D.L. .................................... 71, 72
Bisserier, M. ........................................ 37
Bisson, M. ........................................... 99
Bitsis, T................................................ 82
Bittar, R. .................... 30, 70, 75, 79, 103
Bittar, R.K............................................ 82
Björkbacka, H. .................................... 18
Bjørndal, B. ......................................... 86
Blaak, E. .............................................. 36
Blache, D. ........................................... 27
Blaha, M. ..................................... 81, 112
Blaha, V. .............................. 81, 110, 112
Blaise, S. ....................................... 52, 61
Blanco, G. ........................................... 58
Blanco-Colio, L.M. ............................. 41
Blanco-Vaca, F............................. 10, 33
Blankenberg, S............................. 8, 117
Blé-Castillo, J.L. ................................. 90
Bleda, Moreno, S. ............................ 100
Bleda, S. .................................. 65, 68, 94
Blirando, K. ......................................... 60
Bloedon, L.T. ...................................... 81
Blom, D.......................................... 23, 44
Blom, D.J. ........................................... 81
Blomberg, B.A. ................................... 45
Bobcikova, P..................................... 112
Bobescu, E. ................................ 92, 127
Bobik, A. .............................................. 18
Bobryshev, Y.V. ................... 70, 71, 100
Boby, C................................................ 43
Boccara, F............................. 52, 83, 100
Bochaton-Piallat, M.-L. ............... 59, 60
Bochem, A. ......................................... 42
Boddi, M. ...................................... 70, 95
Boehm, B.O........................................ 77
Boeing, H. ........................................... 32
Bogachev, O. ..................................... 30
Böhm, B.O. ....................................... 101
Boileau, C. .................................... 26, 50
Bolbos, R. ........................................... 64
Boldrini, B. .......................................... 20
Bombo, R............................................ 30
Bonacina, F. ................................. 33, 34
Bond, M. ............................................. 59
Bondarenko, S.A. .............................. 67
Bonde, Y. ............................................ 83
Bongard, V. ...........................77, 85, 105
Boni, F................................................. 97
Bonnefont, Rousselot, D. ........... 75, 79
Bonnefont-Rousselot, D.30, 50, 70, 103
Bonnet, F. ........................................... 35
Bonnet, J. ........................................... 84
Bonnet, Jacques ................................ 25
Bono, J.O.................................... 96, 102
Boren, J. ............................................. 16
Borén, J. ............................................. 53
Boren, Jan .......................................... 28
Borodachev, E.N. .............................. 70
Borràs, M. ........................................... 54
Borucka, J. ......................................... 62
Boshtam, M. ....................................... 70
Bosi, E............................................... 121
Bosisio, R. .......................................... 96
Bot, I. ................................................... 41
Botnar, R. ........................................... 98
Botnar, R.M. ....................................... 58
Bottazzi, B. ......................................... 34
Bøttcher, M. ........................................ 95
Botto, N. ............................................ 108
Bouacida, L. ............................... 92, 104
Bouchaert, E. ..................................... 28
Bouchard, P. ...................................... 64
Bouchareychas, L. ............................ 67
Boudys, L............................................ 81
Boue, S. ............................................ 117
Boughzala, E...................................... 83
133
Bouillet, B. ........................................... 27
Bouloumié, A. ..................................... 49
Boumaiza, I. .......................... 83, 92, 104
Bourbon, M. ........................................ 81
Bourghardt-Fagman, J. ..................... 69
Bouslama, A. ........................ 83, 92, 104
Boussel, L. .......................................... 46
Boussetta, T. ...................................... 65
Bouzourene, K. .................................. 17
Boytsov, S. .......................................... 91
Bozon, D. ............................................ 82
Bozzetto, L. ......................................... 43
Braamskamp, M. ................................ 81
Bracho, M. ........................................... 40
Brady, A.J. .......................................... 17
Brady, Adrian JB ................................ 17
Brady, I. ............................................... 36
Brandão, S.A. ................................... 101
Brattelid, T........................................... 86
Braunersreuther, V. ........................... 48
Breuer, O. ........................................... 83
Briand, O. ............................................ 74
Brianezi, L. ........................................ 115
Bricca, G. .............................. 60, 63, 101
Bridges, I. ............................................ 77
Brindisi, M.-C. ................................... 104
Brinton, E.A......................................... 33
Brites, F. ............................................ 108
Brito, Filho, S.B.D. ................... 126, 127
Brito, V........................................... 38, 68
Brockmann, E.-C................................ 72
Broisat, A. ........................................... 99
Brokopp, C. ......................................... 47
Brøndum-Jacobsen, P. ............... 40, 54
Broniec, A. .......................................... 57
Brouri, M............................ 104, 105, 115
Brouwers, M. ...................................... 50
Broyer, M. ........................................... 74
Brucker, E. .......................................... 79
Bruckert, E. .....3, 15, 30, 50, 70, 81, 103,
121, 123
Bruckert, Eric ...................................... 20
Brudi, P.......................................... 85, 86
Brufau, G. ............................................ 30
Brun, C. ............................................... 59
Brunet, A............................................. 87
Brunner, S. ......................................... 87
Brusberg, M........................................ 35
Bruyndonckx, L. ............................... 104
Bublikov, D. ...................................... 107
Bubnova, M.G. ................................. 108
Budkhashvili, M. ................................ 78
Buerke, M. .......................................... 64
Buijsse, B............................................ 32
Bulas, J. .............................................. 79
Bulatova, E.R. .................................... 78
Bulgarelli, A. ....................................... 68
Burcelin, R. ................................... 49, 75
Burnett, J.R. ....................................... 82
Burns, T.L. ............................................ 7
Burokienė, N. ................................... 118
Bursill, C. ............................................ 42
Buscato, M. ........................................ 37
Busch, M. ............................................ 47
Busnelli, M. .... 33, 35, 58, 62, 63, 86, 126
Butoi, E. .............................................. 41
Byrkjeland, R.................................... 116
C
Cabeza, Letrán, L. ..................... 92, 109
Cabeza-Letran, M.L. ....................... 121
Cabou, C. ........................................... 75
Cabré, A. ............................................ 36
Cagliero, P.................................. 81, 120
Cain, V.A. ........................................... 44
Cakmak, H.A. ............................... 59, 94
Cakmak, S. ......................................... 46
Cal, R. ................................................... 6
Calabresi, L. ................................. 58, 73
Calanca, I.V........................................ 78
Calandra, S. ....................................... 26
Calandra, Sebastiano ......................... 5
Caligiuri, G.................................... 21, 38
Calin, M............................................... 41
Calzada, C.......................................... 34
Camaré, C. ......................................... 38
Cambien, F..............................8, 15, 117
Çamkıran, V. ...................................... 89
Camont, L. .............................42, 72, 108
134
Camponova, P. .................................. 42
Can, G. ................................................ 94
Canaple, L. ......................................... 69
Canário-Almeida, F............................ 92
Canet-Soulas, E. ................................ 64
Canizales-Quinteros, S. .................... 99
Canonne-Hergaux, F. ........................ 52
Cantero, X. .......................................... 80
Cantor, H. ............................................ 38
Cao, A.................................................. 18
Cao, G. .................................................. 6
Capeau, J.................................. 100, 102
Capel, E. ........................................... 100
Cappelli, S. ......................................... 61
Caraballo, R........................................ 10
Carillon, J. ......................................... 118
Cariou, B. .......................... 6, 44, 76, 102
Carlsson, M......................................... 53
Carlzon, D. ............................................ 7
Caro, N. ..................................... 109, 121
Caron-Debarle, M. ..................... 83, 100
Caron-Houde, S. .............................. 105
Carreau, V. ................................... 50, 81
Carrera, M.J. ..................................... 110
Carretta, R. ......................................... 35
Carrié, A. ................... 50, 79, 81, 82, 113
Carrilho, A. ........................................ 109
Cartland, S. ......................................... 11
Cartland, S.P. ..................................... 42
Cartocci, G. ......................................... 97
Carvalho, L.S. ..................................... 71
Casagrande, M.L. ............................ 115
Casasnovas, J.A. ............................... 84
Casella-Filho, A. ......................... 72, 115
Caslake, M. ................................... 31, 76
Casola, C. ......................................... 100
Caspar, Bauguil, S. .......................... 117
Casquero, Dominguez, S. .......... 97, 98
Cassol, A. ............................................ 78
Cassorla, G. ........................................ 65
Castagné, R.......................................... 8
Castaing-Berthou, A. ......................... 52
Castellano, J. ........................................ 6
Castell-Rodríguez, A.E. .................... 90
Castelnuovo, S. .................................. 96
Castiñeiras-Landeira, M.I. ................ 57
Catakoglu, A.B. ................................ 126
Catalan, M. ....................................... 126
Catalano, C. ....................................... 97
Catalano, G. ....................................... 63
Cataneo, L. ......................................... 40
Catapano, A. ...................................... 85
Catapano, A.L.2, 3, 4, 13, 33, 34, 37, 52,
62, 67, 68, 94, 112
Catapano, Alberico L. ........ 2, 3, 4, 5, 13
Catharino, R.R. .................................. 90
Caulfield, M.J. .................................. 124
Caussy, C. .......................................... 31
Cavalcante, M.F. ............................. 123
Cavarape, A. .................................... 115
Cecchettini, A. .................................... 62
Cefalù, A.B. ........................................ 51
Celebi, H. .......................................... 126
Cerda, A. ............................................ 85
Cerillo, A. ............................................ 61
Cerutti, C. ................................... 63, 101
Cesana, F. ........................................ 110
Ceska, R. ............................................ 99
Cha, J.-J. ............................................ 70
Cha, K.S. .......................................... 111
Chaaba, R. ..........................85, 101, 126
Chaabane, C. ..................................... 59
Chacin, L. ........................................... 40
Chagas, A.C.P. ................................ 115
Chahed, H. ................................... 31, 76
Chahine, M.N. .................................... 60
Chai, F. ............................................. 116
Chaichana, T...................................... 60
Chaignot, C. ....................................... 32
Chakraborty, M. ................................... 6
Challa, A. .................................... 88, 104
Chalmers, N. ...................................... 18
Chan, C....................................... 91, 114
Chan, D.C................................... 22, 103
Chan, T. .............................................. 46
Chandrakala, A.N. ............................. 65
Chang, C.-J. ....................................... 91
Chang, S.-F. ....................................... 69
Chang, S.G. ..................................... 112
Chang, Y.-C. ...................................... 71
135
Changarotti, J. .................................. 119
Channon, K.M. ................................. 112
Chantepie, S. ...................... 72, 103, 108
Chantzichristos, V. ............................. 57
Chao, T.-H. ......................................... 29
Chapman, J.M. ................................. 108
Chapman, M John ......................... 2, 25
Chapman, M.J. ...... 2, 13, 22, 42, 72, 90,
103, 121
Chapouly, C. ....................................... 28
Charles, A.-L............................... 34, 113
Charlton-Menys, V. .................... 72, 125
Charnaux, N. ...................................... 57
Charniot, J.-C. .............................. 75, 79
Charniot, J.-P. .................................... 75
Charradi, K.......... 79, 103, 119, 120, 121
Charriere, S. ....................................... 82
Charrière, S. ........................... 31, 74, 82
Chatelais, M. ....................................... 51
Chaturvedi, N. .................. 49, 78, 89, 95
Chatzizisis, Y. ....................................... 5
Chaudhari, H.S................................. 109
Chaudhari, S.M. ................................. 47
Chauveau, F. ...................................... 64
Chavan, S. .......................................... 72
Chebli, S............................................ 112
Chelombitko, M. ................................. 66
Chelombitko, M.A. ............................. 67
Chen, C.-C. ......................................... 46
Chen, H. .............................................. 52
Chen, I.-C............................................ 29
Chen, J.-H. .................................. 29, 113
Chen, J.-Y. ................................ 103, 114
Chen, P. .............................................. 65
Chen, S. .............................................. 56
Chen, Y. ................................ 29, 40, 123
Chen, Y.-R. ....................................... 100
Cheng, Y.-J. ...................................... 125
Cherfils, C. .................................... 70, 75
Chernova, E........................................ 72
Chernushevich, O.I. ........................... 79
Chernyavskiy, A. ........................ 91, 127
Cheta, I. ............................................. 107
Chi, Y. .................................................. 33
Chia, Y.C. .................................. 111, 112
Chiang, A. ........................................... 71
Chiappetta, C. .............................. 28, 67
Chiappino, D. ..................................... 61
Chiara, M. ..................................... 62, 63
Chicheva-Ivanova, M.M. ................. 100
Chien, M. ............................................ 18
Chien, Y.-S. ........................................ 71
Chiesa, G....... 33, 35, 58, 62, 63, 86, 126
Chiharu, N. ......................................... 56
Chiheb, S. ......................................... 105
Chillarón, J.J. ........................... 109, 110
Chin-Dusting, J. ................................. 27
Chinetti-Gbaguidi, G. ........................ 67
Ching, S. ........................................... 112
Ching, S.M........................................ 111
Chiosso, R. ................................. 96, 102
Chiou, H.-Y. ...................................... 100
Chlopicki, S. ............................... 89, 121
Chłopicki, S. ............................... 57, 106
Chmielewska, M. ............................... 38
Chmilewsky, F. .................................. 57
Cho, K.-H. ............................73, 117, 119
Cho, M.-C. .................................. 32, 103
Cho, T.-H. ........................................... 46
Choi, B. ............................................... 36
Choi, C. ............................................... 36
Choi, C.U. ........................ 36, 53, 63, 122
Choi, D.-J...................................... 32, 43
Choi, E.K. ........................................... 66
Choi, E.-Y. .................................... 70, 76
Choi, I.S. ............................................. 95
Choi, J.H. .......................................... 111
Choi, J.Y. .......................................... 112
Choi, S.H. ........................................... 49
Choi, Y.H. ................................... 98, 112
Choquet, P. ...................................... 113
Choqueux, C. ..................................... 62
Chou, C.-H. .............................. 103, 114
Choudhury, R.P. .............................. 112
Christensen, G. ................................ 113
Christoffersen, B.Ø. .......................... 95
Chroni, A............................................. 71
Chu, P.-H. ..................................... 29, 91
Chugunova, Y. ................................. 118
Chukkapalli, S. ................................... 63
136
Chumakova, G. 100, 102, 103, 118, 125
Chung, H. ............................................ 76
Chung, I.-M. ........................................ 43
Chung, W.J. ...................................... 102
Chung, W.-Y. ...................................... 78
Cicek, M. ........................................... 109
Cicha, I. ............................................... 68
Cifkova, R. .................................... 40, 96
Cinquanta, P. ...................................... 58
Ciociola, E. .......................................... 31
Cioni, G. ........................................ 70, 95
Cipollone, F......................................... 90
Cipriano, P. ......................................... 43
Cirovic, S. .......................................... 119
Citti, L. ................................................. 62
Civeira, F. ............................................ 84
Clara, F................................................ 58
Claude, S. ........................................... 43
Clavey, V. ............................................ 74
Clement, K. ................................... 30, 70
Clement, M. ........................................ 38
Clément, N. ......................................... 60
Clerico, A. ......................................... 108
Cochran, B.J. ...................................... 27
Cocozza, S. ........................................ 43
Coelho, O.R. ....................................... 78
Coen, M. .............................................. 60
Cofán, M.............................................. 84
Cohen, A. ...................................... 52, 83
Cohen, M. ......................................... 105
Cohen, R. .......................................... 116
Cokkinos, D.V..................................... 84
Coletta, P. ........................................... 31
Colhoun, H. ......................................... 36
Colin, S. ............................................... 74
Collet, X. .............................................. 75
Collet, Xavier ...................................... 27
Colletes, J.H.G. .................................. 83
Colom, A. ............................................ 75
Colombo, C. ...................................... 110
Combescure, C. ................................. 47
Comte, B. .......................................... 122
Condorelli, G....................................... 37
Çoner, A. ..................................... 89, 107
Conraads, V...................................... 104
Conradie, K.R. ................................... 85
Conte, F. ............................................. 43
Conti, B. .............................................. 16
Contini, A. ......................................... 127
Contreras-Duarte, S. ......................... 34
Cooney, J. .................................... 31, 76
Cooper, S. .......................................... 56
Copin, C. ............................................. 67
Copponi, G. ................................ 40, 107
Corbier, C. ........................................ 106
Corral, P. ............................................ 58
Corrales, D. ................................ 92, 121
Correa, M............................................ 60
Correig, X. .......................................... 36
Corsini, A. ................ 37, 62, 94, 125, 127
Corti, R. ............................................... 47
Corvera-Tindel, T. ........................... 111
Cosentino, N. ............................. 40, 107
Coskun, A.U. ................................ 29, 55
Cosson, C........................................... 75
Cosson, E. ................................ 105, 110
Costa, L. ............................................. 52
Costa, S. ............................................. 71
Costabile, G. ...................................... 43
Costagliola, D. ............................. 52, 83
Costaz, C. ........................................... 74
Costet, P. ........................... 6, 37, 76, 102
Cotoi, O............................................... 18
Cottin, Y. ....................................... 53, 58
Couraud, P.O. .................................... 34
Courtier, A. ......................................... 47
Coutureau, T. ................................... 121
Couvert, P. ..............................70, 79, 82
Covaciu, A. ................................. 92, 127
Covas, M.I. ......................................... 35
Cozma, A. ......................................... 104
Crea, F. ....................................5, 40, 107
Crisci, I. ............................................... 51
Cristol, J.-P....................................... 118
Crociati, L. ........................................ 100
Croft, K. ............................................. 119
Cruz, Ferreira, R. ............................... 53
Cuchel, M. ...................................... 3, 81
Cudejko, C.......................................... 28
Cuesta, Torres, L.F. .......................... 27
137
Cuniberti, L. ........................................ 82
Cutrin, J.C. ........................................ 119
Cutuli, L. ........................................ 33, 34
Czarnecka, D. ................................... 127
Czyzynska, I. .............................. 89, 121
de, Faria, E.C. ................. 71, 78, 83, 128
De, Gendt, K. ..................................... 69
De, Haro, J. .............................65, 68, 94
de, Haro, Miralles, J. ....................... 100
De, Henauw, S..................................... 7
de, Jager, S.C.A. ......................... 41, 61
de, Jong, R.C.M........................... 18, 47
de, Leite, Jr, A.C. ............................. 115
de, Leon, H....................................... 117
De, Lonlay, P. .................................... 80
De, Nardis, V...................................... 90
de, Oliveira, Izar, M.C. ...................... 85
De, Oliveira, S.................................... 95
De, Paoli, F. ....................................... 67
De, Pellegrin, A.................................. 86
De, Smet, E. ....................................... 30
de, Smet, E.D. ................................... 22
De, Vos, W. ........................................ 36
De, Vries, M.R. ................. 18, 41, 47, 61
de, Winther, M. .................................. 67
De, Winther, M. .................................. 18
Deanfield, J.E. ................................... 13
Debelle, L. .......................................... 61
Deblache, T. ....................................... 75
deBlois, D. .......................................... 68
Deckert, V........................................... 76
deFaire, U........................................... 36
Defesche, J. ....................................... 51
Defesche, J.C. ............................. 26, 51
Dejouvencel, T. .................................. 48
Del, Ben, M. ....................................... 84
Del, Castillo, D. .................................. 74
Del, Porto, F. ...........................28, 62, 67
Del, Turco, S. ..................................... 59
Del, Valle, R. .............................. 96, 102
Delatour, V. ........................................ 79
Delay, M. ............................................ 74
Delbosc, S. ............ 34, 38, 48, 57, 64, 73
Delcore, M.G. ..................................... 43
Delgado, L. ......................................... 38
Della, Corte, G. .................................. 43
della, Latta, D. .................................... 61
Della, Pepa, G. .................................. 43
Della, Rocca, C............................ 28, 67
Dellepiane, A.................................... 108
D
Da, Porto, A. ..................................... 115
Dadamyants, N. ................................. 96
Dadamyants, N.G. ............................. 88
D'Agostino, M.N. ................................ 51
Dahlbom, I. ......................................... 18
Dalamaga, M. ..................................... 93
Dalla-Riva, J. ...................................... 73
Dallegri, F............................................ 47
Dallinga-Thie, G. .......................... 10, 36
Dallinga-Thie, G.M. ...................... 51, 55
Dallinga-Thie, Geesje ........................ 22
Dallongeville, J. ................................ 123
Damaskos, D. ..................................... 84
Damelou, A. ...................................... 114
Damonte, E. ........................................ 77
Dang, B.Q. .................................... 34, 56
D'Angelo, A. ........................................ 51
Daniels, S.R.......................................... 7
Daniil, G. ............................................. 71
Dart, A.M. ............................................ 27
Das, S. ................................................. 75
Dashkova, A. .................................... 100
Daugareil, C...................................... 117
Davey-Smith, G. ................................... 7
Davids, J. ............................................ 52
Davidson, W.S. .................................. 72
Davies, A.H. ........................................ 63
Davlouros, P. .................................... 114
Day, W.W. ......................................... 101
D'Cruz, D............................................. 98
De, Blasis, G....................................... 90
de, Boer, J.F. ................................ 49, 72
de, Bruin, R.G....................................... 8
De, Castro-Orós, I.............................. 84
De, Caterina, A.R............................. 108
de, Craen, A.J.M. ............................... 88
de, Faire, U. ...................................... 124
138
Dellera, F. ......................................... 126
Dementjeva, N. ........................ 107, 110
Demougeot, C. ................................. 122
den, Hartog, G. ................................... 74
Dencker, M. ...................................... 116
Deniset, J.F......................................... 60
Denisova, D. ....................................... 79
Dent, R. ............................................... 44
Denyanets, S. ................................... 114
D'Erasmo, L. ....................................... 84
Derex, L. .............................................. 46
Descamps, O. ............................. 85, 121
Desgranges, C. .................................. 28
Desideri, G. ......................................... 90
Desilles, J.P. ....................................... 34
Devillers, M. .................................. 26, 50
Devlin, J.J. .......................................... 88
Devold, H. ......................................... 122
Dhaouadi, N........................................ 63
Dhar, K. ............................................... 51
Dhenain, M. ........................................ 64
Di, Bartolo, B. ......................... 11, 37, 42
Di, Bartolo, B.A................................... 38
Di, Costanzo, A. ................................. 84
Di, Filippo, M........................... 31, 74, 82
di, Gioia, C. ................................... 28, 67
di, Giuseppe, R. ................................. 32
Di, Leo, E. ........................................... 51
Di, Marino, L. ...................................... 43
Di, Taranto, M.D. ................................ 51
Diallo, D. ............................ 48, 56, 57, 73
Diani, E. ............................................... 67
Dias, N.V. ............................................ 75
Diaz, O. ............................................... 66
Diaz-Zagoya, J.C. .............................. 90
Dibrov, E. ............................................ 60
DiCioccio, T. ....................................... 87
Diczfalusy, U....................................... 74
Diederichsen, A.C.P. ......................... 45
Dierke, J. ............................................. 32
Dietel, B. .............................................. 68
Di-Filippo, M. ...................................... 82
Dijkstra, M. .......................................... 31
Dikkers, A............................................ 49
Dikur, O. .............................................. 39
Diniz, G.M. ........................................ 116
Dionyssiou-Asteriou, A. .................... 93
Djalalov, F. ......................................... 88
Djekic, D. ............................................ 92
Dlouha, D............................................ 99
Dmitrieva, O. ...................................... 87
Dobordzhginidze, L. .......................... 40
Dobrcucki, L.W. ................................. 57
Dobreanu, D. ...................................... 92
Dobrucki, I.T. ...................................... 57
Doddapattar, P................................. 124
Doering, L.V. .................................... 111
Doi, M. ................................................. 93
Dolan, S. ........................................... 106
Dollet, L............................................. 102
Domagala, Z.A. ................................ 116
Domei, T. ............................................ 29
Domeij, H. ........................................... 63
Domenig, C. ..................................... 114
Domitrz, K........................................... 73
Dong, J. .............................................. 73
Dorea, E.L. ......................................... 85
Dorighello, G.G. ............................... 101
Doroszko, A...................................... 126
Dörr, M. ............................................. 110
dos, Santos, J.C. ......................... 71, 72
Douek, P.-C........................................ 46
Doulamis, I. ...................................... 119
Dourado, P.M. .................................. 115
Drahun, A. .................................. 89, 121
Drake, I. .............................................. 17
Drakopoulou, M. .......................... 38, 45
Drandarov, K. ..................................... 98
Drapkina, O.M. ................................... 88
Drechsler, C. .................................... 101
Drexel, H. .......................................... 102
Driss, F. .............................................. 65
Dritsa, V. ..................................... 97, 104
Drogari, E. .......................................... 81
Dronca, M. ........................................ 106
Drosos, A.A. ............................. 106, 126
Drożdż, K.M. ...................................... 38
Du, Plessis, A.M. ............................... 81
Duaip, G. ............................................ 82
Duan, Z. ............................................ 124
139
Dubois, N. ......................................... 101
Dubray, C. ......................................... 107
Duca, L. ......................................... 52, 61
Duchateau, G.S.M.J.E. ..................... 43
Duchêne, E. ........................................ 81
Ducimetiere, P. ................................... 54
Dudek, K. .......................................... 114
Dukat, A. ................................... 108, 115
Dukát, A. ............................................. 79
Dulak, M.G. ......................................... 60
Dullaart, R. .......................................... 72
Dullaart, R.P. ...................................... 72
Dullaart, R.P.F. ................................... 49
Dumitriu, I.E. ....................................... 11
Dumont, S. .......................................... 82
Dunér, P. ............................................. 18
Dunn, L. ............................................... 42
Duran, M.C. ...................................... 121
Durán, M.C. ................................ 92, 109
Durand, T. ......................................... 122
Durante, C. ......................................... 31
Durlach, V. .......................................... 61
Durlach, Vincent ................................. 26
Dutra-Rodrigues, M.S. ...................... 78
Duvillard, L. ................................. 27, 104
Dwyer, T. ......................................... 7, 32
Dzięgiel, P. .......................................... 38
Dzingalasevic, G. ............................... 94
Eisenhofer, G. .................................... 40
Eklund, C. ........................................... 96
Ekmekci, H. ........................................ 59
Ekmekci, O.B. .................................... 59
Ekroos, K. ........................................... 35
El, Khoury, P. ............................... 30, 63
Elbaz, M. ............................................. 85
Eldor, R. ............................................ 108
Elens, L. .............................................. 81
Elia, L. ................................................. 37
Elias, J.J. ............................................ 95
Elikomov, V. ..................................... 125
Elisaf, M. ..................................... 88, 104
Elisaf, M.S. ................................... 76, 86
El-Menyar, A. ....................110, 114, 115
Elofsson, M. ....................................... 10
Elonen, N. ........................................... 72
Elvevoll, E......................................... 122
Elvevoll, E.O. ................................... 122
Emoto, N............................................. 11
Empana, J.-P. .................................... 54
Empen, K. ......................................... 110
Endo, K. ....................... 31, 109, 111, 123
Endo, T. .............................................. 62
Endoh, H............................................. 32
Enomoto, M. ..................................... 121
Enquist, P.-A. ..................................... 10
Entz, L. .............................................. 127
Ercan, M.G. ...................................... 126
Erdmann, J. ........................................ 68
Eren, M. .............................................. 94
Erer, B. ................................................ 94
Ergang, P............................................ 64
Ergen, A. ............................................. 83
Erglis, A. ................................... 107, 125
Ergur, B.U........................................... 69
Ericson, U. .............................17, 39, 101
Ericsson, M. ....................................... 75
Eriksson, J. ......................................... 33
Eriksson, M. ............................10, 31, 44
Eriksson, U. ........................................ 31
Erlinge, D. ........................................... 22
Ernerudh, J................................... 66, 67
Escolà-Gil, J.C. .................................. 33
Esparza, Gómez, L. ........................ 100
E
Easton, R. ......................................... 123
Eastwood, S. ...................................... 49
Eatough, R. ................................. 72, 125
Ebelt, H................................................ 64
Ebina, Y. ............................................ 118
Eck, P. ............................................... 123
Edfeldt, K. ........................................... 66
Edjlalipour, M. ..................................... 87
Edsfeldt, A. ................................. 75, 110
Edvardsen, E. ................................... 116
Eeckhoute, J. ...................................... 67
Egido, J. .............................................. 41
Ehnholm, C. ............................ 10, 33, 48
Eilertsen, K.-E. ................................. 122
140
Esparza, L. .................................... 68, 94
Espinosa, González, M.C. .............. 117
Esquirol, Y. ....................................... 105
Esquivel, C.................................. 96, 102
Esteller, M. .......................................... 74
Estruch, R. .......................................... 35
Etxebarria, A. ...................................... 80
Euthimiou, V. .................................... 120
Evaldson, C. ....................................... 67
Evans, I. .............................................. 59
Ewing, M.M. ...................... 18, 41, 47, 61
Extebarria, A. ...................................... 81
Ezhov, M. ...................................... 86, 87
Feinstein, S.B. ................................... 28
Feinstein, Steven B. .......................... 28
Feldman, C.L. .............................. 29, 55
Felekos, I. ........................................... 38
Felix, S.B. ......................................... 110
Ferchaud, Roucher, V. ................... 122
Ferchaud-Rouchet, V........................ 95
Ferchichi, S. ................................. 31, 76
Ferin, R. .............................................. 91
Fernandes, C.R. ................................ 95
Fernandes, M. .................................... 92
Fernández, E. .............................. 38, 54
Fernandez, I. .................................... 119
Fernandez, Quero, M.................. 97, 98
Fernández-Laso, V. .......................... 41
Fernández-Marrero, Y. ..................... 38
Ferrannini, E. ............................... 20, 35
Ferré, R....................................... 17, 102
Ferreira, E.B. ............................ 126, 127
Ferreira, F........................................... 92
Ferreira, R. ....................................... 116
Ferri, L......................................28, 62, 67
Ferri, N. .......................... 37, 94, 125, 127
Ferrieres, J. ................................ 54, 105
Ferrières, J. .............................77, 81, 85
Ferronato, S. ...........................64, 65, 67
Ferruelo, A.......................................... 94
Fesel-Fouquier, V. ............................. 70
Feugier, P. .................................. 63, 101
Feuillet, F. ........................................... 76
Feve, B. ............................................ 102
Fidan, Y. ........................................... 121
Filip, G................................................. 61
Filip, M. ............................................. 116
Filip, S. .............................................. 112
Filipovsky, J.................................. 40, 96
Filippatos, T.D.................................... 76
Fink, G. ............................................. 116
Finsen, A.V....................................... 113
Fiol, M. ................................................ 35
Fiorelli, S............................................. 33
Fischer, S. .......................................... 86
Fisher, E.A.................................... 11, 37
Fisher, J. ............................................. 94
Fiskesund, R. ..................................... 47
F
Fabre, A. ............................................. 49
Fabre, J.-E. ................................. 34, 113
Fabris, B. ............................................. 35
Fabryova, L. ...................................... 108
Fagret, D. ............................................ 99
Fajardo, C.M. ...................................... 85
Falchi, A.G. ....................................... 101
Falcioni, E. ........................................ 107
Falcón, V. ............................................ 38
Fallanca, A. ....................................... 110
Faludi, A.A. ................................... 76, 96
Fan, J........................................... 29, 123
Fang, L. ............................................... 27
Fantozzi, C.............................. 28, 62, 67
Farnier, M. ..................... 9, 13, 81, 85, 86
Farnier, Michel...................................... 9
Fartushna, O.Y. ................................ 108
Fatoki, J.O......................................... 120
Faure, P. ........................................... 122
Favari, E. ............................................. 71
Fechner, A. ....................................... 120
Federspiel, M.-C. ............................... 70
Fedi, S. ................................................ 70
Fedorowicz, A............................. 57, 106
Fedoseeva, L.S. ................................. 78
Fehérvári, M. .................................... 127
Feidt, C. ............................................. 106
Feig, J.E. ............................................. 37
Feillet, F. ............................................. 80
141
Fjornes, T. ........................................... 92
Flegar-Meštrić, Z. ............................. 115
Fletcher, J. .......................................... 65
Florentin, M. ........................................ 86
Flores, Le-Roux, J.A................ 109, 110
Flouriot, G. .................................... 29, 37
Fobker, M. ........................................... 76
Fogelstrand, L. ................................... 41
Fogelstrand, P. ................................... 69
Fonseca, F.A. ....................... 43, 85, 101
Fonseca, H.A. ................................... 101
Fontaine, C. .................................. 29, 37
Foody, J. ............................................. 85
Ford, I. ................................................. 88
Forgues, P. ................................... 44, 87
Forrest, C. ......................................... 124
Fortun, M. ............................................ 92
Fortunato, G. ...................................... 51
Foscarini, J.M. ............................ 96, 102
Fotopoulos, A. .................................. 106
Fouchier, S.W............................... 26, 51
Fouquier, V.F. ..................................... 82
Fourcade, J. ........................................ 77
Fournier, N. ......................................... 30
Fracassi, F. ......................................... 40
Fraga, A. ............................................. 38
França, C.N. ....................................... 85
France, M. ................................... 72, 125
Franceschini, G. ................................. 58
Franceschini, S.A............................... 93
Franckx, H......................................... 104
Franco, S. ........................................... 60
Franczyk-Zarow, M. ......................... 121
Franczyk-Zarow, M.A. ....................... 89
Franzosi, M.G. .................................. 100
Fredenrich, A. ..................................... 81
Freeman, L. ........................................ 22
Freyer, J. ............................................. 68
Friand, V.............................................. 57
Frias, M. .............................................. 48
Friberg, P. ........................................... 40
Frikke-Schmidt, R. ............................. 84
Frisdal, E. ...................................... 30, 74
Froemming, G.R.A. .................... 66, 120
Frostegård, A. ....................... 47, 63, 124
Frostegård, J. ........................47, 63, 124
Fu, H. .................................................. 64
Fu, Y. ................................................... 27
Fuenffinger, N. ................................... 32
Fuentes, S. ......................................... 36
Fuentes-Prior, P. ............................... 10
Fuertes, N........................................... 44
Fujioka, N. .......................................... 45
Fujioka, T. ......................................... 111
Fujishima, Y. .................................... 111
Fujita, Y................................................. 6
Fujiyoshi, A................................... 91, 95
Fukami, A. ........................................ 121
Fukuda, A. ........................................ 123
Fukunaga, H. ..................................... 58
Fülöp, P. ............................................. 95
Fumagalli, H.F. .................................. 93
Funck-Brentano, C. ........................... 52
Fundinho, C...................................... 116
Furukawa, T. ...................................... 58
Furuyama, S. ................................... 108
Futema, M. ......................................... 80
Fysekidis, M. ............................ 105, 110
G
Gaál, K. ............................................... 72
Gabriel, S............................................ 50
Gadeau, A.P. ..................................... 52
Gadeau, A.-P. .................................... 28
Gaestel, M. ......................................... 64
Gafarov, V. ....................................... 117
Gafarova, A. ..................................... 117
Gagliano, T. ........................................ 60
Gagulin, I. ......................................... 117
Gaillet, S. .......................................... 118
Gajda, M. .......................................... 121
Gajdosik, J................................ 108, 115
Gajos, G. ............................................ 39
Galabova, G. ...................................... 87
Galán-Garcia, P. ................................ 80
Galano, J.-M. ................................... 122
Galassini, A. ....................................... 70
Galchinskaya, V............................... 110
Gale, C.P. ......................................... 124
142
Galeeva, N. ....................................... 110
Gallagher, P...................................... 114
Galli, E. .............................................. 108
Gambert, P. ........................................ 58
Gämperli, O. ....................................... 47
Gan, A.M. ............................................ 41
Gan, L.-M. ........................................... 96
Gandara, A. ...................................... 125
Gandhi, H. ........................................... 78
Gandjbakhch, I. .................................. 75
Gannar, F. ......................................... 104
Ganugi, E. ........................................... 70
Ganzetti, G...................... 35, 62, 63, 126
Gapon, L. .................................. 107, 110
Garcia, Carro, J. ............................... 125
Garcia-Arguinzonis, M......................... 6
García-Sánchez, C. ........................... 77
Garelnabi, M. ............................ 116, 123
Garjani, A. ........................................... 66
Garlanda, C. ....................................... 34
Garlaschelli, K. ........................... 33, 112
Garlichs, C. ......................................... 68
Garmy-Susini, B. ................................ 38
Garnotel, R. ........................................ 52
Garofaro, A. ........................................ 76
Garon, A. ............................................. 82
Garrido, Zambrano, E.C. ................ 117
Garzone, P.D. ............................... 44, 87
Gasevic, D. ......................................... 40
Gašpar, &. ........................................... 79
Gasparini, D...................................... 115
Gaston, A.-T. ...................................... 38
Gaudet, D............................................ 81
Gauthier, K.......................................... 69
Gautier, E. ..................................... 64, 67
Gautier, T. ..................................... 10, 27
Gavrilova, N.E. ................................... 79
Gayral, S. ............................................ 52
Gebauerova, M. ................................. 99
Geerling, J.J. ...................................... 16
Geiger, K. .......................................... 102
Geller-Rhomberg, S. ....................... 102
Gensini, G.F. ................................ 70, 95
Gentile, M. ........................................... 51
Geny, B. .............................................. 34
Georgiadis, I. .................................... 119
Germain, M. ......................................... 8
Gerszten, R. ....................................... 25
Geryk, L. ............................................. 94
Ghaleb, Y............................................ 50
Ghannam, M.M. ....................... 104, 120
Ghezzi, C. ........................................... 99
Ghosh, M. ........................................... 76
Ghosh, S.M. ....................................... 65
Giacco, A. ........................................... 43
Giacco, R. ........................................... 43
Giacobbe, C. ...................................... 51
Giannattasio, C. ............................... 110
Giannopoulou, V. ............................... 82
Gidlund, M. ....................................... 101
Gielen, S. ............................................ 64
Giezek, H. ........................................... 86
Giglioli, C. ........................................... 70
Gijbels, M............................................ 67
Gilabert, R. ................................. 35, 126
Gilibert, S. ........................................... 57
Gille, A. ............................................. 123
Gillott, R.G. ....................................... 124
Gilly, F.N. .............................................. 4
Gilmanov, D. ...................................... 93
Ginsberg, H. ................................... 2, 14
Giral, P. ... 22, 32, 67, 75, 81, 82, 90, 103,
113
Girard, E. ...................................... 26, 30
Girerd, X. .......................................... 113
Giridhar, R. ......................................... 78
Girish, M.P.......................................... 75
Girodo, A.M. ..................................... 116
Girona, J. ............................................ 17
Gisletun, U.......................................... 92
Giugliano, R.P.................................... 44
Giunta, G. ........................................... 82
Gizas, V. ........................................... 114
Gkrozou, F.......................................... 57
Gladine, C. ....................................... 122
Glauber, M.................................... 61, 93
Glinkina, I............................................ 97
Głodzik, J. ......................................... 116
Goday, A........................................... 110
Goeritzer, M. .................................... 124
143
Gogou, M. ......................................... 119
Gohara, S............................................ 55
Gojkovic-Bukarica, L. ...................... 119
Goldman, Rosas, L. ........................... 86
Golledge, J.......................................... 44
Golovach, I.V. ................................... 113
Golovach, S.V. ................................. 113
Gomaraschi, M. .................................. 73
Gomes, E.I.L....................................... 83
Gomez, Lira, M. ...................... 64, 65, 67
Gomez, Rosso, L. ............................ 108
Gomez-Guerrero, C. .......................... 41
Gomita, K. ........................................... 47
Gomułkiewicz, A. ............................... 38
Goncalves, I...................................... 110
Gonçalves, I........................................ 75
Gonçalves, R. ..................................... 96
Gonzaga, C................................... 76, 96
Gonzalez, A. ....................................... 40
González, C. ................................. 34, 68
González-Juanatey, J.R. .................. 57
González-Peteiro, M. ......................... 57
Gori, A.M. ...................................... 70, 95
Gori, T.................................................. 53
Gorlova, O........................................... 70
Gosukuma, M.C. ................................ 85
Götberg, M. ......................................... 22
Gottrand, F............................................ 7
Goudev, A. .......................................... 58
Goudevenos, I. ................................. 114
Goudevenos, J.A. ............................ 120
Goueffic, Y. ......................................... 95
Goujard, C. ......................................... 63
Gourdy, P. ............................... 29, 37, 49
Gower, J.D. ....................................... 124
Gracheva, E........................................ 66
Graham, A......................................... 106
Grammer, T. ....................................... 83
Grammer, T.B............................... 77, 80
Grandoso, L. ....................................... 80
Grangeot, R. ..................................... 101
Grass, D.S. ......................................... 10
Grassos, H. ......................................... 38
Gratchev, A. ........................................ 65
Gratsiansky, N. ................................... 40
Grebe, M. .......................................... 113
Grebenshchikova, I. .......................... 97
Gregersen, I. ...................................... 65
Greil, G. .............................................. 98
Grenkowitz, T. .................................... 76
Griffo, E............................................... 43
Grigore, L.................................... 33, 112
Grillo, A. .............................................. 35
Griñán, T............................................. 38
Gritsenko, O. ............................ 103, 125
Grivel, J.-C. .............................51, 61, 64
Grives, A. ............................................ 47
Grodzicki, T. ..................................... 116
Groen, B. ...................................... 30, 36
Gromova, E. ..................................... 117
Gronlund, C. ................................. 98, 99
Grova, N. .......................................... 106
Gruetter, R.......................................... 17
Grufman, H. ...................................... 110
Grundtman, C. ................................... 53
Grunenwald, E. .................................. 29
Grzegorek, I. ...................................... 38
Guaita, S............................................. 36
Guardado, J. ...................................... 92
Guardamagna, O....................... 81, 120
Guardiola, M. ..................................... 74
Guastella, G. ...................................... 60
Guedj, K. ....................................... 38, 61
Guerci, B........................................... 100
Guerin, M. .................... 26, 30, 63, 70, 74
Guermaz, R. ......................104, 105, 115
Gui, Q.-J. ............................................ 51
Guichardant, M. ................................. 65
Guichot, Y.D. ...................................... 22
Guiguet, M. ......................................... 83
Guilland, J.-C. .................................... 58
Guillaume, M. ..................................... 49
Guillaumet, A. .................................... 74
Guillerm, E.......................................... 75
Guimaraes, E.S. ................................ 85
Guisado, Rasco, A. ..................... 97, 98
Gullberg, B. ........................................ 39
Gullestad, L. ............................... 65, 113
Gumbiner, B. ................................ 44, 87
Guo, S. .............................................. 124
144
Gupta, G.K. ......................................... 43
Gupta, N. ............................................. 50
Gupta, S.K. ......................................... 75
Gurevich, V. ........................................ 78
Gurzeler, E.......................................... 31
Gustin, M.-P. ............................... 63, 101
Guterres, S.S. ................................... 123
Guyton, J.R. ........................................ 85
Guzeloglu, M. ..................................... 60
Guzik, T. ...................................... 61, 116
Guzik, T.J. ..................................... 60, 66
Gvozdyk, M. ........................................ 82
Gybernatorova, E.E. ........................ 105
Gylling, H. ......................................... 105
Hammami, S. ............................. 85, 126
Hamre, M. ........................................... 92
Hamrefors, V. ..................................... 17
Hamrour, F. .............................. 105, 115
Hamsten, A. ....................................... 36
Han, S.H. ......................... 48, 89, 95, 102
Han, X. .......................................... 33, 56
Handberg, A. ...................................... 50
Handgraaf, S. ..................................... 49
Hannou, S. ....................................... 105
Hannou, S.A. ...................................... 28
Hanotin, C. ......................................... 87
Hansel, B. ..............................32, 82, 103
Hansson, G.K. ............................. 41, 66
Hara, M. ............................................ 106
Harada-Shiba, M. .................44, 80, 106
Haraguchi, H. ..................................... 39
Haraguchi, Y. ................................... 120
Harangi, M. ............................72, 80, 102
Harith, H. ............................................ 11
Harnek, J. ........................................... 22
Harrison, G. ................................ 91, 114
Harrison, M.J...................................... 34
Harvey, D............................................ 81
Hasan, S.T. ...................................... 126
Hasballa, R......................................... 71
Hasegawa, H. .................................. 125
Hashemizadeh, H. ........................... 117
Hashimoto, T...................................... 64
Hasokawa, M. ............................ 39, 120
Hassim, N.F. ...................................... 58
Hatri, A. ..............................104, 105, 115
Haulon, S. ........................................... 67
Havekes, L.M. ................... 16, 49, 65, 71
Havinga, R.......................................... 30
Hayashi, H. ......................................... 42
Hazan, E. ............................................ 60
He, Y. .................................................. 47
Heasman, J. ................................. 49, 78
Hebert, H. ........................................... 73
Hecking, M. ........................................ 49
Hedegaard, M. ..................................... 8
Hedin, U. ............................................. 66
Hedjazi, L............................................ 76
Hedley, T.E. ....................................... 60
H
Haas, B................................................ 54
Haas, G.-M. ...................... 116, 127, 128
Habalova, V. ....................................... 99
Habenicht, A. ...................................... 21
Habibinejad, H. ................................... 63
Hack-Ryoung, K. ................................ 78
Haddad, O. ......................................... 57
Hadi, N.R. ........................................... 65
Haeggström, J. ................................... 63
Hägerstrand, L. .................................. 35
Haghjooy, Javanmard, S. ................. 56
Hagiwara, N. ....................................... 47
Hahalis, G. ........................................ 114
Haidinger, M. ...................................... 49
Hajkova, J. ........................................ 112
Hakki, Kazazi, E. ................................ 46
Halici, F. ............................................ 110
Hall, A.S. ........................................... 124
Hällgren, P. ......................................... 61
Halonen, J. ........................................ 105
Haluzik, M. ........................................ 110
Halvorsen, B. ................................ 65, 80
Hama, S. ..................................... 72, 125
Hamamatsu, A. .................................. 62
Hamazaki, N. .................................... 118
Hamdis, N. ........................................ 119
Hamlat, Khennaf, N. .......................... 74
Hammami, M. ..................... 85, 101, 126
145
Heeren, J. ........................................... 31
Hegele, R.A. ....................................... 81
Heinle, H. .......................................... 119
Heinonen, S. ....................................... 31
Heinonen, S.E. ................................... 35
Heizmann, C.W. ................................. 59
Hellberg, S. ......................................... 46
Hellstrand, S. ...................................... 39
Hendrikx, T. ........................................ 22
Henein, M. ......................... 61, 97, 98, 99
Hense, H.W. ....................................... 32
Heras, M........................................ 17, 36
Herbeth, B. ........................................ 106
Hermanns, H.M. ................................. 47
Hermansson, C. ................................. 66
Hernandez, Y. .................................. 119
Herová, M. .......................................... 41
Herrera, A.M. ...................................... 60
Herreras, Z........................................ 126
Hersberger, M. ................................... 41
Heuillet, M. .......................................... 79
Heusch, G. .......................................... 37
Hewing, B............................................ 37
Heyden, M. ......................................... 53
Hidalgo, P. .......................................... 34
Hiemstra, H. ........................................ 43
Hiemstra, P.S. .................................... 65
Higaki, Y. ............................................. 54
Hildebrandt, M. ................................... 45
Hindmarch, C. .................................... 59
Hindy, G. ............................................. 17
Hirai, Y. .............................................. 121
Hirata, A. ........................................... 122
Hirata, K. ....................................... 39, 75
Hirata, K.-I. ...................... 11, 74, 75, 120
Hirata, M........................................ 56, 76
Hirata, M.H. ......................................... 85
Hirata, R.D.C. ..................................... 85
Hirawa, N. ........................................... 88
Hirche, F.............................................. 32
Hirohata, S. ......................................... 93
Hirsch, E.............................................. 52
Hisakawa, N. ...................................... 94
Hisamatsu, T. ............................... 91, 95
Hitos, K. ............................................... 65
Hjuler, Nielsen, M. ............................. 50
Hlaváčková, M. .................................. 60
Hlawaty, H. ......................................... 57
Ho, C.-S. ................................... 103, 114
Hoefler, G. ........................................ 124
Hoekstra, J. ........................................ 36
Hoekstra, M. ....................................... 42
Hoelschermann, H. ......................... 113
Hoeng, J. .......................................... 117
Hoerstrup, S. ...................................... 47
Hoffmann, M.M. ......................... 83, 101
Hofker, M. ........................................... 16
Hofker, M.H. ....................................... 71
Hofker, Marten ................................... 16
Hoh, B.P. ............................................ 72
Høilund-Carlsen, P.F. ....................... 45
Holaj, R. ............................................ 125
Holleboom, A. .................................... 42
Holleboom, A.G. ................................ 55
Holleman, F. ....................................... 36
Holm, N.R. .......................................... 95
Holm, S. ........................................ 65, 86
Holmgren, A. ...................................... 61
Holst, J. ............................................... 36
Holven, K. ........................................... 65
Holven, K.B. ....................................... 80
Holzer, M. ..................................... 49, 83
Homan, R. .......................................... 22
Homer-Vanniasinkam, S. ................. 94
Honarpour, N. .................................... 22
Hong, B.-K. ......................................... 70
Hong, K.W. ......................................... 38
Hong, S.P. ........................................ 112
Hong, T.J. ......................................... 111
Honye, J. ............................................ 29
Hoogeveen, R. ................................... 44
Hooper, A.J. ....................................... 82
Hori, M. ............................................. 106
Horner, D.S. ................................. 62, 63
Horovitz, A. ......................................... 84
Horvath, K. ......................................... 91
Hosseini, H. ........................................ 18
Hoteit, C. ............................................. 48
Ho-Tin-Noé, B. ............................. 30, 48
Hounslow, N. ................................ 22, 90
146
Hovingh, G.K. ..................... 2, 42, 51, 55
Hovingh, K. ......................................... 26
Howell, S.J. ....................................... 124
Hoymans, V. ..................................... 104
Hsieh, F.-I. ........................................ 100
Hsieh, I.-C. .......................................... 46
Hsu, C.................................................. 69
Hsu, L.-J. ........................................... 112
Hsu, S.-P............................................. 69
Hu, F. ..................................................... 9
Hu, Frank .............................................. 9
Hu, M. .................................................. 87
Hua, S.................................................. 66
Hua, X.................................................. 63
Huang, F. ............................................ 44
Huang, J. ........................................... 101
Huang, P.-H. ........................... 20, 29, 61
Huang, T. .......................................... 107
Huang, Y.-Y. ....................................... 29
Hubacek, J. ......................................... 99
Hubacek, J.A. ..................................... 99
Huby, T. ......................................... 57, 67
Hueb, W. ............................................. 72
Hughes, A. .......................................... 49
Hughes, A.D. .......................... 78, 89, 95
Huizinga, E.G. .................................... 61
Huk, I. ................................................ 114
Hultén, L.M. ........................................ 66
Humphries, S.E. ........................... 80, 81
Hunter, W.J. ........................................ 43
Huovinen, T. ....................................... 72
Hurme, R. ............................................ 35
Hurt-Camejo, E. ................................. 10
Husche, C. .......................................... 74
Hussain, T. .......................................... 98
Hussein, A. ....................................... 110
Hutten, B. ...................................... 26, 81
Huttl, M. ............................................... 54
Huusko, J. ........................................... 31
Huynh, K. ............................................ 30
Hwang, H.S......................................... 95
Hyötyläinen, T. ................................... 33
Hyspler, R. ........................................ 110
Hϋbner, K. ........................................... 33
I
Ibañez, J.M. ........................................ 92
Ibarretxe, D. ..........................17, 36, 102
Ibrahimi, P. ................................... 98, 99
Ichiki, T. .............................................. 64
Idborg, H. ............................................ 66
Idzior-Waluś, B. ......................... 80, 127
Igarashi, A. ....................................... 118
Ikeda, N. ..................................... 58, 103
Ikeda, Y............................................... 94
Ikemoto, T. ......................................... 29
Ikewaki, K. .......................................... 40
Ikhlef, S. .............................................. 42
Ikitimur, B............................................ 59
Ilìna, L. ............................................... 86
Ilerigelen, B. ....................................... 59
Iliadis, S. ........................................... 119
Iliescu, C. .............................................. 7
Ilnicka, P. .......................................... 126
Ilyinskaya, O.P. .................................. 67
Imaeva, A. .................................. 40, 107
Imaizumi, T. ...................................... 121
Imamura, H. ................ 31, 109, 111, 123
Imamura, S. ........................................ 75
Inazu, A......................................... 50, 80
Indermuehle, A. ................................. 98
Inoue, T......................................... 50, 80
Intharapetch, P. ....................84, 99, 100
Ionova, Z.I. ......................................... 99
Iozzo, P. .............................................. 28
Iozzo, Patricia .................................... 28
Irvine, H. ............................................. 50
Isayeva, A........................................... 77
Isbir, S. ................................................ 83
Isbir, T. ................................................ 83
Ishibashi, S......................................... 73
Ishida, T. .......................... 39, 74, 75, 120
Ishihara, N. ....................................... 123
Ishizaka, N........................................ 106
Iso, H. .................................................. 48
Issa, B. ........................................ 72, 125
Itabe, H. ............................................ 123
Itai, K. ................................................ 111
Ito, H.............................................. 86, 93
147
Ito, Y. ............................................. 77, 93
Ivanisevic, J. ....................................... 94
Ivanova, M. ......................................... 84
Ivanova, O. ............................. 51, 61, 64
Ivashkin, V. ......................................... 88
Iwamoto, M. .................................. 62, 93
Iyengar, S.S. ....................................... 72
Izar, M.C. ..................................... 43, 101
Izard, J.-C. ........................................ 118
Izumi, T................................................ 56
Jegerschöld, C. .................................. 73
Jenei, Z. .............................................. 95
Jeney, V. ............................................. 29
Jenkins, P. .......................................... 97
Jennbacken, K. .................................. 35
Jensen, E............................................ 85
Jensen, G.B. ...................................... 32
Jensen, I.J. ....................................... 122
Jensen, I.-J....................................... 122
Jeon, S.W. ........................................ 112
Jeppsson, A. ...................................... 66
Jerling, J.C. ........................................ 85
Jessup, W........................................... 74
Jeurissen, M. ...................................... 22
Jevnikar, M. ........................................ 35
Jezkova, K. ......................................... 57
Jiang**, Y. ........................................... 73
Jiang, X.-C............................................ 6
Jiang, Z.S. .......................................... 29
Jiang, Z.-S. ......................................... 51
Jin, J. ........................................... 68, 116
Jo, S.-H. .............................................. 90
Joh, T. ........................................... 44, 87
Johansson, E. .............................. 98, 99
Johansson, M.E. .....................41, 66, 69
Johns, R. .......................................... 114
Johnson-Levonas, A.O. .................... 85
Jonak, P. ............................................. 56
Jonasson, L. ................................. 66, 67
Jondeau, G. ........................................ 61
Jones, P.J......................................... 123
Jonke, V. ........................................... 115
Jonker, L. ............................................ 36
Jönsson-Rylander, A.-C. .................. 35
Jorge-Galarza, E. .............................. 99
Joumard-Cubizolles, L. ................... 122
Jozkowicz, A. ..................................... 60
Juárez-Rojas, J.G. ............................ 99
Juárez-Rojop, I.E............................... 90
Jude, B. ............................................... 67
Jude, E. ............................................... 95
Juhász, I. ............................................ 95
Juhnevica, D. ................................... 107
Juhola, J. .............................................. 7
Jukema, J.W. ........ 18, 41, 47, 49, 61, 88
J
Jaber, Y. .................................... 105, 110
Jabłońska, K. ...................................... 38
Jacob, M.-P......................................... 62
Jacob, N. ........................................... 113
Jafari, Dinanai, N. .............................. 70
Jahreis, G.......................................... 120
Jakic, B. ............................................... 53
Jakobsson, P.-J.................................. 66
Jakubowski, M. ................................. 126
Jalali, A. ............................................... 46
James, R.W. ....................................... 48
Jamnitski, A. ....................................... 20
Jamroz-Wiśniewska, A. ..................... 41
Janczak, D. ......................................... 38
Jandl, K. ............................................ 124
Jang, H.C. ........................................... 49
Jänis, M. .............................................. 35
Janus, A. ........................................... 126
Jaramillo, J.S. ..................................... 60
Jardim, C.C. ...................................... 116
Järvelin, M.-R. .................................... 33
Jaschke, C. ......................................... 64
Jashari, F. ..................................... 98, 99
Jasiński, K. ........................................ 106
Jaspard-Vinassa, B. .......................... 28
Jasztal, A. ........................... 89, 106, 121
Jauhiainen, M. ..... 10, 22, 31, 33, 48, 72,
128
Jauhiainen, Matti ................................ 10
Javorsky, M......................................... 99
Jawad, A.H.M. .................................... 16
Jegere, S. .......................................... 125
148
Jula, A.................................................. 33
Julius, U. ............................................. 86
Jullien, G. ............................................ 93
Julve, J. ......................................... 10, 33
Jung, I.-H. ........................................... 68
Juno, C. ............................................... 87
Juonala, M. ............................... 7, 32, 36
Jurka, A. ............................................ 103
Kanyilmaz, S. ................................... 109
Kapelak, B. ......................................... 61
Kara, E. ............................................. 119
Karabina, S. ....................................... 18
Karabina, S.-A. .................................. 47
Karadag, B. ........................................ 59
Karadeniz, F.O................................... 94
Karadi, I. ........................................... 118
Karádi, I. ............................................. 78
Karagedik, H. ..................................... 83
Karagiannis, C. .................................. 54
Karanasos, A. .............................. 38, 45
Karatzas, T. ...................................... 119
Karčiauskaitė, D. ............................. 118
Kardassis, D. ........................................ 5
Kardum, Paro, M.M. ........................ 115
Karhunen, P.J. ................................... 63
Karim, S. ............................................. 40
Karlinskaya, M. .................................. 97
Karlson, B.W. ..................................... 44
Karlsson, M.K. ............................. 7, 116
Karp, K. ............................................. 106
Karpenko, M.A. .................................. 99
Karper, J.C. ....................... 18, 41, 47, 61
Karpov, Y. ........................................... 91
Kasagi, F. ........................................... 91
Kasbi, Chadli, F. ................................ 35
Kashiwagi, A. ..................................... 91
Kashiwase, K. .................................. 109
Kaski, J.C. .......................................... 11
Kasmas, S.H. ..................................... 43
Kassi, E............................................... 93
Kassimis, G. ..................................... 114
Kassner, U.................................... 76, 80
Kastelein, J................................... 26, 81
Kastelein, J.J.P. ................................. 51
Kastorini, C.-M. ................................ 120
Katano, H............................................ 61
Kathiresan, S. .............................. 50, 51
Katkó, M. ............................................ 80
Kato, A. ............................................... 79
Kato, K. ............................................. 111
Kato, R. ............................................. 121
Katsilambros, N.L. ........................... 119
Katsuda, S. ......................................... 80
K
Kacem, K. ........................................... 63
Kacem, S. ........................................... 83
Kachkovskii, M.A.......................... 78, 92
Kadota, A. ....................... 78, 91, 95, 103
Kadowaki, S........................................ 95
Kadowaki, T. ....................................... 91
Kahli, A. ............................................... 53
Kähönen, M. ........................... 7, 36, 101
Kajinami, K.......................................... 45
Kajiya, M. ............................................ 93
Kakino, A. .............................................. 6
Kakkavas, A...................................... 114
Kalachikov, S. ..................................... 18
Kalantzi, K. ........................................ 114
Kalinowski, L....................................... 57
Kalinskaya, A. ..................................... 58
Kalka, D............................................. 116
Kaltenecker, C. ................................... 49
Kaminnyi, A......................................... 66
Kaminnyi, A.I. ..................................... 84
Kamiya, K.......................................... 118
Kamstrup, P.R. ............................. 20, 32
Kanai, A. .............................................. 56
Kanai, H. ........................................... 125
Kanellakis, P. ...................................... 18
Kanellou, A. ........................................ 82
Kang, D.O. .......................................... 36
Kang, S.M. .......................................... 49
Kang, W.C......................................... 102
Kanjuh, V. ......................................... 119
Kannenberg, F. .................................. 76
Kanno, K. ............................................ 94
Kanse, S............................................ 113
Kantas, D. ......................................... 120
149
Kaudewitz, D. ................................... 114
Kaufmann, P.A. .................................. 98
Kauhanen, J. ...................................... 39
Kautznerova, D. ................................. 28
Kavurma, M. ................................. 11, 37
Kavurma, M.M. ............................. 38, 42
Kawai, Y. ............................................. 45
Kawakami, M. ..................................... 32
Kawamoto, T. ..................................... 94
Kawana, H. ................. 31, 109, 111, 123
Kawano, M. ....................................... 118
Kawasaki, M. .................................... 105
Kawase, R. ....................................... 109
Kawashiri, M.-A. ........................... 50, 80
Kawata, M. .......................................... 74
Kawatsu, Y. ................................. 78, 103
Kawecki, C. ......................................... 61
Kazanis, K. .......................................... 93
Kazdova, L. ......................................... 54
Kazemi, S.A.N. ................................... 91
Kazuma, S.M. ................................... 123
Kee, F. ................................................. 54
Kei, A.A. .............................................. 86
Keles, D. .............................................. 69
Keles, I. ............................................... 94
Kemaloglu, T. ..................................... 94
Kempen, H. ......................................... 73
Kenjaev, M. ......................................... 89
Kerek, F. .............................................. 68
Kerksiek, A.......................................... 30
Kerner, W. ......................................... 110
Kerry, Z................................................ 69
Kersten, S. .................................... 10, 75
Kersten, Sander ................................. 10
Kesavalu, L. ........................................ 63
Kessal, F. .......................... 104, 105, 115
Kessler, K.......................................... 114
Kettunen, J.......................................... 33
Keul, P. ................................................ 37
Keyamura, Y. .................................... 123
Khachigian, L. ..................................... 37
Khachigian, L.M. ................................ 38
Khalil, A. .............................................. 42
Khallou-Laschet, J. ............................ 38
Khambata, R.S. .................................. 65
Khan, F. .............................................. 64
Khan, N. .............................................. 40
Khanfir, L. ......................................... 104
Kharbanda, R.K. .............................. 112
Khasanova, Z. .................................... 84
Khatib, R. .......................................... 124
Khedoe, P.P.S.J. ............................... 65
Kidouche, R........................................ 79
Kidron, M. ......................................... 108
Kiec, A.D........................................... 121
Kiechl, S. .......................................... 114
Kihara, S. ............................................ 79
Kikuchi, K.......................................... 106
Kim, B.R. ............................................ 43
Kim, C.D. .................................38, 59, 66
Kim, C.J. ............................................. 88
Kim, D.-Y. ........................................... 68
Kim, E.J. .......................... 36, 53, 63, 122
Kim, H. .............................................. 103
Kim, H.-D. ........................................... 69
Kim, H.-H. ................................... 98, 112
Kim, H.-J. ............................................ 38
Kim, H.-S. ........................................... 90
Kim, J. ......................................... 73, 103
Kim, J.-R. .......................................... 117
Kim, J.W. ......................... 36, 53, 63, 122
Kim, J.-Y. .................................... 70, 119
Kim, K.S. ........................................... 112
Kim, M.-A. ..................................... 78, 88
Kim, M.-J. ..................................... 32, 74
Kim, S. ...................................53, 63, 122
Kim, S.-H. ..................................... 78, 90
Kim, S.-M. ........................................... 73
Kim, S.W............................................. 36
Kim, Y. ................................................ 48
Kim, Y.H. ............................................ 59
Kimura-Hayama, E. ........................... 99
Kimura-Wozniak, T............................ 59
Kindt, I. ................................................ 51
King, A. ............................................. 114
Kingwell, B.A. ..........................22, 30, 44
Kinoshita, N. ................................. 74, 75
Kinova, E. ........................................... 58
Kipinski, L. ........................................ 116
Kirchstetter, W. .................................. 87
150
Kirichenko, N. ..................................... 92
Kirkby, N.S. ....................................... 114
Kishimoto, I. ........................................ 80
Kishiro, M. ........................................... 58
Kishor, Kumar, G. .............................. 85
Kiss, Z.......................................... 78, 118
Kitamura, K. ........................................ 47
Kitas, G.D............................................ 20
Kitayama, M. ....................................... 45
Kivelä, A. ............................................. 31
Kiyonaga, A. ....................................... 54
Kjoelsnes, G. ...................................... 92
Klainman, E. ..................................... 116
Kleber, M.E. .................... 77, 80, 83, 101
Kleijn, D.P.V.D. .................................. 66
Klein, C. ............................................. 107
Klein, S. ............................................. 101
Klimcakova, L. .................................... 99
Klingenberg, R. .................................. 47
Klinger, M. ......................................... 114
Kliuk, Ben-Bassat, O. ...................... 105
Kloch-Badełek, M. ............................ 127
Klöckl, L. ............................................ 112
Knop, F. ............................................... 36
Knuuti, J. ............................................. 46
Ko, N. ................................................... 18
Kobayashi, J. ...................................... 50
Kobayashi, T............................... 40, 109
Koch, M. .............................................. 47
Kodydková, J. ..................................... 82
Koeda, Y. ............................................ 48
Koenig, W. .......................................... 28
Koh, K. ................................................. 89
Koh, K.K. ............................... 89, 95, 102
Kohashi, M. ....................................... 123
Koike, M. ............................................. 30
Koivuniemi, A. .................................... 70
Kolar, F. ............................................... 64
Kolb, D............................................... 124
Koleda, P. ......................................... 116
Kolovou, G. ................................... 81, 84
Kolovou, V. ................................... 81, 84
Komanasin, N. ...................... 84, 99, 100
Komir, I. ............................................... 77
Komuro, I. ......................................... 109
Kon, N. .............................................. 109
Koncsos, P. ...................................... 102
Kondo, K. .................................... 39, 120
Kones, R. ............................................ 17
König, W. .......................................... 101
Konings, M. .................................. 22, 30
Konnov, M. ......................................... 40
Konovalov, G. .................................... 86
Konrad, R. .......................................... 50
Kontny, F. ........................................... 92
Konttinen, J. ....................................... 96
Kontush, A. .................... 42, 72, 103, 108
Konuklugil, B. ................................... 121
Kootte, R............................................. 36
Kopecky, C. ........................................ 49
Korandji, C.......................................... 58
Korbut, R. ..................................... 60, 61
Koren, M.J. ......................................... 44
Kormi, I. .............................................. 61
Korneeva, O.N. .................................. 88
Korotaeva, A.A................................... 84
Korou, L.-M. ..................................... 119
Koryagina, N. ............................... 91, 93
Kosaki, A. ........................................... 59
Koshy, V. .......................................... 110
Kosola, J. ............................................ 69
Kostakou, P. ....................................... 84
Kostal, M. .......................................... 112
Kostapanos, M. .................................. 88
Kostogrys, R.B. .......................... 89, 121
Kotak, B. ............................................. 87
Kotoulas, C................................. 97, 104
Koubaa, N. ................................. 85, 126
Koulaouzidis, G. ................................ 97
Koutoulakis, E. ........................... 97, 104
Koutsogiannis, N. ............................ 114
Kovalcsik, E........................................ 11
Kovanen, P......................................... 14
Kovanen, P.T. .................................... 22
Kovanen, Petri ............................. 14, 23
Kovarik, J. ........................................... 49
Koverech, A.............................28, 62, 67
Koyama, T. ....................................... 123
Kozarov, E. ......................................... 18
Koziolova, N. ...................................... 79
151
Krajcoviechova, A. ....................... 40, 96
Královec, K. ........................................ 94
Krämer, S.D. ....................................... 98
Krane, V. ........................................... 101
Kratky, D. .......................................... 124
Krause, B. ........................................... 22
Krechler, T. ......................................... 82
Krempf, M. .......4, 26, 35, 44, 81, 95, 122
Krempf, Michel ..................................... 7
Kremzer, A.A. ..................................... 56
Krepuska, M. .................................... 127
Krievina, G. ............................... 103, 106
Krneta, M. ........................................... 92
Krogh-Sørensen, K. ........................... 65
Krska, Z. ............................................ 112
Kryvorot, S. ......................................... 56
Kucinskiene, Z.A. ............................... 79
Kučinskienė, Z.A. ............................. 118
Kühnast, S. ......................................... 49
Kuiper, J. ........................... 18, 41, 47, 61
Kuivenhoven, J.A. .................. 26, 42, 55
Kuivenhoven, Jan A. ......................... 26
Kukharchuk, V. ................................... 91
Kukharchuk, V.V. ............................... 84
Kukongwiriyapan, U. ........... 84, 99, 100
Kulesza, J. ........................................ 125
Kulikov, I.............................................. 84
Kumahara, H. ..................................... 54
Kume, N. ............................................. 86
Kumon, Y. ........................................... 94
Kuo, M.-S. ............................................. 6
Kurano, M. ........................................ 106
Kuranova, A. ....................................... 47
Kurl, S. ................................................. 39
Kurteva, T. .......................................... 58
Kurtoglu, H. ....................................... 126
Kusachi, S. .......................................... 93
Kusano, K. .......................................... 86
Kusters, D.M. ...................................... 51
Kusuhara, H........................................ 42
Kuznetsov, A. ..................................... 91
Kuznetsov, A.S................................. 124
Kuznetsov, V. ........................... 107, 110
Kvasnicka, J. .............................. 40, 112
Kvasnicka, T. .............................. 40, 112
Kwakernaak, A................................... 72
Kwan, P. ........................................... 126
Kwok, S....................................... 72, 125
Kwon, H.M. ................................... 70, 76
Kwon, S.W.......................................... 70
Kyaw, T. .............................................. 18
Kyrolainen, H. .................................... 69
Kzhyshkowska, J. ........................ 65, 74
L
La, Guardia, P.G. .............................. 90
La, Motta, C........................................ 59
Laaksonen, R. ............................ 35, 101
Labbadia, G........................................ 31
L'Abbate, A. ........................................ 20
Labrador, Aldana, E.R. ................... 127
Laffargue, M. ................................ 16, 52
Lagarde, M. .................................. 34, 65
Lagerstedt, J.O. ................................. 73
Lagrost, L...................................... 27, 76
Lahikainen, A. .................................... 10
Lähteenmäki, H. ................................ 22
Lalere, B. ............................................ 79
Laman, J.D. ........................................ 66
Lamaze, C. ......................................... 26
Lamb, C. ........................................... 114
Lambert, G. ....................... 19, 31, 51, 73
Lamboley, J.-L. .................................. 46
Lamminmäki, U.................................. 72
Lamotte, C. ........................................... 7
Lamuela-Raventós, R.M. ................. 35
Landmesser, U. ........................... 47, 77
Lang, S. ........................................ 52, 83
Langlois, J.-B. .................................... 64
Langslet, G. .................................. 44, 80
Langsted, A. ....................................... 32
Lanhers, M.-C. ................................. 106
Lannoy, M. .......................................... 62
Lanska, M. .................................. 81, 112
Lanska, V...................................... 28, 99
Lantelme, P. ....................................... 63
Lantieri, O. ........................................ 120
Lapergue, B.............................34, 56, 57
Lappalainen, J. .................................. 30
152
Lapshataeva, O. ............................... 107
Larrieta-Carrasco, E. ......................... 99
Larsson, M. ................................... 10, 93
Lascols, O. ........................................ 100
Latkovskis, G. ................................... 107
Latouche, C. ....................................... 44
Latz, E. ................................................ 18
Latz, Eicke .......................................... 18
Laukkanen, J. ..................................... 39
Laukkanen, J.A. ................................. 39
Laurent, S. .......................................... 96
Laurila, P.-P. ....................................... 33
Lautsch, D. .......................................... 86
Laville, M. ............................................ 35
Lavoie, J.-M. ..................................... 115
Lavrador, M.S. .................................... 30
Lawrence, G. .............................. 91, 114
Lawson, D. ........................................ 124
Layeghkhavidaki, H. ........................ 106
Lazarevic, A. ....................................... 92
Lazaro, I. ............................................. 41
Le, Bras, M. .................................. 44, 76
Le, Goff, W........................ 30, 70, 72, 74
Le, May, C..................................... 6, 102
Le, Q.-H............................................... 34
Leach, N.V. ....................................... 106
Leander, K. ......................................... 36
Leask, R.L. .......................................... 56
Lebedeva, A. .......................... 51, 61, 64
Lebray, P. ............................................ 32
Lebrun, S. ......................................... 117
Lecerf, J.-M. ........................................ 50
Lechuga-Sancho, A.M....................... 10
Lecour, S. ............................................ 48
Ledesma, M. ................................. 60, 84
Lee, B.-H. ............................................ 37
Lee, B.K. ....................................... 70, 76
Lee, B.-S. ............................................ 48
Lee, C.-H........................................... 113
Lee, E.M. ............................................. 36
Lee, H.C. ........................................... 111
Lee, H.-E. ............................................ 99
Lee, H.-L. ...................................... 78, 90
Lee, H.W. .......................................... 111
Lee, J.B. ............................................ 112
Lee, K................................................ 102
Lee, K.H. ............................................. 95
Lee, M.K. ............................................ 27
Lee, R. ........................................ 86, 112
Lee, S.J....................................38, 59, 66
Lee, W.-S............................................ 69
Lee, Y.S. ........................................... 112
Lee-Rueckert, M. ............................... 33
Lefai, E. ............................................... 31
Lefeber, D.J........................................ 55
Lefebvre, P. ........................................ 67
Legeai, C. ........................................... 63
Legedz, L. ................................... 63, 101
Lehtimäki, T...........................33, 63, 101
Leighton, B. ........................................ 35
Leiherer, A. ....................................... 102
Leitão, F. ............................................. 79
Leite, Jr, A.C.d.A. ...................68, 71, 72
Lejnieks, A. ....................................... 106
Lekka, S. ............................................. 84
Lemozy, S. ......................................... 77
Lencova, O. ........................................ 57
Lenfant, F. .......................................... 37
León, M. .............................................. 84
Leopizzi, M. .................................. 28, 67
Leppänen, P. ...................................... 31
Leprince, P. ........................................ 75
Lerchbaum, E. ................................... 83
Leren, T.P........................................... 50
Leschenko, I.G............................. 78, 97
Leschenko, V.A. .......................... 78, 97
Leseche, G. ........................................ 48
Lesna, J. ........................................... 110
Lesnik, P. ............................................ 67
Lestavel, S.................................... 26, 74
Letessier, E. ......................................... 6
Letourneur, D. .................................... 57
Levade, T............................................ 80
Levashov, S. ...................................... 97
Levels, J. ............................................ 20
Levin, M. ............................................. 53
Levkau, B............................................ 37
Levonen, A.-L. ................................... 30
Levy, P. ....................................... 64, 122
Lewis, A. ....................................... 31, 76
153
Lewis, G. ............................................. 15
Lezoualc'h, F. ..................................... 37
Lhomme, M. .......................... 42, 72, 108
Li, F. ..................................................... 74
Li, J.-F.................................................. 51
Li, J.Y. .................................................. 63
Li, J.-Y. ................................................ 63
Li, K.W. ................................................ 80
Li, S. ................................................... 124
Li, S.-Y. ................................................ 20
Li, W..................................................... 67
Li, X. ..................................................... 52
Li, Y.-H. ............................................... 29
Liang, H. .............................................. 87
Liao, J.K. ........................................... 113
Libby, P. ...................................... 1, 4, 62
Liberopoulos, E.N. ............... 86, 88, 104
Libersa, C.............................................. 7
Lichtenstein, L. ................................... 16
Lien, L.-M. ......................................... 100
Liepold, E. ......................... 116, 127, 128
Liljenbäck, H. ...................................... 46
Lim, H.E. ......................... 36, 53, 63, 122
Lim, H.-J. ........................................... 103
Lim, P. ................................................. 52
Lim, S. ................................................. 49
Lim, S.I. ............................................... 36
Lima, P. ............................................... 76
Limam, F. .................................. 120, 121
Limon, I................................................ 60
Lin, C. .................................................. 30
Lin, H.-J. ............................................ 100
Lin, J. ................................................... 85
Lin, S.-J. .................................. 20, 29, 61
Lin, W.-W. ........................................... 93
Lin, W.-Y. .......................................... 100
Lin, Y. .................................................. 43
Lin, Y.-S. ............................................. 91
Lindbom, M. ........................................ 53
Lindholm, H................................. 96, 105
Lindvig, H.W. ...................................... 80
Lins, L.C. ............................................. 85
Lipp, M. .............................................. 113
Litsardopoulou, A. ............................ 120
Litvinov, D. ........................................ 108
Liu, A. .................................................. 47
Liu, E. .......................................... 29, 123
Liu, F.T. ............................................... 29
Liu, H. .................................................. 73
Liu, H.B. ............................................ 118
Liu, H.-Q. ............................................ 66
Liu, L.S. ............................................... 29
Liu, M. ................................................. 65
Liu, P. ................................................ 124
Liu, P.-Y. ...................... 29, 112, 113, 114
Liu, Q................................................... 33
Liu, T. .................................................. 44
Liu, X. .................................................. 73
Liu, Y. .......................................... 72, 125
Liu, Y.-C. ............................................. 46
Liu, Z. .................................................. 33
Liuni, A. ..................................52, 53, 125
Ljunggren, Ö. ....................................... 7
Llanos, Guerrero, C. ....................... 117
Llaverias, G. ....................................... 33
Llorente-Cortes, V. .............................. 6
Llort, M. ............................................. 102
Lodder, R. ........................................... 32
Lohez, O. ...................................... 60, 63
Longo, A. ............................................ 16
Lonsky, V. ........................................... 62
Lonzi, J.P. ......................................... 102
Lookene, A. ........................................ 10
Looker, H. ........................................... 36
López, de, Maturana, Carrasco, I. 100
Lopez, de, Maturana, I...................... 65
López, Lluva, M.T. ........................... 117
López-Maturana, I. ............................ 68
López-Requena, A. ........................... 38
Loppnow, H. ....................................... 64
Lorbeer, R. ....................................... 110
Loretz, C. ............................................ 41
Lorgis, L. ............................................. 53
Lorin, J. ......................................... 53, 58
Lőrincz, H. .............................72, 80, 102
Losurdo, P. ......................................... 35
Lotteau, V. .......................................... 66
Lottenberg, A.M. ................................ 30
Lou, C. .................................................. 6
Loued, S. ............................................ 42
154
Louedec, L. ........... 34, 38, 48, 57, 61, 62
Lounatmaa, K. .................................... 63
Lourenço, A. ....................................... 92
Lourenco, L.P. .................................... 38
Lövgren, J. .......................................... 72
Lowe, R.S. .......................................... 86
Loyau, S. ............................................. 34
Lu, J. .................................................... 33
Luc, G. ..................................... 50, 54, 81
Luca, M.C. ..................................... 52, 53
Lucas, A. ......................... 28, 52, 63, 105
Ludvigsen, T.P. .................................. 95
Ludwig, S. ................................... 34, 113
Luhman, C.J.F. ................................. 101
Lundberg, A. ....................................... 67
Lundberg, A.M. ................................... 41
Lundqvist, A. ................................. 53, 66
Lundström, E. ................................... 106
Lüscher, T.F. ...................................... 47
Lutjohann, D. ...................................... 22
Lütjohann, D. .......................... 30, 74, 83
Lychov, V. ......................................... 107
Lystsova, N. ...................................... 110
Lyytikäinen, L.-P. ....................... 40, 101
Mæhre, H.......................................... 122
Mæhre, H.K. ..................................... 122
Mafalda, B. ......................................... 79
Maggi, L. ............................................. 82
Maggio, R. .......................................... 16
Maglione, F. ....................................... 37
Magni, P. ............................................ 96
Magnussen, C.G. .......................... 7, 32
Magnusson, L.U. ............................... 66
Magré, J. ............................................... 6
Magrè, J. ........................................... 102
Mahini, H. ................................. 116, 123
Maier, W. ............................................ 47
Maifrino, L......................................... 115
Maillard, L. .......................................... 57
Maindonald, R.E. ............................. 124
Maiocchi, G. ..................................... 125
Majdalawieh, A. ................................. 30
Majeed, S. .......................................... 65
Majewski, P. ..................................... 125
Majewski, W. .................................... 125
Majnaric, L. ....................................... 111
Majnaric, L.T. ..................................... 93
Majul, C............................................... 86
Mak, S. ................................................ 53
Makariou, S.E. ........................... 88, 104
Makedou, A. ..................................... 119
Makedou, K. ..................................... 119
Mäkelä, K.-M. ................................... 101
Mäkinen, P. ........................................ 31
Makino, H. .................................. 80, 124
Makino, Y............................................ 79
Makita, Y. ...................................... 29, 55
Makoveichuk, E. ................................ 31
Makris, G. ......................................... 114
Maksimov, V. ..................................... 84
Malec, M.M. ...................................... 121
Malecki, M. ....................................... 121
Małecki, M.T. .................................... 127
Malek, I. .............................................. 28
Malet, N. ............................................. 52
Malinska, H. ....................................... 54
Mallat, Z. ............................................. 41
Mallavia, B. ......................................... 41
Mallias, I. ............................................ 82
M
Ma, X. .................................................. 52
Maatouk, F. ................................... 31, 76
Mabuchi, H.................................... 50, 80
Macaluso, L. ....................................... 35
Macášek, J.......................................... 82
Mach, F. ........................................ 47, 48
Machado, R. ....................................... 30
Machida, T. ......................................... 75
Machtoub, L.H. ................................... 98
Maciag, J. ............................................ 66
Macic, Dzankovic, A. ......................... 92
MacKay, D.S..................................... 123
Mackay, M........................................... 40
Madden, S. ......................................... 22
Madder, R.D. ...................................... 22
Madjid, M. ........................................... 32
Madrigal-Matute, J. ............................ 41
Maegawa, H. ...................................... 91
155
Mallol, R. ............................................. 36
Malysheva, O. .................................. 107
Malyutina, S. ....................................... 84
Mamareli, V................................. 97, 104
Mamarelis, I.E. ................................. 104
Mameri, A.......................................... 115
Mammeri, A. ..................................... 104
Mañas, García, M.D. ....................... 117
Mandic-Radic, S................................. 94
Mandolini, C........................................ 90
Manduteanu, I. ................................... 41
Mangas, A. .......................... 92, 109, 121
Mangione, A. ...................................... 43
Manolopoulos, V.G. ........................... 81
Manolopoulou, D. ............................... 84
Manthey, H.D. .................................... 47
Mantovani, A....................................... 34
Manzini, S. .....33, 35, 58, 62, 63, 86, 126
Marais, A.D. ........................................ 81
Marais, D. ...................................... 31, 51
Maranghi, M. ........................... 10, 31, 84
Maranhao, R.C. ................................ 115
Maranhão, R.C. ...................... 68, 71, 72
Maraninchi, M. .................................. 101
Marcais, C. .......................................... 82
Marçais, C. .................................... 31, 74
Marcantonio, P. .................................. 90
March, K. ............................................. 95
Marchan, Carranza, E. .................... 117
Marchetti, G. ....................................... 60
Marchon, C. ...................................... 115
Marciniak, W. .................................... 116
Marcoyannopoulou, Fojas, H. ........ 101
Marcucci, R. .................................. 70, 95
Marduel, M. ......................................... 50
Margariti, P. ...................................... 126
Margaritis, M. .................................... 112
Margolis, L. ............................. 51, 61, 64
Marina, Breysse, M.......................... 117
Marinari, E..................................... 28, 67
Mark, L. ............................................. 118
Márk, L. ............................................... 78
Markatseli, T.E. ................................ 126
Markovic-Lipkovski, J. ..................... 119
Markus, H.S. ..................................... 114
Marleau, S. ......................................... 68
Marmash, N........................................ 65
Marmontel, O. .............................. 74, 82
Marotta, G. ......................................... 51
Marques, L. ........................................ 52
Marques-Pinheiro, A. ........................ 26
Marre, M. .......................................... 120
Marsche, G. .................................. 49, 83
Marszałek, A. ................................... 125
Marta, D. ........................................... 110
Martin, C. ...................................... 80, 81
Martin, L. ............................................. 57
Martín-Campos, J.M. ........................ 10
Martinez, Comendador, J.M. ........... 88
Martinez, L.................................... 52, 85
Martinez, L.O. .................................... 16
Martinez, M. ....................................... 54
Martinez, Martinez, A. ................. 97, 98
Martínez-González, M.Á................... 35
Martín-Ventura, J.L. .......................... 41
Martiny, L. ........................................... 52
Mary-Krause, M. .......................... 52, 83
März, W. .......................... 77, 80, 83, 101
Marzocchi-Machado, C.M. ............... 93
Marzougui, F. ................................... 104
Mas, A. .............................................. 110
Masana, L..............................17, 36, 102
Mascoli, F. .......................................... 60
Mashayekhi, S. .................................. 66
Maslak, E. ................................... 89, 121
Maślak, E. ......................................... 106
Masoura, C. ........................................ 44
Massama, L...................................... 121
Mastroiacovo, D................................. 90
Masuda, D. ................................. 87, 109
Masuda, T. ....................................... 118
Mata, K. .............................................. 95
Mateo-Gallego, R. ............................. 84
Mateuszuk, L.............................. 89, 121
Matos, L.N. ................................... 43, 85
Matsuda, M. ....................................... 94
Matsuda, T. ........................................ 54
Matsumoto, T. .................................... 32
Matsumura, T. .................................... 55
Matsunaga, A. .................................. 108
156
Matsuo, K. ........................................... 73
Matsuoka, E........................................ 59
Matsuoka, T. ....................................... 79
Matsushima, T. ................................. 106
Matsuyama, A. ................................. 109
Mattei, C. ........................................... 101
Matter, C.M. ........................................ 47
Mattner, F............................................ 87
Maurice, P. .................................... 52, 61
Mavronasiou, E. ............................... 114
Mayasari, D.S. .................................... 11
Mayer, O. ...................................... 40, 96
Mayr, M. ............................................ 114
Mažeikienė, A. .................................. 118
Mazer, N.A. ................................... 33, 77
Mazerkina, N.A................................. 105
Mazighi, M..................................... 34, 56
Mazur, A. ........................... 107, 118, 122
Mazzolai, L.......................................... 17
Mazzone, A. .......................... 61, 93, 108
Mazzucco, S. .......................... 64, 65, 67
Mazzuco, T.L. ................................... 109
Mc, Loughlin, S. ............................... 119
McDonald, K. ...................................... 56
McKeigue, P. .......................... 36, 49, 78
McKenney, J.M. ................................. 87
McLaughlin, K............................. 52, 125
McNamara, R. .................................... 22
Meagher, E.A. .................................... 81
Meani, P. ........................................... 110
Mechtouff, L. ....................................... 46
Medbury, H. ........................................ 65
Medeiros, A.M. ................................... 81
Medvedeva, E. ................................... 60
Medvegy, M. ..................................... 102
Meguro, Y. .......................................... 93
Mehinagic, D....................................... 92
Mehri, S. .............................. 85, 101, 126
Mehta, V. ............................................. 59
Meikle, P. .......................................... 119
Meikle, P.J. ................................... 22, 30
Meilhac, O. .......34, 38, 48, 56, 57, 64, 73
Meinitzer, A. ...................................... 101
Melander, O. ....................................... 17
Melchionna, S..................................... 99
Meletta, R. .......................................... 98
Mellal, K. ............................................. 68
Mellis, S. ............................................. 26
Mellström, D. ........................................ 7
Melnichenko, A.A. ............................. 71
Melnichenko, G. ................................. 97
Melone, M. .............................48, 71, 105
Mendoza, J. ........................................ 26
Mendoza-Barberà, E......................... 10
Menegazzi, M. ................................... 67
Mensink, R. ........................................ 30
Mensink, R.P................................ 22, 74
Mention, K. ......................................... 80
Merino, J. ...............................17, 36, 102
Merkely, B. ....................................... 127
Merkler, A. .......................................... 82
Merlin, M. ............................................ 74
Meroño, T. ........................................ 108
Metaxa, V. .......................................... 44
Metelskaya, V.A................................. 79
Metso, J. ........................................... 128
Meurs, I. .............................................. 65
Meydani, M. ...................................... 126
Mező, I. ....................................... 78, 118
Mezzano, D. ....................................... 34
Mezzetti, A.......................................... 90
Miantezila, Basilua, J. ....................... 83
Miarka, P. ......................................... 127
Micallef, P.A. ...................................... 66
Miccoli, R. ........................................... 51
Miceli, A. ............................................. 93
Michalsky, D. .................................... 125
Michel, J.B. ..............................34, 38, 48
Michel, J.-B. ..............................5, 30, 34
Michel, J.-B. ....................................... 48
Michel, J.-B. ....................................... 56
Michel, J.-B. ....................................... 57
Michel, J.-B. ....................................... 61
Michel, J.-B. ....................................... 64
Michel, J.-B. ..................................... 114
Michishita, R. ..................................... 54
Mickley, H. .......................................... 45
Mihas, C. ............................................ 84
Mikhailidis, D.P. ......................45, 49, 50
Mikolajczyk, T. ............................. 60, 61
157
Mikołajczyk, T. .................................. 116
Mikolajczyk, T.P. ................................ 66
Miled, A. ........................................ 31, 76
Milei, J. .............................................. 119
Milenkovic, D. ..................... 43, 107, 118
Milidis, T. ............................................. 82
Milionis, H.J. ..................................... 120
Miliou, A. ............................................. 44
Miljkovic, M. ........................................ 94
Millar, J. ................................................. 2
Miller, K. .............................................. 26
Miller, S.A............................................ 82
Min, P.-K. ............................................ 70
Minakawa, Y. ...................................... 93
Miname, M. ......................................... 42
Minelli, S............................................ 107
Ming, J. ................................................ 47
Ming, W. .............................................. 65
Minicocci, I. ................................... 10, 31
Mintale, I............................................ 125
Minutolo, A. ......................................... 16
Miranda-Zamora, R. .......................... 90
Mirel, D. ............................................... 33
Mislea, O. .................................. 104, 107
Mitani, K. ........................................... 123
Mitchenko, O. ..................................... 82
Miteva, Y. .......................................... 108
Mitrofanov, K.Y. ................................ 100
Mitrogianni, Z. ..................................... 76
Mitterhofer, A.P. ........................... 28, 67
Mittlboeck, M. ................................... 114
Miura, K. ............................ 48, 77, 91, 95
Miura, S. ............................................ 108
Miura, Y. .............................................. 62
Miyagawa, N. ...................................... 95
Miyamatsu, N. ............................ 78, 103
Miyamoto, Y. ....................................... 80
Miyashita, K. ................................. 74, 75
Miyoshi, T...................................... 86, 93
Mizue, H. ............................................. 93
Mizuno, S. ..................................... 29, 55
Mizuno, T. ................................... 42, 106
Mlynarik, V. ......................................... 17
Mmamarelis, I.E. ................................ 97
Modéer, T............................................ 63
Mody, F. ............................................ 111
Moesgaard, S.G. ............................... 95
Mohd, Ishak, N.H............................... 66
Mohd, Ismail, A. ......................58, 66, 72
Mohd, Kornain, N.K........................... 58
Mohd, Mokhsin, N.A.......................... 72
Mohd, Nawawi, H. ..................58, 66, 72
Moisenovich, M. ................................. 74
Moldoveanu, E. ................................ 110
Mollaki, V. ........................................... 81
Möller, B. .......................................... 106
Mombelli, G. ....................................... 96
Momiyama, Y. .................................. 121
Momot, A. ......................................... 100
Monaco, C. ......................................... 63
Monguchi, T. .............................. 39, 120
Monier, S. ......................................... 104
Monk, D. ............................................. 74
Montalescot, G................................. 5, 8
Montali, A............................................ 31
Montecucco, F. ............................ 47, 48
Monterio, A.M. ................................. 101
Moon, J. .............................................. 95
Moon, M.K. ......................................... 49
Moore, K. ............................................ 15
Moore, K.J. ......................................... 37
Moore, X.L. ......................................... 27
Morand, C. ...........................43, 107, 118
Morange, P.-E.................................... 54
Mordhwaj, P. .................................... 108
Moreira, T.B. ................................ 71, 72
Moreno, J.-A. ..................................... 56
Moreno, L.A.......................................... 7
Moreyra, E. ................................. 96, 102
Morgantini, C...................................... 35
Mörgelin, M. ....................................... 73
Mori, K....................................39, 74, 120
Mori, M. ......................................... 50, 80
Mori, T. ...................................... 119, 120
Mori, Y................................................. 59
Moriarty, P.M. ................................... 124
Morimoto, A. ............................... 78, 103
Morino, A. ................................... 78, 103
Morita, H. ............................................ 86
Morozov, A. ........................................ 18
158
Morozov, I.A. ...................................... 62
Morvan, M. .......................................... 38
Moshkin, A.V. ................................... 105
Moskaleva, N. ..................................... 56
Mossinson, D. ................................... 116
Mostowik, M. ....................................... 39
Motazacker, M.M. .............................. 55
Motocu, M. ........................................ 104
Moulias, A. ........................................ 114
Moulin, P. .............4, 9, 31, 34, 74, 81, 82
Moulin, Philippe .............................. 4, 15
Moulopoulos, L. .................................. 82
Moura, F. ............................................. 78
Mousavinasab, S.N. .......................... 91
Moussa, A. .................................... 83, 92
Moutzouri, E. ...................................... 88
Movassaghpur, A. .............................. 66
Mozwillo, J.S..................................... 121
Mrowiecki, T. ...................................... 61
Mrowiecki, W. ..................................... 61
Mrudula, Spurthi, K. ........................... 85
Mu, L. ................................................... 98
Muačević-Katanec, D. ....................... 82
Muchova, L. ...................................... 120
Muderrisoglu, H. ............................... 109
Müderrisoğlu, H. ......................... 89, 107
Muggia, C.......................................... 101
Mühlberg, K. ..................................... 107
Mulder, M. ........................................... 70
Muller, A. ........................................... 119
Müller, A. ............................................. 98
Muller, C. ....................................... 37, 70
Müller, G.............................................. 86
Muller, J.E. .......................................... 22
Müller-Werdan, U............................... 64
Muller-Wieland, D. ............................. 86
Münch, R. ............................................ 68
Mündlein, A. ...................................... 102
Münzel, T. ............................................. 8
Murakami, M. ...................................... 75
Murakami, Y. ................................ 48, 95
Murano, T. ................................... 31, 111
Muro, A. ................................... 52, 62, 94
Murohara, T. ............................... 58, 103
Musikhina, N. ............................ 107, 110
Musil, F. ............................................ 110
Musliner, T.......................................... 85
Mustafina, S. .................................... 102
Mysliwiec, M. .............................. 78, 111
N
Na, J.H. ..................................53, 63, 122
Na, J.O................................................ 36
Nachtigal, P. ..........................57, 89, 120
Naderi, G.A. ....................................... 70
Nael, C. ............................................. 122
Naelten, G. ....................................... 123
Naessen, T. ........................................ 93
Nagano, C. ....................................... 123
Nagashima, S. ................................... 73
Nagayama, D. ............. 31, 109, 111, 123
Nagel, E. ............................................. 98
Nagumo, A. ................. 31, 109, 111, 123
Nair, A. ................................................ 81
Nair, D. ................................................ 81
Nakajima, H...........................39, 74, 120
Nakajima, K. ................................. 74, 75
Nakamoto, K. ..................................... 94
Nakamura, K. ..................................... 86
Nakamura, M. .............................. 32, 48
Nakamura, S. ............................... 29, 55
Nakamura, Y. ............................... 76, 91
Nakandakare, E. ...................30, 83, 109
Nakandakare, E.R. .......................... 128
Nakanishi, C. ................................ 50, 80
Nakaoka, H. ..................................... 109
Nakatani, K....................................... 109
Nakayama, K. .................................... 11
Nakayama, R. .................................... 93
Nakbi, A. ..................................... 85, 126
Naknadakare, E. ................................ 78
Namiki, A. ........................................... 55
Nanjee, M.N. ...................................... 33
Nanobachvili, J. ............................... 114
Naoi, S. ............................................... 42
Napoli, A. ............................................ 97
Nara, M. .............................................. 75
Narbute, I. ......................................... 125
Narverud, I.......................................... 80
159
Nash, G. .............................................. 34
Näslund, U. ......................................... 61
Natali, A. ........................................ 20, 35
Natoli, A.K. .......................................... 44
Nauck, M. .......................................... 110
Naukkarinen, J. .................................. 33
Nawawi, H. ........................................ 120
Nayeri, H. ............................................ 70
Nazarkina, I.M. ................................... 78
Nazih, E.-H. ........................................ 35
Ndiaye, N.C. ..................................... 106
Neffati, S. .................................... 92, 104
Neggazi, S. ......................................... 74
Negrao, C.E. ..................................... 115
Negrean, V................................ 104, 107
Negre-Salvayre, A. ............................ 70
Nègre-Salvayre, A. ...................... 37, 38
Negro, A. ....................................... 28, 67
Nekaies, Y. ................................. 79, 119
Nematbakhsh, M. ............................... 56
Nemeckova, I. ............................ 57, 120
Nemoto, T. .......................... 73, 109, 122
Nessler, J. ........................................... 39
Nestel, P............................................ 119
Neumayer, C. ................................... 114
Newby, A.C. ........................................ 59
Newby, D.E. ...................................... 124
Newman, J. ....................................... 122
Ng, T.W. .............................................. 30
Ngallhy, E.......................................... 105
Ngo, Sock, E.T. ................................ 115
Nguyen, M.T. .................................... 110
Nguyen, P. .......................................... 35
Niccoli, G. .................................... 40, 107
Nicholls, S. .......................................... 22
Nicholls, S.J. ....................................... 45
Nicoletti, A. .......................................... 38
Nicoll, R. .............................................. 97
Nielsen, S.F. ....................................... 40
Nieuwdorp, M. .................................... 36
Nieves, J. ............................................ 80
Nighoghossian, N. ....................... 46, 64
Niimi, M. ............................................ 123
Niiyama, M. ......................................... 32
Nijhuis, M.M.O. ................................... 66
Nikfar, S. ..................................45, 49, 50
Nikiforov, N. ........................................ 74
Nikiforov, N.G. ................................... 70
Nikitin, Y. ............................................ 84
Nikitskaya, E. ............................... 51, 64
Nikolaou, C......................................... 38
Nikolaou, V. ...................................... 120
Nikolic, D. ................................45, 49, 50
Nilsson, J. ........................ 18, 21, 75, 110
Nilsson, Jan........................................ 21
Nilsson, M. .................................... 7, 110
Nilsson, S. .......................................... 75
Nilsson, S.K.................................. 10, 31
Ninio, E. .................................18, 47, 117
Nishida, M. ....................................... 109
Nishikawa, T. ............................. 78, 103
Nishimoto, O. ..................................... 94
Nishinari, M. ....................................... 56
Nishio, M. .......................................... 122
Nishiuchi, J. ........................................ 94
Nishiyama, H...................................... 94
Nissen, S. ........................................... 15
Nitulescu, M. .................................... 110
Niwano, S. ........................................ 118
Nizomov, A. ........................................ 89
Nizomov, A.A. .............................. 65, 89
Noa, M. ............................................... 38
Nobecourt, E. ..................................... 44
Nobrega, O. ........................................ 71
Noce, V. .............................................. 97
Noda, C............................................. 118
Noels, H. ............................................. 67
Noeva, E. ............................................ 47
Nofer, J.-R. ......................................... 76
Nofroni, I. ...................................... 28, 67
Noguchi, T. ................................... 50, 80
Nogueira, M................................ 53, 116
Nohara, A. .................................... 50, 80
Nollace, A. .......................................... 74
Nony, S. .............................................. 82
Norata, D. ........................................... 33
Norata, G.D. ... 33, 34, 37, 52, 62, 67, 68,
94, 112
Norata, Giuseppe Danilo .................. 23
Nordestgaard, B. ............ 1, 3, 28, 36, 55
160
Nordestgaard, B.G. 7, 20, 32, 40, 54, 84
Nordestgaard, Børge ........................... 3
Nosaka, K. .......................................... 93
Nosalski, R.................................... 60, 66
Noto, D. ............................................... 51
Novak, K............................................ 125
Novakovic, R. ................................... 119
Nozadze, D. ........................................ 75
Nozako, M. ........................................ 123
Ntalas, I. ............................................ 114
Nunes, V. ............................................ 30
Nunes, V.S.......................... 83, 109, 128
Núñez, I. .............................................. 35
Nurgazieva, D..................................... 65
Nurmohamed, M.T. ............................ 20
Nusshold, C. ..................................... 124
Nykonenko, O................................... 114
Nyrén, R. ............................................. 75
Ohsuzu, F. ........................................ 121
Oikonen, M. .................................. 36, 40
Oikonomou, E. ................................... 44
Okada, T. .......................................... 109
Okamura, T. ........ 48, 77, 78, 80, 91, 103
Okayama, A. .............................. 77, 111
Oksala, N. ......................................... 101
Oktay, G. ............................................ 69
Okumura, K. ............................... 58, 103
Okutsu, R.......................................... 123
Okyay, K. .............................89, 107, 109
Oláh, A.V. ........................................... 72
Olano-Martin, E. ................................ 80
Oliva, I. ................................................ 74
Olivato, S. ................................64, 65, 67
Olivecrona, G. .........................10, 31, 75
Olivecrona, T...................................... 31
Oliveira, A.E.F.D. ..................... 126, 127
Oliveira, H.C.F. ................................ 101
Olkkonen, V........................................ 31
Olkkonen, V.M. .................................... 6
Olkkonen, Vesa M ............................... 6
Ollivier, V. ..................................... 30, 61
Olsen, L.H. ......................................... 95
Omata, K. ......................................... 125
Omezzine, A. ........................83, 92, 104
Ong, H................................................. 68
Onoda, T..................................... 32, 111
Onodera, M. ....................................... 32
Öörni, K......................................... 10, 22
Opstad, T.B. ....................................... 55
Oravec, S.............................79, 108, 115
Orekhov, A. ........................................ 72
Orekhov, A.N. ........... 62, 70, 71, 74, 100
Orekhova, V.A. .................................. 71
Oresic, M. ........................................... 33
Orho-Melander, M. ...............17, 39, 101
Orsoni, A..................................... 90, 103
Orsoni, A.K. ........................................ 22
Ortega, E. ......................................... 126
Ortiz, G. .............................................. 34
Osaba, L. ............................................ 80
Ose, L. ................................................ 80
Oshima, S................................... 35, 109
Osipenko, A.N.................................... 77
O
Obika, S. ............................................. 44
Obrowsky, S. .................................... 124
Obuchi, A. ......................................... 121
Oda, H. ................................................ 58
Odurny, A. ......................................... 114
Oe, H. .................................................. 86
Ogawa, M. ........................................... 32
Oguiza, A. ........................................... 41
Ogura, M. ............................................ 40
Oh, D.J. ........................... 36, 53, 63, 122
Oh, G.T................................................ 68
Oh, J.-H. ............................................ 111
Oh, P.C........................................ 89, 102
Ohama, T. ......................................... 109
Ohguro, T. ........................................... 94
Ohira, M. ..................... 31, 109, 111, 123
Ohkawa, K. ......................................... 93
Ohkubo, T. .............................. 77, 91, 95
Ohlsson, C. ........................................... 7
Ohmori, R.......................................... 121
Ohno, Y. .............................................. 86
Ohnuki, T. ......................................... 127
Öhrvik, J. ............................................. 36
Ohsawa, M. ................................. 48, 111
161
Østerud, B. ........................................ 122
Osuga, J.-I. ......................................... 73
Oszkinis, G. ...................................... 125
Otero-Losada, M. ............................. 119
Othmani, K. ....................................... 119
Ott, A. ................................................ 102
Ottaviano, G. .................................... 119
Ou, H.-Y. ............................................. 29
Oudar, O. ............................................ 57
Ougerram, K. ...................................... 95
Ouguerram, K. ................ 26, 35, 50, 122
Out, C. ................................................. 36
Ouyang, X.-P. ..................................... 71
Ovsyi, I. ............................................... 65
Oyedokun, B. .................................... 120
Ozansoy, G. ...................................... 121
Ozbal, S. ............................................. 69
Özçalık, E.......................................... 107
Ozerova, I.N. ...................................... 79
Ozturk, Z. ............................................ 59
Palombo, D. ....................................... 47
Palotie, A. ........................................... 33
Pan, X. ................................................ 30
Panagiotakos, D.B. ......................... 120
Panagopoulou, I. ............................... 88
Panariti, F. ........................................ 125
Pane, B. .............................................. 47
Panes, O............................................. 34
Pang, J.............................................. 103
Panizon, E. ......................................... 35
Pankajakshan, D. .............................. 51
Panov, D. .......................................... 117
Pantopoulou, A. ............................... 119
Panzoldo, N.B. ......................71, 83, 128
Papadimitriou, L................................. 44
Papafaklis, M.I. ............................ 29, 55
Papageorgiou, G. ............................ 119
Papagoras, C. .......................... 106, 126
Papanikolaou, A. ............................... 45
Papastefanou, E. ............................... 82
Paradela-Dobarro, B. ........................ 57
Paradossi, U. ................................... 108
Paradowski, M. ................................ 102
Paragh, G. ......... 72, 78, 80, 95, 102, 118
Parahuleva, M.................................. 113
Paranhos, G. ...................................... 90
Parfenov, A. ....................................... 39
Parfenova, N.S. ............................... 124
Parhofer, K. .......................................... 5
Park, C.G. ........................................... 36
Park, C.-G. ......................................... 53
Park, C.-G. ......................................... 63
Park, C.-G. ....................................... 122
Park, C.M............................................ 95
Park, D.-G. ................................... 78, 90
Park, G.-Y. .......................................... 73
Park, H.-Y. .................................. 32, 103
Park, J.E. ............................................ 48
Park, J.H. .................................... 63, 122
Park, K.-H. ........................................ 117
Park, S.Y. ................................38, 59, 66
Park, Y.W. ........................................ 112
Parker, J. ............................................ 53
Parker, J.D. ................................ 52, 125
Parkes, H. ........................................... 79
P
Pacha, J. ............................................. 64
Pacienza, N. ....................................... 82
Packard, C. ................................... 19, 25
Packard, Chris .................................... 19
Padilla, N. .......................................... 101
Pados, G. .................................... 78, 118
Padra, J. .............................................. 80
Padro, T. ............................................... 6
Pagano, S. .......................................... 47
Pagnier, A. .......................................... 80
Pagoni, S. ............................... 54, 82, 95
Paillard, F. ................................. 121, 123
Paim, B.A. ......................................... 101
Pais, de, Barros, J.-P. ....................... 27
Pais, R. ................................................ 32
Pal, P. .................................................. 78
Palacios, L. ......................................... 80
Palagi, P.M. ........................................ 60
Palatkina, L. ........................................ 88
Palladini, G. ........................................ 61
Palmer, M.K. ....................................... 44
Palmieri, C. ....................................... 108
162
Parlevliet, E.T. .................................... 16
Parodi, O. ...................................... 62, 67
Parolini, C. .......... 33, 35, 58, 62, 63, 126
Parra, E.S. ............................ 78, 83, 128
Parri, A. ............................................. 109
Parthasarathy, S. ................. 11, 65, 108
Parviz, B. ........................................... 113
Pasanisi, F. ......................................... 43
Paschopoulos, M. .............................. 57
Pashang, M......................................... 46
Pasqual, N. ......................................... 47
Passarelli, M. .................................... 109
Passet, M. ........................................... 30
Pasterkamp, G. .................................. 66
Patankar, J.V. ................................... 124
Patti, L. ................................................ 43
Patuzzo, C. ......................................... 65
Paul, J.-L. ............................................ 30
Paula, H. ............................................. 53
Paultre, C. ................................... 63, 101
Paumelle, R. ............................... 28, 105
Paus, A. ............................................... 92
Pavanello, C. ...................................... 96
Pavão, M.L.......................................... 91
Pavlova, M.G. ................................... 105
Pavlunina, T. ....................................... 66
Pavlunina, T.O. .................................. 84
Pawlak, D. ................................... 78, 111
Pawlak, K. ................................... 78, 111
Paximadas, S. .............................. 54, 95
Pazzucconi, F. .................................... 96
Pedersen, H.D. ................................... 95
Pedersen, T. ....................................... 19
Pedersen, Terje.................................. 19
Pedrico, D. ........................................ 102
Pedro-Botet, J. ......................... 109, 110
Pedros, C. ........................................... 52
Peel, S. ................................................ 98
Peitsch, M.C. .................................... 117
Peitzsch, M. ........................................ 40
Pellegatta, F. ........................ 67, 68, 112
Pellegrin, M. ........................................ 17
Pellet-Many, C. ................................... 59
Pelosi, G........................................ 62, 67
Peloso, G. ........................................... 50
Pencina, M.J. ..................................... 45
Pende, A. ............................................ 47
Peng, J................................................ 73
Peng, J.-Y. .......................................... 51
Pera, M. ............................................ 109
Pereira, A............................................ 92
Pereira, V.H........................................ 92
Pereira-da-Silva, T. ........................... 53
Pérez, A. ....................................... 38, 68
Perez, Martinez, P........................... 119
Pérez-López, J................................... 84
Pérez-Méndez, O. ............................. 77
Pergolini, D......................................... 31
Perkov, S. ......................................... 115
Perlini, S. ............................................ 61
Pernalete, Bustos, I.C. .................... 117
Perova, N.V. ....................................... 79
Perrea, D.N. ..................................... 119
Perret, B. ...................................... 16, 85
Perret, M. ............................................ 64
Perret, P. ............................................ 99
Perrin-Cocon, L. ................................ 66
Perrot, L. ............................................. 82
Perségol, L. ...................................... 104
Persson, A. ....................................... 110
Persson, L. ......................................... 39
Pervushina, N. ................................... 70
Pessi, T. .............................................. 63
Petelina, T. ............................... 107, 110
Petit, J.-M. .................................. 27, 104
Petrak, O. ......................................... 125
Petrashevskaya, T. ......................... 110
Petrek, M. ........................................... 62
Petri, M. .............................................. 64
Petrides, F. ......................................... 51
Petrii, M.H. ........................................ 122
Petrischeva, A.................................... 93
Petrischeva, A.V. ............................... 91
Petrkova, J. ........................................ 62
Petrlova, J. ......................................... 73
Pettersen, A.Å.................................... 55
Pettersson, K. .............................. 18, 72
Pfeiferova, J. .............................. 57, 120
Philippe, M.......................................... 38
Phinikaridou, A................................... 58
163
Picard, P............................................ 123
Pichler, M. ........................................... 86
Piechota-Polanczyk, A. ................... 114
Pierce, G.N. ........................................ 60
Pietri, S. ............................................. 100
Pigna, G. ............................................. 31
Pignatti, P.F. ....................................... 65
Piksasova, O. ..................................... 36
Pilecki, W. ......................................... 116
Pileggi, S. .......................................... 100
Pillegand, C. ..................................... 105
Pillois, X. ............................................. 84
Pillot, B. ................................................. 6
Pilz, S. ......................................... 83, 101
Pinegina, N. .................................. 51, 64
Pinilla, Echeverri, N. ........................ 117
Pinna, C. ............................................. 58
Pinotti, E. ............................................. 51
Pinto, G.A............................................ 85
Pintó, X. ............................................... 35
Pinyol, M. .......................................... 126
Piotrowska, A. .................................... 38
Piqueras, Flores, J. .......................... 117
Pirault, J. ............................................. 67
Pirk, J................................................... 28
Pirruccello, J.P. .................................. 50
Pirvulescu, M. ..................................... 41
Pirvulescu, M.M.................................. 41
Pissaridi, K. ................................. 97, 104
Pitha, J. ......................................... 28, 99
Pitivej, Thurakit, P. ..................... 84, 100
Pitsavos, C.......................................... 44
Plana, N. ............................... 17, 36, 102
Plantaz, D. .......................................... 80
Plat, J......................... 14, 22, 30, 74, 118
Plomp, J.J. .......................................... 65
Pocoví, M. ........................................... 84
Podhorska-Okołów, M. ...................... 38
Pogorelova, O. ................................... 91
Pohlmann, A.R. ................................ 123
Poitry-Yamate, C................................ 17
Pojskic, B. ........................................... 92
Pojskic, M. ........................................... 92
Pokrovsky, S................................. 86, 87
Poledne, R. ............................. 28, 64, 99
Polimeni, L.......................................... 84
Polis, A.B. ........................................... 85
Polonskaya, Y. ................................. 127
Polyanskaya, E. ................................. 79
Ponkin, S. ........................................... 91
Pons, J. ............................................... 87
Popova, A. .......................................... 65
Portelance, S.G. ................................ 68
Português, J. ...................................... 92
Posadas-Romero, C. .................. 77, 99
Posadas-Sánchez, R. ....................... 99
Postmus, I. ......................................... 88
Potekhina, A. ...................................... 47
Poteshkin, Y. ...................................... 97
Potor, L. .............................................. 29
Povoa, R.M. ....................................... 43
Power, P. ...............................48, 71, 105
Pozzi, C. ........................................... 112
Prathiba, N. ........................................ 85
Prehn, C. .................................... 75, 110
Prieur, X. ....................................... 6, 102
Princen, H.M.G. ........................... 49, 71
Proietta, M. ..............................28, 62, 67
Prokazova, N. .................................... 66
Prolini, C. ............................................ 86
Proniewski, B. ............................ 57, 106
Prosser, H. ......................................... 42
Prostran, M. ................................ 94, 113
Protti, A. .............................................. 58
Proust, C........................................... 117
Provatorov, S. .................................... 47
Prüfer, J. ........................................... 107
Prüfer, N. .................................. 107, 112
Prugger, C. ......................................... 54
Pucheu, Y. .......................................... 84
Puig, de, Dou, J. .............................. 110
Pujos-Guillot, E. ............................... 122
Pukite, K. .......................................... 113
Pulakazhi, Venu, V.K. ............52, 62, 94
Puntmann, V. ..................................... 98
Puntoni, M. ......................................... 62
Puntoni, M.R. ..................................... 67
Puri, R. ................................................ 22
Pussinen, P. ....................................... 61
Pylaeva, E. ......................................... 47
164
Rantakömi, S.H. ................................ 39
Rantapää-Dahlqvist, S.................... 106
Raposeiras-Roubín, S. ..................... 57
Ras, R.T. ............................................ 43
Rashid, S. ..............................48, 71, 105
Raskina, K. ......................................... 47
Rasmussen, K.L. ............................... 84
Rastelli, F.......................................... 112
Ratziu, V. ............................................ 32
Raungaard, B. .................................... 50
Rauramaa, R...................................... 39
Ravagnani, F.G. ................................ 90
Ray, K.K. ............................................ 45
Ray, P.C. ............................................ 75
Raymond-Letron, I. ........................... 37
Rebhi, L. ................................83, 92, 104
Recio, C. ............................................. 41
Reddy-Luthmoodoo, M. .................... 44
Redfors, B. ......................................... 53
Reel, B. ....................................59, 60, 69
Reffelmann, T. ................................. 110
Rehakova, L. ...................................... 64
Reiber, I. ..................................... 78, 118
Reichardt, F........................................ 75
Reija, Lopez, L. ................................ 125
Reijnders, D. ...................................... 36
Reiner, Ž. ............................................ 82
Reiner, Zeljko ..................................... 17
Rejeb, J..................................83, 92, 104
Remaley, A. ........................................ 22
Remaley, A.T. .................................... 27
Ren, Z. ................................................ 29
Renard, M. ........................................ 109
Renault, M.-A. .................................... 28
Rensen, P.C.N. ................. 16, 49, 65, 71
Rensen, S........................................... 71
Ressureição, K. ............................... 115
Retterstøl, K. ...................................... 80
Revuelta-Lopez, E............................... 6
Rewiuk, K. ........................................ 116
Rey, A. .............................................. 122
Reynaud, A. ....................................... 84
Rha, S.-W. ....................... 36, 53, 63, 122
Riahin, A. ............................................ 63
Riant, E. .............................................. 49
Pyysalo, M. ......................................... 63
Q
Qian, H. ............................................... 40
Qian, S. ............................................... 33
Quan, H. .............................................. 40
Quax, P. ........................................ 18, 61
Quax, P.H.A. ................................. 41, 47
Quelhas, I............................................ 92
Quillard, T. .......................................... 62
Quinn, C.M. ......................................... 74
Quintao, E. .......................................... 30
Quintao, E.C.R. ............................ 78, 83
Quintão, E.C.R. ................................ 128
Quon, M. ............................................. 89
R
Raal, F. .......................................... 22, 44
Raal, F.J. ....................................... 15, 44
Rabelink, T.J......................................... 8
Rabès, J.-P. .................................. 26, 50
Rached, F.H. ...................................... 42
Radenković, M. ................................ 113
Rader, D. ............................................. 10
Rader, D.J. .................................... 10, 81
Radovic, B. ....................................... 124
Ragia, G. ............................................. 81
Ragino, Y. ................................... 91, 127
Rahimian, R. ....................................... 56
Rahman, T. ....................................... 120
Rainger, E. .......................................... 34
Raitakari, O. ........................................ 33
Raitakari, O.T. ............ 7, 32, 36, 40, 101
Raitoharju, E. .................................... 101
Rajesh, Kumar, G. ............................. 85
Rakowska, A..................................... 116
Ramet, J. ........................................... 104
Ramón, J.M. ..................................... 109
Ramos, J. .......................................... 118
Ramos, S.G. ....................................... 95
Rancic, Z. ............................................ 98
Rangé, H. ............................................ 64
Ranheim, T. ...................................... 113
165
Ribalta, J. ...................................... 36, 74
Riccardi, G. ......................................... 43
Ricordeau, P. ...................................... 32
Riga, M. ............................................... 45
Rigotti, A.............................................. 34
Riklund, K............................................ 61
Rim, S.-J. ............................................ 70
Rio, P. .......................................... 53, 116
Riou, L.M. ............................................ 99
Ripatti, S.............................................. 33
Ritsch, A. ............................................. 77
Rivellese, A. ........................................ 17
Rivellese, A.A. .................................... 43
Rivera, Bernardoni, E. ..................... 117
Rivera, M. ............................................ 63
Rivieccio, A. ........................................ 43
Rizos, C.V. .......................................... 86
Rizos, E.C. .......................................... 76
Rizzo, L. .............................................. 62
Rizzo, M. ................................. 45, 49, 50
Ro, H.-S. ............................................. 30
Roatti, A. ............................................. 59
Robciuc, M. ......................................... 10
Robert, L. ............................................ 52
Roberto, M. ......................................... 40
Robillard, P. ................................ 90, 108
Robin, I. ............................................. 104
Rocchiccioli, S. ................................... 62
Rochette, L. .................................. 53, 58
Rodiño-Janeiro, B.K. ......................... 57
Rodriguez, C..................................... 109
Rodríguez, C. ..................................... 92
Rodriguez, J. ...................................... 65
Rodríguez, J. ...................................... 68
Rodriguez, Leal, C. .......................... 121
Rodríguez, M.A. ................................. 36
Rodríguez, Ortega, K.D. ................. 127
Rodriguez, Padilla, J. ...................... 100
Rodríguez-Granillo, G. .................... 119
Rodríguez-Rey, J.C. .......................... 84
Roeten, M.K. ......................................... 8
Roeters, van, Lennep, J. ................... 70
Roeters, van, Lennep, J.E. ............... 51
Rog, T. ................................................. 70
Rogolino, A. .................................. 70, 95
Rogowski, J. ....................................... 57
Rogowski, O. .................................... 105
Rogoza, A........................................... 91
Roguin, N............................................ 96
Rohrer, L............................................. 71
Roig, R. ............................................... 10
Roivainen, A. ...................................... 46
Rojo, D. ............................................... 82
Romain, C. ....................................... 118
Romanelli, M.G. ................................. 67
Romanov, V. ...................................... 82
Romanov, Y. ...................................... 66
Romdhane, M. ................................. 104
Rome, S. ............................................. 31
Romero, Rodriguez, N. ............... 97, 98
Romero, Vazquianez, M. ............ 97, 98
Romero-Hidalgo, S. .......................... 99
Romero-Mamani, E.S. ...................... 35
Romier-Crouzet, B. ........................... 61
Romijn, H. ........................................... 36
Romijn, J.A. .................................. 16, 71
Ronda, N. ........................................... 71
Roquilly, A. ......................................... 76
Ros, E. ............................... 17, 26, 35, 84
Rosa, J. ............................................. 125
Rosales, R. ......................................... 74
Rosenbaum, D. .....................32, 82, 113
Rosengren, B. .................................... 10
Rosic, A. ............................................. 92
Rosing, K. ........................................... 76
Ross, R. ................................................ 9
Rossetti, M.B.................................... 116
Rossi, M. ............................................. 20
Rossignol, P. ...................................... 48
Rossomanno, S. ................................ 77
Rouanet, J.-M. ................................. 118
Rouer, M. ............................................ 38
Rouis, K. ............................................. 92
Roulot, D........................................... 105
Roussel, R. ................................. 32, 120
Rousselot, D.B. .................................. 82
Roux-Lombard, P. ............................. 47
Rovani, J.C. ...................................... 101
Roy, J. ................................................. 66
Rubanenko, O.A. ......................... 78, 92
166
Rubba, P. ............................................ 51
Rubio, Alvarez, J. ....................... 88, 125
Rubio, Taboada, C. ......................... 125
Rubtsov, P.M. ..................................... 62
Rudel, L. .............................................. 22
Rudler, M. ........................................... 32
Rudling, M. .............................. 39, 76, 83
Ruidavets, J.B. ................................. 105
Ruidavets, J.-B. .................................. 85
Ruivo, J. .............................................. 59
Ruiz-Gutiérrez, V. .............................. 35
Ruiz-Valdepeñas, Herrero, L.......... 117
Rukh, G. ............................................ 101
Ruokonen, A. ...................................... 33
Ruotolo, A. .......................................... 51
Ruotsalainen, A.-K. ............................ 30
Rusiecki, L. ....................................... 116
Russell, D............................................ 94
Rusu, R. ............................................ 106
Ryazankina, N. ................................... 64
Rybalkin, I. .......................................... 75
Rye, K.-A. ................................ 27, 31, 42
Rysz, J. ............................ 45, 49, 50, 102
Ryu, J.K. ............................................ 112
Saito, S. ........................................ 29, 55
Saito, Y. .............................................. 13
Saito, Yasushi .................................... 13
Saitoh, Y. ............................................ 95
Saka, S. .............................................. 88
Sakai, K. ............................................. 73
Sakamoto, S. ..................................... 74
Sakata, K. ..............................32, 48, 111
Sakly, M. ...................... 79, 103, 104, 119
Sako, H. ............................................ 108
Sakri, F.H............................................ 72
Saku, K. ............................................ 108
Sakuma, K. ....................................... 111
Sala, A. ............................................. 126
Sala, F......................................33, 37, 68
Salagovic, J. ....................................... 99
Sałakowski, A. ................................. 116
Sala-Newby, G.B. .............................. 59
Salari, P. ..................................45, 49, 50
Sala-Vila, A. ................................. 17, 35
Salazar-Pelaez, L.M.......................... 60
Sales, K.P.F.d. ......................... 126, 127
Salleron, J. ........................................... 7
Salles, J. ............................................. 90
Salomaa, V......................................... 33
Salvayre, R. .............................37, 38, 70
Samarut, J. ......................................... 69
Samokhodskaya, L.A. ....................... 62
Samokhodskaya, L.M. ...................... 62
Samovilova, N.................................... 66
Samoylova, E.V. ................................ 84
Sampaio, E....................................... 109
Sanak, M. ................................... 80, 127
Sanders, J.-S.F.................................. 49
Sanjib, Sahu, K. ................................. 85
Santos, I. ............................................ 80
Santos, N. ................................... 53, 116
Santos, R.D. ............................3, 42, 115
Santos, Raul D................................... 23
Santos, S. ........................................... 71
Santovito, D........................................ 90
Santtila, M. ......................................... 69
Sanyanusin, P.................................. 108
Sanz, B. .............................................. 80
Sapegin, A. ......................................... 78
S
Sabaka, P. ................................ 108, 115
Sabatine, M.S. .................................... 44
Sabbadini, R. ...................................... 38
Sabench, F. ........................................ 74
Sabin, M.A. ........................................... 7
Sadeghian, H. ..................................... 46
Sadek, A............................................ 110
Saely, C. .............................................. 86
Säemann, M.D. .................................. 49
Safarova, M. ................................. 86, 87
Sagan, A. ............................................ 61
Saha, D. .............................................. 99
Saha, S.......................................... 94, 99
Sahebjam, M. ..................................... 46
Sahoudi, A. ......................................... 52
Saiki, A. ....................... 31, 109, 111, 123
Saint-Charles, F. ................................ 67
Saito, N................................................ 57
167
Saponaro, C. ...................................... 59
Saponjski, J. ....................................... 98
Saraiva, F.K. ....................................... 78
Saraste, A. .......................................... 46
Sarcina, C. ........................................ 112
Sarin, A.-P........................................... 33
Sarkadi, H. ........................................ 127
Sartini, S.............................................. 59
Sarutipaiboon, I. ......................... 99, 100
Sasaki, H........................................... 111
Sasaki, M. ......................................... 120
Sasiela, W.J........................................ 87
Sassolas, A. ............................ 31, 74, 82
Sastre, C. ............................................ 41
Sato, K........................................... 32, 47
Sato, N. ............................................... 77
Sato, Y. ................................ 31, 111, 123
Sattar, N. ......................................... 1, 20
Sattar, Naveed ................................... 20
Sattler, W. ......................................... 124
Saukko, P............................................ 46
Sawabe, M. ......................................... 62
Sawamura, T. ....................................... 6
Sawayama, Y. .................................. 124
Sayeh, A............................................ 113
Sazonova, M.A. ................................ 100
Sbrana, S. ........................................... 67
Scalissi, N. .......................................... 90
Scarlett, S. ........................................ 124
Scarpellini, E....................................... 16
Schaefer, E. .................................. 22, 91
Schaper, N. ......................................... 50
Scharin, Täng, M................................ 53
Scharnagl, H. .......................... 77, 80, 83
Scherbakova, L. ............................... 127
Scherrer, D.Z. ............................. 83, 128
Schiavino, D. .............................. 40, 107
Schibli, R. ............................................ 98
Schiopu, A. ......................................... 18
Schipf, S. ........................................... 110
Schlecht, K.......................................... 64
Schlein, C............................................ 31
Schmermund, A. ................................ 97
Schmid, M. .......................................... 41
Schmid, S.......................................... 112
Schmidt, C. ......................................... 53
Schmidt, I.............................................. 8
Schmidt, S.E. ..................................... 95
Schmidt, W. ........................................ 87
Schnecke, V. ...................................... 36
Schneider, Wolfgang......................... 11
Schonewille, M................................... 30
Schoppet, M. ...................................... 11
Schott, A.-M. ...................................... 46
Schuchardt, M. ......................... 107, 112
Schunkert, H. ..................................... 68
Schwandt, P. .....................116, 127, 128
Schwartz, C. ....................................... 22
Scott, R. ........................................ 22, 44
Scuro, A. ....................................... 65, 67
Sebzda, T. ........................................ 116
Sechi, L.A. ........................................ 115
Segarra, E. ....................................... 110
Segawa, T. ..............................32, 48, 94
Segre, A. ........................................... 115
Segura, E.................................. 109, 121
Seidlerova, J. ..................................... 96
Seleznev, E. ....................................... 60
Seljeflot, I. ................................... 55, 116
Selseth, B. .......................................... 92
Selvaraj, V. ......................................... 60
Selvarajan, K...................................... 65
Selvey, S. ........................................... 44
Semenova, A. .................................... 75
Semenovykh, P. .............................. 110
Sener, M. .......................................... 126
Senthong, V. .........................84, 99, 100
Sentieri, C........................................... 59
Seo, H.S. ...............................36, 53, 122
Seo, H.-S. ........................................... 63
Seo, J. ......................................... 89, 102
Seo, J.-B. ............................................ 78
Seo, K.W. ........................................... 59
Seppälä, I. ........................................ 101
Seres, I. ........................... 72, 80, 95, 102
Sergeeva, E.G. .................................. 99
Sergienko, I. ....................................... 75
Serhan, N. .......................................... 16
Serlie, M. ............................................ 36
Serrano, Jr, C.V. ................................ 42
168
Serre, V. .............................................. 50
Sérusclat, A. ................................. 64, 82
Settasatian, C. .............. 84, 99, 100, 108
Settasatian, N. .............. 84, 99, 100, 108
Sevin, G. ............................................. 69
Seye, C................................................ 33
Shah, A................................................ 85
Shah, C. .............................................. 87
Shah, P.K. ........................................... 81
Shahamfar, J. ..................................... 39
Shahamfar, M. .................................... 39
Shahbaz, M......................................... 86
Shakhtshneider, E. ............................ 84
Shamburek, R. ................................... 22
Shanahan, C.M. ................................. 11
Shapira, I. .......................................... 105
Sharaf, A. .......................................... 110
Sharifi, M. ............................................ 81
Sharma, P.L.......................................... 8
Sharma, S. ............................................ 8
Shattat, G. ......................................... 123
Shchelkunova, T.A. ........................... 62
Shchukin, Y......................................... 60
Shear, C.L. ........................................ 123
Shearman, C. ................................... 114
Shearston, K. ...................................... 31
Shelton, D. .......................................... 87
Sheu, W.H.-H. .................................... 71
Shi, G.-Y.............................................. 29
Shibata, M. .......................................... 55
Shibata, M.-A. ..................................... 44
Shiffman, D. ........................................ 88
Shikata, K.......................................... 124
Shima, A...................................... 78, 103
Shimizu, T. .......................................... 58
Shin, D.-G. ........................................ 117
Shin, E.K. .............................. 89, 95, 102
Shin, M.-S. .......................................... 43
Shinichi, O. ......................................... 56
Shinohara, M. ............................. 39, 120
Shirai, K. ...................... 31, 109, 111, 123
Shiri-Sverdlov, R. ................... 16, 22, 71
Shishkina, V........................................ 66
Shishkina, V.S. ................................... 67
Shpektor, A. ...................... 51, 58, 61, 64
Shuvalova, Y.A. ................................. 84
Siedlecka, D. .................................... 121
Siedlinski, M. ...................................... 60
Siekierzycka, A. ................................. 57
Siekmeier, R. ..................................... 83
Sierra, Quiroga, J. ..................... 88, 125
Siest, G. ............................................ 106
Signoretto, C. ..................................... 64
Sijbrands, E. ....................................... 70
Sijbrands, E.J. .................................... 51
Silbernagel, G. ............................. 77, 83
Sillesen, H. ......................................... 25
Silva, E. ............................................... 40
Silva, J.C.Q. ....................................... 71
Silva, S........................................ 53, 116
Silva, T. ............................................. 116
Silvennoinen, R. ................................ 33
Silvola, J. ............................................ 46
Simerzin, V.V. .............................. 78, 92
Simion, V. ........................................... 41
Simkus, G. .......................................... 40
Simonova, G. ................................... 102
Simonsen, J.A.................................... 45
Simonsen, U. ....................................... 8
Simonyi, G. ....................................... 102
Singla, D. ............................................ 11
Singparu, P. ..................................... 108
Sinisalo, J. .................................... 61, 96
Siores, E. ............................................ 38
Sironi, M. ............................................ 34
Sirtori, C.R. ................ 62, 63, 81, 96, 126
Sistonen, H....................................... 105
Sitar-Taut, A.V. ................................ 104
Sitek, B. ...............................57, 106, 121
Sivenius, J. ......................................... 39
Sjåstad, I........................................... 113
Sjöberg, S........................................... 83
Sjouke, B. ..................................... 26, 51
Skålén, K. ........................................... 53
Skalska, A. ....................................... 116
Skjelland, M........................................ 65
Skop, V. .............................................. 54
Skórka, T. ......................................... 106
Skorupan, N. .................................... 113
Skoumas, I. ........................................ 44
169
Skrbic, R.............................................. 92
Skuja, I. ..................................... 103, 106
Slagboom, P.E. .................................. 88
Slama, M. ............................................ 52
Sloan, J.J. ........................................... 10
Sluimer, J.C. ....................................... 47
Smahelova, A. .................................. 110
Smaoui, M. .................................. 85, 126
Smedby, T......................................... 106
Smirnov, A.N. ..................................... 62
Smirnova, N. ....................................... 52
Smith, D. ........................................... 126
Soares, M. ........................................... 29
Sobenin, I.A. ................... 62, 70, 71, 100
Sobotka, L. ........................................ 110
Sobrino, M. ................................. 92, 109
Södergren, A. ................................... 106
Söderlund, S. ................................ 33, 48
Soeters, M........................................... 36
Soffientini, U. .................................... 106
Sohrabi, B. .......................................... 66
Sokhanvar, S. ..................................... 91
Solheim, S. ....................................... 116
Somleva, D. ........................................ 58
Son, K.-H. ........................................... 32
Sonestedt, E. ...................................... 39
Sonmez, H. ......................................... 59
Sonoda, N. .................................. 78, 103
Soran, H. ..................................... 72, 125
Sörensen, K. ....................................... 61
Soriano, F. ........................................ 110
Sormaz, L............................................ 92
Soronen, J. ......................................... 33
Sorontila, K. ........................................ 84
Sorsa, T. .............................................. 61
Soto, Y. .......................................... 38, 68
Souza, R. .......................................... 115
Spasova, N. ........................................ 58
Specchia, C. ..................................... 100
Spina, R. ............................................. 51
Spinella, G. ......................................... 47
Sponseller, C.A. ................................. 90
Sposito, A.C.................................. 71, 78
Sprandel, M.C. ................................. 115
Sprandel, M.C.O. ............................... 72
Staels, B. ..................... 6, 28, 67, 74, 105
Staffler, G. .......................................... 87
Stafford, R. ......................................... 86
Stalenhoef, A. .................................... 51
Stalenhoef,, A. ................................... 25
Stamboul, K........................................ 53
Stan, D. ............................................... 41
Stancak, B. ......................................... 99
Stanek, V. ........................................... 99
Stangl, G.I. ......................................... 32
Stanisić, M. ....................................... 125
Stanke-Labesque, F.................. 64, 122
Staňková, B. ....................................... 82
Starzyk, J. ......................................... 127
Stathogiannis, K. ......................... 38, 45
Stead, A. ............................................. 91
Stef, M................................................. 80
Stefanadis, C. .........................38, 44, 45
Stefanovic, A. ..................................... 94
Stefanutti, C. ...................................... 81
Steg, P.G. ........................................... 52
Stehouwer, C. .................................... 50
Stein, E. .............................................. 77
Stein, E.A........................... 19, 22, 44, 87
Steinhagen-Thiessen, E. ............ 76, 80
Steinkasserer, A. ............................... 68
Steinvil, A.......................................... 105
Stender, S. ........................................... 8
Stengel, D......................................... 117
Stępień, A. ........................................ 102
Stępień, M. ....................................... 102
Stepnowska, M. ................................. 57
Sterba, M. ........................................... 57
Stergiopulos, N. ................................. 60
Sternak, M. ................................. 57, 106
Stewart, R. .......................................... 89
Stijn, C.V........................................... 103
Stitziel, N. ........................................... 50
Stocco, B. ........................................... 93
Stojakovic, T. ..................................... 80
Stojanov, M. ....................................... 94
Stojanović, M. .................................. 113
Stojkovic, I.A. ................................... 101
Stokmane, A.S. ................................ 113
Stone, P.H. ................................... 29, 55
170
Straniero, S. ........................................ 39
Strasky, Z. ............................. 57, 89, 120
Strauch, B. ........................................ 125
Stroes, E. .............................. 5, 9, 36, 42
Stroes, E.S.G. .................................... 55
Stroes, Erik ........................................... 8
Struijk, J.J. .......................................... 95
Stübiger, G.......................................... 76
Stucchi, M. ........................................ 110
Stukena, I. ................................. 103, 106
Stutler, K. ............................................ 32
Stypmann, J........................................ 76
Su, J..................................................... 63
Subhanova, I. ................................... 120
Succi, S. .............................................. 99
Suffee, N. ............................................ 57
Sugiura, T. .......................................... 94
Sugiyama, D. ........................ 77, 78, 103
Sugiyama, Y. ...................................... 42
Suh, J.-W. ........................................... 49
Suh, S.-H. ................................... 98, 112
Suh, S.Y. ..................................... 95, 102
Sulzbach, M. ................................. 76, 96
Sumino, H. .......................................... 75
Sumpio, B. ........................................ 113
Sumrit, C. .......................................... 108
Sun, L. ............................................... 120
Sun, Z. ..................................... 46, 60, 98
Sunagawa, K. ..................................... 64
Superville, A. ...................................... 74
Sur, S................................................... 60
Surakka, I. ........................................... 33
Surekha, Rani, H................................ 85
Surur, A. .............................................. 96
Sutton, A. ............................................ 57
Suwa, J................................................ 94
Suzuki, M. ............................. 58, 90, 103
Sved, I. ................................................ 56
Sviridov, D........................................... 27
Sweidan, K........................................ 123
Swergold, G.D. ............................. 26, 87
Swiader, A. ......................................... 37
Synetos, A. ................................... 38, 45
Syrycki, M. ........................................ 116
Sytdykov, I.H. ..................................... 78
Szahidewicz-Krupska, E. ............... 126
Szawrowicz-Pelka, T. ..................... 116
Szeberin, Z. ...................................... 127
Szeffler, A. .......................................... 57
Szuba, A. .................................... 38, 126
Szutowicz, A. ..................................... 73
T
Tabet, F. ............................................. 27
Tabib, A. ........................................... 114
Tada, H. .............................................. 50
Taddei, A. ......................................... 108
Taghlit, R. ......................................... 119
Taguchi, N. ................................. 58, 103
Taharboucht, S. ................104, 105, 115
Tahna, T. .......................................... 116
Tailleux, A. .............................28, 74, 105
Takagi, W. .......................................... 93
Takahashi, K. ..................................... 58
Takahashi, M. .................................... 73
Takahashi, R. ............................. 58, 103
Takahashi, S. ............................... 29, 55
Takahashi, T. ..................................... 32
Takahashi, W. .................................. 127
Takai, A............................................. 106
Takamatsu, H. ........................... 35, 109
Takashima, N. .............................. 91, 95
Takata, K. ........................................... 77
Takbou, K. ........................................ 110
Takeda, K. .......................................... 93
Takhashi, M...................................... 102
Takizawa, S...................................... 127
Takkand, A. ...................................... 107
Tamakoshi, A. .................................... 48
Tamura, R. ......................................... 94
Tan, A.R. ............................................ 22
Tan, R. ................................................ 30
Tanabe, K. .......................................... 45
Tanaka, F. .................................... 32, 48
Tanaka, H. .......................................... 54
Tanaka, N. ........................................ 120
Tanaka, S. .......................................... 55
Tang, C.-K. ..............................42, 51, 71
Tang, J. ............................................... 33
171
Tang, Z.H. ........................................... 29
Tanganelli, P....................................... 61
Tangirala, R.K. ................................. 103
Tania, S. .............................................. 79
Taniguchi, H. .................................... 121
Tanno, K...................................... 48, 111
Tantipanichteerakul, K. ....... 84, 99, 100
Tapper, E. ........................................... 30
Tararak, E.M. ...................................... 67
Tarasov, K........................................... 35
Taraszkiewicz, D. ......................... 77, 85
Tarau, R. ........................................... 106
Tarhan, N. ......................................... 121
Tarugi, P.............................................. 51
Taskinen, M.-R. .................... 1, 9, 33, 48
Taskinen, Marja-Riitta ................... 9, 25
Tatsidou, P........................................ 114
Tatsumi, Y. .................................. 78, 103
Tatsuno, I. ................... 31, 109, 111, 123
Taurino, M. .............................. 28, 62, 67
Tavares, E.R....................................... 68
Tavridou, A. ........................................ 81
Tay, C. ................................................. 18
Tcimbal, S. ........................................ 127
Teerajetgul, Y. .................................. 108
Teffahi, N. ......................................... 105
Tegani, D.M. ....................................... 43
Teiger, E.............................................. 52
Teijeira, Fernandez, E. ...................... 88
Teixeira, D........................................... 49
Tejedor, D. .......................................... 80
Tellis, K.............................................. 104
Temchenko, A. ................................... 70
Terasaka, N. ....................................... 42
Tercé, F. .............................................. 75
Ternovoy, S. ....................................... 97
Terraneo, B. ........................................ 96
Tershakovec, A.M. ............................. 85
Terzis, I................................................ 82
Tesfaye, S. .......................................... 54
Tesmenitsky, Y. .................................. 62
Thabut, D. ........................................... 32
Theelen, W. ........................................ 67
Theodoropoulos, K.C. ..................... 114
Theron, H.D.T..................................... 81
Thiyagarajan, S. ................................ 86
Thomassen, A.................................... 45
Thomsen, M. ................................ 36, 55
Thorsson, O. .................................... 116
Tibolla, G. ..................................... 37, 68
Ticha, A............................................. 110
Tidone, C. ......................................... 112
Tietge, U. ............................................ 72
Tietge, U.J. ................................. 72, 103
Tietge, U.J.F. ............................... 10, 49
Tillander, P. ........................................ 92
Tillin, T. .............................. 49, 78, 89, 95
Tillmanns, H. .................................... 113
Tilly, P. ........................................ 34, 113
Tilstam, P............................................ 67
Tinelli, C. ........................................... 101
Tinoco, I. ..............................92, 109, 121
Tipping, P. .......................................... 18
Tiret, L. .......................................... 8, 117
Tiseo, G. ............................................. 31
Titkov, A. ............................................. 78
Tivesten, Å. .................................... 7, 69
Tkac, I. ................................................ 99
Toana, B. .......................................... 110
Tobayama, H. .................................... 58
Tobina, T. ........................................... 54
Toczek, J. ........................................... 99
Toda, T. .............................................. 62
Toft, E. ................................................ 95
Toftegaard, L.A. ............................... 116
Toh, B.-H. ........................................... 18
Toh, R. ...................................39, 74, 120
Tokgozoglu, L. ............................. 19, 25
Tokgozoglu, Lale ................................. 5
Toledo, E. ........................................... 35
Tölle, M. .................................... 107, 112
Tomankova, T. ................................... 62
Tomaschitz, A. ........................... 83, 101
Tomassini, J.E. .................................. 85
Tomaszewski, M. ............................... 23
Tomlinson, B. ..................................... 87
Tomoike, H. ........................................ 80
Tomono, J. ................................. 35, 109
Tonar, Z. ............................................. 28
Topchii, I. .......................................... 110
172
Toplak, H. .................................... 86, 101
Toprak, M.S. ....................................... 59
Torii, S. ................................................ 95
Toro, R. ............................... 92, 109, 121
Torqueti, M.R. ..................................... 93
Tosolini, L............................................ 50
Toth, P.P. .......................... 45, 49, 50, 85
Touat, Z. .............................................. 61
Touche, V............................................ 74
Tousoulis, D........................................ 45
Toutouzas, K. ............................... 38, 45
Touw, J. ............................................... 70
Towers, G.W....................................... 85
Tran-Dinh, A. ................................ 56, 57
Trautwein, E.A. ................................... 43
Travert, F. ........................................... 32
Trayssac, M. ....................................... 38
Trégouët, D.-A...................................... 8
Tremoli, E............................................ 34
Tretjakovs, P..................................... 103
Trichia, E. .......................................... 120
Trimech, T. .................................... 31, 76
Trimeche, A. ..................................... 103
Triolo, M. ....................................... 72, 96
Tripoten, M. ......................................... 91
Triscari, J. ........................................... 86
Tritapepe, L................................... 28, 67
Trivella, M.G. ................................ 62, 67
Trnovska, J. ........................................ 54
Trombeta, I. ...................................... 115
Trombetta, I.C. ................................. 115
Trompet, S. ......................................... 88
Troutt, J. .............................................. 50
Tsai, L.-M. ................................. 113, 114
Tsai, S.-H. ........................................... 61
Tsai, W.-C. ................................ 103, 114
Tsai, Y.-S. ........................................... 29
Tsay, P.-K. .......................................... 46
Tselepis, A. ......................... 57, 104, 114
Tselepis, A.D. ..................................... 76
Tselovalnikova, T.Y. ........................ 105
Tseng, P.-C......................................... 71
Tseng, S.-Y. ........................................ 29
Tsiamis, E. .................................... 38, 45
Tsifetaki, N. ....................................... 106
Tsigkas, G. ....................................... 114
Tsimihodimos, V. ............................... 76
Tsimikas, S. ........................................ 81
Tsiouris, S. ....................................... 106
Tsoumani, M. ................................... 114
Tsuchiya, T. ........................................ 45
Tsuda, M. ...................................... 29, 55
Tsukamoto, K. .................................. 106
Tsuneyama, K.................................. 106
Tu, Y.-L. .............................................. 51
Tufan, C. ........................................... 121
Turer, A. .............................................. 94
Turgeman, Y. ..................................... 96
Tybjærg-Hansen, A. ........... 7, 54, 55, 84
Tybjaerg-Hansen, Anne ..................... 5
Tzanetakou, I. .................................. 119
Tzavella, E.......................................... 76
U
Uboldi, P. ......................... 52, 62, 94, 112
Uchida, H. ......................................... 124
Uchida, H.A. ..................................... 124
Ucieda-Somoza, R. ........................... 57
Udata, C. ...................................... 44, 87
Ueda, Y. ...............................73, 109, 122
Ueland, T. ......................................... 113
Ueno, E. .............................................. 45
Ueshima, H. ...................... 48, 77, 91, 95
Uesugi, T. ......................................... 127
Ugarte-Pedrero, X. ............................ 80
Uitti, J. ................................................. 96
Ulleryd, M.A.................................. 41, 66
Umebayasi, R. ................................. 124
Undas, A. ............................................ 39
Unhammer, Njerve, I....................... 116
Urazgildeeva, S. ................................ 78
Urazovskaya, I. .................................. 58
Urbánek, M. ........................................ 82
Urbanski, K......................................... 61
Urinov, M.B. ....................................... 89
Urpi-Sarda, M. ................................... 33
Urtane, I. ................................... 107, 113
Usta, E. ............................................. 126
173
Vanoosterhout, S............................... 22
Varbo, A. ......................................... 7, 55
Varejckova, M. ................................... 89
Varela, C..................................65, 68, 94
Varela, Casariego, C. ..................... 100
Varela, Perez, L.M. ........................... 48
Varela-Perez, L.................................. 57
Vargas-Alarcón, G....................... 77, 99
Varma, N. ........................................... 98
Varret, M. .................................26, 50, 64
Vasankari, T. ...................................... 69
Vasilieva, E. ...................... 51, 58, 61, 64
Vasina, L............................................. 78
Vaslin-Reimann, S. ........................... 79
Vatier, C. ............................................. 82
Vattulainen, I. ..................................... 70
Vávrová, L. ......................................... 82
Vázquez, A.M. ............................. 38, 68
Vcev, A. ...................................... 93, 111
Vecka, M. ............................................ 82
Vedel, S. ............................................. 50
Vedie, B. ............................................. 30
Védie, B. ............................................. 26
Velsko, I. ............................................. 63
Vemmos, K.N. .................................. 120
Vendrame, F. ..................................... 78
Vengrenyuk, Y. .................................. 37
Venn, A. .......................................... 7, 32
Vercesi, A.E. .............................. 90, 101
Verdier, C. .......................................... 85
Verdugo, R. ...................................... 117
Vergely, C..................................... 53, 58
Verges, B. ........................................... 27
Vergès, B. ......................................... 104
Verhoeven, A. .................................... 70
Verhoeven, G. .................................... 69
Véricel, E. ..................................... 34, 65
Vermeer, M. ....................................... 43
Verny, M.-A. ..................................... 122
Verola, O. ........................................... 79
Veselovskaya, N. ..... 100, 102, 103, 118,
125
Vetrani, C............................................ 43
Vialettes, B. ...................................... 101
Vianello, A. ................................... 61, 93
V
Vacula, I. ............................................. 79
Vagionas, I. ......................................... 93
Vahromeeva, E. ................................ 103
Valayannopoulos, V. ......................... 80
Valdivielso, J.M. ................................. 54
Valensi, P. ................................. 105, 110
Valente, S. .......................................... 70
Valéra, M.-C. ...................................... 29
Valéro, R. .......................................... 101
Valinsky, L. ....................................... 116
Vallez, E. ..................................... 28, 105
Valls-Pedret, C. .................................. 26
Vallvé, J.C. .......................................... 74
van, Bockxmeer, F.M. ....................... 82
Van, Craenenbroeck, A................... 104
Van, Craenenbroeck, E................... 104
van, den, Oever, I. ............................. 20
van, der, Giet, M. ..................... 107, 112
Van, der, Hoorn, J.W.A. .................... 49
van, der, Made, S.M. ....................... 118
van, der, Tuin, S.J.L. ............. 16, 49, 71
van, der, Veer, E.P. ............................. 8
van, der, Vorst, E. .............................. 42
van, der, Zee, L. ................................. 70
van, Eck, M. .................................. 42, 65
Van, Gaal, L.......................................... 9
Van, Ganse, E. ................................. 123
van, Gils, J.M. ....................................... 8
van, Gorp, P.J. ................................... 22
van, Greevenbroek, M....................... 50
van, Ierssel, S................................... 104
Van, Nood, E. ..................................... 36
Van, Noolen, L. ................................ 122
van, Schaik, R. ................................... 81
van, Zonneveld, A.J. ............................ 8
Van, Zyl, T........................................... 85
Vanags, L. ........................................... 42
Vandenbroucke, I............................... 74
Vandenput, L. ....................................... 7
Vanderdionck, S................................. 28
Vanek, J. ....................................... 40, 96
Vanhoutte, J. ................................ 28, 67
Vanikova, J. ...................................... 120
174
Vickers, K.C. ....................................... 27
Vidal-Piñeiro, D. ................................. 26
Vidé, J................................................ 118
Vidjak, V. ........................................... 115
Vigeral, C. ......................................... 100
Viglione, F. .................................... 62, 67
Vigna, G.B. ......................................... 81
Vigouroux, C. .............................. 83, 100
Viikari, J. .............................................. 36
Viikari, J.S. ............................................ 7
Viikari, J.S.A. ...................................... 32
Viiri, L................................................... 63
Vik, R. .................................................. 86
Viklicky, O. ........................................ 112
Villa, Gil-Ortega, M. ..................... 97, 98
Villard, E.F. ............................. 30, 63, 70
Villarreal-Molina, T. ............................ 99
Villasmil, J.J. ....................................... 40
Villegas, del, Ojo, J. ......................... 105
Vinaixa, M. .......................................... 36
Vindis, C. ....................................... 37, 70
Vinel, A. ............................................... 29
Virga, N. .............................................. 84
Virginio, V.W. ................................ 71, 78
Viscomi, C. .......................................... 16
Vissers, D.......................................... 104
Visvikis-Siest, S................................ 106
Vitale, M. ............................................. 43
Vitanov, V............................................ 99
Vitek, L. ............................................. 120
Vittos, A. ............................................ 110
Vittos, O. ........................................... 110
Vivanco, F. .......................................... 61
Vlachos, I.S....................................... 119
Vladimirskaya, T. ............................... 56
Vlasik, T. ............................................. 75
Vlaskou, E. .......................................... 47
Vlasova, E. .......................................... 86
Vo, S. ................................................... 30
Voevoda, M........................... 84, 91, 127
Volkov, V. ............................................ 77
Volkova, E. .......................................... 97
Völzke, H. .......................................... 110
von Eckardstein, Arnold .............. 22, 27
von, Bonin, A. ..................................... 87
von, Dryander, M. .............................. 86
von, Eckardstein, A. .................... 27, 71
Vongpromek, R.................................. 70
Vorobjov, R. ..................................... 107
Vorobjova, E. ................................... 107
Vorobyev, R.I. ................... 78, 91, 92, 97
Vorobyeva, E.N. ............... 78, 91, 92, 97
Vorrsjö, E. ..................................... 31, 75
Voss, J.C. ........................................... 73
Voss, S.S. ........................................... 32
Voulgari, C...............................54, 82, 95
Vovchenko, M. ................................... 77
Vozzi, F. .............................................. 67
Vrablik, M............................................ 99
Vrablík, Michal ................................... 18
Vranckx, R. ....................................... 114
Vreugdenhil, A.C.E. .......................... 22
Vrieze, A. ............................................ 36
Vrints, C. ........................................... 104
Vromman, A. ...................................... 60
Vučić, M. ............................................. 82
Vuilleumier, N. ................................... 47
Vujic, N. ............................................ 124
Vukcevic, V. ....................................... 98
Vulic, D. .............................................. 92
W
Wada, F. ............................................. 44
Wada, S. ............................................. 44
Wadhwa, N. ........................................ 87
Wagenaar, G.T.M. ............................. 65
Wahbi, K. ............................................ 52
Walenbergh, S. .................................. 22
Wallaschofski, H. ............................. 110
Wållberg-Jonsson, S....................... 106
Walus-Miarka, M. .............................. 80
Waluś-Miarka, M. ............................ 127
Wan, H. ............................................... 87
Wan, Y.-L............................................ 46
Wanden-Berghe, C. ................ 117, 127
Wang, C.............................................. 65
Wang, C.-K....................................... 118
Wang, G. ............................................ 51
Wang, H.-J. ........................................ 69
175
Wang, K.-Y. ........................................ 93
Wang, L. .............................................. 76
Wang, M.-C............................... 103, 114
Wang, N. ....................................... 65, 74
Wang, P. ............................................. 52
Wang, R. ....................................... 29, 33
Wang, Y. ................................. 16, 71, 73
Wang, Z. ........................................ 29, 56
Wanner, C. ........................................ 101
Warner, T.D. ..................................... 114
Wasserman, S.M. .................. 22, 44, 77
Watanabe, F. .................................... 123
Watson, S. .......................................... 34
Watts, G.F. .................................. 22, 103
Weber, C. ............................................ 67
Weidmann, H.................................... 117
Weikert, C. .......................................... 32
Weill, A. ............................................... 32
Weir, J.M. ............................................ 30
Wen, M.-S. .......................................... 46
Wendelin-Saarenhovi, M. ................. 40
Werdan, K. .......................................... 64
Werzowa, J. ........................................ 49
Westendorp, R.G.J. ........................... 88
Wester, P. ..................................... 98, 99
Wevers, R. .......................................... 55
Whatling, C. ........................................ 38
Wheatcroft, S. ..................................... 94
White, A.J............................................ 30
Whittall, R.A. ....................................... 80
Wiart, M. .............................................. 64
Wick, G. ............................................... 53
Widhalm, K. ........................................ 76
Widimsky, J....................................... 125
Wiegman, A. ....................................... 81
Wiinberg, N. ........................................ 95
Wijngaard, P.L. ................................... 73
Wiklund, O. ....................................... 1, 7
Wiklund, Olov ................................. 1, 15
Wikström, A.-K. .................................. 93
Wild, P.S. .............................................. 8
Wilhelmson, A.S................................. 69
Wilk, B.K............................................ 121
Willan, K.L. ........................................ 124
Willeit, P. ........................................... 114
Willems, van, Dijk, K. .............16, 49, 71
Williams, B........................................ 124
Williams, E.D...................................... 89
Williams, H. ........................................ 65
Winsauer, G. ...................................... 87
Winslop, A. ......................................... 18
Winther, S........................................... 95
Wirfält, E. ...................................... 17, 39
Wirth, J. ............................................... 32
Wlazeł, R.N. ..................................... 102
Wohlfahrt, P. ................................ 40, 96
Wohns, D. ........................................... 22
Wojciechowska, W. ......................... 127
Wojciechowski, J. .............................. 57
Wojcieszczyk, J. .............................. 116
Wójcik, T. ............................................ 57
Wojta, J. ............................................ 114
Wolf, P. ............................................... 83
Wolfs, M.G.M. .................................... 71
Wollmer, P. ....................................... 116
Wolska, A. .......................................... 73
Wolski, K............................................. 22
Womperski, K. ................................. 116
Wong, A.T.Y. .............................. 22, 103
Wong, G. ...................................... 22, 30
Wong, J.Y. .......................................... 27
Wong, M.C. ........................................ 65
Wood, S.M........................................ 124
Worsch, M. ....................................... 113
Wouters, K.................................. 28, 105
Wozniak, M. ....................................... 57
Woźniakiewicz, E. ........................... 127
Wright, A. ...................................... 49, 78
Wright, S.D. ...................................... 123
Wróblewska, M. ................................. 73
Wu, C.-H. .......................................... 114
Wu, H.-L. ............................................ 29
Wu, Y. ................................................. 52
Wuczkowski, M. ................................. 76
Wymann, M. ....................................... 52
Wyss, C.A........................................... 47
X
Xanthopoulou, I. .............................. 114
176
Xie, D. .................................................. 51
Xu, F. ................................................... 22
Xu, Q. .................................................... 8
Xu, Qingbo ............................................ 8
Yilmaz, O. ........................................... 69
Yin, K............................................. 42, 51
Yin, W.-H. ........................................... 93
Ylä-Herttuala, S. .......................... 30, 31
Yndestad, A...................................... 113
Yokoyama, S...................................... 80
Yongsakulchai, P............................. 100
Yoon, Y. .............................................. 76
Yoon, Y.W. ......................................... 70
Yoshida, S. ......................................... 62
Yoshikawa, T. .................................. 123
Yoshimura, A. .................................. 121
Yoshimura, E. .................................... 54
Younis, N. ................................... 72, 125
Yu, C.-C. ........................................... 100
Yu, J. ................................................... 48
Yu, Z.Y. ............................................... 29
Yuldasheva, N. .................................. 94
Yvan-Charvet, L................................. 23
Y
Yadav, M.R. ........................................ 78
Yadav, R. .................................... 72, 125
Yagi, K. .......................................... 11, 80
Yagyu, H. ............................................ 73
Yahalom, M......................................... 96
Yahya, R. ............................................ 70
Yamada, K. ......................................... 61
Yamada, M. ........................................ 48
Yamagishi, M. ............................... 50, 80
Yamagishi, T..................................... 125
Yamaguchi, T. ............ 31, 109, 111, 123
Yamamoto, J. ..................................... 39
Yamamoto, T. ..................................... 44
Yamamura, S. ............................ 31, 111
Yamamuro, D. .................................... 73
Yamanaka, S. ..................................... 94
Yamashita, S. ............................. 87, 109
Yan, B. ................................................. 11
Yan, Z. ................................................. 63
Yan, Z.-Q. ..................................... 41, 66
Yang, C.-M. ......................................... 64
Yang, L.J. ............................................ 66
Yang, Y.L. ........................................... 87
Yannarelli, G. ...................................... 82
Yao, Q. ................................................ 28
Yarmolovsky, A. ............................... 116
Yassin-Norena, L.M. .......................... 60
Yasuda, G. .......................................... 88
Yasuda, T.............................. 39, 74, 120
Yasuhara, H........................................ 44
Yatsu, K. .............................................. 88
Yazici, A.C. ....................................... 109
Yefimova, N. ..................................... 110
Yefsah, A. ......................................... 119
Yen, F.T. ........................................... 106
Yeni, P. ................................................ 63
Yildirir, A. ........................................... 109
Yıldırır, A. .................................... 89, 107
Z
Zabunova, M. ........................... 107, 125
Zaccagna, F. ...................................... 97
Zachary, I............................................ 59
Zago, V.H.D.S.............................. 78, 83
Zago, V.H.S...................................... 128
Zaid, M. ............................................... 95
Zair, Y. ................................................ 26
Žák, A.................................................. 82
Zak, P................................................ 112
Zakaroff, A. ......................................... 49
Zakke, I. ............................................ 125
Žáková, P. .......................................... 94
Zalba, G. ............................................. 41
Zalewski, J.......................................... 39
Zampetaki, A. ................................... 114
Zanetti, M............................................ 35
Zannis, V.I. ......................................... 71
Zarakauska, L. ................................. 107
Zarzecka, A. ..................................... 125
Zatz, H. ......................................... 76, 96
Zavyalova, L. ...................................... 79
Zawadzki, C. ...................................... 67
Zechner, R.......................................... 25
177
Zeiher, A................................................ 8
Zekri, S. ............................. 104, 105, 115
Zelina, M. .................................. 108, 115
Zelinka, T. ......................................... 125
Zeller, M. ....................................... 53, 58
Zeller, T. ........................................ 8, 117
Zemankova, L............................. 89, 120
Zerbinati, C. ........................................ 60
Zernecke, A. ....................................... 47
Zerrad, A. .......................................... 108
Zhai, Y.Z............................................ 118
Zhang, F. ............................................. 33
Zhang, H. ............................................ 16
Zhang, J. ............................................. 56
Zhang, J.-J. ......................................... 51
Zhang, L. ............................................. 30
Zhang, R. ............................................ 56
Zhang, T. ........................................... 118
Zhang, X.-Y......................................... 66
Zhang, Y...................................... 73, 124
Zhao, S. ............................................. 123
Zhelankin, A.V. ................................. 100
Zheng, D. ............................................ 52
Zhong, L. ............................................ 52
Zhou, B. ........................................ 29, 67
Zhu, L. ................................................. 73
Zidek, W. .................................. 107, 112
Zidzik, J............................................... 99
Zikou, A.K. ........................................ 126
Zilov, A. ............................................... 97
Zilov, A.V. ......................................... 105
Zimetti, F............................................. 71
Zimmerova, I. ..................................... 81
Zingg, J.-M. ...................................... 126
Zinser, E. ............................................ 68
Zmojdzian, M. .................................. 122
Zo, J.-H. .............................................. 78
Zoetendal, E. ...................................... 36
Zoroufian, A........................................ 46
Zsíros, N. .......................................... 102
Zulj, M. ................................................ 93
Zulkafli, N............................................ 58
Zyatenkova, E. ................................... 88
178

final programme

Transcription

Similar documents

Le nuove Linee guida neLLa prevenzione cardiovascoLare: aLLa

79th EAS CONGRESS

Presentazione di PowerPoint

Diapositiva 1 - Terapia Intensiva dell`età Pediatrica (0

16th Bandung Scientific Meeting Of Indonesian Society

scelta dell`intervento

GULDKANT

scarica pdf qui

GPS Co-Ordinates of All OurTour Blog Motorhome Stopovers

Modelli animali_4_13_C File

Studies and publications

CLASSICS (2oz) 12. THE DOWNTOWN CAESAR 12. FRAGOLA

Programma - Società italiana di neurologia

ORS 2016 Program Book - Orthopaedic Research Society

Tuesday Daily Newspaper - 2016 AGU Fall Meeting